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Recently, phage lytic enzymes (also known as endolysins or, simply,
lysins) have received considerable attention as potential antibacterial agents.
During the infective cycle of double-stranded DNA phage, these peptidoglycan
hydrolases are responsible for digesting the cell wall of the host bacterium and
freeing newly-assembled viral particles. At the same time, an increasing body of
evidence has demonstrated that recombinantly-purified phage lysins—when
added exogenously—can potently kill Gram-positive bacteria, whose
peptidoglycan is accessible from the extracellular space. Consequently, lysins
have been proposed as novel enzybiotic (i.e. enzyme-antibiotic) molecules that
could serve as novel weapons in the fight against drug-resistant bacteria. Most
lysins characterized to date were initially identified through either recombinant
screening or DNA-sequencing of phage genomes. Recent technological and
methodological advances, however, have drastically increased the potential
avenues for lysin identification. The goal of the work presented here to exploit
and expand upon these advances so that the identification of new lysins is
increasingly rapid and straightforward.
This thesis is subdivided into four interrelated sections, each of which
represents a distinct study into a novel approach/method for cloning phage

lysins. The first study (Chapter 2) addresses the issue of bacterial genomic
sequencing and how the rapidly expanding database of bacterial genomes
represents a vast source of proviral lysins. Focusing on the anaerobic pathogen
Clostridium perfringens, the genomes of 9 recently-sequenced strains were
computationally mined for prophage lysins and lysin-like ORFs (open reading
frames), revealing several dozen proteins of various enzymatic classes. Of these
lysins, a muramidase (termed PlyCM) from strain ATCC 13124 was chosen for
recombinant analysis based on its dissimilarity to the only other previouslycharacterized C. perfringens lysin. Following expression and purification, various
biochemical properties of PlyCM were determined in vitro, including pH/saltdependence and temperature stability. The enzyme exhibited activity at low
g/ml concentrations, and it was active against 23/24 strains of C. perfringens
tested.
Chapters 3 and 4 focus on the emerging field of viral metegenomics, a term
which refers to the bulk extraction and analysis of DNA from environmental
phage without prior laboratory culture of any particular virus. Phage
metagenomes have been shown to be incredibly complex and diverse, and the
goal of these chapters was to tap into this diversity through functional
metagenomic screens for lytic enzymes. Chapter 3 first addresses a preliminary
methodological issue, namely the fact that uncultured phage samples generally
do not provide sufficient quantities of DNA for ready screening. A novel E-

LASL protocol (for expressed linker amplified shotgun library) was developed
that combines linker amplification of enzyme-digested DNA with subsequent
topoisomerase cloning into linearized expression plasmids. As proof-ofprinciple, genomic and metagenomic E-LASLs were constructed and screened
for antibacterial and hemolytic activity in an Escherichia coli host. Six Bacillus
anthracis phage lysins were cloned in the process, along with a virulence factor of
the aerolysin gene family.
Chapter 4 proceeds to address an additional methodological issue
surrounding metagenomic lysin identification: the question of how to identify
lysin-encoding clones in a functional screen when the targeted bacteria are not
pre-defined. A novel two-step screening technique was devised for this purpose.
It involves a primary screen in which transformed E. coli clones were identified
that demonstrated colony lysis following exposure to nebulized inducing agent.
This effect, which can be due to the expression of membrane-permeabilizing
phage holins, was discerned by the development a hemolytic-effect in
surrounding blood agar. The selected clones were then overlaid with autoclaved
Gram-negative bacteria (specifically Pseudomonas aeruginosa) to assay directly for
recombinant expression of lytic enzymes, which are often encoded proximally to
holins in phage genomes. This method was combined with the aforementioned
E-LASL technique and applied to a viral metagenomic library constructed from
mixed animal feces. Twenty-six lytic enzymes were cloned in this screen,

including both Gram-positive-like and Gram-negative-like enzymes, as well as
several atypical lysins whose predicted structures are less common among
known phage.
Finally, Chapter 5 takes the above techniques and reapplies them outside
the context of metegenomics, returning to individual genomes as sources of lytic
enzymes. Specifically, 2 lysins were cloned from prophage of Streptococcus suis,
an important veterinary and emerging zoonotic pathogen. One of these S. suis
enzymes (PlySs1) was identified by applying the two-step screen to the genome
of an unsequenced clinical strain. The other (PlySs2) was identified in a manner
similar to the clostridial lysin PlyCM, by analyzing the published genomes of
various sequenced strains. Finally, PlySs1 was subject to chromatographic
purification and in vitro analysis against numerous suis and non-suis strains of
streptococci. Currently, both PlySs1 and PlySs2 are involved in a collaborator’s
ongoing in vivo trial employing experimentally-infected pigs.

Alla mia bella Bamboulaine…
La ragazza più speciale del mondo.
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CHAPTER 1
Phage, Phage Lysins, and
their Molecular Identification

BACTERIOPHAGE AND THEIR BIOLOGY
Nearly a century has now passed since the initial discovery of
bacteriophages, a term that has come to encompass any virus that infects a
bacterial host. In 1915, Frederick Twort reported that filtered suspensions of
environmental samples were capable of producing ―glassy areas‖ on plates of
Micrococcus, and he proposed a bacterial virus as one of several possible causes
(Twort 1915). Two years later, similar findings were reported for enteric bacilli
by Felix d‘Herelle, who was more adamant of the viral nature of the
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phenomenon (1917). It was d‘Herelle, in fact, who originally coined the term
bacteriophage, derived from Greek and signifying bacteria-eater. At that time, it
would have been difficult to predict the global significance of these viruses and
the massive body of research that would go into studying their biology and
applications. Bacteriophages (or phages) are crucial players in bacterial ecology
and pathogenesis; they were important experimental tools in the development of
the modern field of molecular biology; and they—along with the proteins they
produce—can be utilized for various biotechnological and biomedical purposes,
many of which have become evident only recently. It is this latter area of applied
phagology that is the focus of the present thesis.

Bacteriophage taxonomy. Phages can be subdivided into several families (see
Figure 1.1) based on their structural morphology and the nature of their genetic
material (Fauquet et al. 2005). The large majority of the 5000+ phages examined
to date belongs to the order Caudovirales (Ackermann and Abedon 2001), defined
as non-enveloped viruses with protein tails and linear, dsDNA genomes
(ranging from tens to 100+ kb in length). The caudoviruses are further
subdivided into three families based on their specific tail-architecture:
Siphoviridae—long, noncontractile tails; Myoviridae—intermediate length,
contractile tails; and Podoviridae—short, noncontractile tails. Outside the
caudoviruses, there exist several non-tailed families of phages with more
divergent biological properties.
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Myovirus

Podovirus
Siphovirus
Figure 1.1a Phage Morphologies—Caudoviruses
Phage in the order Caudovirales possess linear, dSDNA genomes and
proteinacious tails. The order is divided into the above three families
based on the tail morphology (see text).
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Tectivirus

Corticovirus

Plasmavirus
Figure 1.1b Phage Morphologies—Lipidic dsDNA Phage
The tectiviruses and corticoviruses both possess external icosehedral capsids with a
lipid membrane lying directly beneath (not evident in the above images). The two
families differ in terms of capsid and genome organization. Whereas the
corticovirus genome is circular and highly supercoiled, the tectivirus genome is
linear with terminal inverted repeats.
By contrast, the plasmaviruses possess an external lipid envelope, a pleomorphic
geometry, and a circular genome. They are only known to infect the mycoplasmal
genus Acholeplasma.
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Inovirus (Filamentous Phage)

Microvirus

Figure 1.1c Phage Morphologies—ssDNA Phage
The inoviruses consist of a non-enveloped rod of filaments surrounding a
circular, ssDNA genome. The microviruses possess a linear, ssDNA genome

and a non-enveloped, icosehedral capsid.

5

Levivirus

Cystovirus

Figure 1.1d Phage Morphologies—RNA Phage

The cystoviruses possess a linear, segmented, dsRNA genome. They are
charactarized by a double capsid with a surrounding lipid envelope. The
leviviruses possess a linear, positive-stranded, ssRNA genome and a nonenveloped, spherical capsid.

NOTE: The preceding images were taken, with permission, from the ViralZone

website (www.expasy.org/viralzone, Swiss Institute of Bioinformatics). It should
also be noted that three other phage families are known to exist in addition to the
ones pictures above (Lipothrixoviridae, Fuselloviridae, and Rudiviridae). These
viruses, however, are only known to infect archaea and are not considered here
with the bacteriophage proper.
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These include several other DNA phages: Tectiviridae and Corticoviridae—
dsDNA, possessing a lipid membrane internal to the capsid; Plasmaviridae—
dsDNA, possessing an external lipid envelope; Inoviridae—ssDNA with a
filamentous morphology; and Microviridae—ssDNA with an icosahedral
morphology. Phage families with RNA genomes include: Cystoviridae—dsRNA
with an enveloped capsid; and Levivirus—ssRNA with a non-enveloped capsid.
The caudoviruses possess by far the broadest range of known hosts, and
examples have been defined that infect virtually all bacterial phyla. For any
single caudovirus, however, the host range is often limited to a particular
bacterial species or a subset of strains within that species. Nonetheless, a number
of phages have been observed that infect various species within a given genus or
even across genera (Hyman and Abedon 2010). For the non-caudoviral phage
families, the taxonomic range of hosts (at least among phage isolated to date) is
far narrower. For example, the tectiviruses are the only non-caudoviral family
known to infect Gram-positive bacteria, and several phage families
(plasmaviruses, cystoviruses, corticoviruses) have only been defined for a single
bacterial genus (Fauquet et al. 2005).

Phage life-style. In terms of the bacteriophage lifecycle, various examples have
been observed among the above taxonomic families. These range from
replication and extrusion in the absence of host death (in the case of the
filamentous inoviruses, Calendar and Inman 2005) to rapid and complete host
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lysis. For some of the rarer phage families, relatively few details are known on
the molecular level. And even for the ubiquitous caudoviruses, the majority of
mechanistic information is defined for model viruses (often E. coli  phages), and
these details do not necessarily apply universally. Broadly speaking, though, the
lifecycle of the tailed phages can be broken down into two possible categories:
lytic and lysogenic. The lytic (or virulent) phages co-opt the host‘s
transcriptional apparatus following DNA injection, replicating and assembling
within in the cytoplasm and inducing bacteriolysis from within. Within 30
minutes of initial infection, up to several hundred progeny viruses are released
and the life-cycle begins anew (Karam 1994). Macroscopically, the tell-tale sign
of actively-lysing phages is the clearing zone, or plaque, that results on a lawn of
host bacteria (Figure 1.2). (The molecular mediators of host lysis—phage lytic
enzymes—are the principle focus of this thesis and are described later in much
greater detail).
By contrast, lysogenic (or temperate) phages are faced with a decision
following infection: either they can [1] begin the above lytic cycle or [2] enter into
a proviral state in which their DNA is incorporated into the host genome (Figure
1.3). The latter pathway is possible because these phages encode regulators that
repress transcription of lytic-pathway proteins (Little 2005). Lysogenic phages
also typically encode an integrase that is responsible for the site-specific
recombination of their genome into the bacterial chromosome (van Duyne 2005).
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Figure 1.2 Phage Plaques
In this image, purified lytic phage have been dropped onto a lawn of their host
bacteria. The resulting clearing zones are known as plaques. The majority of the
above plaques are considered macro-plaques; here, the initial titer of phage was so
high that it is impossible to differentiate individual plaque-forming-units (PFUs).
At the bottom of the image, however, several micro-plaques are evident (indicated

with arrow). Each one is derived an single ancestral phage (i.e. each micro-plaque
is clonal). NOTE: The above image originally appeared in Abshire et al. (2005). It
has been reproduced here with permission (American Society for Microbiology,
Licensing Number 2482280006256).
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Figure 1.3 Lysogeny Versus Lysis
Upon initial infection, lysogenic phage may either begin the lytic cycle or enter
into a proviral state (the lysogenic cycle). These alternate pathways are depicted
above for E. coli and its -phage. In the image, the cos site of the phage genome is

noted; this refers to the terminal portions of the linear DNA molecule that
circularize prior to recombination with the host chromosome. NOTE: The above
image originally appeared in Campbell (2003). It has been reproduced here with
permission (Nature Publishing Group, Licensing Number 2482130951344).
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Alternatively, some lysogenic phages do not physically integrate their DNA;
rather, their genomes independently propagate in the host cytoplasm as linear
(Ravin 2003) or circularized (Bourhy et al. 2005) episomes. It must be
emphasized that the individual molecular steps governing lysogenization
represent an expansive field onto itself (Ptashne 1994). Very broadly stated, the
lysogeny-versus-lysis decision is governed by a combination of probabilistic
factors, the number of infecting viral particles, and the host bacterium‘s
metabolic status at the time of infection (Zeng et al. 2010).
Prophages can replicate for numerous generations within the host without
synthesis of progeny viral particles. At some point, however, reactivation may
take place: the phage genome is excised from the chromosome and viral
replication commences, culminating in host lysis. The stimulus for reactivation is
typically DNA damage (chemical or UV-induced) or other physiological
stressors on the host. The best-characterized molecular pathway involves the
bacterial SOS system, a response to damage-induced ssDNA in the cell (Little
and Mount 1982). Even in the absence of stressors, some prophages will reactive
spontaneously within their host, albeit at a far less frequent rate (~10-4 to 10-5
cells, Little 2005).
Conversely, other prophages may remain incorporated for such an
extended period that they decay and lose their ability to reactivate, becoming
defective (or cryptic) (Casjens 2003). More recent research has indicated that
prophage DNA, both intact and defective, may occasionally excise itself from the
11

chromosome without completion of the lytic pathway. This phenomenon was
exploited as an elegant experimental means of curing a polylysogenized bacterial
strain of its prophages in vitro (Euler 2010).
Phage ecology. With the complex interplay between phage and host, it is hardly
surprising that phages are crucial players in the field of microbial ecology. In
fact, the importance of phage in shaping the global microbiome cannot be
understated, especially when one considers the ubiquity of these viruses within
the environment. The numbers that have been reported on the topic are truly
staggering: it is thought that 1031 phage particles exist globally (the majority
residing in the oceans); there are up to 10 phages for every single bacterium on
earth; an estimated 1023 phage infections occur every second; and ~20% of the
marine biomass is turned over every day by phages (Suttle 2007; Hatfull 2008).
Resultantly, phages are major participants in biogeochemical pathways,
particularly when it comes to the solubilization of biomass and the dynamics of
carbon respiration/fixation (Abedon 2006).
On the level of individual bacterial species and their genotypic and/or
phenotypic properties, phages likewise serve crucial roles. In general, the
movement of genetic information between cells via phages, transduction, is one
major modes of horizontal gene transfer that exist for bacteria (Birge 2006). This
includes both generalized transduction, in which bacterial DNA is mistakenly
packaged into the phage capsid, as well as specialized transduction, in which a
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prophage DNA excises itself from the bacterial genome but takes with it a stretch
of adjacent chromosome. Lysogenization in itself can also lead to the acquisition
of important genetic material. Although many viral genes are repressed in the
proviral state (e.g. structural and lytic cassettes), this is not true for all prophage
genes (Canchaya et al. 2004). Various prophage transcripts are expressed,
including ones that can affect the behavior of the host and its ability to survive,
proliferate, and infect (Broudy and Fischetti 2003).
The relationship between lysogenization and bacterial phenotype is
particularly characterized as it relates to the virulence of bacterial pathogens
(Breitbart et al. 2005). A number of pathogenic bacterial species have been
identified for which a crucial virulence factor is prophage-encoded or included
on chromosomal islands that have evolved from prophage (Novick et al. 2010).
These include: shiga toxin for enterohemorrhagic E. coli, cholera toxin for Vibrio
cholera, and superantigents for toxic shock-inducing Streptococcus pyogenes. The
preceding list is far from exhaustive, however, and new phage-encoded
virulence factors are often identified (for a more complete review of the topic,
the reader is referred to Boyd and Brüssow 2002 or Chapters 7 - 18 of Waldor et
al. 2005). Prophages could likewise enhance the ability of bacterial pathogens to
persist in environmental reservoirs, as was recently proposed for Bacillus
anthracis by Schuch and Fischetti (2009).
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PHAGE IN BIOTECHNOLOGY AND BIOMEDICINE
The field of phage biology is clearly diverse, incorporating aspects of
molecular genetics, ecology, and infectious disease. (The discussion to this point
has not even touched upon the areas of bacteriophage evolution and interphage
recombination, see Hendrix 2002 or 2005). At the same time, the above topics are
all connected in that each one attempts to study phages in their own right. Basic
phage research, however, is only one side of the coin as to why investigators are
so interested in these microscopic juggernauts. Since their discovery, phages
have also been utilized as experimental tools for answering broader questions
facing the scientific community. Applied phage research is equally expansive, as
phages and phage-products can serve in a variety of manners as industrial and
biomedical agents. Illustrated in the following section, these other aspects of
phage science have their own rich histories, ones that are still actively unfolding.

Phages and molecular biology. First and foremost, any discussion of phage-astools would be incomplete without mentioning their indispensible role in the
development of the field of modern molecular biology. A number of classic
experiments establishing the molecular principles of genetics were dependent on
bacteriophages as model ―organisms.‖ For instance, the nature of genetic
mutations was revealed by experiments involving the de novo generation of
phage resistance in E. coli (Luria and Delbruck 1943; Lederberg and Lederberg
1952). Following the initial identification of DNA as the heritable genetic
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material (Avery et al. 1944), important confirmatory evidence was provided by
Hershey and Chase using selective radiolabelling of the T2 phage (1952). And
the triplet nature of DNA code was subsequently established by Crick et al. by
observing the altered plaque morphologies following mutagenesis of the T4
phage (1961).
Moving ahead, while the discipline of molecular biology is now wellestablished, phages are still intimately involved in day-to-day research efforts. A
variety of common laboratory reagents (primarily involved in nucleic acid
modification) are recombinantly-expressed enzymes originating from phages.
These include benchtop staples such T4 DNA ligase and polynucleotide kinase,
as well as more recent additions such as Bacillus phage φ29 polymerase (a highly
processive polymerase used in whole-genome amplification). A review of
phage-encoded proteins that could serve as applied tools was recently provided
by Schoenfeld et al. (2010).
It is important to emphasize that a great deal of current research in
molecular biology (including this thesis) involves the functional screening of
DNA libraries to identity proteins with targeted properties. Phage-based cloning
systems are commonplace in this regard. In fact, one of the first widespread
cloning vectors was the E. coli -phage (Chauthaiwale et al. 1992). By inserting a
fragmented DNA library into a specific position in the -genome (followed by in
vitro viral packaging and host infection), one could generate a large set of clonal
plaques, each encoding and expressing a unique recombinant insert.
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In large part, -libraries have given way to other generalized cloning
methods (involving plasmids, cosmids, and artificial chromosomes).
Nevertheless, a related screening technique is still widely used for elucidating
protein-ligand and peptide-ligand interactions: phage display (Paschke 2006;
Gupta et al. 2005). Here, a DNA-library is ligated in-frame with a phage‘s coat
protein (both filamentous and tailed phages have been used). This generates a
set of recombinant phages, which are exposed in bulk to a molecular target
immobilized on a solid interface. Phages that bind the target via their surface
fusion-protein are isolated, enriched, and identified through subsequent rounds
of infection and selection. Outside of basic scientific discovery, applications of
phage display include the identification of drugs and drug targets, as well as the
development of molecular imaging agents (Newton and Deutscher 2008).
Phage typing. While -cloning and phage display involve the generation of
genetically-modified viruses, other important applications utilize wild-type
phages for generating information. In the fields of epidemiology and clinical
microbiology, susceptibility to phage infection is a classic method of typing
bacterial strains on the sub-species level. By analyzing which phages (from a
predefined panel) are capable of infecting a bacterial isolate, it is possible to track
the flow of pathogens within the human population. Most notably, phage typing
is used in the study of Salmonella strains (Threllfall and Frost 1990), although
schemes for other bacteria have been reported (Engel 1978, Mokrousov 2009). In

16

a related application, the specificity that a phage demonstrates for a particular
host can be utilized to identify an unknown bacterial isolate. For example, while
clinical isolations are admittedly rare, a classic test for the positive identification
of B. anthracis involves its susceptibility to infection by -phage (Brown and
Cherry 1955; Abshire 2005). More recently, culture-free methods for the rapid
identification of bacterial pathogens have been developed that rely upon ELISAbased detection of selectively-amplified phages (Rees and Dodd 2006;
www.microphage.com).
Phage therapy. With these diverse applications, researchers have clearly
exploited bacteriophages in creative and sophisticated ways. At the same time,
there exists another avenue of applied phage research that—while tremendous in
its potential benefits—is theoretically quite straightforward. Simply put, phages
have the ability to kill bacteria, and bacteria have the ability to cause infections…
therefore, phages might be used to treat infections! In fact, the idea of phage
therapy dates back nearly as long as the discovery of phages themselves. Shortly
after his (co)discovery of these viruses, d‘Herelle began employing them to treat
human infections, often with a great deal of reported success. These include his
oft-cited application of phages to treat cases of Shigella dysentery in Paris in 1919,
as well as later work with cholera and plague patients in India (Summers 1999).
In 1923 he founded along with Georgian microbiologist Giorgi Eliava (who
shortly after was executed by Stalin-era Soviet agents) the International
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Bacteriophage Institute in Tbilisi, a center dedicated to phage-based treatment of
infectious disease.
In the years that followed, the future for phage-as-pharmaceuticals
seemed incredibly bright. (For more detailed historic and scientific information
on phage therapy—from its beginnings to the present day—the reader is referred
to numerous recent review articles and book chapters: Abedon et al. 2010 and
accompanying articles; Górski et al. 2009; Housby and Mann 2009; Górski 2007;
Merril et al. 2006; Sulakvelidze and Kutter 2005; McKinstry and Edgar 2005;
Sulakvelidze et al. 2001; Chanishvili et al. 2001; Summers 2001; Carlton 1999). By
the early 1940‘s, more than 100 publications had been devoted to phage therapy
(Krueger and Scribner 1941; Eaton and Bayne-Jones 1934), and pharmaceutical
companies had begun marketing phage-based products in several countries
(L‘Oréal in France, Behringwerke in Germany, and Eli Lilly in the United States)
(Häusler 2006).
Unfortunately, the results and reception of this initial work was mixed at
best, with variable treatment success-rates and much skepticism among the
scientific community. In retrospect, many of the initial problems can be
attributed to poor purification quality, a lack of proper control groups in clinical
trials, and insufficient understanding of phage biology (e.g. using lysogenic
phage instead of strictly lytic phage) (Housby and Mann 2009; Sulakvelidze et al.
2001). Nevertheless, these results soon lead to the abandonment of phage-
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therapy research in Western countries, especially in light of the development of
small-molecule antibiotics that occurred around the same time.
By contrast, phage therapy continued unabated in Eastern Europe during
the decades that followed. This work was especially prominent at the
aforementioned International Bacteriophage Institute in Georgia (now known as
the Eliava Institute, www.eliava-institute.org) as well as at the Hirszfeld Institute
of Immunology and Experimental Therapy in Wroclaw, Poland
(www.aite.wroclaw.pl/phages/phages.html). Over the years, these centers
reported numerous successful trials for various combinations of Gram-positive
and Gram-negative pathogens and anatomic sites of infection (Sulakvelidze et al.
2001). Due to language barriers and cold-war era geopolitical realities, however,
few of the results reached (or were evaluated by) Western scientists at the time
the research was conducted. It is only recently, in fact, that many written
accounts of Eastern European phage therapy are starting to become available to
the English-speaking world (Chanishvili 2009).
This broadened access to data has corresponded to a rekindled global
interest in phage therapy. Changing attitudes have been motivated largely by
the emergence of antibiotic-resistant bacterial pathogens (Wax et al. 2008), along
with the decreasing efficiency and profitability associated with the development
of new small-molecule antibiotics (Donadio et al. 2010). In this light, Western
scientists began reconsidering phage therapy in earnest during the 1980‘s and
90‘s. The initial focus was on animal models of human disease, including rodent
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and ruminant models of E. coli and Pseudomonas aeruginosa infections (Smith et al.
1982; Smith et al. 1983; Soothill 1994). Subsequent model studies dealt with other
pathogen-animal combinations; a summary of this work was recently provided
by O‘Flaherty et al (2009).
Moving ahead rapidly, phage-therapy research in Western nations has
now progressed to actual human trials. The first double-blinded clinical study
involving phage therapy was recently completed in the United Kingdom (Wright
et al. 2009). This phase II trial, which involved 24 patients with chronic P.
aeruginosa otitis media, demonstrated both efficacy and safety in treated patients
versus controls. Although efficacy data is still pending, a phase I safety trial was
likewise recently completed in the United States involving phage treatment of
venous leg ulcers (Rhoads et al. 2009). In addition to these studies, done in
association with (respectively) BioControl Limited and Intralytix Incorporated, a
number of other biotechnology companies have recently been established that
are developing phage-therapy products in pre-clinical phases (reviewed in
Housby and Mann 2009).
One should note that this research is taking place alongside—and, often,
in collaboration with—the continued use of phage therapy in its traditional
Eastern European bastions. For instance, a clinical trial is currently underway
involving the Eliava Institute and Belgian physicians to treat burn infections with
a cocktail of Staphylococcus and Pseudomonas phages, and initial quality-control
data has already been reported (Merabishvili et al. 2009). Various other
20

examples of current phage therapy can be found in the above-mentioned review
articles. A corollary message to all this work is that, if an individual patient is
interested in phage therapy—and is willing to travel and pay—various avenues
presently exist for obtaining it (www.phagetherapycenter.com).
It is important to emphasize that the potential utility of phage therapy
extends beyond the treatment of human disease. Naturally, the same basic
principles that apply to infections in man also apply to veterinary infections, and
phage therapy has been explored as a novel means of treating disease in
livestock and poultry (Johnson et al. 2008). The use of phage to treat plant
pathogens is likewise an intriguing possibility (Balogh et al. 2010), and EPAapproved phage cocktails are already commercially available for controlling
Xanthomonas and Pseudomonas infections (i.e. bacterial speck) in tomato and
pepper plants (omnilytics.com/products/agriphage/agriphage4.html). In
general, phage therapy shows great promise in the field of food science, as the
viruses could be used to prevent spoilage or to curtail the transmission of foodborne illness. Just recently, in fact, the Food and Drug Administration approved
a cocktail of Listeria phage for use as an additive to commercial meat and cheese
products (FDA Code of Federal Regulations 21CFR172.785).
At this point, it is worthwhile to consider briefly the relative pros and cons
of using purified phages as antibacterial agents. These points are summarized in
Table 1.1.
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Phage advantages

Phage disadvantages

Easy to isolate and propagate

More complex pharmacology than
traditional small-molecule antibiotics

Can overcome resistance

Potentially immunogenic

Self-replicating

Subject to degradation as
proteinacious compounds

Act synergistically in a cocktail
or in combination with other
antibiotics

Need to select for virulent phage to
prevent genetic transfer

Inhibits Gram-positive and
Gram-negative organisms

Bacterial strains can develop
resistance

Some phage products already
have regulatory approval

Many phages can have a limited
host range

Potential for use in numerous
environments (human, animal,
food, biofilm, etc.)

Broader regulatory and consumer
acceptance still required

Historically have been in use for
nearly a century
Possibility to genetically
engineer phage
Specific bacterial targets

Table 1.1 Advantages and Disadvantages of Phage Therapy
This table was adapted from O’Flaherty et al. (2009) with permission (John Wiley
and Sons, Licensing Number 2486030498200).
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The biggest advantage to phage therapy is largely self-evident: namely, that
phages provide an alternate mechanism for killing bacterial pathogens,
particularly those that already demonstrate antibiotic resistance. Phages also
represent a unique sort of smart antibacterial agent whose concentration naturally
amplifies itself at the relevant site of infection. Moreover, given their host
specificity, phages should not affect commensal and probiotic human flora in the
same manner as traditional antibiotics, a relevant issue given the increasing
prevalence of antibiotic-associated illnesses such as Clostridium difficile-associated
enteritis (Kuijper et al. 2006).
An inherent corollary to the latter point is that phage therapy is inherently
not broad-spectrum, and could not be employed for empiric therapy before the
causative species of an infection is defined. Likewise, even for a particular
bacterial species, not all strains are equally susceptible to different phages. This
would necessitate the use of phage cocktails to ensure coverage, a practice that is
already common in ongoing trials. If phage therapy were to become widespread,
an additional concern would involve the potential development of resistance
among bacteria. As with small-molecule antibiotics, bacteria are known to
possess several mechanisms for acquiring resistance to phage infection. These
include the variation of surface epitopes (for initial phage binding), the
horizontal acquisition of restriction enzymes, and the use of CRISPR genomic
sequences (Hyman and Abedon 2010).
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Outside these hurdles, the fact the phages are proteinacious particles
naturally confers more complicated pharmacological parameters (involving
application, biodistribution, biodegradation, and possible immunogenicity).
Overall, while such drawbacks would likely preclude it from supplanting the
role of antibiotics entirely, phage therapy could still serve as an important
supplementary treatment strategy, particularly in the case of chronic infections
or when initial options fail.

THE LYTIC ENZYMES OF BACTERIOPHAGES
Although it could be considered in a state of product development for nearly
a century, phage therapy (at least the idea behind it) is a long-established
antimicrobial strategy. At the same time, it is not the only phage-based approach
for fighting bacterial pathogens. More recently, another strategy has arisen that
does not utilize phages in their entirety, but rather a particular class of phageencoded proteins: the phage lytic enzymes (also known as phage lysins, endolysins,
or just lysins). As described previously, the final stage of infection for tailed
phages involves the lysis of the host cell with release of viral progeny—the phage
lytic enzymes are molecular facilitators of this event.
These enzymes are expressed late in the cycle of phage infection, and they
are responsible for digesting the peptidoglycan of the host bacterium. This
compromises the strength of the cell wall and subjects the bacterium (which
experiences positive turgor pressure up to 25 atmospheres) to immediate osmotic
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lysis (i.e. bacteriolysis-from-inside). Biotechnological interest in phage lysins has
peaked in recent years after it was shown that exogenously-applied lysin can
effectively kill Gram-positive bacteria (i.e. bacteriolysis-from-outside). This
phenomenon has forced phage lysins into the spotlight as potential anti-infective
agents in their own right, and has sparked a general interest in enzyme-based
antibiotics, or enzybiotics. (As with phage therapy, a number of recent reviews
have examined the biology and applications of phage lysins, including: Fischetti
2010; Villa and Veiga-Crespo 2010; Courchesne et al. 2009; O‘Flaherty et al. 2009;
Fischetti 2008; Hermoso et al. 2007; Fischetti et al. 2006; Borysowski et al. 2006;
Fischetti 2005a; Fischetti 2005b; Young 2005; and Loessner 2005).
The concept of lysin therapy. The ability of phage lysins to act as antibacterial
agents is fundamentally linked to the structure of the bacterial cell envelope. As
noted above, the potential targets for lysin therapy would be limited to Grampositive species. Without an outer membrane, their peptidoglycan layer is
directly accessible to lysin treatment from the extracellular space. Gram-negative
bacteria, by contrast, are generally insensitive to lysin treatment due to the
protective effect of their outer membrane1. Despite a narrower target range, lytic
enzymes do offer an important advantage over intact phage: while bacteria have
co-evolved with predatory phage for millions of years (hence their resistance
mechanisms), exogenous lysin treatment is an unnatural phenomenon.
Consequently, the development of resistance should not occur readily— to date,
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acquired lysin resistant has not been observed in experimental trials (Loeffler et
al. 2001; Schuch et al. 2002). Other relative advantages and disadvantages of
phage lysin therapy are listed in Table 1.2.
Like intact phage, purified lytic enzymes would provide an alternative
bactericidal mechanism for antibiotic-resistant pathogens. Much of the
excitement surrounding these enzymes stems from the potency and specificity
they demonstrate toward their particular Gram-positive targets. In buffered
solutions (referred to as in vitro conditions), lysins exert a rapid lethal affect at
low g/ml-concentrations (Schuch et al. 2002; Porter et al. 2007), sometimes even
less (Nelson et al. 2001). Within minutes or seconds of lysin addition, a
concentrated solution of live Gram-positive bacteria will undergo a several log
decrease in viability with complete loss of turbidity (see Figure 1.4). Typically, a
given lysin demonstrates activity against the bacterial species that the encoding
phage infects (Loeffler et al. 2001), although some cross-reactivity can exist
toward other species within the same genus or related genera (Nelson et al. 2001;
Yoong et al. 2004). In the following paragraphs, I will provide a broad overview
of the lysin field, including their biochemistry, genetics, and development as
applied biomedical tools.
Lysin enzymology. A particular phage lysin can target one of several bonds
within the peptidoglycan (or murein) macromolecule (Figure 1.5).
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Lysin advantages

Lysin disadvantages

Not self-replicating, more
targeted defined control

Not self-replicating

Protein therapeutic

Protein; therefore, susceptible to
inactivation

Resistance not yet reported

To date not yet successfully applied
against Gram-negative bacteria

Possibility to genetically
engineer lysins

Potentially immunogenic

Specific bacterial targets
Could be used as a prophylactic
and for treatment

Table 1.2 Advantages and Disadvantages of Lysin Therapy
This table was adapted from O’Flaherty et al. (2009) with permission (John
Wiley and Sons, Licensing Number 2486030498200).
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Figure 1.4 Bacteriolytic Acitivy of Phage Lysins
Depicted here is the effect of the PlyG lysin (encoded by the -phage) on B. anthracis.
[A] Untreated cells, phase contrast microscopy (PCM); [B] 1 min post-treatment,
PCM; [C] 15 min post-treatment, PCM; [D] 1 min post-treatment, transmission
electron microscopy (TEM); [E] 10 min post-treatment, TEM. Overall, by 1 min posttreatment, the cells’ gross morphology is compromised and cytoplasmic contents are
budding through the cell wall (arrows). By 10 min, the cell wall is largely digested
and only cellular ghosts remain. NOTE: The above image originally appeared in
Schuch et al (2002). It has been reproduced here with permission (Nature Publishing
Group, Licensing Number 2482150387937).
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Transglycosylase

Glucosaminidase

MurNAc
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GlcNAc
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CrossCross-Bridge
Endopeptidase

Figure 1.5 Bond Specificity of Phage Lysins

A summary of the chemical structure of peptidoglycan is depicted above (MurNAc =
N-acetyl-muramic acid; GlcNAc = N-acetyl-glucosamine). Bonds targeted by known
phage lysins are designated with an arrow. To date, lysins have been identified that
target nearly every backbone, stem, and cross-bridge position within the
macromolecule. The reader should note, however, that the above image is
oversimplified: the identity of the cross-bridge (denoted here as X-X) can vary

considerably among bacterial species. In Gram-negative organisms (and some Grampositive ones), there is a direct cross-bridge between the position #3 and position #4
stem peptides. The identity of the stem peptides themselves can likewise differ after
the position #1 L-Ala (see Vollmer et al. 2008 for examples).
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The nomenclature of these enzymes is admittedly rather complex and (at times)
inconsistent, but can generally be categorized as follows (Fischetti 2008). [1]
Muramidases (also referred to as muraminidases or lysozymes) cleave the 1-4 bond
between N-acetylmuramic acid (MurNAc) and N-acetyl-glucosamine (GlcNAc).
[2] Glucosaminidases cleave the 1-4 GlcNAc-MurNAc bond. [3] Lytic
transglycosylases (LTs) cleave the 1-4 MurNAc-GlcNAc bond and reform a 1,6anhydrobond within MurNAc (i.e. they do not generate a reducing end). [4]
Alanine-amidases cleave the amide bond between the C3-lactate of MurNAc and
the -position L-alanine of the pentapeptide stem. [5] Endopeptidases cleave
subsequent peptide bonds within the pentapeptide stem (- or -positions) or the
interstem cross bridge. The specific designation of an endopeptidase (e.g.
glycine-glycine endopeptidase or alanoyl-glutamate endopeptidase) depends on
its site of cleavage and the identity of the particular peptides, which vary from
bacteria to bacteria (Vollmer et al. 2008a).
Muramidases, glucosaminidases, and LTs are collectively referred to as
endoglycosylases, as they target the carbohydrate backbone of peptidoglycan at
internal positions of the chain. Moreover, with the exception of the LTs, all
phage lysins are also considered hydrolases based on their mechanism of bond
cleavage. Collectively, people often refer to lysins as peptidoglycan hydrolases or
murein hydrolases—rigorously speaking, this is incorrect due to the existence of
LTs. Practically, though, this is of minor consequence concerning the role of
lysins as enzybiotic agents.
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Another noteworthy distinction involves the difference between enzymatic
activity and protein domain. The enzymatic region of most phage lysins can be
categorized into one of various conserved domains. The bond specificity of the
lysin, however, does not always correspond one-to-one with the identity of this
domain. For instance, among the muramidase lysins that target the MurNAcGlcNAc bond, some possess enzymatic domains that belong to the ―phage
lysozyme‖ family (Weaver and Matthews 1987), while others possess domains of
the ―glycosyl-hydrolase type 25‖ family (Porter et al. 2007). These two domains
diverge sequentially and structurally, but still catalyze the same reaction.
Conversely, CHAP domains have been described among different lysins that
function alternatively as alanine-amidases (Nelson et al. 2006) or endopeptidases
(Becker et al. 2009).
A complete list of enzymatic domains found in phage lysins is provided in
Table 1.3, along with their corresponding bond specificities and representative
examples. The domains are listed according to their Pfam nomenclature (Pfam is
a central database of conserved protein domains—Finn et al. 2010,
pfam.sanger.ac.uk). One should note that, even for a particular enzymatic
domain, primary sequence diversity does exist from lysin to lysin, reflecting the
evolutionary accumulation of mutations. Generally speaking, the degree of
sequence homology between two domains of the same family reflects the
phylogenetic closeness between the encoding phages.
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Pfam
Accession

Domain

Phage Lysozyme

PF00959

Bond
Specificity

Example

Reference

Muramidase

E. coli T4 lysin
[NP_049736]

Inouye and
Tsugita 1966

E. coli  lysin
[NP_040645]

Taylor et al.
1975.

Lytic
Transglycosylase

Soluble Lytic
Transglycosylase

PF01464

Lytic
Transglycosylase

P. aeruginosa KZ144 lysin
[AAL83045]

Briers et al. 2007

Glucosaminidase

PF01832

Glucosaminidase

S. agalactiae LambdaSA2 lysin
[NP_688827]

Pritchard et al.
2007

Glycosyl Hydrolase,
Type 25

PF01183

Muramidase

S. pneumoniae Cp-1 lysin
(CPL-1) [NP_044837]

García et al.
1988

Amidase, Type 2

PF01510

Alanine-amidase

B. anthracis  lysin (PlyG)
[YP_338200]

Schuch et al.
2002

Amidase, Type 3

PF01520

Alanine-amidase

C. perfringens phi3626 lysin
(Ply3626) [NP_612849]

Zimmer et al.
2002b

Alanine-amidase

S. pneumoniae Dp-1 lysin
(PAL) [O03979]

Sheehan et al.
1997

S. agalactiae LambdaSA1 lysin
[NP_687631]

Pritchard et al.
2007

S. dysgalactiae C1 lysin (PlyC)
[AAP42310]

Nelson et al.
2006

S. aureus K lysin (LysK)
[YP_024461]

Becker et al.
2009

Amidase, Type 5

PF05382

Endopeptidase
(-position)

Alanine-amidase
CHAP

PF05257

Endopeptidase
(various positions)

VanY

PF02557

Endopeptidase
(-position)

L. monocytogenes A500 lysin
(Ply500) [YP_001468411]

Korndörfer et al.
2008

M23 Peptidase

PF01551

Endopeptidase
(cross-bridge)

See Caption

See Caption

U40 Peptidase

PF10464

Endopeptidase
(unknown
specificity)

P. aeruginosa 6 lysin
[P07582]

Caldentey and
Bamford 1992

Predicted Lysozyme
(DUF847)

PF05838

Unknown
Muramidase

P. aeruginosa 8 lysin
[NP_524573]

Pei and Grishin
2005

(see caption)

Table 1.3 Conserved Enzymatic Domain within Phage Lysins
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Table 1.3, continued
This table lists the enzymatic domains commonly encountered in phage lysins.
For each domain, the pfam accession number is provided, along with a
representative example among lysins whose properties have been studied
recombinantly (the GenBank accession number of these is given in brackets).
The table also lists the enzymatic specificity for each domain. As is evident,
certain reactions can be catalyzed by more than one domain. In some instances,
a conserved given domain is known to catalyze two different reactions,
depending on the particular enzyme in which it is found. In these instances, an
example is given for each reaction type. For the cross-bridge endopeptidases, a
particular bond is not specified, as the nature of this bond varies considerably
among different species.

For one domain (M23 endopeptidase), no representative example is given. No
definitive phage lysins have (as of yet) been characterized that possess this
domain. Nonetheless, M23 demonstrates peptidoglycan hydrolase activity in
well-characterized non-phage enzymes (for instance, lysostaphin—see Kumar
2008), and the domain can be identified in the sequences of putative phage
lysins. To date, the U40 endopeptidase has only been identified in the genome
of a single dsRNA cystovirus. The DUF847 domain has been identified in a
cystovirus and several caudoviruses (all Gram-negative), and muramidase
activity was recently confirmed in one of the latter (Stojković and RothmanDenes 2007).
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Lysin architecture. For Gram-positive lysins, the enzymatic domain is one
component of a larger overall architecture. As shown in Figure 1.6, these
proteins possess modular structures that typically combine an N-terminal
enzymatic domain with a C-terminal binding domain (Fischetti 2008). The latter
recognizes (at nanomolar affinities) one of various epitopes within the target-cell
envelope. These include surface carbohydrates (Loessner et al. 2002), choline
moieties (García et al. 1990), or peptidoglycan itself (Buist et al. 2008). Like the
enzymatic domains, the binding domains are also categorized into conserved
protein families, a list of which is provided in Table 1.4. For certain domains
shown in the table, the specific molecular target has not yet been defined
experimentally. For some phage lysins, moreover, an extended C-terminal
region is present, but cannot be identified computationally as a conserved
domain. Most likely, these regions do serve binding functions, albeit ones that
have not yet been identified/classified in an organized manner.
For a given bacterial species, it is not uncommon for its phage lysins to
include various combinations of enzymatic and binding domains. For instance,
one lysin might combine an N-terminal muramidase domain with a C-terminal
SH3 domain, while another will combine an alanine-amidase with the SH3
domain (see Chapter 2). In general, phage genomes are modular and are known
to evolve through extensive inter-phage recombination (Hendrix 2005).
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Typical Gram-Positive Lysin

Typical Gram-Negative Lysin

Figure 1.6 Modular Architecture of Phage Lysins
Typically, lysins for Gram-positive bacteria are characterized by an N-terminal
enzymatic region and a C-terminal binding region. There are a variety of
possibilities as to the particular identity of these domains (see Tables 1.1a and
1.1b for examples). Gram-negative bacteria are generally comprised of an
enzymatic domain alone. It should be noted, however, that examples of lysins
do exist (both Gram-positive and Gram-negative) that do not conform to these
standard architectures. These atypical enzymes are discussed at various points
throughout the text (in particular, see Chapters 4 and 5).
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Domain

Pfam
Accession

Binding Target

Example

Reference

Cell Wall Binding
Repeat

PF01473

Choline

S. pneumoniae Cp-1 lysin
(CPL-1) [NP_044837]]

García et al.
1988

CPL-7

PF08230

Unknown

S. pneumoniae Cp-7 lysin
(CPL-7) [P19385]

García et al.
1990

LysM

PF01476

Peptidoglycan

L.fermentum PYB5 lysin
(Lyb5) [ABP88927]

Hu et al. 2010 ;
Buist et al. 2008

Amidase-2
Associated domain

PF12123

Surface
carbohydrate
(GlcNAc-ManNAc)

B. anthracis  lysin (PlyG)
[YP_338200]

Schuch et al.
2002 and
personal
communications

SH3, Type 3

PF08239

Unknown, perhaps
surface protein

C. perfringens 13124 prophage
lysin (PlyCM) [YP_685420]

Chapter 2

SH3, Type 5

PF08460

Unknown, perhaps
surface protein

B. anthracis BG-1 lysin
(PlyBeta)
[EU258891]

Schmitz et al.
2008

PG-1

PF01471

Peptidoglycan

P. aeruginosa KZ144 lysin
[AAL83045]

Briers et al. 2007

PG-3

PG09374

Presumptively
peptidoglycan

P. aeruginosa 8 lysin
[NP_524573]

Pei and Grishin
2005

Table 1.4 Conserved Binding Domains within Phage Lysins
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Table 1.4, continued
Listed here are binding domains (both experimentally-confirmed and
presumptive ones) utilized by phage lysins. Domain accession numbers,
representative examples, and corresponding references are provided. For
cases in which a specific molecular target has been identified, this moiety is
also given. Overall, several caveats must made about this list. First, it is
important to emphasize that it is far from complete. Numerous Gram-positive
lysins—both confirmed enzymes and putative ones for which only a genetic
sequence is known—possess extended C-termini for which no pre-classified
domain is (yet) identifiable bioinformatically.

Second, for a given domain, the precise molecular target is not necessarily

identical in every instance. For example, the amidase 2-associated domain
targeted GlcNAc-ManNAc residues in the B. anthracis strain in which it was
characterized. Although it is likely a carbohydrate-binding domain
universally, the precise glycosidic signature recognized could vary from
species to species (reflecting the primary sequence diversity within the domain
itself). Finally, for the last two domains listed, the specific examples represent
atypical examples of Gram-negative lysins with binding domains. For PG-1,
Gram-positive lysins have also been identified with the domain (for instance,
see Chapter 4). For PG-3, however, the only lysins known to possess it are
Gram-negative (in fact, the example given is encoded by a dsRNA phage,
although known caudoviral sequences also exist).
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Presumably, these cut-and-paste lysin structures resulted from successful
recombination events that occurred within the coding region of the lysin gene
itself.
A general paradigm in lysin research is that the binding domain is largely
responsible for the specificity an enzyme demonstrates toward its particular
Gram-positive target. This concept derives from two different lines of
experimentation. First, it has been demonstrated with various lysins that
truncating the protein after its enzymatic domain greatly diminishes its
bacteriolytic activity (Schuch et al. 2002; Porter et al. 2007). Second, in
experiments with Lactococcus lactis and Streptococcus pneumoniae lysins, the
enzymatic domain of one protein was recombinantly fused with the binding
domain of the other (Sheehan et al. 1996). The authors observed that the latter
domain was sufficient to maintain bacteriolytic activity, even when paired with
an unnatural partner.
It should be emphasized, however, that these statements regarding the
molecular basis of lysin specificity should be taken as common principles and not
universal facts. Given the tremendous diversity of phage, one generally finds that
every so-called rule in phage research has its noteworthy exceptions.
Accordingly, some lysins maintain high activity even with a deleted binding
domain (Horgan et al. 2009). And chimeric lysins have been observed that fail to
effectuate the lysis of either original bacterial species (unpublished observations
and personal communications).
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Although Gram-negative lysins have not (as of yet) demonstrated great
potential as enzybiotic agents, it is worth considering their structural
architecture. Unlike Gram-positive lysins (250 - 400 amino acids), Gram-negative
lysins are typically smaller (150 – 200 amino acids) and consist of an enzymatic
domain alone (see Figure 1.6, Young et al. 2005). In this regard, they more
closely resemble the nonspecific peptidoglycan hydrolases encoded by
eukaryotic organisms, such as animal and plant lysozyme. Overall, there are
several possible explanations for the lack of Gram-negative binding domains.
Given the relative thinness of Gram-negative peptidoglycan (as little as a single
layer) and its lack of decoration with associated molecules, a non-specific lysin
might be all that is required to compromise envelop integrity (Schmitz et al.
2010b). By contrast, Gram-positive peptidoglycan is sufficiently thick (~40
layers) that the extra lytic potency/specificity afforded by the binding domain
might be necessary for lysis.
An alternative (or complementary) explanation could involve the
potential effect of free lysin in a phage-infected Gram-positive population
(Loessner et al. 2002). After bacterial lysis, it is to the advantage of the progeny
phage to locate other viable bacteria so that the infective cycle can expand.
Soluble lytic enzyme, however, would compromise the viability of nearby cells
and prevent them from becoming new hosts. In this regard, the enzyme‘s
binding domain could keep it tethered to the remnants of lysed bacteria,
functionally inactivating it. For Gram-negative bacteria, the outer membrane
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desensitizes the cells to the effect of exogenous lysin in the first place. So even if
molecules of lytic enzyme are diffusing in their vicinity, the cells would remain
viable.
One should note that the above scenarios remain only theories and have
yet to be confirmed with experimental evidence. On the whole, the in vivo
function of the binding domain remains somewhat obscured by the fact that
Gram-positive lysins have only been studied in the context of recombinant
expression and exogenous treatment. To date, the effect of binding-domain
deletions and chimeras has never been investigated in actively-propagating
Gram-positive phages (Young 2005). The situation is further complicated
because—as more and more enzymes are characterized—Gram-negative lysins
have been identified that do, in fact, encode short N-terminal (Briers et al. 2007)
or C-terminal (Pei and Grishin 2005) binding domains. Just as before, the
traditional rules on lysin architecture (as depicted in Figure 1.6) seem full of
apparent exceptions. The same is true for Gram-positive lysins, some of which
contain multiple enzymatic domain (Baker et al. 2006; Pritchard et al. 2007;
Cheng and Fischetti 2007; Becker et al. 2009) or even multimeric subunits (Nelson
et al. 2006).
It is important to emphasize that the component domains listed in Tables
1.3 and 1.4 (both enzymatic and binding) are not exclusive to phage lytic
enzymes. Bacteria themselves encode chromosomal peptidoglycan hydrolases
that are involved in processes such as bacterial growth, division, sporulation,
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and signaling (Vollmer et al. 2008b). Collectively, these enzymes are known as
autolysins, and they can share many of the same domains as phage lysins proper.
In fact, it is thought that phage lysins co-evolved with (or perhaps co-opted) the
autolysins of their bacterial hosts (López et al. 1997). In terms of their modular
architectures, some Gram-positive autolysins share an N-terminal-enzymatic-Cterminal-binding arrangement (García et al. 1985); for many others, however, the
combination of domains is more diverse. Finally, even within phage genomes
themselves, other structural proteins can include peptidoglycan-hydrolase
domains. In particular, tail fibers often contain lytic components that participate
in the process of initial DNA injection (Kanamaru et al. 2004; Kenny et al. 2004;
Piuri and Hatfull 2006). Enzymatic head proteins have likewise been identified
(Moak and Molineux 2004).

Lysin-associated proteins. Although lytic enzymes are ultimately responsible
the affecting bacterial lysis during phage infection, they are not capable of this
phenomenon by themselves. As with all bacterial proteins whose site of activity
is external to the cytoplasmic membrane, the lysins need a mechanism for
traversing this hydrophobic barrier. Unlike bacterial autolysins, which are
typically secreted by the type II sec-mediated pathway, the phage lysins depend
on accessory proteins known as holins (for reviews, see Gasset 2010; Young and
Wang 2006; Young 2005; Wang et al. 2000).
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These transmembrane proteins (typically 50 – 150 amino acids in length)
insert into the cytoplasmic membrane and create lesions (i.e. death rafts) through
which the lysin can diffuse to access the peptidoglycan. The holins, in fact, are
ultimately responsible for the timing of lysis during phage infection. During the
late stage of phage-gene transcription, lytic enzyme accumulates for a period of
time within the bacterial cytoplasm. The actual moment of lysis does not
correspond to a particular lysin concentration, but rather the rapid formation of
holin-induced pores.
While the holins have a conserved (and relatively simple) biological
function, their biochemical specifics are notably complex. Structurally, holins are
organized into three classes based on whether they are comprised of one, two, or
three transmembrane α–helices (four-TM holins have also been observed). On
the level of primary sequence, however, these proteins are remarkable for the
dissimilarity that individual holins can demonstrate toward one another, so
much so that holins have been called ―arguably the most diverse functional class
of proteins known in biology‖ (Young 2005).
The regulation of holin activity is an intricate process involving the
physical interaction of the holin with an additional protein, the antiholin, within
the cytoplasmic membrane. In many cases, the antiholin is encoded by the same
gene as the holin itself, and simply represents transcription from an alternate
start codon (Bläsi and Young 1996); in other cases, it is encoded by an
independent gene (Ramanculov and Young 2001). Overall, the formation of
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functional membrane lesions is thought to depend on the holin-antiholin ratio,
although the mechanistic specifics are variable from phage to phage, often poorly
defined, and beyond the scope of the present text (see the review articles cited
above for additional information).
Once again, it is worth noting that certain phage have been identified
where the typical relationship between lysin and holin does not necessarily
apply. A phage infecting the Gram-positive bacterium Oenococcus oeni encodes a
lysin with a canonical signal peptide for the sec-mediated secretion pathway
(Parreira et al. 1999). Likewise, a secreted autolysin of Enterococcus faecalis was
recently shown to correspond to the lytic enzyme of an integrated prophage; it,
too, includes an N-terminal signal peptide (Mesnage et al. 2008). Interestingly,
both the Oenococcus phage and the Enterococcus prophage also encode putative
holins, and it remains unclear the role of this apparent secretory redundancy.
Another variant situation exists for a group of Gram-negative phages (first
defined for the E. coli P1 phage) whose lysins encode an N-terminal signal-arrestand-release (SAR) sequence (Xu et al. 2004). Although the host‘s sec system
initially engages and exports these lysins, signal peptide cleavage does not occur.
Instead, the lysins remain tethered to the membrane as inactive, periplasmic
proteins. For these phages, the holins (known as pinholins) function by
depolarizing the membrane without the formation of macromolecular lesions
(Park et al. 2007). This effect, however, is sufficient to release the lysins from
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their membrane-bound state, thereby activating the enzymes and inducing
bacterial lysis.
In addition to the holin and lysin, Gram-negative phages can encode two
additional lysis-related proteins that are responsible for destabilizing the outer
membrane (Young 2005). Generically, these proteins are referred to as Rz/Rz1like proteins, after the first such examples to be identified in the E. coli  phage
(Young et al. 1979; Zhang and Young 1999). Rz is anchored to the cytoplasmic
membrane, while Rz1 is an outer membrane-associated protein. The two are
believed to physically interact in the periplasmic space, leading to the
juxtaposition and fusion of the two membranes (Berry et al. 2008). Phages with a
defective Rz/Rz1 cassette are capable of lysis and propagation, but are inhibited
by the extracellular presence of divalent cations (Young et al. 1979).
In terms of their primary sequence, these proteins (much like the holins)
are quite divergent from one another. After the initial identification of Rz/Rz1, a
paucity of homologues was identified in other Gram-negative phages. However,
more recent bioinformatic predictions (combining topology and genomicarchitecture analysis) have revealed that orthologous proteins are nearly
ubiquitous in sequenced Gram-negative phage (Summer et al. 2007). For some
phages, the Rz/Rz1-like proteins seem to be combined as a single polypeptide (a
spanin) that interacts simultaneously with the inner and outer membrane.
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Genomic arrangement of phage lysins. As the preceding sections indicate, at
least two (and sometimes more) proteins are involved in host-cell lysis during
phage infection. It is worth considering the genes that encode these proteins
and, specifically, their proximity within the viral genome. This issue is
particularly relevant to Chapter 4 of the present thesis. If one had to designate a
standard genomic arrangement for lysin-associated genes, it would be as follows
(Wang et al. 2000). The holin/antiholin-encoding ORF is located immediately
upstream and in the same orientation as the lysin-encoding ORF (sometimes the
two reading frames overlap by several nucleotides). These two genes are thus
under control of the same late-stage promoter. In Gram-negative phage, the Rz
and Rz1 genes would also be located nearby (either upstream or downstream),
and often the Rz1 gene is embedded within the Rz gene in a different reading
frame (Summer et al. 2007). These standard genomic architectures are depicted in
Figure 1.7.
Yet again, though, various other arrangements have been reported for
both Gram-positive and Gram-negative phages. These include examples where
the lysin is encoded immediately upstream of the holin, where the lysin and
holin are separated from one another (Dunn and Studier 1983; Schuch et al.
2004), where the holin gene is imbedded within that of the lysin (Loessner et al.
1999), and where the phage encodes two putative holins (Delisle et al. 2006) or
two lysins (van der Ploeg 2007).
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Figure 1.7 Genomic Architecture of Lysin-Associated Genes
The standard genomic relationship among lysin-associated genes is depicted
here. The holin-encoding gene is encoded immediately upstream from the
lysin-encoding gene, and both are under control of the same late-stage
promoter. Often, the holin-encoding gene also encodes the regulatory antiholin:
transcription of the entire ORF yields the antiholin, while transcription from an
alternate stat codon (anywhere from 2 – 10+ amino-acid residues downstream)
yields the holin. In Gram-negative phage, the OM-disrupting genes (Rz/Rz1)
are also frequently encoded nearby. Here, they are depicted immediately
downstream from the lysin, the arrangment found in the E. coli  phage (Young
2005). Overall, it is important to emphasize that the above arrangements for
these genes do not hold true universally. Various other potential architectures
are cited in the text.
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In addition, several phage genomes have been sequenced that (based on
homology analysis) do not seem to encode a lytic enzyme at all (Scholl et al.
2004). Several possibilities could explain this apparent omission. These phages
could encode completely novel lysins that do not correspond to any known
enzymes. Alternatively, they might utilize a structural peptidoglycan hydrolase
(i.e. a tail-lysin) as the lytic agent, or rely upon an endogenous bacterial enzyme
to digest the cell wall. Finally, lysin-encoding genes have been identified among
certain streptococcal and staphylococcal phage that include a self-splicing, group
I intron (Foley at al. 2000; O‘Flaherty et al. 2005). Truly, it appears that the
potential variations that have evolved in phages are only limited by one‘s own
imagination!

Non-caudoviral lytic proteins. The discussion to this point has focused
exclusively on the lytic mechanisms of the caudoviruses. This is understandable
given their overwhelming predominance among known phage. Nonetheless, a
dedicated body of research has also studied lysis for non-tailed phage; this work
will be summarized briefly here. As mentioned previously, all phage families
except the filamentous inoviruses release progeny viruses through host-cell lysis.
For several of these families, the mechanism is reminiscent of the caudoviruses
and involves phage-encoded peptidoglycan hydrolases. This is known to be the
case for the dsRNA cystoviruses (Caldentey and Bamford 1992; Pei and Grishin
2005) and the lipid-associated dsDNA tectiviruses (Verheust et al. 2004). For
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another lipid-associated dsDNA family, the corticoviruses, the mechanism
remains ambiguous. The genome of a single corticovirus (the only known
isolate) has been sequenced and it fails to include any proteins with predicted
murlaytic activity (Krupocič et al. 2007a). Nevertheless, genomic analyses of
various marine bacteria have revealed corticovirus-like prophage elements with
putative lytic enzymes (Krupocič et al. 2007b).
A divergent, and rather intriguing, strategy of host lysis is employed by
the ssRNA leviviruses and the ssDNA microviruses. These phages encode
proteins that are collectively referred to as amurins. Rather than hydrolyze
peptidoglycan, the amurins inhibit the biosynthetic machinery that is responsible
for its synthesis (Bernhardt et al. 2001; Bernhardt et al. 2000). In a mechanism
similar to small-molecule antibiotics, they comprise the cell-wall strength of the
nascent bacteria and induce osmotic lysis. For the dsDNA plasmaviruses, the
mechanism of lysis is not well-established. Given that these phages are only
known to infect mycoplasma (which lack a cell wall), the mechanism almost
certainly does not involve a peptidoglycan hydrolase. Overall, when all the nontailed phages are considered, only the tectiviruses have been observed to infect
Gram-positive species (including the pathogen B. anthracis). So—at least at
current state of the technology—they are the only ones whose lysins seem
compatible with enzybiotics usage.
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Phage lysins into the spotlight. As the discussion to this point illustrates,
phage-lysin research is clearly an expansive field. At the same time, one
important question has not yet been addressed: when exactly were these proteins
first viewed as potential anti-infective agents? The truth is that researchers were
aware of lysins for decades before they were first considered pharmacologically.
(A detailed history of the ―nuts and bolts‖ of lysin identification will be provided
a little later, as the last main section of this introduction.) It was not until the late
1980‘s, in fact, that lysins were first viewed through the prism of applied
microbiology. Interestingly, some of this initial work did not have biomedical
motivations. Several lysins were studied that targeted species of lactic acid
bacteria (LAB) commonly employed by the dairy industry (reviewed in Sable
and Lortal 2005). It was proposed that lysins could facilitate the release of
intracellular enzymes from LAB, enhancing the ripening of fermented food
products.
Throughout the 1990‘s, two other groups—García, López and colleagues
in Madrid and Loessner, Scherer, and colleagues in Munich—began investigating
phage lysins in vitro against various human pathogens, including pneumococci
(García et al. 1988 and 1990), staphylococci (Loessner et al. 1998), and Listeria
(Loessner et al. 1995). While their work demonstrated bacterial killing, the lysin
field did not truly expand until after the turn of the millennium. It was at this
point that Fischetti and colleagues at Rockefeller began utilizing phage lysins in
vivo with animal models of bacterial pathogenesis. Published in 2001, two of the
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first such studies involved pharyngeal colonization of mice with S. pneumoniae
(Loeffler et al.) and S. pyogenes (Nelson et al.). In both cases, a single treatment
with the respective lysins PAL and PlyC abolished bacterial titers hours after
dosing. Similar results were later reported for the PlyGBS lysin following the
pharyngeal and vaginal colonization of mice with S. agalactiae (Cheng et al. 2005).
A common feature of these trials is that they involved selective
decolonization of mucous membrane sites. This is highly relevant given the
pathogenesis of many common Gram-positive bacteria. For virtually all
streptococcal and staphylococcal pathogens, the presence of disease is not simply
a binary issue of ―having the bacteria‖ or ―not having the bacteria‖. Countless
individuals are colonized with these organisms, generally at mucous
membranes, without any clinical signs of infection. The progression to actual
pathology (either at the initial mucous membrane or at distal sites) depends on
this initial colonization, but it is not synonymous with it. In this light, phage
lysins—or, for that matter, intact phages— could be used as targeted
prophylactic agents that prevent the colonization/infection transition. This
application is be relevant even outside the discussion of burgeoning antibiotic
resistance, although the latter issue imparts an even greater sense of priority.
Subsequent in vivo trials have investigated the effect of lysin treatment
against fulminant Gram-positive infections. For example, Schuch et al.
demonstrated the ability of the PlyG lysin to prevent lethality in mice with B.
cereus peritonitis (2002). This work generated significant attention at the time,
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especially in light of heightened bioterrorism concerns over the closely-related
species B. anthracis. In other work, the pneumococcal lysin CPL-1 (different that
the PAL lysin mentioned above) has been used successfully in rodent models of
bacteremia (Loeffler et al. 2003), endocarditis (Entenza et al. 2005), otitis media
(McCullers et al. 2007), and meningitis (Grandgirard et al. 2008).
Just recently, an anti-staphylococcal lysin (ClyS) was utilized
synergistically with traditional antibiotics to treat cutaneous S. aureus infections
in mice. This enzyme is currently employed in an ex vivo trial involving skin
scraping from psoriasis patients (Daniel et al. 2010; Pastagia and Fischetti,
personal communications). Admittedly, the ability to treat particular anatomic
sites with lysin could be limited by the fact that it is a protein. Nevertheless, a
growing body of research (reviewed in Fischetti 2008) has addressed the issues of
biodistribution and immunogenicity of lytic enzymes. The results provide
cautious optimism that these agents might be useful even beyond their most
straightforward application as topical agents. Moreover, just as with bulk phage
therapy, lysins also have potential applications as food additives (see Chapter 2)
and veterinary pharmaceuticals (see Chapter 5). They could likewise be used as
industrial decontaminating agents for surfaces that have been colonized with
planktonic bacteria or biofilms (Donlon 2009).
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PHAGE-LYSIN IDENTIFICATION THROUGHOUT THE YEARS
Despite the work dedicated to phage lytic enzymes of late, the number of
lysins that have been studied functionally is still only a small fraction of the total
lysin pool encoded by global phage. With the numbers alluded to above (1031
worldwide phage particles), bacteriophage are thought to be the single greatest
source of genetic information on the planet. Even among the known
phage/prophage of Gram-positive pathogens, only a small minority have seen
their lytic enzymes cloned, expressed, and examined as anti-infective agents. In
itself, the sheer number of lysins with the potential for development as
enzybiotics makes this class of proteins extremely attractive pharmacologically.
Considering this magnitude, future research will undoubtedly continue to
isolate new lysins to complement those already in development. And while it is
the activity of these enzymes that will ultimately garner attention, the success of
such work is fundamentally dependent on the techniques employed to identify
the proteins in the first place. The purpose of the current section, therefore, is to
address the issue of lysin identification. Following a summary of lysin isolation
prior to modern molecular cloning, I will outline the various techniques
currently available for cloning lysin-encoding genes within phage genomes. The
relative advantages and disadvantages of these approaches will be discussed,
especially in the context of ongoing technological advances. Overall, through the
efficient identification of novel phage lysins, researchers can only broaden the

52

potential impact of these proteins and hasten their development into true clinical
and industrial tools.

Historical perspectives on lysin identification. While medical interest in phage
lysins is a more recent phenomenon, initial observations of these enzymes and
attempts to purify them date back much longer. In 1921, Felix d‘Hérelle first
proposed the existence of a phage-associated enzyme that was capable of lysing
bacteria independently from total phage action. His idea was based on
experiments with alcohol-denatured phage; d‘Hérelle was able to extract an
active agent that could lyse bacilli but not propagate between cultures. Soon
after, Vladimir Sertic reported the isolation of a lysine d’une race du bactériophagie
that was responsible for creating altered morphological zones that surrounded
Escherichia coli plaques proper (1929). The lysin hypothesis was contested at the
time, and it is difficult to judge whether these initial observations were truly due
to the activity of what we now know as phage lytic enzymes. Nevertheless,
other contemporary studies did report the tendency of nonviable Gram-positive
bacteria to lyse when in the presence of live bacteria and their corresponding
phage (Gratia and Rhodes, 1923; Twort 1925; Bronfenbrenner and Muckenfuss,
1927). In retrospect, this activity could be attributed to the diffusion of lysin from
dead cells.
It was not until several decades later that the existence and activity of
lysins were broadly accepted by the scientific community. In 1955, Ralston et al.
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described a lytic agent that appeared in the supernatant of a Staphylococcus aureus
culture following infection by bacteriophage P14. This protein, which they
termed virolysin, could be separated from intact phage through ultracentrifugation and concentrated by ammonium sulfate precipitation (Ralston et
al., 1957). Their work was notable in that the phage enzyme was isolated and
characterized alongside an endogenous lytic enzyme produced by the host
staphylococci—the distinction between these molecules allowed the phage origin
of virolysin to be established. It was subsequently demonstrated that
antigenically-distinct lytic enzymes could be isolated when the S. aureus host was
infected with diverse phage (Ralston and McIvor 1964). In later works, two
staphylococcal lysins (from phages 80 and 53) were purified beyond ammonium
sulfate precipitation by ion exchange chromatography (Doughty and Mann 1967;
Sonstein et al. 1971).
One should note that, in these initial attempts to isolate S. aureus lysins,
the final products did not demonstrate the degree of activity currently associated
with lytic enzymes. Of the above (semi-pure) enzymes, only the phage-53 lysin
could successfully lyse viable staphylococci; the phage-80 lysin was only active
against isolated cell walls and the P14-virolysin required the bacteria to be
―sensitized‖ by one of several additional agents. It is unclear whether this
diminished activity was due to less-than-ideal purification conditions at the time,
or simply reflect the efficacy of these particular enzymes.
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During the same period as this work on staphylococcal enzymes, similar
research was progressing on other bacteria-bacteriophage combinations. Again
with the strategy of isolating the proteins from culture supernatant, lysins were
investigated from phage whose hosts included enterobacteria (Inouye and
Tsugita 1966; Maass and Weidel 1963; Rao and Burma 1971), bacilli (Murphy
1957; Welker 1967), lactococci (Tourville and Johnstone 1966), and streptococci
(Reiter and Oram 1963; Oram and Reiter 1965). Overall, one of the most
extensively studied lysins of this time was that of the C1 phage infecting
Lancefield group C Streptococci. Two 1957 publications documented its ability
to lyse not only live Streptococci of the same type, but also live Group A and E
Streptococci (Maxted; Krause).
Over the following years, several increasingly sophisticated attempts were
made to purify the C1 lysin using a combination of ammonium sulfate
precipitation, gel filtration, and calcium phosphate adsorption (Krause 1958;
Doughty and Hayashi 1961). In the process, it became a valuable tool for
selectively removing and characterizing antigenic components of the
streptococcal cell envelope. The final obstacle to achieving a highly pure protein
preparation (the presence of reactive sulfhydyl groups) was overcome by
Fischetti et al., who utilized reversible sodium tetrathionate protecting groups to
stabilize the lysin during chromatography (1971). Interestingly, these nonrecombinant purification schemes for the C1-phage lysin, currently referred to as
PlyC, endured into the modern era of lysins as enzybiotics. In 2001, PlyC was
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one of the first lysins to effectively decolonize a bacterial pathogen in vivo
(Nelson et al.), even though the encoding genomic region was not cloned and
characterized until several years later (Nelson et al. 2006).

Into the age of molecular cloning. Following the elucidation of the central
dogma of molecular biology, attempts to characterize (and ultimately identify)
phage lytic enzymes through genetic techniques began in earnest by the late
1960‘s. The first lysin amino acid sequence was reported in 1966 by Inouye and
Tsugita for the E. coli T4 phage muramidase. It was determined through Edman
analysis of culture-purified enzyme, and it suggested an approximate nucleotide
sequence by reverse translation. This work on the T4 lysin, in fact, provided
important evidence confirming the very nature of the triplet genetic code. By
inducing mutations in the T4 genome and observing the corresponding frameshifts in the purified lysin, the authors were able to verify Crick‘s hypothesis
regarding the language of DNA codons (Terzaghi et al. 1966; Okada et al. 1968).
The definitive nucleotide sequence for the T4 lysin was not published
until 1983, when Owen et al. successfully cloned the gene by its ability to rescue
a lysis-defective phage strain. This sequence, in turn, allowed several additional
lysin genes to be recognized through nucleotide homology. In 1985, the
Salmonella P22-lysin was identified in this manner from a sequenced fragment of
the viral genome (Rennell and Poteete). The first nucleotide sequence of a Grampositive lysin, from Bacillus subtilis phage 29, was likewise reported one year
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later (Garvey et al. 1986). It is important to note that the above work was
conducted at the same time as the advent of modern protein expression
technology; shortly after their cloning, the T4 and 29 lysins were the first such
enzymes to be expressed and purified recombinantly from E. coli (Perry et al.
1985; Saedi et al. 1987).
With molecular techniques at their disposal, researchers could now
identify lysins directly from phage DNA, and this ability was soon utilized to
search for enzymes against Gram-positive pathogens. One of the first bacterial
species targeted in this regard was S. pneumoniae, as the 1980‘s and 90‘s saw the
cloning, expression, and functional analysis of a number of pneumococcal phage
lysins. The same general strategy was employed in identifying each of these
proteins: following the cloning of an initial prototype enzyme, the gene was
utilized to identify related lysins through Southern blot analysis. Ironically, the
prototype enzyme for these pneumococcal lysins was not actually viral in origin,
but rather a genomic peptidoglycan hydrolase encoded by S. pneumoniae, LytA.
Like the endogenous S. aureus lysin from Ralston et al. (1957), LytA is not a
phage enzyme but rather a chromosomal autolysin. Specifically, LytA is an
alanine-amidase with various roles in pneumococcal physiology, including the
release of cytoplasmic virulence factors during pathogenesis (Jedrzejas 2001) and
the predation of non-competent cells by competent ones within pneumococcal
communities (Guiral et al. 2005).
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García et al. cloned LytA in 1985 through a complementation strategy in
which an S. pneumoniae genomic fragment was identified by its ability to rescue
autolytic activity in a mutant lytA- strain. The resultant sequence was
subsequently used to probe genomic DNA from several S. pneumoniae phages in
order to isolate their lysin genes. Successful hybridizations were noted in many
instances, and the corresponding bands were cloned and sequenced to reveal
viral LytA-homologues. Specifically, the lysins from the following phage were
identified [with corresponding enzyme names]: Cp-1 [CPL-1] (García et al. 1988);
Cp-7 and Cp-9 [CPL-7 and CPL-9] (García et al. 1990); HB-3 [HBL] (Romero et al.
1990); EJ-1 [EJL] (Díaz et al. 1992); and Dp-1 [Pal] (Sheehan et al. 1997).
These enzymes demonstrated varied overall sequence homology to LytA
itself. HBL and EJL are highly homologous to the autolysin throughout their
entire sequence, as they share both LytA‘s N-terminal amidase domain and its Cterminal choline-binding domain. By contrast, CPL- 1, CPL-7 and CPL-9 possess
muramidase activity and are homologous to LytA only at the C-terminal binding
end. Pal likewise demonstrates only C-terminal homology. Although both
lysins possess alanine-amidase activity, Pal encodes a type 5 amidase domain
while LytA encodes a type 2 amidase domain. Of all these pneumococcal
enzymes, CPL-1 has received by the far most attention in subsequent enzybiotic
trials (as described in the preceding section).
As for the hybridization strategy itself, the technique is no longer
commonly used for identifying lytic enzymes. A potential reason for this is
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logistical: with more recent cloning strategies (described in the following
sections), Southern blotting can be relatively cumbersome by comparison. There
also exists the possibility of limiting the results due to the sequence of the
original DNA probe. With this approach, it is only possible to identify genes
with some homology to a prototype sequence. But if a phage is relatively
novel—for instance, in terms of its host bacterium or viral morphotype—suitable
homologues might not exist for its lysin. This is especially problematic
considering that enzymes with highly novel sequences represent some of the
most attractive targets for future discovery.
Nevertheless, if one has good reason to suspect that a desired lysin is
similar in sequence to one already characterized, techniques based on nucleotide
homology can still be quite effective. In this regard, several studies have utilized
PCR-based approaches as more rapid alternatives to Southern blotting. For
example, Morita et al. designed primers from the genomic regions surrounding
the lysin of a B. subtilis phage, which they used to amplify a related enzyme for
B. amyloliquefaciens (2001b). Romero et al. likewise synthesized various primers
based on known LytA-like sequences when attempting to clone the lysins from
two S. mitis phage (2004). These authors successfully identified a primer-pair
that amplified a portion of both enzymes; these partial sequences were
subsequently used to characterize the remainder of the genes by genomic primer
walking (i.e. chain termination sequencing with the genome as the direct
template). It should be mentioned that, although they have not been applied
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specifically to lytic enzymes, several other techniques are available that could
identify a complete lysin gene from only a partial sequence. These include
inverse PCR (Ochman et al. 1988) and semi-random PCR (Hermann et al. 2000).
Phage lysins and functional screening. To avoid the possibility of sequencebased bias, it is ultimately necessary to identify lysin-encoding genes by the
enzymatic activity of their translated proteins. This approach is the foundation
of functional genomic screening, and it has become a common tool for lysin
identification over the past decade. The experimental specifics of lysin-screening
can differ slightly, and these variables are reviewed in the proceeding
paragraphs. Overall, however, such methods represent variations on the same
general theme: [I] phage genomic DNA is isolated and digested into fragments;
[II] the fragments are ligated into an expression vector and transformed into a
host organism; [III] the transformants are clonally propagated and exposed to an
inducing agent to force transcription of the genomic inserts; and [IV] the clones
are analyzed for the acquisition of a phenotype that indicates the presence of a
lysin-encoding gene.
For the first three steps, the experimental considerations are fairly general
in nature and unrelated to the activity of the targeted enzymes. The original
source DNA can be derived from either lytic phage, isolated from the
environment or purchased from commercial sources, or lysogenic prophage,
induced from host bacteria with an appropriate stressing agent (e.g. mitomycin,
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phosphomycin, or UV-treatment). For the fragmentation step, most lysin screens
have utilized a standard shotgun approach to create a random array of genomic
fragments. Here, the phage DNA is partially digested with restriction enzyme,
usually one with a 4-bp consensus sequence. A final length distribution of 1.5 - 3
kb is ideal, as it represents 2 - 3 times the length of typical Gram-positive lysins.
While alternate methods have been used on occasion2, the second step
typically involves ligation of these fragments into an expression plasmid with
transformation of an E. coli host. One should note that other vectors, in theory,
could support longer DNA inserts (i.e. cosmids or bacterial artificial
chromosomes). However, these systems suffer from the fact that they would rely
upon native promoters for recombinant expression. Given the small size of
Caudoviral genomes (several dozen to several hundred kilobases), plasmidbased screens are still capable of identifying lytic clones with high efficiency. In
past studies, for example, hits have typically been observed at a frequency of 0.12% of total colonies (Schuch et al., 2008).
When choosing a particular plasmid for lysin screening, the same
variables must be taken into consideration as during the recombinant expression
of any protein. These include the type of promoter, induction conditions, codon
usage, and the host E. coli strain. For a given lysin, the expression level and
solubility can vary significantly from one system to the next, often in
unpredictable ways. Nevertheless, for a detailed protocol that we have found
generally reliable, the reader is referred to Schuch et al. (2009). The screen
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outlined here utilizes an arabinose-inducible pBAD plasmid, which is attractive
for its tight transcriptional control and the cost-effective nature of the inducing
agent.
For the final steps of a lysin screen, induction and selection of positive
clones, the following experimental manipulations are typically involved.
Transformed E. coli are spread onto agar plates that lack inducing agent,
allowing clones to proliferate without transcription of genomic inserts. These
master plates are replicated onto screening plates whose agar has been
supplemented with inducing agent. After propagating with forced transcription,
the clones are exposed to chloroform vapor to permeabilize the E. coli and allow
free diffusion of the expressed proteins. The clones are overlaid with a soft agar
media containing Gram-positive cells. The plates are observed over time for
clones over which there develops a zone of diminished bacterial density,
indicating the presence of a lysin-encoding gene (see Figure 1.8). The
corresponding clone on the master plate is subsequently identified and expanded
for sequencing and large-scale expression. In early functional screens, the
process occasionally differed in minor aspects (for instance, in the logistics of
replica-plating or cell permeabilization). In current studies, however, this
procedure has become the norm.
The main enduring variable in the process of lysin identification lies at the
end of the procedure, as several options are available regarding the type and
quantity of Gram-positive bacteria in the soft-agar overlay step.
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Figure 1.8 Lysin-Induced Clearing Zone
To identify a phage lystic enzyme in a functional screen, Gram-positive
bacteria are overlayed on permeabilized E. coli clones expressing phage
genomic inserts. The desired clone (indicated above with an arrow) is
identified by the development of a surrounding halo of Gram-positive lysis.
The particular example shown here involves B. anthracis (strain 222) cells
and the PlyB lysin from the BcpI phage (Porter et al. 2006). One should note
that the realtive size and intensity of the of the halo can vary depending on
the particular lysin and the overlaid bacterial species/strain.
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Table 1.5 summarizes these techniques and the individual studies in which they
have been employed over the years. In a few studies, permeabilized clones were
overlaid with concentrated Micrococcus cells (Jayaswal et al. 1990; Bon et al. 1997).
Decreased micrococcal turbidity is a classic method of quantifying the activity of
eukaryotic peptidoglycan hydrolases (Shugar 1952). The majority of screens,
however, have utilized the host bacteria of the phage whose genome was being
screened. This makes intuitive sense considering the specificity that lytic
enzymes demonstrate toward host organisms.
At the same time, several variations do exist as to how these cells are
applied. The permeabilized clones can be overlaid with either [I] concentratedviable bacteria, [II] concentrated-nonviable bacteria (typically autoclaved), or [II]
dilute-viable bacteria. In the first two cases, plates are observed for clones
around which bacterial density decreases, while, in the third, they are observed
for clones around which bacteria fail to proliferate. Previous examples of each
approach include, respectively: several L. monocytogenes lysins (Loessner et al.
1995); an enzyme targeting a novel Staphylococcus strain (Yokoi et al. 2005b); and
the amidase of the  diagnostic phage of B. anthracis (Schuch et al. 2002).
While there has never been a dedicated study comparing the relative
efficacy of these three variations, each type of overlay has been utilized within
the Rockefeller University Laboratory of Pathogenesis with general effectiveness.
One notable benefit, however, of employing dilute-viable cells is its particularly
high level of sensitivity.
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Table 1.5 Lysins Cloned Through Functional Genomic Screening
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Table 1.5, continued
Provided here is a complete list (as of 2009) of recombinantly-expressed
phage lytic enzymes against Gram-positive bacteria for which the original
means of identification was a functional genomic screen. They are
organized by screening methodology, and include the corresponding target
bacteria and year of identification. The methodologies include: overlay by
micrococcal cells; overlay by concentrated, viable Gram-positive bacteria
(GPB) of the target species; overlay by concentrated, nonviable GPB; and
overlay by dilute, viable GPB. For two entries (Shearman et al. 1989;
Henrich et al. 1995), a -phage screening strategy was used in place of a
plasmid-based approach (see Endnotes for more information).

66

Since only enough lysin is required to prevent the growth of a small initial
population, clearing zones are often evident even when an enzyme is not well
expressed under the screening conditions. Using this method, clearing zones
have been observed even in instances when a particular clone does not produce
sufficient lysin for recombinant purification or detection by Coomassie-staining
(unpublished observations).
Several other factors must likewise be considered when selecting a
particular overly technique. For instance, certain bacteria can react poorly to
heat-killing (e.g. with aggregation or lysis), rendering the concentrated-nonviable
approach ineffective. Other bacterial organisms can interact non-specifically
with the E. coli library clones when proliferating in soft agar, leading to
widespread pseudo-clearing clones for the dilute-viable method. While it is
difficult to predict what approach is ideal for a given species/strain, this should
not prevent one from successfully cloning a lytic enzyme. All three techniques
are ultimately straightforward, and (as replica plating is not a time-consuming
step) one can readily conduct multiple types of overlays from each master plate.
Recent additions to functional screening. Despite the general success of the
proceeding techniques, they are not the only functional methods available for
cloning phage lysins. Indeed, several additional strategies have been devised
recently that complement or expedite these approaches. One such example is
holin-based screening for lytic enzymes. As described above, it is the combined
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action of lysin and holin that leads to host-cell lysis and the release of progeny
viral particles. The necessity of both proteins during phage infection explains
why lytic enzymes can be overexpressed recombinantly in E. coli: even if a given
lysin possesses activity against the E. coli peptidoglycan, it cannot exert a toxic
effect as long as it is sequestered in the cytoplasm. By contrast, co-expression of
both lysin and holin can lead to marked toxicity, as holins can integrate nonspecifically into cytoplasmic membranes (including those of an E. coli host).
Due to the genomic adjacency of holins and lysins, lysin-containing
fragments in shotgun libraries commonly encode holins as well. This creates the
potential for selective toxicity of exactly the clones one hopes to identify. When a
lysin-encoding clone is identified in an enzyme-based screen, it is generally one
in which either [I] the holin and lysin happen not to be encoded adjacently in the
particular genome, [II] the holin (fortuitously) is not sufficiently expressed, or
[III] only a limited amount of genomic DNA surrounds the lysin, excluding the
complete holin. Due to the small size of phage genomes and the resultant high
proportion of lysin-encoding clones, the issue of holin toxicity has not proven a
tremendous obstacle in past screens. Nevertheless, several studies have looked
to avoid the situation altogether by selecting for holin-encoding clones. By
targeting the holin genes, it is possible to identify adjacent lysins without
actually observing lysin activity.
In this regard, Delisle et al. utilized a plasmid release protocol to identify a
phage lytic enzyme for the dental pathogen Actinomyces naeslundii (2006). For
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this study, mixed E. coli transformants were grown in a single liquid culture.
Following induced expression, holin-encoding cells would undergo lysis,
releasing their plasmid into the culture media. The plasmids were then purified
and used to retransform a new set of competent E. coli. Through several rounds
of this procedure, the authors were able to enrich for a set of clones encoding the
holin-lysin region, ultimately allowing them to sub-clone and express the lytic
enzyme.
One additional technology with potential relevance to lysin identification
is that of whole-genome amplification. PCR-based methods have recently come into
prominence that allow for general amplification of viral (along with bacterial or
eukaryotic) DNA. These include the use of linker-based amplification (see
Chapter 3), as well as high-diversity primers in combination with the ultraprocessive 29 polymerase. For a review that discusses genome amplification
specifically in the context of viruses, the reader is referred to Delwart et al. (2007).
The significance of these techniques lies in the access they provide to
exceedingly small biological samples, as once-undetectable genetic material is
now available for analysis. From the perspective of lysin screening, wholegenome amplification can significantly expedite the preparation time for library
construction. Purification of phage DNA is a relatively time-intensive process
compared to that of cellular organisms. Depending on the phage and the growth
properties of the host, obtaining a high-enough viral titer for microgram
quantities of DNA (typically required for shotgun cloning) can represent several
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days to several weeks of work. By amplifying a small initial quantity of phage
DNA, one can side-step this issue and obtain essentially a limitless supply of
genomic material.

Lytic enzymes and whole-genome sequencing. Despite this growing array of
techniques, functional screening still represents only one side of the ongoing
effort to clone lytic enzymes. In fact, only ~50% of phage lysins that have been
recombinantly expressed to date were first identified in this manner. Many
others, at the same time, have been the result of genomic sequencing and
nucleotide homology analysis. The field of whole-genome sequencing has
expanded rapidly in recent years (for viruses, bacteria, and eukaryotes), driven
in large part by the development of high-throughput technologies like 454
pyrosequencing and Illumina/Solexa sequencing-by-synthesis (Strausberg et al.
2008). Publications documenting complete phage genomes have become
commonplace, and a growing number of studies now focus on the genomes of
numerous, interrelated phage. To date, 500+ complete phage genomes are
present within the NCBI database (not counting prophage), and this number is
expected to increase substantially in the near future (Hatfull 2008).
The impact of genomic sequencing on lysin research is simple: whenever
the genome of a new phage is reported, another lysin gene is uncovered. Their
enzymatic motifs and overall structure are sufficiently conserved that standard
algorithms (e.g. Blast, Pfam) generally make it possible for one to recognize a
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lytic enzyme from a sequence alone. Overall, identifying these enzymes through
nucleotide homology is not a new concept; it was mentioned before that two of
the earliest-known lysin genes (from the Salmonella P22 and B. subtilis 29 phage)
were discovered based on their similarity to the E. coli T4 lysin. What
distinguishes today‘s bioinformatic analyses is the large (and ever growing) size
of public databases, which allow one not only to locate a lysin gene itself, but
often predict its enzymatic mechanism, domain phylogeny, or even catalytic
residues3. These genes can then be PCR-cloned and tested for and activity.
Table 1.6 provides a chronological list of recombinantly-expressed lysins
whose genes were initially identified though DNA sequence analysis. With a
single exception (O‘Flaherty 2005), the genes were PCR-cloned directly from
genomic DNA. In the one instance, a staphylococcal lysin was interrupted by an
intronic sequence, requiring the investigators to extract mRNA from infected
bacteria and prepare cDNA as an amplification template. Aside from the
increasing number of lysins in recent years, Table 1.6 reveals several important
trends. For instance, whereas earlier lysins were often discovered within partial
genomic sequences (i.e. a fortuitous sampling of restriction fragments), recentlycloned enzymes have generally been identified from complete phage genomes.
Presumably, this reflects both gains in sequencing technology, as well as
improvements in functional techniques that make it possible to clone a lysin
without resorting to partial sequencing.
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Table 1.6 Lysins Cloned Through Genomic Sequencing
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Table 1.6, continued
Organized by date, this table lists recombinantly-expressed lysins against
Gram-positive bacteria which were originally identified through DNA
sequencing and bioinformatic comparison to known proteins. Three
categories are present within the table: enzymes identified through partial
sequencing of a phage genome, those identified through complete
sequencing of a phage genome, and prophage lysins identified through
complete sequencing of the bacterial host genome.
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One should likewise note that four lytic enzymes were amplified not from
the genomes of individual phage, but rather from the genomes of their bacterial
hosts. These include PlyL (Low et al. 2005) and PlyPH (Yoong et al. 2006) from
the Ames strain of B. anthracis, along with the LambdaSa1 and LambdaSa2 lysins
from S. agalactiae 2603 V/R (Pritchard et al. 2007).
Bacterial genomes in themselves represent attractive sources of lytic
enzymes in the form of integrated viral DNA (this, in fact, is the focus of the next
chapter of this thesis). As the genomes of additional bacterial species/strains are
sequenced, the number of prophage lysins that could serve as potential
enzybiotics will only grow further.

Sequence-based versus functional: pros and cons. At this point, it is
worthwhile to consider the relative advantages and disadvantages of identifying
lysins through functional screening versus genomic sequencing and PCRcloning. One of the most attractive features of the latter approach is its
straightforward nature. If one has isolated a phage and wishes to identify its
lysin, genomic sequencing is a method for which success is highly likely. The
primary obstacle here is not cloning the gene itself, but rather identifying a
suitable vector for active expression. This challenge is true for all recombinant
proteins, however, and is equally applicable to functional lysin screens.
A sequence-based approach likewise allows one to mine genomic
databases for lysins that have not yet been studied in detail. In the process, one
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can compare their putative biochemical properties and overall uniqueness
through bioinformatic analysis (again, see Chapter 2). For example, a lysin with
a catalytic domain that is unique for a particular host bacteria is far more
attractive than a lysin that is highly similar to a previously-expressed enzyme.
Overall, while it is not always the case that a desired sequence is present within
public databases, it is always advantageous to check, as this represents easily the
most rapid singular approach to expressing a novel lysin.
Of course, identifying lysins through nucleotide homology does not
always present the best optionquite frequently, the reason is purely logistical.
Despite ongoing technological improvements, genomic sequencing does not yet
represent an insignificant investment of time and resources, and highthroughput access is far from universal. For a majority of laboratories, functional
screening is still the most cost-effective and rapid method for identifying lytic
enzymes from individual phage genomes. With sequence analysis alone,
moreover, there exists a small chance of overlooking a lytic enzyme due to an
atypical sequence. While they are uncommon, lysins are occasionally identified
whose genes deviate significantly from the norm.
The most prominent example is the streptococcal C1 lysin (PlyC),
described previously in this section for its early role in lysin purification. The C1
genomic sequence, reported in 2003, revealed an abnormal lytic region in which
a putative holin (ORF8) lied adjacent to several ambiguous open reading frames
(Nelson et al.). While the theoretical translation of ORF9 corresponded to a
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partial Edman sequence of the purified enzyme, none of ORFs demonstrated
typical lysin features or possessed a molecular mass corresponding to PlyC.
Only when the authors functionally screened the C1 genome and dissected the
ORFs of the lytic clone were they able to determine that PlyC represents a unique
multimeric phage lysin (resulting from ORFs 9 and 11) (Nelson et al. 2006). In
fact, PlyC remains without any homologues among sequenced phage, and it is a
remarkable coincidence that one of the first lysins ever purified is so atypical.
Just recently, another highly novel lysin was reported for the IN93 phage
of the extremophilic bacterium Thermus aquaticus (Matsushita and Yanase, 2008).
Employing a more classical approach, the authors first purified the enzyme from
infected culture supernatant and subjected it to Edman sequencing. The Nterminal amino acids were then cross-referenced to the sequenced genome to
locate the lysin-encoding ORF, which until that point had remained unidentified
due its lack of recognized domains or homology to other proteins. While the
authors did not utilize a functional screen to identify the enzyme, per se, this case
again demonstrates how genomic sequences alone can occasionally be
insufficient for lysin identification. Overall, the value of this particular enzyme
lies not in its anti-infective potentialT. aquaticus is neither Gram-positive nor
pathogenicbut in its ability to retain activity at high temperatures, an attractive
industrial feature.
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OBJECTIVES AND OVERVIEW OF THE THESIS PROJECT
The present body of research. Between sequence-based and functional cloning
approaches, the number of phage lysins that have been subject to recombinant
analysis has steadily increased in recent years. This trend should only continue,
especially if pre-clinical work these enzymes successfully progresses to human
trials. At the same time—and despite their widespread use—the techniques
described above are no longer the only (or even, necessarily, the most efficient)
avenues for identifying new enzybiotic candidates. My doctoral research at
Rockefeller has addressed this very issue. Broadly stated, the work presented in
this thesis explores new approaches for cloning novel phage lytic enzymes. The
underlying motivation for this research is straightforward: by increasing the
number characterized lysins, one will only hasten the development of these
molecules into effective biomedical tools.
The work presented here does not focus on any particular bacterial
pathogen or phage lysin. Rather, the focus is on the process, and how researchers
can move beyond traditional approaches in the lysin field—this includes a
combination of [1] strategy and [2] methodology. Strategy refers to potential
genetic sources of lysins and whether it is possible to look for these enzymes
elsewhere than individual phage genomes. Methodology refers to experimental
techniques and the creation of new protocols that will make cloning lytic
enzymes more efficient and expansive. This thesis is divided into four
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individual sections (Chapters 2 - 5), each of which represents an independent
(yet interrelated) investigation into strategy and/or methodology.
Chapter 2 focuses on bacterial genomic sequencing and its impact on the
lysin field. The recent explosion of sequenced bacterial genomes—which
naturally include integrated prophages—has revealed numerous ORFs that can
be assigned putative lysin functionality based on homology analysis. In the past
several years, in fact, the number of theoretical prophage lysins in computational
databases has come to dwarf the number of lysins whose activity has been
studied experimentally. Identifying prophage lysins via bacterial genomic
sequencing is no different than the phage-sequencing strategy discussed above.
The difference now, however, is that high-throughput sequencing technology
has made entire bacterial genomes (several Mb) as accessible as their smaller
phage counterparts (tens of kb). As a result, numerous prophage enzymes can
be rationally compared and rapidly cloned without ever having to work with
phage itself.
Chapter 2 takes advantage of this information for the pathogenic anaerobe
Clostridium perfringens. The recently-sequenced genomes of 9 strains of C.
perfringens were computationally mined for proviral lytic enzymes, and a
comprehensive list of lysins was constructed and compared. From this list, a
particular enzyme was chosen for cloning, expression, and in vitro analysis based
on its dissimilarity with the only other previously-studied C. perfringens lysin.
Various biochemical properties of this lysin were determined, as well as its
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activity profile against a panel of C. perfringens, non-perfringens clostridia, and
other Gram-positive bacterial species.
By contrast, Chapter 3 of this thesis changes course; it is the first of two
chapters to explore the rapidly expanding field of metagenomics as it relates to
lytic enzymes. Metagenomics refers to the direct expansion of DNA/RNA from
environmental samples without first isolating and cultivating any of the
individual component microbes (the reader is referred to the individual chapter
for a more detailed review). While the initial focus of metagenomics research
was on environmental bacteria, the field has since expanded to include
investigations of uncultured viruses. In these studies, viral particles (consisting
primarily of phage) are separated in bulk from environmental bacteria and other
debris prior to DNA extraction and analysis.
To date, viral metagenomics has been primarily sequence-based in nature;
here, uncultured phage sequences are compared to known genetic databases to
address broad questions of phage biology and ecology. On the other hand,
functional screening of viral metagenomes could provide direct access to
targeted classes of recombinant molecules. Phage lysins, of course, represent an
intriguing example. Nevertheless, functional metagenomic screens for lytic
enzymes would present several distinct challenges. The goal of Chapters 3 and 4
is to address these challenges and make metagenomic lysin screens a reality.
Chapter 3 focuses on the issue of DNA quantity, as environmental phage
samples do not typically provide a sufficient quantity of genetic material for
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functional screening. A technique known as E-LASL (for expressed linker
amplified shotgun library) was developed that combines linker amplification of
fragmented DNA with commercial topoisomerase cloning. This creates a rapid
protocol for constructing (in an E. coli host) expressible plasmid-based libraries
from nanogram quantities of DNA (a typical yield for viral metagenomic
extractions). To validate the technique, various genomic libraries were
constructed from Bacillus phage, and six lytic enzymes for B. anthracis were
successfully cloned. Additionally, a bacterial metagenomic E-LASL was
constructed from the gut contents of an earthworm, and an active virulence
factor was cloned in a subsequent hemolysis screen.
With this method for library construction in place, Chapter 4 develops a
procedure for selecting E. coli transformants that encode and actively express
metagenomic lysins. The method circumvents additional challenges that face
metagenomic lysin screening, ones involving holin-induced toxicity of lysinencoding clones and the choice of an appropriate selection agent (see Chapter 4
for additional information). The technique utilizes two sequential steps: a
toxicity screen is first employed in which colonies are selected for holin-induced
lysis following induced expression. In a secondary step, then, the initial hits are
overlaid with autoclaved Gram-negative bacteria (specifically Pseudomonas
aeruginosa) to assay directly for the production of lytic enzyme. As proof-ofprinciple, a viral metagenomic library was constructed from mixed animal feces
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and subjected to the screen. It was validated by the successful cloning of 26
lysins of various enzymatic activities and diverse modular architectures.
Finally, Chapter 5 takes the techniques developed in the preceding
chapter and reapplies them back to a genomic DNA library. While the two-step
screen was designed with metagenomes in mind, it is still applicable to more
traditional sources of lysins. In this respect, the genome of a clinical strain of
Streptococcus suis (a veterinary and opportunistic human pathogen) was subject
to the screen, and a single prophage lysin was successfully cloned (PlySs1). An
additional prophage lysin (PlySs2) was likewise identified and cloned via
inspection of various published S. suis genomes (i.e. in the same manner as
PlyCM). The PlySs1 lysin was subsequently purified and characterized so that it
could be included in an ongoing veterinary trial involving experimentallyinfected pigs.

Dissertation format. At this point, before going on to present the research itself,
it is necessary to provide some brief logistical information on the format of this
thesis. Although the work presented here is designed to be read as a single
coherent document from beginning to end, Chapters 2 - 5 each represent a
distinct sub-study in its own right. For every individual chapter, the work
described has been drafted into a separate manuscript for publication in a peerreviewed journal. One of the studies (corresponding to Chapters 3) has already
been accepted (Schmitz et al. 2008); the work in Chapter 4 has been submitted
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and is currently under review (Schmitz et al. 2010b); and the work in Chapters 2
and 5 will be submitted shortly. Moreover, it should be noted that portions of
this Introduction and have appeared in similar form in a recently published text
(Schmitz et al. 2010a). As a result of this breakdown, Chapters 2 -5 have been
formatted so that (if desired) each can be read individually without loss of
comprehension.
The layout of Chapter 2 - 5 is each essentially the same. They begin with
an Introduction that provides additional background information on the
particular research-related aspects of the chapter (for instance, this is where the
reader would find an overview of C. perfringens, S. suis, or the field of
metagenomics). The Materials and Methods section details the experimental
protocols employed in the chapter. The data itself is reported in Results, and the
Discussion analyzes the significance of that data in light of the current state of the
field. Several chapters include endnotes that provide additional commentary on
particular points in the text. Chapter 6 reflects upon the entire body of work and
comments on future avenues for lysin discovery (as well as the discovery of
enzybiotics other than phage lysins). A single References section is included at
the end of the document, along with an appendix that provides sequence
information (DNA and amino acid) for all genes cloned here.
From reading this thesis, one should gain an appreciation of just how
rapidly the study of phage lysins and other enzybiotics has accelerated in recent
years. Considering the unrelenting emergence of antibiotic resistance, this work
82

should continue unabated into the foreseeable future. Its eventual goal, of
course, is to develop these agents to the point where they can have a positive
impact on human health. The process will take time, effort, good science, and a
little luck. But, fundamentally, it is still dependent on the efficient and intelligent
identification of candidate enzymes. It is my hope that the work presented here
will contribute to that process, and (at least in a small way) will help bring the
term enzybiotic from a promising idea to a proven reality.

ENDNOTES
1. While it is true that several reports have documented the use of lytic enzymes
against viable Gram-negative organisms (Alakomi et al. 2000; Morita et al. 2001a;
Kim 2004; Briers et al. 2008), this activity was either quantitatively weak or
required the addition of a general membrane-disrupting agent. One should note,
however, that co-treatment of Gram-negative bacteria with a membranepermeabilizing agent and a peptidoglycan hydrolase is already a common
practice: it is the basis of commercial genomic extraction techniques and has
various shortcomings from a drug-development perspective.

2. In the body of the text, we discuss the prevalent strategy for fragmenting and
transforming phage genomic DNA for lysin screening (i.e. shotgun cloning into
plasmid vectors). Although no longer generally employed, alternative screening
techniques were occasionally used in early studies. For example, when cloning
the lysin of a lactococcal phage, Shearman et al. utilized a -phage system that
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relied upon infected E. coli for recombinant lysin expression (1989). Henrich et
al. also employed -phage when cloning a Lactobacillus lysin. This study
involved a defective -strain that required ligation of a complementary lysis
cassette to form plaques on E. coli (1995).
Furthermore, one should note that E. coli is not the only host that, in
theory, could be used for lysin screening. While it has been utilized exclusively
to date, there is nothing about this species that makes it particularly well-suited
for identifying lytic clones (other than the commercial prevalence of E. coli
expression systems). Lysins have been expressed recombinantly from other
bacterial species for purification purposesand, in certain cases, these alternate
species offered superior expression to E. coli (Yoong et al. 2004).

3. It is not always possible, however, to determine such information from a
nucleotide sequence alone. While analysis of a lysin‘s sequence typically reveals
a conserved domainwhich, in turn, implies an enzymatic mechanismlytic
enzymes with ambiguous domains are still reported (see the section ―SequenceBased versus Functional: Pros and Cons‖). Moreover, computational analysis
alone can occasionally make mistakes regarding a lysin‘s biochemical properties.
For example, one recent study describes two S. agalactiae lysins that were
predicted to encode alanine-amidase enzymatic domains. Following expression
and functional testing, they were instead determined to possess endopeptidase
and glucosaminidase activity (Pritchard et al. 2007).
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It is important to note that, for most phage lysins that have been studied
recombinantly, the reported enzymatic activity was based on computational
predictions rather than experimental observations. While these predictions
should be correct in a majority of circumstances, it still leaves open the
possibility for occasional errors.
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CHAPTER 2
Lysins without Phage:
Bacterial Genomes and Proviral Enzymes

INTRODUCTION
Over the past decade, phage lytic enzymes (a.k.a. lysins or endolysins)
have been the focus of a great deal of applied microbiological research (Villa and
Veiga-Crespo 2010; Fischetti 2008; Borysowski et al. 2005; Loessner 2005).
Encoded by virtually all double-stranded DNA phage, lysins are expressed late
in the cycle of phage infection. They are responsible for hydrolyzing the
peptidoglycan of the host bacterium and—along with membrane permeablizing
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proteins known as holins—they allow progeny viral particles to escape the
cytoplasm and reinfect new cells (Gasset 2010).
Biotechnological interest in these proteins stems from their ability to lyse
Gram-positive species when applied exogenously, as the peptidoglycan of these
organisms is directly accessible from the extracellular space. Phage lysins have
been proposed as novel enzybiotic (enzyme-antibiotic) agents against human and
veterinary pathogens, in addition to other potential uses in the areas of food
(Deutsch et al. 2004), agricultural (Kim et al. 2004), and industrial (Ye and Zhang
2008) science. Numerous individual lysins have been recombinantly expressed
and characterized to date, including successful in vivo trials involving various
animal models of colonization and infection (Daniel et al. 2010; Grandgirard et al.
2008; Nelson et al. 2001). Their appeal lies in both their potency and their
specificity toward individual bacterial species, typically the host organism of the
encoding phage.
Both enzymatically and architecturally, the lysins are a highly diverse
group of proteins. Gram-positive lysins are classically modular, 250-400 amino
acids in length, with an N-terminal enzymatic domain and a C-terminal binding
domain (Fischetti 2008). The enzymatic domain itself can target numerous bonds
within the peptidoglycan macromolecule. These include: muramidase (glycan
backbone, Porter et al. 2007), glucosaminidase (glycan backbone, Pritchard et al.
2007), alanine-amidase (stem position ; Schuch et al. 2002), alanoyl-glutamate
endopeptidase (stem position ; Korndörfer et al. 2008), glutaminyl-lysine
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endopeptidase (stem position ; Pritchard et al. 2007), and cross-bridge
endopeptidase (Baker et al. 2006). The C-terminal domain likewise binds one of
various epitopes within the target cell envelope (e.g. surface carbohydrate,
choline, or peptidoglycan itself), and it is largely responsible for the specificity of
a lysin toward particular bacteria (Diaz et al. 1991). Gram-negative lysins, by
contrast, are typically smaller and are comprised of an enzymatic domain alone.
Occasionally, lysins are identified that do not conform to standard architectures,
including Gram-positive lysins with multiple enzymatic domains (Baker et al.
2006), Gram-negative lysins with an N-terminal binding domain (Briers et al
2007), and a multimeric Gram-positive lysin (Nelson et al. 2006).
Most lysins characterized to date have been cloned through traditional
phage genomic techniques (Schmitz et al. 2010a). Here, a phage is first isolated
through environmental sampling or prophage induction, and its genomic DNA
is extracted following laboratory culture. At this point, either the phage genome
may be sequenced and the lysin-encoding ORF identified through sequence
homology with known enzymes, or the DNA can be fragmented and subjected to
a recombinant functional screen. In the latter case, the lysin-encoding fragment
is identified by its ability to confer a bacteriolytic phenotype on a host clone.
While generally successful, these methods are still rather time-consuming and
wholly defendant on the successful isolation/propagation of the initial phage.
Moreover, they cannot predict a priori how novel the identified lysin will be
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relative to previously-characterized enzymes, nor can they assess total lysin
diversity for a particular bacterial host.
In this regard, the rapidly expanding number of published bacterial
genome sequences (1000+ at the time of writing) could prove quite valuable.
Representative genomes have now been sequenced for hundreds of bacterial
species; for many medically/technologically-relevant bacteria, numerous
individual strains have been sequenced
(www.ncbi.nlm.nih.gov/genomes/lproks.cgi). If a particular strain is
lysogenized with prophage, its genome becomes an easy source of lytic enzymes,
which can be rapidly cloned through PCR. In the case of polylysogenized strains
or species with multiple sequenced strains, one can systematically compare the
different lysins and their predicted properties (particularly enzymatic and
binding domains) before choosing which one(s) to express. In the current study,
we wished to do precisely this—computationally analyze all known prophage
lysins for a particular Gram-positive pathogen, and use this information as a
guide for subsequent recombinant analysis.
For this work, we chose to focus on the spore-forming, anaerobic rod
Clostridium perfringens, one of the most frequently encountered species of
clostridia in clinical and environmental laboratories. C. perfringens is a common
component of healthy human feces, and it is found in the digestive tracts of
many other vertebrate and non-vertebrate animals, as well as environmental soil
samples (Matches et al. 1974). Despite its ubiquity, C. perfringens can
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nevertheless be the etiological agent of various pathologies. The species is
taxonomically subdivided into five toxinotypes (A-E) based on the combinatorial
presence of at least 15 exotoxins gene, including alpha, beta, beta-2, epsilon, iota,
and enterotoxin/CPE (Smedly et al. 2004). These toxins may be encoded on
mobile genetic elements and they help determine a strain‘s pathogenic potential.
The most commonly encountered toxinotype of the healthy human bowel
(enterotoxin-negative type A, Carman et al. 2008) can induce myonecrosis in the
context of wound infection (Bryant and Stevens 1997). Enterotoxin-positive type
A strains are prevalent agents of food-borne illness, causing up to 600,000 cases
of self-limited enteritis annually in the United States (McClane 1997). And while
cases are uncommon, type C strains are the agents of the potentially-fatal gut
condition enteritis necroticans (Lawrence 1997). In addition to these human
illnesses, all 5 toxinotypes of C. perfringens have been implicated in various
maladies of poultry and livestock (van Immerseel et al. 2009; Uzal and Songer
2008).
To date, a single phage lysin for C. perfringens has been subject to
recombinant expression and analysis. Zimmer et al. (2002a) induced a temperate
siphovirus (3626) from toxinotype B strain ATCC 3626 and sequenced the
phage‘s 33.5 kB genome. The ORF encoding the lytic enzyme (Ply3626) was
subsequently identified by sequence homology and cloned into an inducible E.
coli expression plasmid (Zimmer et al. 2002b). The authors demonstrated that
crude extracts of the induced E. coli clone were capable of lysing buffered
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suspensions of viable C. perfringens. Although the degree of lysis varied from
strain to strain, every isolate of C. perfringens tested (48/48) demonstrated
susceptibility to Ply3626, even ones that were not susceptible to infection by the
phage itself. In comparison, non-perfringens clostridia and other Gram-positive
genera demonstrated virtually no susceptibility to the lysin. It has subsequently
been suggested that Ply3626 could be used as a topical agent or food additive to
prevent associated illnesses (Jay et al. 2005; Zimmer et al. 2008).
Since the above work on Ply3626, the genomes of 9 different strains of C.
perfringens have been sequenced, all of which contain identifiable prophage
regions (Shimizu et al. 2002; Myers et al. 2006;
gsc.jcvi.org/projects/msc/clostridium/). In the present study, we systematically
examined the prophage lysins in these sequences, comparing them based on
sequence homology and domain composition. In the process, we identified 14
lysin genes and 31 lysin-like genes (the latter being defined as having high
homology to the lysins throughout their entire sequence, lacking a signal
peptide, but not being encoded in a recognizable prophage region). These
proteins could be categorized into three enzymatic classes: type 2 alanineamidase, type 3 alanine-amidase, and muramidase (glycosyl hydrolase, type 25).
Of the identified genes, a muramidase lysin from strain ATCC 13124 was
selected for cloning and expression based on its divergent catalytic mechanism
from Ply3626. Following purification, the enzyme (termed PlyCM, for clostridial
muramidase) was subject to a variety of in vitro tests to determine its potency,
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specificity, and biochemical properties. Overall, this work adds another phage
lysin to the growing list of candidate enzybiotics, demonstrating an important
role for comparative genomics in the development of these proteins.
MATERIALS AND METHODS
Computational identification/analysis of lytic enzymes. The genomes of the
following sequenced strains of C. perfringens were included in this study: ATCC
13124 (toxinotype A, NCBI genome project #304); SM101 (A, #2521); 13 (A, #79);
F4969 (A, #20031); NCTC 8239 (A, #20033); ATCC 3626 (B, #20027); JGS1495 (C,
#20025); JGS1721 (D, #28587); JGS1987 (E, #20029). The first step in compiling a
comprehensive list of prophage lysins was to identify obvious proviral regions
within each genome. This was accomplished through a combination of manual
inspection of the annotated ORFs and use of the prophage prediction algorithm
Prophinder (Lima-Mendez et al. 2008).
The lysin-encoding ORFs within each prophage regions were next
selected. In many cases, these ORFs were already designated explicitly (e.g.
―endolysin‖) by the database annotation. For other prophage, the existing
annotations were insufficient—in these cases, we performed Pfam domain
analysis on the individual proteins in the region (Finn et al. 2009;
pfam.sanger.ac.uk/). A set of several criteria (described in detail in the Results
section) were applied to the Pfam predictions in order to designate a lysin for
each case, and a preliminary list of probable lysin-encoding ORFs was compiled.
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To ensure that no enzymes were overlooked in the process (for instance, ones
encoded within short prophage remnants) the list was subjected to iterative Blast
analysis (Altschul et al. 1990; blast.ncbi.nlm.nih.gov/Blast.cgi). The protein
sequences on the initial list were BlastP-queried against the nine sequenced C.
perfringens genomes. Any newly-identified homologs were added to the original
list, and the process was repeated until no new ORFs were revealed. The
aforementioned criteria were then applied to the expanded list to eliminate any
ORFs that were included erroneously.
The sequences comprising this final list were phylogenetically compared
to one another through the Phylip v3.67 package (Felsenstein 1989;
evolution.gs.washington.edu/phylip.html). The translated protein sequences
were subject to multiple sequence alignment through the ClustalX algorithm,
followed by 1000 rounds of boot-strapping with seqboot. These alignments were
analyzed in turn by the protdist (distance matrix generating) and fitch (tree
generating) algorithms with default settings, and an unrooted consensus tree
was generated with consense. The enzymes were compared with other known
proteins with the BlastP algorithm (blast.ncbi.nlm.nih.gov/Blast.cgi), using
default search settings and the non-redundant protein database (nr). Signal
peptide predictions were made via the SignalP v3.0 server (Bendston et al. 2004;
www.cbs.dtu.dk/services/SignalP/), employing both hidden Markov and
neural network methods and the Gram-positive bacteria organism group.
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Expression and purification of PlyCM. Extracted genomic DNA from C.
perfringens ATCC 13124 was subjected to taq-based PCR amplification with the
following PlyCM-targeted primers:
ACCATGGAAAGTAGAAACAATAATAATTTAAAAGG (fwd) and
GTCAGATATTACTCTAACTAACCTTAAAA (rev). The underlined G in the
forward primer was intentionally altered from the wild-type C at that position (a
Q2E mutation) in order to introduce an NcoI restriction site that overlaps with
the start codon. The PCR amplicon was topoisomerase cloned into pBad-TOPO
(Invitrogen), an arabinose-inducible E. coli expression plasmid. This construct
was subsequently purified, NcoI-digested, and re-circularized to eliminate a
plasmid-encoded N-terminal leader sequence and ensure translation from the
native start codon. This final construct was maintained and expressed in TOP10
E. coli.
To express PlyCM, the clone was grown in LB broth to OD600 ≈ 0.5 and
induced with 0.2% L-(+)-arabinose. Following induction, the culture was shaken
rigorously overnight at 30C; this specific temperature was important, as
inclusion bodies preferentially formed at 37C. The expressing cells were
pelleted, resuspended in 15 mM phosphate buffer pH 7.4, and lysed by three
passages through an EmulsiFlex C-5 homogenizer. Cellular debris was removed
by ultracentrifugation (1 hr, 35,000 X g), and the supernatant was (NH4)2SO4precipitated to 40% saturation (226 g/L). The precipitated protein (which
included the predominant amount of PlyCM) was pelleted, resolubilized in 15
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mM phosphate buffer pH 7.4 (buffer A), and dialyzed against this buffer
overnight.
The protein solution was next passed through a DEAE anion-exchange
column equilibrated against buffer A (fast flow resin, General Electric). Based on
PlyCM‘s theoretical isoelectric point of 5.1, one would predict it to bind to DEAE
at a pH of 7.4. Nevertheless, the protein demonstrated an unusual
chromatographic response: it neither bound the column in earnest nor flowed
directly through it. Rather, there was a transient interaction in which PlyCM
would initially bind the resin, but then slowly elute over 5+ column volumes as
the column was washed with buffer A (see Figure 2.1). Although atypical, this
property provided a fortuitous purification step, as PlyCM could be separated
from the proteins in both the flow-through and tightly-bound fractions. The
PlyCM-containing ―slow wash fraction‖ was immediately passed through a
ceramic hyroxyapatite column (Macro-Prep type II, 40 m, Bio-Rad) equilibrated
against the same buffer A. The lysin demonstrated non-transient binding to this
resin, and it was subsequently concentrated/purified through a 20 columnvolume elution with buffer B (500 mM phosphate buffer pH 7.4), eluting at ~80
mM.
In the hours following purification, we observed that PlyCM would
undergo irreversible precipitation in simple phosphate buffer. Addition of Larginine to the lysin solution mitigated the precipitation, as has been reported for
other recombinant proteins (Hamada et al. 2009).
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DEAE

CHT

Figure 2.1 PlyCM Purification
PlyCM was purified through a combination of DEAE and CHT
chromatography, as described in the Materials and Methods section.
Chromatograms for each successive step are presented here. In both cases, the
peak corresponding to PlyCM is denoted with an arrow.
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As a result, 100 mM L-arginine (pH = 7.4) was included in the PlyCM stockpreparation prior to freezing, lyophilization, and storage at -20C. Overall, the
above protocol generated ~10 mg of purified PlyCM per liter of original E. coli
culture.
In vitro analysis of PlyCM. The activity of PlyCM was examined predominately
through optical density analysis. The various strains/species of bacteria were
grown on agar plates at 37C. Schaedler agar with vitamin K1 and 5% sheep‘s
blood (Becton Dickinson) was employed for clostridial strains (perfringens and
non-perfringens), and the bacteria were grown under anaerobic conditions. For
all non-clostridial strains, brain-heart infusion agar was employed with aerobic
culture. Following overnight growth, bacteria were scraped from the plates and
suspended directly in buffer (which varied depending on the particular
experiment) to the desired optical density. PlyCM or lysin vehicle was added
immediately prior to the start of each experiment, and OD600-measurments were
conducted in 96-well plate format at 22C. For experiments that involved CFUcounts, each C. perfringens sample was diluted over five orders of magnitude,
with triplicate plating at each dilution onto Schaedler agar.
RESULTS
We sought to compile a comprehensive list of phage lysins within all
sequenced genomes of C. perfringens. In doing so, the following criteria were
used for designating a given ORF as a probable lysin: [1] The presence of an N97

terminal enzymatic domain; [2] the presence of a C-terminal binding region1; [3]
the absence of an N-terminal signal peptide; and [4] the absence of any
additional domains with non-lysin function. The third criterion is important
because bacteria encode chromosomal peptidoglycan hydrolases (autolysins)
that are involved in processes such as cell wall turnover, sporulation, and
programmed death (Vollmer et al. 2008b). Some autolysins possess the same
domain architecture as phage lysins, except that they also typically include a
signal peptide and transverse the plasma membrane via the type-II pathway
(rather than with the aid of holins). The fourth criterion is significant because
phage themselves can encode other proteins (i.e. not lysins proper) that include
peptidoglycan hydrolase domains, particularly structural proteins involved with
DNA-injection (Rashel et al. 2008). Usually, however, these structural lysins are
readily discernable by their much greater size (upwards of 1000 amino acids) and
the presence of additional domains.
In total, 45 ORFs were identified with the above criteria. The GenBank
accession numbers for their protein translations are provided in Figure 2.2,
which depicts the predicted evolutionary relationships among the enzymes as a
consensus phylogram. Of the 45 proteins, 23 were predicted to possess Nacetylmuramidase activity with an N-terminal GH-25 domain (glycosyl
hydrolase type 25, Pfam accession number PF01183). The 22 others were
predicted to possess N-acetylmuramoyl-L-alanine-amidase activity.
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Figure 2.2 Lysin-Like ORFs in C. perfringens Genomes
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Figure 2.2, continued
The phylogenetic relationship among C. perfringens enzymes with phagelysin-like architectures is depicted here as a distance-based phylogenetic
tree; the numbers at select nodes represent the consensus values following
1000 rounds of bootstrap analysis. The catalytic domain of each protein is
indicated with the corresponding color scheme (see inset). The proteins for
which pfam analysis predicted a C-terminal SH3 type 3 domain (either a
single or a dual) are marked with an asterisk*. Of these 45 proteins, 14
appear to be phage lysins proper, in that they are encoded within proviral
regions within the C. perfringens genomes. These are denoted with an
underline. The other lysin-like proteins are highly homologous to the phage
enzymes, but reside elsewhere in the chromosome or in an associated
plasmid.
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Three encoded a type 2 alanine-amidase domain (PF01510), while 19 encoded a
type 3 alanine-amidase domain (PF01520). Although these two alanine-amidase
families diverge sequentially, they target the same bond at the beginning of
peptidoglycan‘s pentapeptide stem. The only other characterized C. perfringens
phage lysin, Ply3626, is a type 3 alanine-amidase and is specified in the figure.
At their C-termini, 38/45 enzymes (also denoted in Figure 2.2) contained
either a single or a double SH3-3 binding domain (PF08239). For some of the
proteins, the degree of alignment with the SH3-3 consensus sequence was rather
low (E-value range: 10-17 – 0.03). Although the molecular epitope is not well
characterized, bacterial SH3 domains are commonly found in autolysins and
phage lysins, and they presumed to function in binding the bacterial cell wall
(Xu et al. 2009). The other 7 enzymes possessed extended C-terminal regions (see
Footnote 1), although Pfam failed to recognize any conserved domains. One of
these proteins, ZP_02636955, demonstrated Blast homology with the C-terminal
regions of several of the other 45 enzymes. Most likely, ZP_02636955 possesses
the same binding functionality as the others, although its C-terminal domain
differs too greatly from the SH3-3 consensus for Pfam recognition. Another
enzyme, NP_562054, demonstrated closest C-terminal alignment (E-value ≈ 10-35)
to a segment found within the C. perfringens bacteriocin BCN5 (Garnier and Cole
1986). Finally, a group of 5 muramidases (all clustered together in Figure 2.2),
contained C-terminal regions that—while nearly identical to one another—
showed no homology to any other C. perfringens proteins.
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Based on the selection criteria, we initially assumed all 45 of these proteins
to represent legitimate phage lysins of proviral origin. After inspecting the
position of the ORFs within their respective genomes, however, it soon became
apparent that this was not the case. Many of the proteins (31/45) were encoded
in genomic regions that did not correspond to prophage or prophage remnants.
In fact, several patterns existed as to where these genes were encoded within the
9 sequenced strains, including in the vicinity of UV-inducible bacteriocins. The
common occurrence of these lysin-like proteins within C. perfringens raises several
interesting questions, and the issue will be discussed further in the Discussion
section. Fourteen of the enzymes did reside in clear prophage regions (i.e.
adjacent to other viral proteins). Underlined in Figure 2.2, these enzymes include
a combination of muramidases, type 2 alanine-amidases, and type 3 alanineamidases. The first two categories are of particular interest, as lysins of these
classes have never been purified and characterized for C. perfringens.
We decided to focus our subsequent efforts on a prophage muramidase
encoded by the CPE-negative toxinotype A strain ATCC 13124 (which is also the
original type-strain for the species). We hereafter refer to this protein,
YP_695420, as PlyCM (for C. perfringens muramidase). It is one of 2 prophage
lysins encoded by ATCC 13124, the other being muramidase YP_696011. Several
other non-perfringens phage lysins with GH-25 lytic domains have been
characterized to date. These enzymes are summarized in Figure 2.3a, along with
the binding domains with which they are paired.
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Figure 2.3a Architectural Diversity among GH25 Phage Lysins
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Figure 2.3a, continued
Several phage lytic enzymes containing a GH-25 muramidase domain (all
from non-clostridial phage) have been recombinantly expressed and studied
to date. These are depicted here along with the variety of C-terminal
binding domains with which they are paired. Lysins for which a crystal
structure has been solved are indicated with an asterisk*. Included are:
CPL-1 from Streptococcus pneumoniae, choline bindings repeats (pfam
PF01473; GenBank ABC88204; Hermoso et al 2003); CPL-7 from S.
pneumoniae, eponymous binding repeats (PF08230; AAA72844; García et al.
1990); PlyB from Bacillus anthracis, SH3-5 binding domain (PF08460;

2NW0_A; Porter et al. 2007); PlyPH from B. anthracis, conserved hypothetical
binding domain (PF12123; NP_845154; Yoong et al. 2006); Lyb5 from
Lactobacillus fermentum, LysM binding domains (PF01476; ABP88927; Wang
et al. 2008); and PlyGBS from Streptococcus agalactiae, single SH3-3 binding
domain (PF08239; AAR99416; Cheng et al. 2005). Also listed (in the inset)
are several basic characteristics of the PlyCM lysin studied here.
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In Figure 2.3b, the GH-25 domain of PlyCM is aligned with that of 2 nonclostridial lysins, ones for which crystal structures have been solved (Hermoso et
al. 2003; Porter et al. 2007). As shown, the catalytic residues are conserved in all
3 cases.
PlyCM was recombinantly expressed in E. coli and purified by column
chromatography (Figure 2.4). The lysin showed clear bacteriolytic activity in
vitro against the encoding strain ATCC 13124. When added to a buffered
suspension (20/10 mM phosphate/citrate pH 6.4) of live cells for 1 hr, PlyCM
generated a ~70% reduction in bacterial turbidity at low nM (low-to-sub g/ml)
concentrations (Figure 2.5). The time-versus-OD response for PlyCM is very
similar to that which was observed for Ply3626 against its host strain (Zimmer et
al. 2002b). The required concentration of PlyCM is also commensurate with
values observed for other Gram-positive bacteria and their respective lysins
(Fischetti 2008). The residual turbidity after 1 hr of treatment can be considered a
baseline value for these buffering conditions—neither increasing the lysin
concentration nor the incubation time lead to further OD-declines. The reader
should note that this baseline OD does not correspond to quantitative viability
levels (see CFU analysis below).
Acidity represents one of the most important variables affecting lysin
activity, so we sought to determine the effect of pH on PlyCM. Two sets of ODdrop experiments were conducted in which pH was varied at a constant lysin
concentration.
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Figure 2.3b GH25 Domain Alignment
The GH-25 catalytic domain of PlyCM is aligned with those of CPL-1 and PlyB.
Three-way and pair-wise identities are indicated with a blue/pink/
yellow/gray color-scheme. Putative catalytic residues (see Porter et al. 2007) are
denoted with arrows.
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Figure 2.4 Purified PlyCM
PlyCM was purified following recombinant expression in E. coli. Lane 1:

molecular weight ladder. Lane 2: crude extract of encoding strain prior to
induction. Lane 3: crude extract of encoding strain ~16 hours after induction.
Lane 4: final product following isolation protocol. By visual approximation,
PlyCM is > 90% pure; its band appears at the level of the 37 kDa marker
(predicted MW = 38.7 kDa).
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Figure 2.5a PlyCM-Induced Lysis (Time Course)
Depicted here is a representative example of an OD-drop experiment in
which lysin was added to a buffered suspension (20/10 mM phosphate/
citrate pH 6.4) of live host strain ATCC 13124. A 1.15 M (45 g/ml)
enzyme-treated sample and an untreated control are shown.
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Figure 2.5b PlyCM-Induced Lysis (Variable Concentration)
The PlyCM concentration was decreased 10-1000 fold from the level shown
in (A), and cell lysis was monitored over an hour. The figure reports
treated/untreated OD-ratios (to account for slight possible fluctuation in the
untreated) at 10-min intervals; the average of three independent experiments
is depicted. As the graph indicates, concentrations as low as 11.5 nM (450
ng/ml) were able to bring the OD to a baseline level within 1 hr. In

comparison, hen egg white lysozyme (HEWL, a non-specific eukaryotic
muramidase, NP_990612, PF00062) failed to affect the cells’ turbidity or
microscopic morphology after 1 hr at 500 g/ml.
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First, a broad-range buffer (25 mM boric/phosphoric acid) was utilized with a
variable pH of 3.0 - 10.5 and a PlyCM concentration of 115 nM (4.5 g/ml).
Enzymatic activity was observed between pH = 4.0 - 9.5, with a maximum from
6.5 – 8.0 (Figure 2.6a). To confirm these observations (and fine-tune an optimal
pH), a narrow-range buffer (20/10 mM phosphate/citrate) was utilized with
smaller pH-degradations and a lower PlyCM concentration (11.5 nM, 450
ng/ml). A similar profile was observed here (Figure 2.6b), with pH = 6.4 as the
center of activity.
Considering the acidic environment of the stomach (as well as many food
items), we wished to determine whether the loss-of-activity at low pH
represented a mechanistic inhibition or an irreversible denaturation. The latter
scenario turned out to be the case. PlyCM was buffered at a range of acidic pHs,
followed by titration back to pH = 6.5. Activity was subsequently lost for
samples at pH = 3.3 and below. The pH = 4.3 sample, however, exhibited an
identical lytic profile to the positive control maintained at pH = 6.5 (Figure 2.6c).
Several other biochemical characteristics of PlyCM were likewise
evaluated, in particular the temperature stability of the enzyme (this is important
given the potential use of a C. perfringens lysin in food science). Following
incubation at various temperatures for 30 min, PlyCM demonstrated a sharp loss
of activity (with concomitant flocculation) between 50C and 55C (Figure 2.7).
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Figure 2. 6a Broad pH Dependence
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Figure 2.6b Narrow pH Dependence
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Figure 2.6a/b, continued
[A] 115 nM PlyCM was incubated for 2 hr with suspensions of ATCC
13124 in a variable-pH boric/phosphoric acid buffer (pH: 3.0 – 10.5, 0.5
intervals, n = 3). By the end of the experiment, some degree of activity
was observed between pH = 4 - 9.5, although lysis was maximal from
6.5 – 8. [B] The experiments in [A] were repeated under more sensitive
digestion conditions. This include a 10-fold reduction in PlyCM
concentration and the use of a phosphate/citrate buffer (pH = 5.0 – 9.0,
0.2 intervals, n = 3). After 1 hr, maximal activity was centered around
pH = 6.4.
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Figure 2.6c Irreversible Acid Denaturation
Aliquots of PlyCM were diluted in 20/10 mM phosphate/citrate buffers of
various pH-values, yielding solutions whose final pHs are indicated in the
graph. Each aliquot was titrated back to pH = 6.5 with dibasic phosphate; a
positive control was maintained at pH = 6.5 for the entire experiment.
Following volume normalization (with phosphate/citrate pH = 6.5), lytic
enzyme was added to the cells (final PlyCM concentration = 58 nM, final pH
= 6.5) and lysis was observed for 2 hr. The sample brought to a pH = 4.3
showed identical activity to the positive control, while the others failed to
induce lysis.
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Figure 2.7 Temperature Stability of PlyCM
Stock concentrations of PlyCM were incubated for 30 min at the indicated
temperatures, after which they were added to buffered suspensions (pH 6.4) of
C. perfringens ATCC 13124 at 11.5 nM (450 ng/ml) for 1 hr. The figure reports
the treated/untreated OD-ratio for each temperature at 10-min intervals (n = 4).
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In separate experiments, molar excesses of either EDTA or DTT failed to inhibit
lysin activity (data not shown), indicating that PlyCM is not dependent upon
chelatable cations or intramolecular disulfide binds for activity.
The above experiments were all conducted in low-osmolarity suspensions
in which the only salt was the buffering agent. Seeing as any real-world
application would likely occur in a less hypotonic environment, we evaluated the
effect of salt on PlyCM-induced lysis. The experiments in Figure 2.5 were
repeated with 150 mM NaCl in the lysis buffer. Although the concentrationdependence of PlyCM was virtually identical, the baseline OD of the treated cells
jumped to ~60% of the untreated value (Figures 2.8a and 2.8b). Microscopic
inspection of the cells indicated the reason: in the presence of 150 mM NaCl,
many of the cells collapsed to spheroplast forms without extrusion of their
cytoplasmic contents (see Figures 2.8c and 2.8d, respectively, for phage contrast
and scanning electron micrographs).
In rod-shaped bacteria, the peptidoglycan layer serves two gross
morphological functions. It prevents osmotic lysis of hypertonic intracellular
contents and it maintains the bacilloid morphology, the natural lowest energy
form being coccoid (Pichoff and Lutkenhaus 2007). Presumably, the addition of
NaCl reduced the pressure on the cells to lyse, without affecting the pressureindependent collapse to spheroplasts. Indeed, when these lysin-treated cells
were pelleted and resuspended in salt-free solution, immediate lysis was
observed.
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Figure 2.8a NaCl Effect on Lysis in ATCC 13124 (Time Course)
A single lytic time-course is shown with 1.15 mM PlyCM (45g/ml) and
buffering conditions that include 150 mM NaCl (pH = 6.4).
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Figure 2.8b NaCl Effect on Lysis in ATCC 13124 (Variable Concentration)
The experiment in Figure 4b was repeated with the addition of 150 mM NaCl in
the final lysis buffer (for B, n = 3). The clostridia responded to PlyCM at nearly
identical concentrations as in Figure 4b, except that the OD would fall to a
maximum of 60% the untreated value.
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Untreated

Treated
150 mM NaCl

Figure 2.8c Light Microscopy of Lysin-Treated Cells in 150 mM NaCl
The image compares (1000X magnification) the gross morphology of
untreated ATCC 13124 with that of cells treated with 115 nM PlyCM for 1 hr
in the presence of 150 mM NaCl. Within the treated samples, there exists a
combination of collapsed spheroplasts (black arrow) that have maintained
their cytoplasmic contents and contribute to optical density, as well as
clostridial ghosts and ghost-fragments (red arrow) that have undergone
complete lysis.
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Untreated

Treated
150 mM NaCl

Figure 2.8d SEM of Lysin-Treated Cells in 150 mM NaCl
Scanning electron microscopy was also conducted on untreated and PlyCMtreated ATCC 13124 cells in the presence of 150 mM NaCl. The treated image
is dominated by clostridial spheroplasts; a presumptive ghost is denoted with
the red arrow.
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The preceding observations raise the question of whether the spheroplastlike clostridia are viable. Ultimately, bacterial death following lysin treatment is
a more significant metric than simple optical density. Accordingly, CFU-analysis
was conducted on cells treated in the presence of 150 mM NaCl. Despite the
residual turbidity, the cells were overwhelmingly non-viable. The following
percentages-killed were observed after 1 hr (relative to untreated, n = 5
independent experiments): 11.5 nM (86 – 99.2%); 115 nM (> 99.7%); 1.15 M (>
99.99%). These data indicate that, even in environments that are incompatible
with osmotic lysis, PlyCM exerts a potent lethal effect on ATCC 13124.
We next attempted to gauge the effect of PlyCM on actively-dividing cells.
Unfortunately, minimum-inhibitory-concentration (MIC) analysis in liquid
culture proved unsuccessful. At the concentrations employed in Figures 2.5 and
2.8, PlyCM failed to prevent proliferation of ATCC 13124. (An inoculum of ~5 X
105 cells/ml was used, the minimal value for standard CFU analysis, Wiegand et
al. 2008). Although we would have liked to repeat these experiments at higher
lysin concentrations, a technical barrier prevented it. As mentioned in Materials
and Methods, 100 mM L-arginine was added to the PlyCM stock solution to
prevent enzyme precipitation. Higher lysin concentrations would have likewise
necessitated elevated amounts of L-arginine in the media. In preliminary
experiments, however, we observed that mM-concentrations of this amino acid
could itself impact actively-dividing C. perfringens (the cells would proliferate
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with defective division, yielding elongated rod forms2). With this confounding
variable, we did not feel MIC analysis would be rigorously meaningful.
Finally, the activity of PlyCM was tested in vitro against a panel of other
bacterial species and strains. These include: 24 additional isolates of C.
perfringens (with representative examples of each toxinotype); 10 non-perfringens
clostridia; and 16 non-clostridial species of Gram-positive bacteria. We found it
necessary to conduct these experiments in a buffer (phosphate/citrate pH 6.4)
that included 150 mM NaCl; without this, many strains of C. perfringens would
self-adhere into macroscopic aggregates. Given the above observations
involving spheroplast-formation at 150 mM NaCl, we did not want to rely
exclusively on OD-measurements in evaluating the panel (as is typically done for
assessing a lysin‘s target range). Consequently, a semi-quantitative scoring
system was devised that relied upon microscopic inspection of the samples.
Strains were ranked on scale from 1 (equally sensitive or more sensitive than host
train ATCC 13124) to 4 (insensitive). The results of this panel are summarized in
Table 2.1 (see the table caption for the specific details of the scoring system).
Overall, 23/24 strains of C. perfringens demonstrated susceptibility to the
lysin, although the level varied quantitatively from strain to strain. Outside of C.
perfringens, only 3/10 other clostridia demonstrated susceptibility, and these
were ranked at the lowest level. Both of these findings are highly reminiscent of
patterns observed for Ply3626 (although its panel of strains was evaluated on OD
alone, Zimmer et al. 2002b).
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Species/Strain

Sensitivity

C. perfringens ATCC 13124 (Type A, CPE -)

I (reference)

C. perfringens ATCC 3624 (Type A, CPE -)

II

C. perfringens ATCC 12915 (Type A, CPE +)

II

C. perfringens ATCC 12916 (Type A, CPE +.)

III

C. perfringens ATCC 12917 (Type A, CPE +)

III

C. perfringens ATCC 12919 (Type A, CPE +)

II

C. perfringens ATCC 3626 (Type B)

I

C. perfringens ATCC 3628 (Type C)

I

C. perfringens NCTC 8346 (Type D)

II

C. perfringens ATCC 27324 (Type E)

III

C. perfringens: 3 untyped human fecal isolates

Two—I,
One—II

C. perfringens: 12 untyped canine fecal isolates

Three—I
Seven—II
One—III
One—IV

C. tetani ATCC 19406, C. septicum ATCC 12464,
C. beijerinckii ATCC 8260

III

C. difficile ATCC 43593, C. difficile ATCC 700057,
C. difficile ATCC 9689, C. histolyticum ATCC 19401,
C. sordelli ATCC 9714, C. sporogenes ATCC 3584,
C. bifermentans ATCC 638

IV

S. pyogenes D471, S. agalactiae 090R,
S. pneumoniae R36, S. mutans in-house strain,
E. faecalis V583, E. faecium EFSK-2,
S. aureus RN4220, S. epidermidis ATCC 12228,
M. lysodeikticus ATCC 4698, L. monocytogenes HER1083,
B. anthracis 222, B. cereus ATCC 14579,
B. subtilis SL4, B. thuringiensis HD-73,
B. megaterium in-house strain, G. vaginalis ATCC 14018,
P. aeruginosa PAO1, E. coli TOP10

IV

Table 2.1 PlyCM Species/Strain Specificity
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Table 2.1, continued
The above species/strains of bacteria were evaluated for their susceptibility
to PlyCM. If known, the toxinotype and CPE-status (for toxinotype A) are
listed for C. perfringens strains. Each bacteria was suspended in
phosphate/citrate buffer (pH = 6.4) + 150 mM NaCl and exposed to three

PlyCM-concentrations (11.5 nM, 115 nM, and 1.15 M). 11.5 nM represents
the lowest concentration that brought the host strain ATCC 13124 to
baseline OD (see Figures 4 and 7). After 1 hr, the samples were visualized
at 1000X-magnification and the OD was measured. Each bacteria was
assigned a rank based on the following semi-quantitative criteria: [I] 11.5
nM PlyCM induced complete lysis, or > 9/10 cells had converted from rodforms to spheroplasts; [II] 115 nM PlyCM lead to either preceding
observation; [III] 1.15 M PlyCM induced lysis/spheroplast conversion
(complete or partial); [IV] No lysis or spheroplast conversion was observed
after 1 hr, even at 1.15 M.
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The other non-clostridial bacteria were all insensitive to PlyCM treatment. In
total, this enzyme exhibits the kind of organism-specificity that has come to
characterize phage lysins in general.

DISCUSSION
The work presented here illustrates the general utility of bacterial genomic
sequencing in the identification of candidate enzybiotics. Moreover, the specific
protein expressed and characterized (PlyCM) exhibits potent bacteriolytic ability
in vitro, demonstrating potential as a novel antibacterial agent. In theory, phage
lysins seem well-suited as food additives to combat C. perfringens. It is true that
clostridia are spore-forming species, and that phage lysins are generally not
effective against dormant spores (due to the external exosporium). Nevertheless,
C. perfringens enteritis is not caused by the ingestion of spores, but rather
vegetative cells that have proliferated in food (most commonly meats and meat
broths). Rigorously-speaking, it does not represent food poisoning (i.e. involving
preformed toxin), but rather foodborne infection. It is estimated that ingestion
of > 108 vegetative bacteria are required for clinical symptoms (USFDA 2009). As
a result, an agent that could selectively reduce the overall bacterial load or
prevent its initial proliferation could prove quite useful.
Despite different enzymatic mechanisms, Ply3626 and PlyCM
demonstrated several noteworthy similarities to one another. The timedependant response of the host strain to treatment was nearly identical in both
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cases. And the two enzymes possessed broad activity against a panel of C.
perfringens strains, with little effect against other species and genera.
Quantitatively speaking, however, this level of sensitivity varied somewhat from
isolate to isolate. For both Ply3626 and PlyCM, the treatment-response of the
host strain was more pronounced than certain others. This observation
underscores the importance of developing complimentary lysins with varied
sequences and component domains. In fact, the ability to accomplish this
rationally and rapidly for a given pathogen is an inherent strength of
multigenomic sequence analysis.
In this regard, it would be informative for future work to consider the
combined effect of a muramidase like PlyCM and an alanine-amidase like
Ply3626. For instance, one could observe whether they normalize the strain-tostrain response or act synergistically with one another (as was observed for
pneumococci in Loeffler and Fischetti 2003). Going further, one could even
include non-viral enzymes in a combined treatment pool. Just recently, Camiade
et al. characterized an endogenous C. perfringens peptidoglycan hydrolase (an
autolysin) involved in cell division and stress responses (2010). This protein
(Acp) encodes a glucosaminidase domain (Pfam family PF01832), which is
distinct from all the sequences considered here. While autolysins have not
received as much attention from the applied research community, nothing in
theory would prevent them from functioning as enzybiotics alongside phage
lysins proper.
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In terms of future work on PlyCM, the immediate next steps must involve
the fine-tuning of certain biochemical properties. In particular, the issue of
solubility must be addressed; this would allow for increased concentrations of
lysin to be tested against actively-proliferating cells (either in culture media or in
the presence of actual food products). Possible strategies include the use of
additives other than arginine or the re-engineering of its sequence to increase
solubility. Specifically, the latter option could involve mutagenesis of the
encoding gene or the design of a chimeric lysin that combines PlyCM‘s
enzymatic domain with a different binding domain (either an SH3 domain with a
somewhat varied sequence or another domain type altogether). These strategies
have been employed successfully in the past to optimize the activity of other lytic
enzymes (Cheng and Fischetti 2007; Daniel et al. 2010).
Aside from the goal of enzybiotic development, one other relevant issue in
this chapter warrants further discussion. The initial genomic analysis revealed
numerous enzymes that possessed all the architectural properties of a lysin (Nterminal lytic region, C-terminal binding region, no signal peptide), but that did
not reside in a recognizable prophage region. Conceivably, they could represent
small prophage remnants from their hosts‘ evolutionary history. Nevertheless,
many of them demonstrated conserved genomic arrangements from strain to
strain, suggesting a dedicated in vivo role. In fact, these lysin-like proteins are
probably better classified as host autolysins, and their existence raises several
noteworthy questions. For instance, what biological purpose do they serve for
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the bacteria? And how do they gain access to the peptidoglycan layer without a
secretion signal?
Several of the enzymes (ZP_02863923, ZP_02639407, YP_696189,
ZP_02633392, NP_562418, ZP_02642513, ZP_02952533, YP_698802) are each
encoded in the vicinity of a putative histidine kinase and metallo-beta-lactamase.
They are classified as type 3 alanine-amidases, and are clustered together at the
bottom of the phylogram in Figure 1. Also clustered together in the figure are
several additional type 3 alanine-amidases (YP_699923, NP_040458, YP_209681,
ZP_02954906, YP_699912); for these enzymes, the genomic positioning suggests
an intriguing biological function. They are all encoded near UV-inducible C.
perfringens bacteriocins known as BCN5 proteins3. Four of these lysins are
located on plasmids, while one is chromosomal (ZP_02954906, strain JGS1721).
The BCN5 protein was first identified many years ago (Wolff and Ionesco
1975), as was its encoding gene within pIP404 plasmid of C. perfringens strain
CPN50 (Garnier and Cole 1986; Garnier and Cole 1988). When CPN50 is
irradiated, it undergoes partial autolysis with the induction and release of BCN5.
The resulting culture supernatant (or purified BCN5) is subsequently inhibitory
toward other C. perfringens. The genetic architecture of the BCN5-encoding
region is conserved within the several strains in which it has (now) been
sequenced. In each case, the ~2.7 kb bcn gene is immediately preceded by two
ORFs in the same orientation: the ~500 bp uviA followed by the ~200 bp uviB.
Dupuy et al. recently demonstrated that uviA encodes a DNA-damage inducible
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-factor responsible for bcn transcription (2005), although other aspects of BCN5
activity remain undefined. These include its antibacterial mechanism, as well as
the molecular events responsible for autolysis and concomitant BCN5
externalization (the bacteriocin contains no signal peptide). The role of uviB also
remains unknown, although it has been noted that it demonstrates Blasthomology to a Bacillus subtilis phage holin (Dupuy et al. 2005).
In this regard, the above group of 5 lysin-like proteins offers potentiallyvaluable insights. Each is encoded immediately upstream of uviA on the
opposite strand. When one considers the two ORFs between which uviA is
sandwiched, a hypothetical mechanism for BCN5 release becomes evident: a
phage-like process combining the murlaytic activity of the lysin with membrane
permeabilization by the uviB ―holin‖. The release of the lytic enzyme during
BCN5 induction could also contribute to the anti-clostridial effect attributed to
BCN5 itself.
Although not identical, this mechanism would be reminiscent of several
other ―non-traditional‖ methods by which bacteria externalize intercellular
contents. These include the damage-induced release of colicin from Escherichia
coli (Cascales et al. 2007; Lin et al. 2009), the secretion of virulence factors by C.
difficile (Tan et al. 2001); and the autolysis/allolysis of Streptococcus pneumoniae
during competence-programmed predation (Guiral et al. 2005). The latter
example involves the phage-lysin-like autolysin LytA; this enzyme has been
studied at length, although it too lacks a signal peptide and its export mechanism
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remains undetermined (Novak et al. 2000). Ongoing research will explore these
possibilities, as well as analyze whether similar elements exist in the published
genomes of other clostridia and Gram-positive bacteria.
In conclusion, the increasing ease of genomic sequencing is clearly
transforming the fields of both basic and applied microbiology. These genomes
are sources of both mechanisms and molecules, and it is through their careful
inspection that researchers might uncover new avenues for improving human
health and increasing general knowledge.
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ENDNOTES
1. ORFs that encoded an extended C-terminal region without a Pfam-recognized
binding domain were not excluded on this fact alone. There exist a number of
Gram-positive phage lysins for which this is indeed the case. Most likely, these
C-termini do possess a cell-wall binding functions, albeit ones that have not yet
been characterized and organized into conserved protein families.
2. It should be emphasized that L-arginine, in itself, had no effect on bacterial
turbidity or viability when cells were exposed to the amino acid for a short time
in buffered solution (as in previous experiments).
3. This is the same BCN5 mentioned previously in the text. It demonstrated
sequence-homology to the C-terminus of another C. perfringens lysin considered
here (NP_562054, a type 2 alanine-amidase of evident proviral origin).

**NOTE: In the manuscript to be submitted based on this chapter, the following
individuals will be listed as co-authors (in the stated order): Maria Cristina
Ossiprandi, Kareem Rumah, and Vincent Fischetti.
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CHAPTER 3
Functional Viral Metagenomics I:
The E-LASL Technique

INTRODUCTION
The rapidly growing field of metagenomics provides powerful new
methods for studying environmental microorganisms and the natural products
they synthesize (for reviews, see Green and Keller 2006; Ward 2006; Tringe and
Rubin 2005; Daniel 2005; Handelsman 2004). Metagenomics involves the direct
extraction of DNA or RNA from environmental samples (e.g. soil, sediment,
water, feces), without prior laboratory cultivation of individual species. The
appeal of metagenomics lies in the access it provides to genes and gene products
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that cannot be isolated through typical culture-based techniques. This is
significant considering that only a small percentage of environmental microbial
species (~1% of soil species, for instance) are thought to be culturable under
standard laboratory conditions (Torsvik and Ovreas 2002). Metagenomics is
particularly well suited for the analysis of extreme environments whose
conditions are notably difficult to reproduce in vitro (Baker et al. 2010).
Metagenomics research can be subdivided into two general categories:
sequence-based and functional. In sequence-based studies, the environmental
DNA (eDNA) is sequenced and compared to genetic databases to gain insight
into environmental diversity, phylogeny, and ecology. Notable examples
include a 76-megabase analysis of an acid mine biofilm (Tyson et al. 2004), a 1gigabase analysis of the Sargasso Sea (Venter et al. 2004), and an extensive
analysis of several oceanic samples (Rusch et al. 2007; Yooseph et al. 2007).
In functional metagenomics, by contrast, eDNA is transcribed and
translated directly within a host organism, and clones are screened for the
acquisition of a desired phenotype1. Although functional metagenomics has
constraints—such as the potential for low expression, misfolding, or clonal
toxicity—it has already identified a number of molecules with biotechnological
potential. These include regio- and enantio-selective biocatalysts (Ferrer et al.
2005), enzymes involved in vitamin biosynthesis (Eschenfeld et al. 2001), and
antibiotic-resistance mediators (Donato et al. 2010). These examples are far from
exhaustive, however, and the sorts of agents that could be targeted are
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essentially only limited by one‘s imagination and ability to devise a read-out for
identifying transformants. For several reviews that cover the broad goals of
functional metagenomics, the reader is referred to Li et al. (2009), Uchiyama and
Miyazaki (2009), Ferrer et al. (2005), and Voget et al. (2005).
It is important to note that functional metagenomic targets can be either
proteins transcribed from individual genes or small molecules synthesized by
several enzymes encoded by a contiguous cluster. Antibiotics are the most
prominent example of the latter (Brady et al. 2009; King et al. 2009; Courtois et al.
2003; Gillespie et al. 2002; Brady et al. 2001). In this case, cosmids are typically
utilized as the cloning vector (Brady 2007). Although they suffer (relative to
plasmids) in that induced transcription is not possible, cosmids are capable of
maintaining the lengthier inserts. One challenge regarding this sort of cloning is
that gene clusters are often so large that traditional techniques fail to capture
them in their entirety. This issue was recently addressed, however, by the use of
transformation-associated recombination (TAR), in which overlapping contigs
are reassembled in vivo (Kim et al. 2010). Typically, E. coli is used as the host
organism in metagenomic screens (both for single genes and gene clusters),
although other species have recently been employed with particular advantages
(Craig et al. 2010 and 2008; Kim et al, 2010).
It should also been noted that hybrid sequence-based/functional
approaches have also been used to identify novel agents (Bell et al. 2002,
Marchesi and Weightman 2003). Here, eDNA is amplified with degenerate
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primers targeted against conserved regions of known genes; the resultant
amplicons can then be sequenced and tested for activity. Single-primer genome
walking techniques are also possible, which allow for amplification of targeted
genes without the burden of having to specify a reverse sequence downstream
the gene of interest (Kotik 2009).
In addition to targeted amplification, random amplification has also
proved an important metagenomic tool, as it allows for analysis of small initial
quantities of eDNA (Rohwer et al. 2001; Delwart 2007). This is valuable in
situations where only a small amount of sample is available, where the purity of
the sample is low (Abutencia et al. 2006), or where the analysis involves only a
subset of an environmental population. An example of the latter is the growing
field of viral metagenomics (reviewed in Casas and Rohwer 2007; Delwart 2007,
Edwards and Rohwer 2005), in which bacteriophage particles or other viruses are
isolated prior to DNA (Angly et al. 2007; Breitbart et al. 2002 and 2003) or RNA
(Culley et al. 2006, Zhang et al. 2006) extraction. (The flowchart in Figure 3.1
depicts how the field of metagenomics can be broken-down into its individual
subfields: sequence-based versus functional, bacterial versus viral).
One previously-described method of amplification in viral metagenomics
is the linker-amplified shotgun library (LASL) approach (Breitbart et al. 2002). Here,
viral eDNA is mechanically fragmented, end-modified, and ligated to short
double-stranded linkers; PCR is then performed with primers directed against
the linkers.
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Figure 3.1 Metagenomics Flowchart
In metagenomic analyses, DNA is extracted directly from bulk environmental
samples without the initial isolation and laboratory culture of any individual
organisms. Metagenomics itself can be subdivided into several individual
categories. A primary distinction is between bacterial metagenomics and viral

metagenomics. In the former, total DNA (overwhelmingly bacterial in origin) is
purified from a sample, whereas in the latter, the viral (predominantly
bacteriophage) fraction is separated from the bacterial fraction prior to nucleic
acid extraction. Bacterial and viral metagenomics, in turn, can each be
subdivided into sequence-based and functional (i.e. involving screening)
studies.
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Although typically applied to metagenomic samples, the technique is equally
applicable to genomic samples and could be particularly useful for genomes
where the collection of large quantities of DNA is difficult or time-intensive
(such as with certain environmental bacteriophages or slow-growing microbes).
In this study, we have combined the LASL approach with topoisomerase
cloning to develop a rapid method of constructing expressible libraries with
gene-sized inserts. Topoisomerase cloning utilizes the ability of vaccinia-virus
topoisomerase to associate with terminal CCCTT motifs and ligate singlestranded threonine overhangs to complimentary adenines (Shuman 1994). 3‘adenine overhangs are generated automatically during Taq-based PCR by the
template-independent terminal transferase activity of the polymerase.
Amplification of genomic or metagenomic fragments with Taq polymerase,
therefore, allows for ligation in this manner. Our method is particularly well
suited for functional screens, as commercially-available topoisomerase cloning
kits allow for rapid ligation of PCR amplicons with subsequent inducible
transcription in E. coli. Consequently, we refer to these libraries as ―E-LASLs‖
(expressed linker-amplified shotgun libraries).
The utility of the technique was first demonstrated genomically with
libraries constructed from the DNA of several recently-isolated B. anthracis
bacteriophages. Antibacterial screening led to the identification of six new phage
lytic enzymes with activity against this species. One of these lysins is the closest
known homologue of a heretofore novel Bacillus muramidase, PlyB. Second, a
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metagenomic DNA library was constructed from the gut contents of the
European night crawler Eisenia hortensis. Functional screening of this library
identified a positive clone in a hemolysis screen. The resultant protein—a new
member of the aerolysin family—was purified and its activity confirmed against
erythrocytes from several species, as well as human epithelial cells. It is the first
example (to our knowledge) of a hemolysin isolated through functional
metagenomic screening.
In total, the E-LASL approach may be used to mine for numerous classes
of proteins from environmental bacteria and viruses. It is especially useful in
any scenario (genomic or metagenomic) in which larger quantities of DNA are
difficult or impossible to obtain, or where speed of library construction is of
particular importance.

MATERIALS AND METHODS
Isolation of Bacillus phage DNA. The following commercially-available brands
of bat and bird guano were screened for the presence of anti-Bacillus lytic phages:
[I] High Phosphorous Bat Guano 0-4-0, Fox Farm Soil and Fertilizer Company;
[II] Superswell 0-7-0, Guano Company International, Inc. (GCI); [III] Bat Guano
4-6-2, e-Bio Organic; [IV] Jamaican Bat Guano 1-10-0.2, Sunleaves.com; [V] DryBar Cave Bat 3-10-1, GCI; [VI] Desert Bat 8-4-1, GCI; [VII] Indonesian Bat Guano
0.5-12-0.2, Sunleaves.com; [VIII] Budswell 0-7-0, The Guano Company; [IX]
Peruvian Seabird Guano 10-10-2, Sunleaves.com; [X] Mexican Bat Guano 10-2-1,
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Sunleaves.com; [XI] Original Sea Bird 13-12-2, GCI; [XII] Fossilized Sea Bird 1-101, GCI; [XIII] Peruvian Seabird 10-10-2.5, GCI.
For each sample, ~5 g of guano were added to an equal volume of PBS
(pH = 7.4) and shaken overnight at room temperature. The emulsions were
centrifuged (20 min, 4,000 X g), and the supernatant passed twice through 0.22micron PES filters (Millipore). Samples were loaded into 15-ml spin
concentrators (15 kDa MWCO, Amicon) and reduced to ~100 l. Each
concentrate was spread on freshly solidified fields of BHI soft-agar impregnated
with B. anthracis strain Sterne (3 ml molten soft-agar, 200 l stationary-phase
culture, 10-cm plates).
Plates were incubated overnight at 30C and inspected for plaques, which
were noted for samples I - VII. Of these, isolates I - IV were chosen for further
use in this study (designated BG-1, BG-2, BG-3, and BG-4). Phages were
propagated for three generations on soft-agar, followed by two days of liquid
culture (20 ml BHI, mid-log phase B. anthracis, 30C). Following bacterial
pelleting and sterile filtration, the culture solutions were subject to
ultracentrifugation in a cesium chloride step gradient (150 min, 22,000 X g) and
the phage-containing (1.45)/(1.5) interface was collected (Sambrook et al.
1989). DNA was extracted directly by phenol-chloroform treatment, with
chloroform wash and ethanol precipitation.
In addition to these phages, several additional Bacillus cereus sensu latu
phages (A10, A14, A17, and TSH) were provided by Mr. Tommie Hata of the
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Pingry School (Martinsville, New Jersey). They were isolated from
environmental sources by local high-school students as part of a scienceeducation curriculum (Hata 2010). As they were already purified as high-titer
stocks; these phages were subjected directly to genomic extraction without
further purification.
Isolation of worm-gut DNA. The method was adapted from Steffan and Atlas
(1988). Live earthworms (species Eisenia hortensis) were isolated from forest litter
from Stroudsburg, Pennsylvania. A single large adult was washed twice in
phosphate buffered saline (pH = 7.4) and twice in dH2O. The worm was
transected into four equal sections to ease isolation of gut contents, which were
manually extracted and resuspended in 1X PBS. The contents were pooled,
sterile dH2O was added, and the suspension was vortexed vigorously. The
sample was centrifuged for 10 min at 1000 x g to remove large debris and soil
particles. This step was repeated twice and the supernatants were pooled and
centrifuged at 10,000 x G for 30 min.
The resulting bacterial pellet was resuspended in buffer (350 mM Tris-Cl,
pH 8.0 + 10 mM EDTA) and centrifuged at 10,000 x g for 30 min. The pellet was
resuspended in 1 ml of the same buffer, lysozyme was added (5 mg/ml final
concentration), and the suspension was incubated at 37ºC for 1 hr. Following a
5-min incubation at 60ºC, SDS was added (1% final concentration) and the
suspension was incubated at 60ºC for 10 additional min. The suspension was
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cooled on ice for 1 hr and centrifuged at 12,000 x g for 20 min at 4ºC. Solid
ammonium acetate was added to the lysate to a final concentration of 2.5 M and
centrifuged at 12,000 x g for 30 min at 4ºC. DNA in the supernatant was
precipitated by adding 2.5 volumes of ice-cold ethanol and incubated at -70ºC for
1 hr followed by centrifugation at 12,000 x g for 30 min at 4ºC. The pellet was
washed with 70% ethanol, air-dried, and resuspended in appropriate amount of
TE buffer (10 mM Tris-Cl, pH 8.0, 1 mM EDTA).

Construction of E-LASLs. 0.01 or 0.1 units Tsp509I (diluted in 1X NEB Buffer II)
were added to 100 ng genomic or metagenomic DNA in 50 l total volume 1X
NEB Buffer II. Samples were incubated at 65C for 1 min and an equal volume of
25:24:1 phenol:chloroform:isoamyl alcohol (Roche) was added to terminate the
digestion. The aqueous layer was isolated and washed with 50 l chloroform. 50
l 5 M ammonium acetate and 200 l 100% ethanol were added to precipitate
DNA, which was washed twice in 200 l 70% ethanol. The DNA was desiccated
and the following reagents were added: 6.5 l dH2O, 2 l 20 ng/l linker DNA
(AATTCGGCTCGAG), 1 l 10X ligase buffer, and 0.5 l T4 DNA ligase
(Fermentas). The underlined portion of the linker consists of single-stranded
overhang, complimentary to the overhang generated by Tsp509I.
Based on the average size of the fragmented DNA (~1.5 kb) and assuming
a DNA recovery of 100% following phenol/chloroform extraction (greater than
the actual value), this mixture contains a ~55-fold molar excess of linker-to-insert
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DNA. Following overnight ligation at 16C, 4 l of the reaction mixture were
added to 44 l dH2O, 2 l 10 M linker-targeted primer
(CCATGACTCGAGCCGAATT), and 50 l Taq PCR Master Mix (Invitrogen).
DNA was amplified with the following thermocycling conditions: 95C-1 min.;
(95C-30 s.; 55C-30 s.; 72C-5 min.) X 40; 72C-10 min.
Topoisomerase cloning of genomic/metagenomic inserts. 1 l of the above PCR
reaction mixture was added directly to 3 l dH2O, 1 l 1X salt solution, and 1 l
linearized, topoisomerase-conjugated pBAD expression vector (pBAD-TOPO TA
Expression Kit, Invitrogen). The mixture was incubated at room temperature for
1 min and divided (2 l each) between three 50-l vials of TOP10 chemically
competent E. coli (Invitrogen). Cells were placed on ice for 20 min, heat-shocked
at 42C for 30 s, and placed back on ice for 5 min. 250 l SOC media was added
and the cells were incubated at 37C for 30 min (as opposed to the manufacturersuggested 60 min, to minimize the possibility of clonal expansion). Cells were
spread onto LB agar with ampicillin (500 g/ml), and these master plates were
incubated overnight at 37C.
Colony PCR. Individual colonies were picked and suspended in 25 l 0.5 M
NaOH, to which 25 l 1 M Tris (pH = 8.0) and 450 l dH2O were added. 1 l of
this mixture was added to 1 l 10 M BadF primer
(ATGCCATAGCATTTTTATCC), 1 l 10 M Bad3 primer
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(GCAGTTCCCTACTCTGCC), 12 l dH2O, and 50 l Taq PCR Master Mix
(Invitrogen). The BadF and Bad3 target sites are located, respectively, 160 bp
upstream and 284 bp downstream from the point of topoisomerase-mediated
cloning. Thermocycling was conducted under the same conditions as during
library construction. Certain amplified inserts were sent for sequencing with
BadF and/or Bad3 primers to Genewiz, Inc. (South Plainfield, NJ).

Functional screening of clones. To identify clones with antibacterial activity,
two different screening methodologies were used. [1] For the BG-1, BG-2, BG-3,
and BG-4 libraries, master plates were replicated with sterile velvet onto LB-agar
with 0.2% arabinose (the pBAD-TOPO plasmid is arabinose inducible) and
incubated overnight at 30C. E. coli cell membranes were permeabilized by a 15min exposure to chloroform vapor. The cells were overlaid with 7 ml molten
BHI soft-agar containing 5 l overnight culture of B. anthracis (Sterne),
Pseudomonas aeruginosa (PAO1), or Staphylococcus aureus (RN4220). Plates were
left at room temperature for 5 hr, transferred to 4C for overnight storage,
returned to room temperature the following day, and placed back at 4C for one
more night. Plates were inspected for clearing zones devoid of bacteria. [2] For
phages BG-3, BG-4, A10, A14, and A17, the E-LASL were also screened using a
novel hemolysis-based method that relies upon the toxic effect of the adjacent
holin. This technique is the focus of Chapter 4, and the reader is referred there
for experimental details.
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For hemolysis screens, master plates were constructed and replicated as in
method [1] above. Permeabilized clones were overlaid with 6 ml molten BHI
soft-agar containing 1 ml defibrinated sheep blood (Cleveland Scientific). Plates
were placed directly at 37C and monitored for hemolytic zones. For any
observed hit in the above screens, the corresponding colony on the master plate
was identified, expanded, and retested in a second experiment. Confirmed hits
were subject to PCR and sequence analysis.
Qualitative analysis of lysin activity. An E. coli clone expressing PlyBeta was
streaked onto LB-agar with 0.2% arabinose and incubated overnight at 30C.
Cells were chloroform permeabilized and soft agar overlays were conducted as
described above with a variety of bacterial species/strains. These were: B.
anthracis Sterne, B. anthracis RS222, B. cereus ATCC 10987, B. cereus ATCC 14579,
B. cereus 13100; B. cereus 4429/73 FRI-16, B. cereus 03BB87, B. cereus E33L ZK, B.
thuringiensis HD73, B. thuringiensis HD866, B. thuringiensis Al Hakam, B. subtilis
SL4, B. mycoides 6462, B. megaterium in-house strain, Staphylococcus aureus RN4220,
L. monocytogenes HER 1083, Streptococcus pyogenes D471, and S. agalactiae O90R.
All species were grown in BHI soft agar at 37C in ambient atmosphere. Plates
were inspected for clearing zones around the PlyBeta expressing patches;
permeabilized patches of non-transformed E. coli TOP10 were used as negative
controls.
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Purification of environmental aerolysin. The aerolysin-containing E. coli clone
was expanded in 2 liters of LB at 37C. At OD600 = 0.5, arabinose was added to a
final concentration of 0.2%, and the cells were incubated for 4 more hr. Cells
were pelleted and the culture supernatant was subject to ammonium sulfate
precipitation. (NH4)2SO4 was slowly added to 40% saturation, and the solution
gently rotated for 12 hr at 4C. The precipitate was spun down (20 min, 7,000 X
g), dissolved in 10 ml 10 mM phosphate buffer (pH = 7.4), and dialyzed for 24 hr
against 100-fold excess of this buffer with three buffer changes.
The dialysate was loaded onto a MonoQ anion exchange column
(Amersham), and eluted with a gradient of 10 mM phosphate buffer (pH = 7.4),
1M NaCl. Hemolytic activity was observed in the fractions corresponding to ~33
mM NaCl. These fractions were pooled together and subject to SDS-PAGE,
which revealed a single ~48-kDa band upon Coomassie staining. Protein
concentration was determined using BCA analysis with albumin standards. 50
l of protein at 117 ng/l was submitted to the Rockefeller University
Proteomics Facility for 10 cycles of N-terminal sequence analysis.
Quantitative hemolysis assay. Hemolysis was quantified using a variation of
the protocol of Eschbach et al. (2001). Defibrinated sheep and rabbit blood and
alsevers-treated chicken blood were purchased from Cleveland Scientific
(Cleveland, OH). Human blood was drawn from a healthy donor (with
informed consent) into a heparinized vacuum tube (BD) immediately prior to
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use. All samples were centrifuged (10 min; 2,500 X g), and the plasma and
leukocyte layers removed. Erythrocytes were washed 4 times and resuspended
in PBS to 109 cells/ml. 10-l aliquots of this suspension were diluted to 100 l
with PBS containing various concentrations of aerolysin. Samples were
incubated for 1 hr at 37C. A 0% hemolysis standard was created by adding 10 l
of the 109 cells/ml suspension to 90 l PBS, which was incubated for 1 hr at 37C.
A 100% hemolysis standard was created by adding 10 l of the suspension to 80
l dH2O, followed by 37C incubation and brief vortexing; 10 l 10X PBS were
then added.
Following incubation, 900 l PBS were added to all experimental samples
and standards, and 250 l of the supernatant were loaded into the wells of a 96well plate. The supernatants of the 0% and 100% hemolysis standards were
mixed to create intermediate standards. Absorbance was measured at  = 410
and hemolysis of the experimental samples was calculated through linear
reduction versus standards. The aerolysin itself exhibited negligible absorbance
at this wavelength.
Computational analysis. Metagenomic sequences were analyzed with the
TBlastX algorithm (translated query versus translated database;
www.ncbi.nlm.nih.gov/Blast/). Searches were conducted against the nonredundant database (nr) with a maximum reported E-value of 0.001 and all other
parameters at default value (Altschul et al. 1997). For the genes cloned in this
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study, homologues were identified through the BlastX algorithm (translated
query versus protein database) with default parameters. Predicted enzymatic
and binding domains were assigned through Pfam analysis (Finn et al. 2009;
pfam.sanger.ac.uk/)
Multiple sequence alignment of known aerolysins was conducted with
ClustalX, v1.81 (ftp-igbmc.u-strasbg.fr/pub/ClustalX/; Thompson et al. 1997).
From this alignment, phylogenetic analysis was performed with PHYLIP v3.67
(evolution.genetics.washington.edu/phylip.html; Felsenstein 1989); DNA
distance and parsimony methods were employed with 1,000 rounds of
bootstrapping and all other parameters at default value. The sequences cloned in
this study were submitted to GenBank with the following accession numbers:
BG-1 lysin (PlyBeta), EU258891; BG-2 lysin, EU258892; BG-3 lysin, EU258893;
environmental aerolysin (AerM), EU258894. The sequences for lysins BG-4, A14,
and TSH lysins have not yet been submitted to GenBank, although they are
reported in the appendix of this thesis.

RESULTS
Construction of E-LASLs. To conduct functional genomic and metagenomic
screens, a rapid technique was devised that combines linker amplification with
topoisomerase cloning. The overall E-LASL procedure is outlined in Figure 3.2.
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Figure 3.2 Constructing an E-LASL
Genomic or metagenomic DNA (represented by the circle at the upper-left) is
enzymatically fragmented by brief exposure to Tsp509I. A short segment of
linker DNA with a complementary overhang is ligated to both ends of the
fragments. PCR is conducted with Taq polymerase and a primer targeted against
the linker sequence. The resultant amplicons have a range of molecular weights,
but all posses 3’-adenine overhangs. The agarose gel at bottom-right depicts
bacteriophage genomic DNA (left lane) alongside its E-LASL amplification
products (middle lane). The amplicons are cloned directly into linearized pBAD
plasmids using commercial topoisomerase cloning. E. coli are transformed with
the plasmids and screened for the acquisition of a desired phenotype (in our
case, using soft agar overlay experiments).
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Rather than fragmenting DNA with a mechanical shearing apparatus (as in
previous studies, Breitbart et al. 2002 and 2003), we instead relied upon brief
enzymatic digestion with Tsp509I. The four-nucleotide consensus sequence
(AATT) would be expected to appear once every 256 bases of random DNA. As
shown in Figure 3.3a, the following conditions for partial digestion lead to the
desired gene-sized lengths after amplification: 100 ng genomic or metagenomic
DNA; 0.01 or 0.1 units Tsp509I; 50 l reaction volume; and a 1 min digestion at
65C.
The length distributions of the amplicons ranged from 500 bp to 4 kb,
with the maximum intensity centered around ~2 kb (for 0.1 units of enzyme) or
~3 kb (for 0.01 units of enzyme). The length distribution of pooled, unamplified
genomic DNA digested under the same conditions differed in that it extended to
a slightly lower mass (~300 bp) and contained prominent amounts of undigested
DNA (Figure 3.3b). The undigested DNA, however, is not amplified during
linker-based PCR and is non-contributory to the final libraries.
We should note that it is possible that the amplified libraries contained
ligated chimeras of two or more digested fragments (possibly the origin of the
longest E-LASL fragments). Such chimeras are of little concern, however, given
the functional nature of the screens and the fact that the majority of digested,
unamplified DNA was gene-sized or greater in length. In preliminary
experiments, E-LASLs were also constructed with 10 ng and 1 ng of starting
DNA.
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Figure 3.3a E-LASL Amplification Products
Lanes 2-5 depict E-LASLs constructed from four Bacillus phage genomic

samples (100 ng DNA/sample; 1 min digestion; 0.01 unitsTsp509I; 2 l
reaction product/well). The lane 6 E-LASL was constructed from
metagenomic DNA extracted from earthworm gut contents (100 ng DNA; 1
min digestion; 0.1 units Tsp509I; 2 l reaction product/well).
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Figure 3.3b Digested DNA Prior to Linker Amplification
Lane 2 contains undigested phage genomic DNA. 1 ug was digested under the
same conditions as during E-LASL construction: 0.1 units Tsp509I/100 ng
DNA/50 l reaction volume (lane 3) and 0.01 units Tsp509I/100 ng DNA/50 l
reaction volume (lane 4). The undigested DNA, however, is not amplified
during PCR and is non-contributory to the final libraries. We should note that
the amplified libraries could contain ligated chimeras of two or more digested
fragments (the likely origin of the longest E-LASL components of 1a). These are
of little concern, however, given that these are functional screens and that the
majority of unamplified DNA is gene-sized or greater in length.
151

With these quantities, however, the success and efficiency of library construction
were variable (most likely due to the physical loss of DNA during laboratory
manipulations involved in E-LASL construction). Consequently, all libraries
used in this study were constructed from 100 ng starting DNA.
Following E. coli transformation, the mean insert size of the library was
determined through colony PCR and gel electrophoresis of randomly selected
clones. The average insert size for the worm-gut metagenomic library digested
with 0.1 units of Tsp509I was 1.99  0.61 kb (n = 65), while for the phage genomic
libraries digested with 0.01 units it was 2.27  0.74 kb (n = 97, across all libraries).
During this gel electrophoresis, a number of bands (~34%) ran at ~450 bp,
corresponding to a circularized vector without any insert (verified through
sequencing). These bands were not included as part of the above mean length
calculations. Such clones also appeared in control experiments in which E. coli
were transformed with a topoisomerase reaction mixture from which the insert
DNA was omitted.
While the presence of these self-ligated clones in the final libraries was an
unavoidable byproduct of the cloning kit, they did not affect the subsequent
functional screens. Fortuitously, any clones containing this plasmid failed to
proliferate in the presence of arabinose. The translated 36 amino-acid
polypeptide encoded by these plasmids (consisting of an N-terminal
enterokinase domain, a V5 epitiope, and a C-terminal His-tag) apparently
hindered E. coli growth when overexpressed by itself. Conversely, all clones that
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did successfully transfer from the master plates to the arabinose plates were
observed to contain a plasmid with a genomic/metagenomic insert.
In terms of colony yield, the number of individual clones that could be
generated per topoisomerase cloning reaction (1 l enzyme-conjugated plasmid,
1 l E-LASL, 4 l buffer) varied depending on the given cloning reaction and
decreased with the age of the cloning kit (we recommend using freshlypurchased kits). For all libraries considered2, the average number of clones per 6
l reaction was 1187 (range: 596 – 2713). This number reflects the colonies that
successfully transferred onto arabinose plates, thus specifically excluding
colonies whose plasmids lacked an insert. We should note that increasing the ELASL volume in a given reaction mixture or gel-purifying and concentrating the
E-LASL prior to ligation did not improve (and, in fact, diminished) the colony
yield.
Screening of bacteriophage genomic libraries. Various lytic bacteriophage
capable of infecting B. anthracis (strain Sterne) were isolated from commercially
available brands of bat guano. E-LASLs derived from four of these phages (BG1, BG-2, and BG-3, and BG-4) were subjected to soft agar overlay screens in
search of colonies with acquired antibacterial activity against B. anthracis. In
general, such screens of bacteriophage genomes are ideal for testing the utility of
the E-LASLs. All double-stranded DNA phage encode a cell wall hydrolase
(known as a bacteriophage lytic enzyme, or lysin) with activity against the host
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species. These enzymes are expressed at the end of a phage infective cycle, and,
along with a pore-forming protein known as a holin, are responsible for lysing
the host and freeing newly assembled viral particles. Lysins have generated
considerable pharmacological interest due to their ability to lyse Gram-positive
pathogens when added exogenously (Fischetti 2008 and 2005).
In bacterial-overlay screens, we were able to clone the lysin genes from
three of the four libraries tested: BG-1, BG-2, and BG-3. In screens conducted
during the development of the E-LASL protocol, we likewise cloned the wellcharacterized PlyG lysin from genomic DNA of the Bacillus  phage (Brown and
Cherry 1955, Schuch et al. 2002). The proportion of positive lysin hits among all
clones varied for each library: BG-1: 8 confirmed hits, 640 clones screened; 
phage: 2 confirmed hits, 1600 clones screened; BG-2: 1 confirmed hit, 540 clones
screened; BG-3: 1 confirmed hit, 2710 clones screened. For the BG-4 phage, 1220
clones were screened, but no hits were generated.
Each of the 8 confirmed hits for BG-1 encoded the full-length lysin,
although no two contained flanking DNA of identical lengths. Six of these 8
clones, moreover, encoded the lysin on the strand whose transcription was not
under control of the arabinose-inducible promoter (indicating the presence of an
endogenous promoter with strong activity in E. coli). When considering only the
two clones with the lysin in the forward orientation, the proportion of hits for
BG-1 (2/640) is closer to that of BG-2 and  phage. For BG-3, the one confirmed
lysin hit encoded only the N-terminal fragment of the complete protein. This
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fragment was still sufficient to create a zone of mildly decreased Bacillus density
and altered coloration, allowing for identification. The remainder of the gene
was sequenced through genomic primer walking.
Additionally, E-LASLs from BG-3, BG-4, and four other Bacillus phages
(A10, A14, A17, and TSH) were screened for lytic enzymes using a novel
technique described in Chapter 4. With this approach, the BG-3 lysin was
successfully re-cloned (in its entirety, without the need for primer walking) and
the BG-4 lysin was identified for the first time. Of the three new phages, the
lysin for the A14 phage was successfully cloned. The A10 and A17 E-LASLs
were not subsequently rescreened using the standard cellular-overlay technique,
and their lysins remain undetermined.
Based on Pfam domain prediction, the majority of the cloned lysins (BG-2,
BG-3, BG-4, A14, and TSH) are N-acetylmuramoyl-L-alanine-amidases. The first
five of these enzymes possess an N-terminal type 2 alanine-amidase motif, while
the TSH lysin possesses a type 3 alanine-amidase motif. Blast analysis suggests
that this enzymatic specificity is very common among Bacillus phage and
prophage lysins, with PlyG lysin as a notable example (Schuch et al. 2002). By
contrast, the BG-1 lysin is predicted to have N-acetylmuramidase activity with a
glycosyl hydrolase, type 25 domain; this motif appears less common among
known Bacillus phages. At their C-termini, all the above lysins possess either a
single or dual SH3 binding domain; BG-1 and the TSH lysin encode type 5 SH3
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domains, while the others encode type 3 SH3 domains (see the Appendix for
exact positional details).
The BG-1 lysin (henceforth referred to as PlyBeta) demonstrates homology
throughout its entire sequence to only one other known lysin3—PlyB lysin from
the Bacillus BcpI phage, which was also recently characterized by the Fischetti
laboratory (Porter et al. 2008). PlyB and PlyBeta are each other‘s closest known
homologues (E-value = 10-143). They share 78% nucleotide identity and 81%
amino acid identity (Figure 3.4). The crystal structure of PlyB‘s catalytic domain
(residues 1-190) was recently solved (Porter et al. 2008). Based on this structure,
all active site residues are conserved between PlyB and PlyBeta, with a single
exception. The tyrosine residue at position 160 of PlyB (part of the proposed
substrate-binding interface) corresponds to a threonine residue at position 161 of
PlyBeta. The most noted region of divergence between the two lysins is a 9
residue Asn-rich stretch beginning at position D189 of PlyBeta, immediately
following the end of the catalytic domain. This region of PlyBeta also encodes an
additional cysteine residue, increasing the total number of cysteines in PlyBeta to
3 (PlyB encodes 2 cysteines).
The activity of PlyBeta was examined qualitatively against a variety of
Bacillus species. Soft agar overlay experiments were conducted with a PlyBetaexpressing E. coli clone and 14 strains composed of B. anthracis, B. cereus, B.
thuringiensis, B. subtilis, B. mycoides, and B. megaterium.
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Figure 3.4 Sequence Comparison of PlyB and PlyBeta
The lysins share 81% amino acid identity, including all putative catalytic
residues (noted with arrowheads). The most prominent area of divergence is a
9-residue, Asn-rich stretch immediately following the catalytic domain at
position 189.
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PlyBeta (like PlyB) is active against B. anthracis and other bacilli, although the
activity varies considerably between species/strains. Clearing zones were noted
for 7/14 strains: 2/2 B. anthracis, 3/6 B. cereus; 1/3 B. thuringiensis, 1/1 B. subtilis,
0/1 B. mycoides, and 0/1 B. megaterium. Representative examples of susceptible
and non-susceptible strains are shown in Figure 3.5. Clearing zones were not
observed for soft-agar overlays conducted with PlyBeta and strains of
Streptococcus, Staphylococcus, and Listeria.

Screening of worm gut metagenomic library. An E-LASL was next constructed
with DNA extracted from the gut contents of a single European night crawler
(Eisenia hortensis). Prior to functional screening, a brief sequence-based analysis
was performed to verify the bacterial origin of the extracted DNA. The inserts of
50 clones were subjected to a single sequencing read (37.8 kb total). When
analyzed with the TBlastX algorithm, 46 of the 50 reads returned known
homologues. For each read, we calculated the relative contribution of different
taxa to the total number of hits. The average of these values across the 46 reads
is shown in Table 3.1a.
The most highly represented group is the proteobacteria (66%), with proteobacteria making the largest contribution (38%). Firmicutes contributed
~13% of hits, with all other bacterial phyla each contributing less than 5%.
Viruses, archaea, and the eukaryotic kingdoms likewise contributed less than 5%
each.
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TOP10

(A)

PlyBeta

B. thuringiensis HD73
Figure 3.5 PlyBeta Clearing Zones
In soft agar overlay experiments, PlyBeta-expressing E. coli clones created
clearing zones for some, but not all, species/strains of Bacillus. Depicted
here are representative examples of strain that [A] did and [B] did not
demonstrate susceptibility.
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TOP10

(B)
PlyBeta

B. cereus 13100
Figure 3.5, continued

160

BACTERIAL TAXA
Proteobacteria

Proportion of
TBlastX Hits
0.663

-Proteobacteria
-Proteobacteria
-Proteobacteria
/-Proteobacteria

Firmicutes
Actinobacteria
Bacteroides/Chlorobi
Cyanobacteria
Spirochaetes
Other Bacteria
Animal
Plant
Fungi
Protozoa
Archaea
Virus

0.381
0.122
0.010
0.0567
0.134
0.038
0.025
0.021
0.019
0.020
0.032
0.011
0.006
0.005
0.015
0.011

Table 3.1a Taxonomic Distribution of Metagenomic BLAST Hits
Forty-six of 50 metagenomic sequences generated BLASTX homologies, for
which the encoding organisms were noted. The proportion of individual taxa
among all hits was calculated for each sequence. Listed above are the average
of these values across the 46 sequences.
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The top hit for each of the 46 reads was bacterial in origin (Table 3.1b), and 11 of
the 46 top hits were from various species of the genus Aeromonas, suggesting a
gut environment dominated by aeromonads.
The metagenomic library was subject to soft agar overlay screens in which
5005 permeabilized clones were each overlaid with B. anthracis (Sterne), P.
aeruginosa (PAO1), S. aureus (RN4220), and sheep‘s blood. The blood-agar screen
was included here due to the bacterial origin of the extracted DNA, with its
potential for identifying encoded hemolytic virulence factors. Indeed, while no
clearing zones were observed in the bacterial screens, a zone of -hemolysis was
noted around a single clone in the blood-agar screen (see Figure 3.6a). The
clone‘s metagenomic insert was sequenced and BlastX analysis showed it to
encode a new member of the aerolysin gene family.
Aerolysin is a pore-forming exotoxin encoded by various Aeromonas
species. The protein is secreted through the type II pathway, and—following a
C-terminal cleavage event in solution or at the target cell surface—it
multimerizes and inserts into eukaryotic plasma membranes (Fivas et al. 2001).
When the hemolytic clone was further tested, it was found that chloroform
permeabilization was not required for hemolysis. The clone had acquired a hemolytic phenotype when grown on blood agar (Figure 3.6a, inset), indicating
the aerolysin is recognized by the E. coli type II secretion system (both inner and
outer membrane components).
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TAXA

Top Hits

Aeromonas
Salmonella
Escherichia
TAXA
Clostridium
Shewanella
Aeromonas
Psuedomonas
Salmonella
No Match
Escherichia
Clostridium
Bacillus, Branchiostoma, Rhizobium,
Enterococcus,
Methylococcus,
Shewanella
Salinibacter, Pseudoalteromonas
Streptococcus,
Bordetella,
Psuedomonas

11
5
4

Top3 Hits
3
11
35
34
3
3
3
1 Each
3

Synechocystis, Rhodopseudomonas,
No Match
Oceanobacillus,
Rhodopirellula,
Parachlamydia, Yersinia,
Nitrobacter,
Psychromonas
Bacillus,
Branchiostoma,
Rhizobium,
Enterococcus, Methylococcus,
Salinibacter, Pseudoalteromonas
Streptococcus, Bordetella,
1 Each
Synechocystis, Rhodopseudomonas,
Oceanobacillus, Rhodopirellula,
Table
3.1b Top BLAST Hits by Genus
Parachlamydia,
Yersinia,
Nitrobacter, Psychromonas

For each of metagenomic sequences, the encoding organism of the hit with the
lowest e-value was noted. The table compiles these hits organized by genus,
with Aeromonas being the most highly represented.
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Figure 3.6a Positive Hemolysin Clone
During the metagenomic screen of worm-gut contents, a single positive
clone was observed in blood agar overlay screens (indicated by arrow).
The corresponding colony on the master plate was identified,
amplified, and shown to contain a metagenomic DNA insert encoding
a novel aerolysin (AerM). When propagated on LB-blood agar, this E.
coli clone demonstrated -hemolysis without chloroform
permeabilization (depicted in the inset).
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Overall, aerolysin sequences have been reported for a number of
Aeromonas species/strains (Epple et al. 2004; Wang et al. 2003 and 1996; Fujii et
al. 1998; Khan et al. 1998; Husslein et al. 1998; Hirono and Aoki 1993; Chopra et
al. 1993; Hirono et al. 1992; Howard et al. 1987; Chakraborty et al. 1986; Howard
and Buckley 1986). When compared to these proteins, the new aerolysin
(subsequently referred to as AerM) demonstrated an average Clustal nucleotide
alignment score of 71.1 (range: 68-78) and an average amino acid alignment score
of 73.2 (range: 68-79) (all pairwise E-values < 10-120). Phylogenetic analysis,
moreover, showed it to occupy a relatively unique evolutionary position relative
to other aerolysins (Figure 3.6b). Considering that the other aerolysins did not
always group according to their species, however, one cannot surmise whether
AerM is encoded by a different strain of one of the species listed in Figure 5b or a
different aeromonad species entirely.
AerM was purified so that its activity could be confirmed quantitatively.
In SDS-PAGE, the protein ran at a molecular weight of ~48 kDa (Figure 3.6c and
d). This is the predicted mass of AerM following C-terminal cleavage. To verify
this assumption—and not the alternate possibility of a nonspecific degradation
product of coincidental molecular weight—Edman sequencing was conducted.
The N-terminus was shown to begin at residue A24 (immediately following the
predicted position of signal peptide cleavage), implying the presence of the final
processed protein (Figure 3.6e).
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Distance Method

Figure 3.6b Aerolysin Phylogeny

Multiple sequence alignment was conducted with AerM and all other nonredundant aerolysin sequences in the NCBI database: A. hydrophila I
(GeneBank accession number M16495); A. hydrophila II (X65044); A. hydrophila
III (X65045); A. hydrophila IV (AY611033); A. hydrophila V (AF41110466); A.
hydrophila VI (M84709); A. hydrophila VII (DQ40826); A. hydrophila VIII
(AY378303); A. sobria I (X65046); A. sobria II (AY157998); A. sobria III (Y00559);
A. salmonicida I (X65048); A. trota I (AF064068); A. caviae (AAC44637).
Phylograms constructed from these alignments (using DNA parsimony and
distance methods, distance shown here) indicate that AerM occupies a relatively
unique evolutionary position relative to the other aerolysins. Bootstrap
consensus values (out of 1000) are indicated at their respective nodes.
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Figure 3.6c Purification of AerM
AerM was secreted by the encoding E. coli into the culture supernatant. As
a result, the cell-cleared media was ammonium sulfate-precipitated and
the total extracellular protein fraction was collected, resuspended, and

subject to Mono-Q anion exchange chromatography. The peak
corresponding to AerM (as determined by drop tests onto blood agar) is
indicated with an arrow.
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50 kDa

Figure 3.6d Purified AerM
In SDS-PAGE, AerM ran at a molecular mass slightly below 50 kDa.
The predicted molecular mass of the initial translated protein
(preproaerolysin) is 54.5 kDa. Following inner membrane
translocation and N-terminal cleavage, the protein (proaerolysin) has
a predicted mass of 52.0 kDa. The final, processed protein (following
C-terminal cleavage) has a predicted mass of 47.5 kDa. The mass of
the purified protein above suggests that it was isolated in this form.
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Figure 3.6e Edman Sequencing of AerM
To confirm the that AerM was recognized and secreted by the E. coli secmediated pathway— and to verify the predicted position of signal peptide
cleavage—the purified protein was subject to N-terminal sequencing by the
Rockefeller Proteomics Facility. Indeed, both were confirmed, as the
predicted N-terminal position of purified AerM was A24.
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The activity of AerM against various erythrocytes was tested with an in
vitro hemolysis assay. While the toxin showed activity against all cells tested
(sheep, rabbit, chicken, human), the specific sensitivity varied among the species
(Figure 3.6f). Under the assay conditions (108 RBC/ml in PBS, 1 hr incubation,
37C), the erythrocytes could be ranked by increasing sensitivity as follows:
sheep (complete hemolysis at 200 nM) < human < chicken < rabbit (complete
hemolysis at 5 nM). The activity of AerM was also confirmed against an actively
dividing mammalian cell line, Detroit 562 (human pharyngeal carcinoma). When
added to a 75% confluent culture, 2 nM AerM induced near total cellular
dissociation with loss of viability by 48 hr (images not shown). Boiling AerM
prior to its addition to culture media abolished the cytotoxic affect, indicating
that the cellular response was attributable to the protein itself and not residual
endotoxin contamination from the purification protocol.
DISCUSSION
We describe here a novel technique for screening genomic or
metagenomic DNA that utilizes a combination of PCR amplification and
topoisomerase cloning. This expression-based approach has several strengths
that make it a useful tool in the search for metagenomic proteins of interest.
Library construction is rapid and straightforward, and only nanogram quantities
of DNA are required.
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Figure 3.6f AerM-Induced Hemolysis of RBCs.
Erythrocytes from several species all showed susceptibility to Aer M in a

quantitative in vitro hemolysis assay. Rabbit erythrocytes demonstrated the
highest sensitivity, sheep erythrocytes demonstrated the lowest sensitivity,
while human and chicken erythrocytes demonstrated intermediate sensitivity.
For each measurement, n = 6, except human (n = 3). Several hemolysis
measurements extend slightly above the 100% value. This is merely an artifact
of the experimental standards; in these cases, AerM-induced hemolysis

exceeded hypotonic hemolysis (defined as 100%).
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Moreover, the use of commercially-available cloning products makes the
technique desirable for laboratories that are entering the field of metagenomics
and might lack dedicated expression systems. Overall, the great potential of
metagenomics is attracting much attention, so the development of simple,
functional screens could broaden accessibility to an already rapidly growing
science.
A particularly well-suited application for the technique is the functional
screening of viral metagenomes. Viral metagenomics is an emerging area in
which bacteriophage particles (or other viruses) are purified from environmental
samples prior to library construction. Given that bacteriophages are likely the
most abundant genetic entities on Earth (Hatfull 2008), metagenomics provides a
powerful tool for investigating their ecology and diversity. Previous viral
metagenomic studies have utilized linker amplification, as phage DNA is
relatively scarce relative to the total metagenomic pool. Nevertheless, this work
has been entirely sequence-based in nature (Angly et al. 2007; Culley et al. 2006;
Zhang et al. 2006; Breitbart et al. 2002 and 2003). Functional viral metagenomics
could provide an important compliment, especially in the search for antibacterial
proteins (e.g. phage lysins) or ones involved in bacterial pathogenesis (e.g.
phage-encoded virulence factors).
The E-LASL approach is likewise applicable to functional screening of
bacterial metagenomes (such as the worm-gut contents screened here). Although
used here to identify a new hemolysin, the method is equally applicable in
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mining for other classes of active proteins. By simply changing the readout of
the soft agar overlay step, for instance, one could search for various bacteriaencoded antibiotics or biocatalysts. In the case of antibacterial proteins, the
screens could target cell wall remodeling enzymes (autolysins), peptide
antibacterial compounds (bacteriocins), or lysins from integrated prophage.
Given the size of bacterial genomes, such genes would comprise a smaller
proportion of the total DNA and would likely necessitate that a greater number
of clones be screened to generate hits. It is therefore not surprising that the
relatively small metagenomic screen conducted here against B. anthracis, S.
aureus, and P. aeruginosa did not identify any antibacterial proteins.
One should note that the E-LASL method admittedly has several
limitations that must be taken into consideration. Like all functional
metagenomic screens, there is always the possibility that foreign proteins may
misfold, not express, or prove toxic to the host species. Moreover, the technique
would not be expected to identify secondary metabolites from environmental
organisms, as the DNA inserts are too short. Ultimately, the insert-length cannot
exceed the substrate length limit of the polymerase itself. Considering current
polymerase technology, it is theoretically possible to construct an E-LASL with
inserts in the range of tens of kilobases (i.e. for use in cosmids). At the same
time, commercially-available systems do not yet exist that would make such
libraries compatible with topoisomerase cloning.
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It is important to mention that there are several other ways in which the
method presented here could be adapted to fit specific situations. Although
Tsp509I was employed here to fragment DNA, other restriction enzymes exist
with suitable 4-bp consensus sequences. For instance, one might employ BfuCI
(/GATC) or MspI (C/CGG), especially if dealing with a more GC-rich organism
or environmental sample. Enzymatic digestion of DNA could even be omitted
entirely in favor of mechanical fragmentation, although this would create a need
for overhang digestion and blunt-ended ligation (as in previous studies, Breitbart
et al. 2002 and 2003). We also envision a protocol in which RNA is extracted in
bulk from an uncultured sample. An E-LASL could then be constructed from
reverse-transcribed metagenomic cDNA.
In the current study, several functional proteins were identified through
the E-LASL technique. Although they are presented more as proof-of-principal,
these proteins raise several issues that, in themselves, merit further discussion.
For instance, the B. anthracis lysins cloned here further expand the list of
potential enzybiotics that have been identified for this important bioterrorismrelated pathogen (Porter et al. 2008; Yoong et al. 2006; Low et al. 2005; Schuch et
al. 2002). Moreover, the AerM protein represents the first example of a hemolytic
virulence factor characterized through metagenomics. Although hemolysis of
blood agar is a classic method of identifying bacterial species, surprisingly few
metagenomic screens have focused on an acquired hemolytic phenotype.
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To our knowledge, the only previous examples are the studies of Rondon
et al. (2000) and Gillespie et al. (2002). In the former, the authors identified a
number a hemolytic BAC clones from a soil-derived metagenomic sample. This
screen was performed as proof-of-principal of their screening technique,
however, and the responsible molecules were not identified. In Gillespie et al. (a
follow-up of the previous paper), one of these clones was investigated further
and was demonstrated to encode a biosynthetic enzyme leading to the
production of the small molecule turbomycin.
Admittedly, AerM is not a protein whose cloning would have absolutely
required a metagenomic approach. Aeromonads are generally culturable, so the
AerM-encoding species presumably could have been isolated from the worm gut
first, and the aerolysin cloned through genomic techniques. Nevertheless, this
approach would have required considerably more effort (as well as the specific
original intent of looking at this genus). In general, environmental virulencefactor screening represents an interesting avenue for future metagenomic
screening. Given the role they play in pathogenesis and inter-species
competition, the identification of such proteins could prove valuable from an
ecological or infectious disease perspective.
In summary, we have presented here a novel method for constructing
genomic and metagenomic expression libraries from small initial quantities of
extracted DNA. This plasmid-based approach utilizes linker-amplification and
topoisomerase cloning, and provides a rapid, technically straightforward, and
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adaptable means of functional screening in an E. coli host. Overall, the E-LASL
approach may be utilized to mine uncultured bacterial or viral populations for
novel antibiotics, as well as other protein compounds with pharmacological,
industrial, or pathogenic potential.
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ENDNOTES
1. The distinction between sequenced-based and functional metagenomics is
blurred somewhat by certain publications that refer to the homology-based
prospecting for desired enzymes as functional (Schoenfeld et al. 2010). In the
current text, however, the term functional is reserved recombinant screens, and
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not sequence-based searches that subsequently lead to PCR-cloning and
functional analysis (as in Chapter 2).

2. The numbers regarding transformation efficiency are those that were
originally reported in Schmitz et al. (2008). They were derived from the E-LASLs
for phages BG-1, BG-2, BG-3, BG-4, and the worm-gut metagenome. Colonies
were not counted when the phage-genomic E-LASLs were used in combination
with the holin-based hemolysis screen. The latter screens, in fact, transpired after
this data was originally published. They represent the preliminary work that led
to the development of screening technique itself (see Chapter 4). The
information is included in this chapter so that Chapter 4 can best reflect the
format that appeared in Schmitz et al. (2010b).

3. This was true at the time of original publication in 2008. Since that time,
genomic sequencing of numerous Bacillus strains has revealed various other
lysin-genes with an N-terminal GH-25 domain and a C-terminal SH3-5 domain.
PlyB and PlyBeta remain each other‘s closest known homologue, but their overall
architecture can no longer be considered unique among Bacillus. To date, none of
these other enzymes has been studied recombinantly.
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**NOTE: In the published manuscript based on this chapter (Schmitz et al. 2008),
the following individuals were included as co-authors (in the stated order): Anu
Daniel, Mattias Collin, Raymond Schuch, and Vincent Fischetti.
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CHAPTER 4
Functional Viral Metagenomics II:
A Novel Phage Lysin Screen

INTRODUCTION
The field of metagenomics has expanded rapidly in recent years, providing
access to environmental microorganisms that would remain unapproachable by
standard, culture-based methods. The foundation of metagenomics lies in the
direct extraction of DNA/RNA from environmental samples (e.g. soil, water, or
feces), without prior isolation of individual microbial species (reviewed in Green
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and Keller 2006, Tringe and Rubin 2005). It has been estimated that only a small
proportion of naturally occurring microbesapproximately 1% of soil bacteria,
for instanceare culturable under standard laboratory conditions (Torsvik and
Ovreas 2002). In this light, metagenomics has become an increasingly common
tool for studying diverse ecosystems, from around the globe to within the human
body.
Overall, metagenomics research can be divided into two general
categories: sequence-based and functional. In the former, environmental DNA is
sequenced in mass and compared with genetic databases to address broad
questions of ecology, taxonomy, and diversity. Some of the most extensive
metagenomic studies to date have been sequence-based in nature, benefiting
greatly from the development of high-throughput sequencing technologies.
Notable examples include a 76-megabase study of an acid-mine biofilm (Tyson et
al. 2004), a 1-gigabase analysis of the Sargasso Sea (Venter et al. 2004), and a 6.3gigabase sampling of global oceanic samples (Rusch et al. 2007).
In functional metagenomics, by contrast, environmental genes are
recombinantly expressed within a host organism, which is monitored for the
acquisition of a desired phenotype. Rather than provide insight into entire
ecosystems, functional studies aim to identify individual molecules with
biomedical or industrial value. Such compounds may either be proteins
(encoded directly by environmental genes) or small molecules (synthesized by
several enzymes of a gene cluster). Numerous classes of molecules have been
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identified to date, with particular interest in the areas of biosynthesis, biomass
degradation, and antibiotic discovery (reviewed in Brady et al. 2009, Uchiyama
and Miyazaki 2009, Voget et al. 2005).
While bacteria provide the majority of DNA to most metagenomic pools,
recent studies have begun focusing on subsets of total environmental
populations. A prominent example is viral metagenomics, in which viral particles
(predominately bacteriophage) are purified from cellular material prior to DNA
extraction (reviewed in Delwart 2007, Edwards and Rohwer 2005). Although the
yield of DNA from environmental phage isolates is generally low, PCRamplification techniques have been developed to overcome this issue (Breitbart
et al. 2002, Schmitz et al. 2008). Viral metagenomic analyses have been
conducted on a growing number of samples, including ones purified from soil
(Fierer et al. 2007), sea-water (Breitbart et al. 2002, Williamson et al. 2008), and
human feces (Breitbart et al. 2003).
These studies have revealed a remarkable abundance of novel sequences,
supporting the notion that phage represent the largest source of untapped
genetic diversity on the planet (Hatfull 2008). Despite this wealth of information,
however, viral metagenomic studies to date have remained predominantly
sequence-based in nature. In this regard, functional screens of viral
metagenomes could provide a large source of recombinant molecules.
Recently, one class of phage-encoded protein has received particular
attention from the biotechnology field: phage lytic enzymes (also referred to as
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endolysins or lysins) (reviewed in Fischetti 2005, Fischetti et al. 2006). These
peptidoglycan hydrolases are expressed late in the infective cycle of doublestranded DNA phage, andalong with a membrane permeablizing protein
known as a holinthey are responsible for disrupting the bacterial cell envelope
and freeing progeny viral particles.
Despite this conserved biological function, phage lysins (especially Grampositive ones) are a tremendously diverse group of proteins whose enzymatic
specificity includes various bonds within the peptidoglycan macromolecule.
They include glycosyl hydrolases that target the polysaccharide backbone
(muramidases/lysozymes and glucosaminidases), alanine-amidases that target
the initial L-alanine of the pentapeptide stem, and endopeptidases that target
subsequent peptide bonds in the stem or cross-bridge. While lysins of Gramnegative phage generally consist of an enzymatic domain alone, Gram-positive
lysins are modular and combine an N-terminal lytic domain with a C-terminal
binding domain that can recognize various epitopes within the target cell
envelope.
Although researchers have known of lysins for decades, interest has
increased markedly in recent years after it was proposed that they could act as
novel anti-infective agents against Gram-positive pathogens, whose
peptidoglycan is directly accessible from the extracellular space (for instance in
Nelson et al. 2001, Schuch et al. 2002, Cheng et al. 2005). A growing number of in
vitro and in vivo studies have confirmed the ability of recombinantly expressed
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lysins to kill such organisms, and their appeal lies in both the potency and the
specificity they demonstrate toward individual Gram-positive species. This
enzybiotic value of phage lysins goes alongside additional proposed applications
in the areas of food (Deutsch et al. 2004), agricultural (Kim et al. 2004), veterinary
(Celia et al. 2008), and industrial science (Matsushita and Yanase 2008, Ye and
Zhang 2008).
Considering this potential, lytic enzymes represent an intriguing
functional target for viral metagenomic screens. At the same time, identifying
lysins in this manner would present several distinct challenges. Aside from
general concerns common to all functional screens (e.g. protein expression and
solubility), metagenomic lysin identification would face the following particular
issues.
(I) Clonal toxicity: Recombinant lysin expression is typically well-tolerated
by host bacteria, as the enzymes are sequestered in the cytoplasm away from the
peptidoglycan layer. Holins, on the other hand, interact nonspecifically with
plasma membranes and are generally toxic to an E. coli host, inducing
bacteriolysis from within (9). Since holins are short (~100 residues) and often
encoded adjacent to lysins, they can lead to selective toxicity of many of the
clones one hopes to identify. In a metagenomic screen, where numerous lysins
are present within a single library, this effect could lead to a significant loss of
positive hits. (II) Target bacterial species: In standard phage genomic screens,
lysin-encoding clones are selected by their ability to kill the host bacterium of the
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encoding phage, which generally demonstrates the highest sensitivity. In a
metagenomic screen, however, numerous host species of unknown origin could
be present, confounding this choice of screening agent.
To address these issues, we have devised a novel functional strategy for
the general cloning of lytic enzymes from uncultured phage DNA. It utilizes a
plasmid-based E. coli expression system and consists of a two-step process.
Following induction by nebulized arabinose, clones are first screened for holinmediated lysis by a hemolytic effect they create in the surrounding blood agar.
These initial hits are then restreaked as patches and overlaid with Gram-negative
cells whose outer membranes have been permeabilized by autoclaving, serving
as a general source of peptidoglycan. The clones are observed for surrounding
Gram-negative clearing zones to assay directly for the recombinant production of
lytic enzymes encoded adjacent to the holins.
As proof-of-principle, we applied our methodology to a viral
metagenomic library constructed from mixed animal feces, identifying 26
actively-expressed lysins of diverse molecular architectures. The first of its kind,
this study presents a general model for lysin identification through viral
metagenomics, highlighting the potential of this field for cloning proteins of
biotechnological or academic value.
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MATERIALS AND METHODS
DNA library construction. Fecal specimens were collected at the Long Island
Game Farm Wildlife Park and Children‘s Zoo (Manorville, New York) from the
following species: giraffe, zebra, donkey, domestic goat, llama, lion, and bison.
Additionally, two dried fecal specimens were obtained from commercial sources:
bat guano (Fox Farm Soil and Fertilizer Company) and cricket droppings
(www.cricketpoo.com).
Viral fractions were purified by an adaptation of the procedure of Casas
and Rohwer (2007). In summary, fecal samples (~100 g each) were suspended in
an equal volume of PBS (pH 7.4) and agitated overnight at 4C.
Particulate/cellular material was removed by centrifugation, followed by two
passages through a 0.22-micron filter. Phages were precipitated by addition of
polyethylene glycol 10,000 MW (10% w/v). Centrifuged precipitates were
pooled to form a collective phage library, which was subject to
phenol/chloroform extraction and ethanol precipitation. Phage DNA was
separated from co-precipitated compounds by agarose gel electrophoresis and
extraction of high molecular weight DNA. From this material, an expressible
linker amplified shotgun library (E-LASL) was constructed, as previously
described (see Chapter 3).

Lysin screening methodology. Amplified metagenomic inserts were ligated into
the arabinose-inducible pBAD plasmid using the TOPO-TA Expression Kit
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(Invitrogen). Transformed clones were initially plated onto LB-agar
supplemented with 100 g/ml ampicillin and 5% defibrinated sheep‘s blood.
Following overnight growth at 37C, clones were subject to an initial toxicity
screen to isolate potential holin-encoding clones. Plates were sealed in a
container into which a nebulized solution of aqueous arabinose (20% w/v) was
pumped for 1 hr. Following induction, the plates were returned to 37C and
observed for colony lysis, as indicated by the development of a zone of
hemolysis in the surrounding blood agar. Hits were identified over the
subsequent 6-8 hr period, as nonspecific blood-agar oxidation (i.e. alphahemolysis) would often appear around colonies at longer times (~16 hrs).
Chosen clones were streaked onto separate LB-ampicillin plates (lacking
arabinose) and allowed to repropagate without induced expression.
For the secondary (i.e. lysin-targeting) screen, the above hits were
streaked as patches onto LB-ampicillin plates supplemented with 0.2% arabinose.
Following overnight expression at 37C, cells were exposed to chloroform vapor
(15 min) to kill and permeabilize any still-viable E. coli (by this point, many cells
had already undergone lysis due to holin expression). The patches were then
overlaid with molten soft agar containing autoclaved P. aeruginosa (see below),
and observed for clearing zones for up to 24 hr. For all lytic clones, the encoded
metagenomic insert was sequenced with plasmid-targeted primers (Genewiz;
South Plainfield, NJ). When primer-walking was required to sequence an insert
in entirety, appropriate oligonucleotides were designed and ordered (Operon).
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Preparation of Gram-negative overlay. Gram-negative soft agar was prepared
as follows: P. aeruginosa strain PAO1 was grown to stationary density in BrainHeart Infusion media. Cells were pelleted and resuspended in PBS pH 7.4 to half
the volume of the original liquid culture. Agar was added directly to this
suspension (7.5 g/L), which was autoclaved for 15 min at 122C, 15 psi.
Solidified aliquots were stored at 4C until the time of use, at which point they
were melted and equilibrated at 55C. For a single 150-mm Petri dish, 15 ml of
soft agar was overlaid.

Computational analysis. Protein sequences of the cloned lysins were subject to
BlastP analysis to identify known homologues among defined organisms
(blast.ncbi.nlm.nih.gov/Blast.cgi). As a reference database, the NCBI nonredundant sequence collection (nr) was utilized. Putative catalytic and binding
domains were assigned via Pfam v24.0 (Finn et al. 2010; pfam.sanger.ac.uk).
Multiple sequence alignment of cloned lysins (amino acid sequence) was
conducted with the ClustalX algorithm (Thompson et al. 1997). From this, a
phylogenetic tree was constructed with the PHYLIP v3.67 software package
(Felsenstein 1989) using the Protdist and Kitch programs (default settings).
RESULTS
A plasmid-based shotgun library was constructed with pooled DNA
extracted from the phage fraction of multiple animal fecal samples. In order to
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clone lytic enzymes from this metagenomic pool, we first sought to address the
issue of holin-based clonal toxicity. Rather than attempt to mitigate the effect, we
instead chose to exploit it by selecting for toxic clones. In the literature, there
exists one example in which a lysin-encoding clone was identified through the
lytic activity of its adjacent holin. When screening a genomic library from
Actinomyces naeslundii phage AV-1, Delisle et al. utilized a ―plasmid release‖
protocol in which mixed E. coli transformants were grown in a single liquid
culture (2006). Holin-encoding cells would undergo lysis following induced
expression, releasing their plasmids into the culture media, from which they
could be purified and characterized. Their approach was adapted here for
metagenomic libraries, in which numerous targeted clones are present within a
single library.
Following transformation, E. coli clones were plated onto agar media
supplemented with 5% sheep‘s blood, but lacking arabinose inducing agent. The
latter was supplied via a nebulized mist only once the clones had proliferated to
visible colonies. In the hours following arabinose induction, colonies undergoing
lysis could be visualized by the appearance of subtle, yet definitive, hemolytic
zones in the surrounding blood agar (Figure 4.1). This effect was often
accompanied by the development of a viscous colony-phenotype: when a pipette
tip was touched to a hemolytic colony and lifted up, the bacterial mass would
adhere in a string-like manner between the tip and the agar surface.
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Figure 4.1 Preliminary Hemolysis Screen
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Figure 4.1, continued
Depicted here are seven E. coli Top-10 clones on LB-ampicillin
supplemented with 5% sheep’s blood. Each clone is transformed with a
pBAD plasmid containing a different protein-encoding insert. A-Top left:
empty plasmid; B-Top right: aerolysin, a hemolytic bacterial exotoxin

encoded by the genus Aeromonas; C-Center left: Bacillus anthracis phage
alanine-amidase with adjacent holin; D-Center middle: lysin PlyM14 from
this study with adjacent holin; E-Center right: arbitrary metagenomic
insert from this study; F-Bottom left: Bacillus anthracis phage alanineamidase without adjacent holin; G-Bottom right: Bacillus anthracis phage
muramidase without adjacent holin. Prior to induction with nebulized
arabinose, the clones are indistinguishable against the blood agar
background. Following induction (apparent at 6 hrs and more prominent
at 24 hrs), a zone of hemolysis is present around the clones encoding
holin/lysin combinations (C and D). No such zones are present
surrounding the clones encoding empty plasmid (A), random sequence
(E), or lysin only (F and G). The aerolysin-encoding clone (B) is included
as a positive control of a dedicated hemolytic transformant.
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Presumably, both the hemolysis and the viscosity were due to the release of
intracellular contents from the lysing colonies. The hemolytic effect could
likewise be attributable to interactions between the expressed holins and the
blood-agar erythrocytes, as holins have been shown capable of permeablizing
eukaryotic membranes in vitro (Agu et al. 2007).
Approximately 200,000 clones were screened in this manner, and 502
preliminary hits were identified and repropagated on media lacking inducing
agent. To confirm the identity of the cloned inserts, 52 of these hits were subject
to DNA sequencing. Forty-one unique clones were observed in this analysisof
these, 17 contained ORFs that encoded both a complete holin and a complete
lysin gene (as determined through Blast-homology analysis); 4 encoded a
complete holin with only a partial (i.e. truncated) lysin; 2 encoded complete
holins without any recognizable lysin; and 18 did not demonstrate homology to
either holins or lysins. The latter 18 inserts encoded ORFs with a variety of
predicted functions, including a number phage structural proteins and DNAinteracting proteins. For 5 inserts, Blast analysis did not reveal any putative
genes of known function.
As these sequencing results indicate, the hemolysis screen was not
absolutely specific for holin/lysin cassettes, although this finding is not
unexpected. In theory, the technique could select for any toxic proteins that
compromise the viability (and, resultantly, the envelope integrity) of the host E.
coli. Moreover, even among those clones encoding putative lysins, this initial
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screen does not reveal which ones express soluble, active enzymes in the
recombinant system. A secondary screen was thus necessary to specifically
identify these clones.
For this step, we exploited the cell-envelope properties of Gram-negative
bacteria. To explain, viable Gram-negative cells are generally resistant to
exogenous lysin treatment, as their peptidoglycan layer is surrounded by the
lipophilic outer membrane. Once this membrane is compromised, however, they
become highly sensitized to enzyme action. This includes lysis by both nonspecific eukaryotic lysozymes (forming the basis of many commercially-available
extraction kits), as well as by phage lytic enzymes from viruses that infect other
bacterial species (Briers et al. 2007). This sensitivity is attributable to the thinness
of the Gram-negative peptidoglycan layer, and it is reflected in the very structure
of Gram-negative phage lysins. As mentioned above, Gram-positive lysins
possess both an N-terminal enzymatic domain and a C-terminal binding domain
(which leads to target specificity), while Gram-negative lysins are classically
comprised of an enzymatic domain alone (Fischetti 2005).
Consistent with these properties, we have previously observed
(unpublished findings) that clearing zones appear in soft-agar experiments in
which autoclaved Gram-negative cells are exposed to any number of diverse
Gram-positive lysins with muramidase or alanine-amidase activity (Figure 4.2a).
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Figure 4.2a Lysin-Encoding Clones with
Pseudomonas Overlay (Genomic)
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PlyM4

PlyM6

PlyM22

PlyM19

Figure 4.2b Lysin-Encoding Clones with
Pseudomonas Overlay (Metagenomic)
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Figure 4.2, continued
Various lysin-encoding clones are overlaid here with autoclaved P.
aeruginosa PAO1. [A] Previously characterized phage lysins. As opposed to
the negative control (top), Gram-negative clearing zones are apparent
around E. coli clones encoding CPL-1 (Streptococcus pneumoniae
muramidase), PlyG (Bacillus anthracis alanine-amidase), PlyB (Bacillus
anthracis muramidase), and PlyCM (Clostridium perfringens
muramidase). In each case, the cells were streaked onto LB-agar
containing arabinose inducing agent, allowed to proliferate overnight, and
chloroform permeabilized prior to Gram-negative overlay. [B]
Metagenomic lysin hits. Four representative examples of the 26 enzymes

cloned during this study are depicted here (PlyM4, PlyM6, PlyM19, and
PlyM22). As mentioned in the text, these clones (which encode
holin/lysin combinations) often demonstrated toxicity when streaked onto
arabinose-containing agar. This is particularly evident for the clones
encoding PlyM4, PlyM6, and PlyM19, in which punctate colonies
(presumably down-regulated mutants) have proliferated upon a lysed E.

coli patch.

195

While this phenomenon was of little practical significance when cloning lytic
enzymes by standard genomic techniqueshere, the encoding phage and target
species are known a priori it could be useful for identifying unknown lysins
from a metagenomic pool. (We should note that permeabilized Gram-negative
cells are not broadly susceptible to endopeptidase lysins, as the peptidoglycan
cross-bridge varies considerably among bacterial species; a more detailed
discussion of this point is provided in the Discussions section of this chapter).
To these ends, the 502 hits identified in the initial hemolysis screen were
generously restreaked as patches onto arabinose-containing agar and tested for
their ability to lyse a soft-agar overlay of autoclaved P. aeruginosa, strain PAO1.
This particular Gram-negative species/strain was chosen as the screening agent
based on the visual clarity of the clearing zones it produced in preliminary
experiments. Seeing that the 502 strains were selected for the toxicity of their
encoded insert, the streaked patches obviously did not proliferate well on the
arabinose plates; following overnight incubation, they were often comprised of
lysed cells with occasional punctate colonies (presumably recombinant mutants
with down-regulated insert expression, see Figure 4.2b). Nevertheless, even with
little growth, enough recombinant protein was synthesized to produce distinct
clearing zones in the overlay.
In total, 65 positive clones were identified in the secondary screen (Figure
4.2b), which were shown by sequencing to encode 26 unique lysins (denoted as
PlyM1-PlyM26, GenBank accession numbers HM011589-HM011614). Of these
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enzymes, 15 were observed for the first time during the secondary screen, while
11 had had been identified previously during the aforementioned sequencing of
52 hemolytic clones. Conversely, 6 of the putative lysins identified during the
initial sequencing (PlyM27-PlyM32, GenBank accession numbers HM011615HM011620) were not detected by the secondary screen, attributable to insoluble
or insufficient recombinant expression.
Based on Pfam analysis, the 26 actively-expressed enzymes comprise a
variety of molecular architectures and enzymatic motifs. They are summarized
in Table 4.1 along with their putative domain assignments and known
homologues among defined organisms. (For a complete list of Blast homologues,
refer to the on-line supplementary information of the associated article.) The
majority of the genes (PlyM1-PlyM20) encode typical Gram-positive lysins, with
an N-terminal catalytic region and a C-terminal binding region. Of these 20
genes, 15 encode full-length lysins and 5 encode slightly truncated proteins (as
an artifact of library construction) that lack the final portion of the C-terminal
region but retain detectable catalytic activity. Of the 6 remaining lysins, 3
represent typical Gram-negative lysins (comprising only a catalytic domain,
PlyM22-PlyM24) while 3 posses attypical architectures uncommon among
bacteriophage (PlyM21, PlyM25-PlyM26). As expected, a large majority of the
lysin-expressing clones (24/26, exceptions being PlyM18 and PlyM19) also
encode a short, adjacent ORF that can be assigned putative holin functionality
based on its database homologues and/or predicted transmembrane topology.
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Table 4.1 Cloned Metagenomic Lysins
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Table 4.1, continued
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Table 4.1, continued
The 26 actively-expressed lysins cloned in this study are summarized
here. [A] Lysin name. [B] GenBank accession number. [C] Protein length in
amino acid residues. Five lysins (indicated with trunc.) were cloned as
enzymatically active C-terminal truncations; for these proteins, the indicated
length is that which was included on the plasmid insert. [D] Predicted
enzymatic domains. The reader is referred to the text or Supplementary
Document 1 for corresponding Pfam accession numbers. [E] Predicted cellwall binding domains. For PlyM1, the protein was truncated within the Cterminal region, preventing an accurate prediction of a binding domain. Pfam
analysis did not recognize conserved binding domain for the Gram-positive
lysins PlyM17 and PlyM21, although a distinct C-terminal region exists that
presumably serves this purpose. Binding domains were not predicted for 4/5
Gram-negative lysins (PlyM22-PlyM24, PlyM26). [F] Database homologues.
Cloned lysins were subject to BLASTP analysis to identify homologues among
sequenced bacteria/phage. In many instances, a lysin demonstrated highest
homology to proteins encoded by a particular bacterial genus/species (or its
phage). The identities of these taxa are identified here, and the degree of
homology is indicated numerically with E-values (or a minimum E-value if
numerous proteins demonstrated a continuous range of homology). In other
cases, as noted, no genus/species was preferentially represented among the
closest BLASTP hits.
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Among the Gram-positive lysins, Pfam domain analysis suggests that all
20 possess N-acetylmuramoyl-L-alanine-amidase activity: 8 are predicted to be
type 2 amidases (Pfam family PF01510), and 12 are predicted to be type 3
amidases (PF01520). Although these two protein families diverge sequentially,
they target the same bond at the beginning of peptidoglycan‘s pentapeptide
stem. At the C-terminal ends of the Gram-positive lysins, a variety of cellenvelope binding domains are likewise predicted. These include: 10 PG-1 motifs
(PF01471); 1 PG-3 motif (PF09374); 5 SPOR motifs (PF05036); 1 SH3 type 5 motif
(PF08460), 1 LysM motif (PF01476), and 1 amidase II-associated domain
(PF12123). For two of the Gram-positive enzymes (PlyM17 and PlyM21), a clear
C-terminal region is present, even though Pfam analysis fails to predict a binding
motif. Most likely, these regions do possess binding functions, albeit ones that
have not yet been categorized as conserved protein families.
Multiple sequence alignment of PlyM1-PlyM20 reveals strong similarities
among some of the cloned proteins, summarized phylogenetically in Figures 4.3a
and b. In particular, PlyM5 – PlyM11 demonstrate high sequence homology with
one another, with pairwise sequence identities of 91-95% on the nucleotide level
and 95-98% on the amino acid level (all E-values < 10-159). PlyM3 and PlyM4
share this homology with PlyM5-PlyM11 at the C-terminus, but diverge in their
enzymatic regions. These lysins were presumably derived from a group of
highly similar phage infecting one of the component bacterial species of the fecal
sample.
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1.18

Figure 4.3a Similarity among Gram-Positive Hits (Non-Bootstrapped)

The sequence homology among the typical Gram-positive lysins (PlyM1-PlyM20)
is organized here as a contemporaneous-tip phylogenetic tree (one branch length
is included as reference). Several clusterings are apparent, especially PlyM5PlyM11; these enzymes are depicted as a single node in the image, as their degree
of homology (90+ pairwise nucleotide/amino acid identity) prevents individual
visual differentiation. The reader should note that this tree was generated from a
single multiple sequence alignment (MSA) so that the distance-values between
proteins would be most visually apparent as the branch lengths.
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Figure 4.3b Similarity among Gram-Positive Hits (Bootstrapped)
Bootstrap analysis (100 rounds) was also conducted on the original MSA of

PlyM1-PlyM20 and a consensus cladogram was generated. As in [A],
PlyM5-PlyM11 have been collapsed here to a single node. The bootstrap
consensus values are indicated at their respective nodes.
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When the sequences of PlyM5-PlyM11 are compared to known proteins via Blast
analysis, they demonstrate closest homology (E-values ≈ 10−16) to two putative
prophage lysins from the sequenced genomes of Delsulfotomaculum reducens MI-1
and Alkaliphilus metalliredigins QYMF, both spore-forming organisms of the class
Clostridia.
The remainder of the Gram-positive lysins were likewise subject to Blast
analysis; for many of the proteins (PlyM1-PlyM4, PlyM13-PlyM17, PlyM19), the
closest homologues are encoded by phage/prophage infecting Bacillus and
related genera. In general, these homology findings are consistent with the fecal
origin of the library, although one should not draw conclusions on the ecology of
the sample based on this information alone. Aside from potential biases inherent
in functional screening, it is important to emphasize that the sample was not a
natural ecosystem in the first place, but rather a combination of several fecal
samples pooled to increase diversity. Overall, if one is interested in viral
metagenomics as a tool for studying microbial ecology, sequenced-based
approaches are superior to functional screens.
Among the lysins that do not demonstrate typical Gram-positive
structures, PlyM21 possesses two distinct catalytic regions—an N-terminal M23
endopeptidase domain (PF01551) and a central lambda phage-like muramidase
domain (PF00959). While it is uncommon, several lytic enzymes from Grampositive phage have been characterized that possess multiple catalytic domains
(Cheng et al. 2005, Wang et al. 2009). It is currently unclear what, if any,
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advantage is offered by this extended architecture. By contrast, lysins PlyM22PlyM24 are relatively short in length and consist of single catalytic domain
without any C-terminal binding region, an arrangement typical for Gramnegative phage. These three enzymes are each predicted to have the same
muramidase domain (PF00959), although they share only moderate primary
sequence homology with one another.
Finally, PlyM25 and PlyM26 differ significantly from the other enzymes
cloned in this study and, in general, represent poorly characterized varieties of
lytic enzymes. Domain analysis of PlyM25 predicts an N-terminal PG-1 binding
motif (residues 3-38), but fails to recognize any catalytic domain. Rather,
residues 76-249 correspond to a domain of unknown function (PF11860), from
which the enzymatic activity presumably originates. Blast analysis of PlyM25
reveals several dozen ORFs of moderate homology (E-values: 10-20 – 10-40) within
the genomes of sequenced Gram-negative phage/prophage. Virtually none of
these homologues, however, are currently annotated as lysins, exceptions being
ORF12 of P. aeruginosa phage phiCTX (Nakayama et al. 1999) and ORF27 of
Burkholderia cepacia phage Bcep781 (Summer et al. 2006). The latter two enzymes
share the PG-1/DUF architecture of PlyM25, although only the Burkholderia
protein has been assigned lytic function experimentally (its enzymatic class
remains undetermined).
For PlyM26, Pfam analysis predicts neither a cell-wall binding nor a
peptidoglycan hydrolase motif, but rather a chitinase enzymatic domain
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(PF00182). While it is conceivable that PlyM26 represents a dedicated phageencoded chitinase with cross-reactivity to Pseudomonas peptidoglycan (and not a
lysin proper), this is an unlikely scenario. The first four nucleotides of PlyM26
overlap with an upstream 101-amino acid ORF containing three predicted
transmembrane domains, making it a strong candidate for an adjacent holin.
Moreover, given the structural similarity of chitin to peptidoglycan—and the fact
that chitinases belong to the same protein clan (Pfam CL0037) as muramidases,
glucosaminidases, and transglycosylases—it is more probable that PlyM26
represents a lysin of one of the later functionalities whose sequence merely
deviates from the norm.
As with PlyM25, Blast analysis of PlyM26 reveals a number of
homologues among sequenced Gram-negative phage/prophage. Again,
however, few are annotated as phage lytic enzymes and (to our knowledge) none
have been recombinantly expressed and characterized biochemically. Taken
together, lysins PlyM25/PlyM26 and their database homologues argue that the
complexity of many Gram-negative lysins is more complex than the classical
picture suggests, reinforcing the need for further research in the field.
DISCUSSION
Overall, the above study represents one of the first functional screens of a
viral metagenomic sample, and the technique serves as a general method for
cloning lytic enzymes from uncultured phage. This naturally raises the
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question—what applied or basic purposes could such screens serve? One
possibility involves the identification of new enzymes with antibiotic activity
against medically-relevant bacteria. To these ends, the 26 lysin-expressing clones
were overlaid with various species of autoclaved Gram-positive pathogens. One
of the enzymes (PlyM12) did produce clearing zones against Bacillus anthracis
and Enterococcus faecium. It was subsequently sub-cloned to exclude the adjacent
holin and subjected to preliminary chromatographic purification (data not
shown). Nevertheless, when tested against live organisms in OD-drop
experiments, PlyM12 failed to show activity comparable to previouslycharacterized lysins, and it was deemed a poor candidate for further study.
Given the specificity that lysins show toward individual Gram-positive bacteria,
finding a medically-relevant lysin would likely depend on whether a phage
infecting that pathogen was represented in the original metagenomic pool.
When one considers the origin and relative simplicity of the current library, it is
not overly surprising that no such enzymes were identified here.
Metagenomic lysin screens could also be useful for identifying enzymes
that are active under a desired set of biochemical conditions (temperature, pH,
salts, etc…). For instance, several proviral lytic enzymes have been
characterized from thermophilic species with the motivation that temperature
resistance is an industrially attractive feature for peptidoglycan hydrolases (Ye
and Zhang 2008, Matsushita and Yanase 2008). In this regard, a strength of
metagenomics is its ability to study extreme environments whose bacteria/phage
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are difficult to culture under laboratory conditions (Ferrer et al. 2007). One could
easily envision isolating the phage fraction from an extreme environment (such
as in Santos et al. 2010) and screening it for lytic enzymes with the above
technique, circumventing the need for laboratory culture or prophage induction.
For such cases, the buffered agar in which the secondary Gram-negative
detection agent is suspended (here, PBS pH 7.4) could be varied to reflect the
biochemical conditions under consideration.
That said, one must note that a sequence-based study of an environment
(extreme or otherwise) could also identify lytic enzymes, as the assembled
contigs of sequenced viral metagenomes have revealed numerous putative
examples (Breitbart et al. 2002, Breitbart et al. 2003, Fierer et al. 2007, Williamson
et al. 2008). Nevertheless, if the stated goal is to identify proteins of a particular
functionality, clonal screening represents a far more rapid and cost-effective
approach. Sequencing data alone does not predict what proteins are actively
expressed in a recombinant host, and any candidate genes identified with highthroughput sequencing would have to be re-cloned via PCR into an appropriate
expression vector.
All of this, moreover, presupposes that a DNA-sequence shows sufficient
homology to other lysins already annotated in the database. In fact,
metagenomic lysin screening is perhaps most useful in a very academic sense—
the identification and characterization of new classes of catalytic and binding
domains. Although lysins are already known to be remarkably diverse, enzymes
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are still identified with completely novel sequences (Matsushita and Yanase
2008, Nelson et al. 2006). Even the simple library employed here yielded several
clones whose identity as phage lysins would not have been obvious from their
sequences alone. Accordingly, the characterization of PlyM25 and PlyM26
remains a subject of ongoing study, as does the screening of new libraries for
additional novel enzymes.
Finally, it is important to note one limitation of this screening protocol and
mention several ways it could be adapted to fit particular needs. Clearly, the
method is capable of identifying lysins with glycosyl-hydrolase or alanineamidase activity. At the same time, only one endopeptidase was cloned here
(PlyM21), and this lysin possessed a secondary muramidase domain. In fact,
endopeptidases present a particular obstacle for the technique, as it would be
impossible to identify all endopeptidases using a single bacterial species in the
soft agar overlay step.
While the polysaccharide backbone of peptidoglycan and the initial Lalanine of the pentapeptide stem are highly conserved among bacteria,
considerable variability exists at the other stem positions and within the peptide
cross-bridge (Vollmer et al. 2008a). Without the targeted bond, Gram-negative
peptidoglycan would not be susceptible to a Gram-positive endopeptidase. For
instance, as opposed to the clearing zones in Figure 4.2a (involving previouslycharacterized amidases and muramidases), no clearing zones were observed
when several defined endopeptidases were applied to autoclaved P. aeruginosa.
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To ensure endopeptidase coverage against a particular Gram-positive species,
therefore, one could conduct the secondary screen in duplicate, including that
species along with the general Gram-negative screening agent.
Another potential variation in the protocol could involve omitting the
preliminary hemolysis screen entirely and progressing directly to the Gramnegative overlay step. In this case, one would replica-plate the original
transformants onto additional LB-ampicillin plates (without arabinose, to avoid
clonal toxicity), which could then be nebulized with inducing agent, chloroform
treated, and overlaid with heat-killed P. aeruginosa, Clearing zones could then be
traced to the respective colonies on the master plates. One potential advantage
of this approach is that it could identify lysins from phage where the lysin and
holin are not adjacent, which is the case in a minority of circumstances. Our
rationale for not utilizing this approach here is that, on a single-colony scale, the
hemolytic phenotype is more visually detectable than a clearing zone in a softagar overlay, which is better suited for the larger E. coli patches employed in the
secondary screen. Nevertheless, the two approaches are hardly mutually
exclusive and one could easily include both while screening a viral library to
maximize lysin discovery.
Overall, the functional screening process described here is both
straightforward and generalizable, allowing one to mine for biotechnologicallyand academically-relevant enzymes from the largest genetic pool on the planet.
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CHAPTER 5
Back to Basics:
Applying New Techniques to Genomic Samples

INTRODUCTION
Streptococcus suis is a Gram-positive, α- or -hemolytic bacteria that is
known for the variety of infections that it causes in pigs, including meningitis,
septic arthritis, pneumonia, and bacteremia (Segura and Gottschalk 2004). It
frequently leads to fatalities among commercial swine, and is especially
problematic among newborn animals (Staats et al. 1997). S. suis is likewise an
emerging zoonotic agent and can induce similar pathologies in humans as seen
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in pigs (almost exclusively in those with occupational exposure to the animals)
(Feng et al. 2010).
Reported veterinary and human cases of S. suis infection date back to the
1950‘s and 1960‘s (Field et al. 1954; Arends and Zanen 1988), although the species
was not formally defined until 1987 (Kilpper-Bälz and Schleifer). Taxonomically,
S. suis does not belong to the seven standard clusters of streptococci, nor does it
group conveniently among Lancefield antigenic classifications (Facklam 2002).
Instead, it is subdivided into 35 serotypes that depend on the nature of its
polysaccharide capsule (Higgins et al. 1995). Various biochemical parameters
have been defined for clinical identification of S. suis (Higgins and Gottschalk
1990). In practice, however, presumptive isolates are typically confirmed by
antigenic or genetic methods (Lun et al. 2007).
The pathogenesis of S. suis infections in swine involves the initial
colonization of the nasopharynx and palatine tonsils. The bacteria are thought to
invade the tonsils, followed by dissemination via the lymphatics and/or efferent
blood vessels; intracellular dissemination within host phagocytes has also been
proposed (Segura and Gottschalk 2004). A number of potential S. suis virulence
factors have been identified (reviewed in Staats et al. 1997), although the precise
molecular mediators of pathogenesis are not well-defined. The extracellular
capsule is necessary for infection, and serotype 2 strains are most commonly
observed worldwide. It is important to note, however, that not all serotype 2
strains are virulent and other serotypes are frequently seen to cause disease. In
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particular, serotype 9 infections are becoming more prominent in certain
geographic regions (Blume et al. 2009). Complicating the situation further,
colonized animals are often observed without signs of infection, and they are
believed to play an important role in the epidemiology of S. suis (Luque et al.
2009). Dedicated environmental reservoirs have not been identified, although
the isolation of the bacteria from other animal species suggests a more
widespread distribution (Devriese et al. 1991).
The etiology of disease in humans likewise remains poorly understood. In
all, there have been ~550 clinical cases of S. suis infection reported worldwide,
with ~75 associated deaths (Feng et al. 2010; Lun et al. 2007). Many of these
deaths stemmed from 1998 and 2005 outbreaks in China, which were particularly
troubling given their association with a novel streptococcal toxic shock syndrome
(Tang et al. 2006). It has been calculated that the annual risk of infection for
employees of pig farms and slaughterhouses is roughly 3/100,000 (Arends and
Zanen 1988). These estimates, however, are confounded by more recent
immunological analyses of asymptomatic swine workers in the USA, ~10% of
whom demonstrated high-titer seroconversion for S. suis antibodies (Smith et al.
2008). Moreover, it has been suggested that most hospital laboratories would
misidentify S. suis isolates without a particular reason for suspecting the
pathogen, as it falls outside typical diagnostic algorithms for human infections
(Gottschalk 2004).
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Considering the broad relevance of S. suis, there is great deal of interest in
strategies for preventing its transmission within animal populations. While most
S. suis isolates are sensitive to traditional antibiotics, there are significant
downsides to large-scale antibiotic prophylaxis of swine (Staats et al. 1997).
Vaccine development is naturally an area of focus, and positive results have been
obtained during previous in vivo trials (Swildens et al. 2007). Commercially, it is
not uncommon for animals to be vaccinated empirically with inactivated bacteria
(Baums and Valentin-Weigand 2009; Haesebrouck et al. 2004). Nevertheless, the
safety and overall efficacy of this practice are uncertain, and concerns remain
regarding immunity across S. suis serotypes. As a result, innovative approaches
for curtailing infections would be highly welcome.
In this light, phage lytic enzymes (also known as endolysins or lysins)
have garnered much attention recently as novel antibacterial agents (reviewed in
Villa and Veiga-Crespo 2010; O‘Flaherty et al. 2009; Fischetti 2008). These
peptidoglycan hydrolases (targeting a variety of specific bonds) are encoded by
virtually all dsDNA phages and are responsible for digesting the host cell well
during phage infection. This leads to osmotic lysis of the bacteria and release of
viral progeny. Biotechnological interest in these proteins stems from their ability
to lyse Gram-positive bacteria when applied exogenously, as the peptidoglycan
of these species is continuous with the extracellular space. Lysins have been
proposed as potential enzybiotic agents, and are notable for the potency and
specificity they demonstrate toward particular bacteria (generally, species that
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the encoding phage infects or closely-related organisms). In a number of in vivo
trials, lysins have successfully eliminated targeted pathogens from colonized
and/or infected mucous membranes (Daniel et al. 2010; Cheng et al. 2005;
Loeffler et al. 2001; Nelson et al. 2001).
To date, two phages infecting S. suis have been isolated and studied.
Harel et al. (2003) induced a siphoviral prophage from the genome of a serotype
2 strain, although the identity of its lysin remains undetermined. More recently,
Ma and Lu (2008) isolated a lytic phage from nasal swabs of healthy pigs,
sequencing its 36 kb genome. This phage, termed SMP, demonstrated a limited
host range, infecting only 2/24 S. suis strains within serotype 2. The same group
later PCR-cloned and recombinantly expressed the SMP lysin (LySMP); the
enzyme demonstrated broad bacteriolytic activity in vitro against several
serotypes (albeit with the addition of protease inhibitors and at somewhat higher
concentrations, 50+ μg/ml, than typically associated with phage lysins). The
main drawback of LySMP was technical: the recombinant protein did not fold
properly by itself and was only active in the presence of reducing agents, which
could complicate potential in vivo trials (Wang et al. 2009).
In the current study, we sought to expand and evaluate the collection of
known S. suis lysins. Through a combination of functional screening and
sequence analysis of recently-published genomes, we identified two new
prophage lytic enzymes (termed PlySs1 and PlySs2). PlySs1 is a homologue of
the above-mentioned LySMP (but demonstrating superior expression
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properties), while PlySs2 represents a divergent class of enzyme altogether. Both
lysins were purified and characterized biochemically, and they are currently
being employed in an ongoing in vivo trial involving experimentally-infected
pigs. In the present thesis, I describe the cloning of PlySs1 and PlySs2, as well as
the in vitro characterization of the former. Overall, through agents like these, it is
possible to expand the potential of enzybiotics into the often overlooked—but,
nevertheless, crucial—world of veterinary microbiology.

MATERIALS AND METHODS
Prophage functional screening. The genomes of several clinical strains of S. suis
were subjected to functional shotgun screens is search of lytic enzymes from
incorporated prophage. Microgram quantities of gDNA were briefly subjected to
restriction digestion with Tsp509I (NEB). Fragments 1.5 – 4 kb in length were
isolated via agarose-gel electrophoresis and ligated into EcoRI-linearized
pBAD24 plasmid (Guzman et al. 1995). This plasmid confers ampicillin
resistance and allows for arabinose induction of the recombinant insert.
To identify lysin-encoding clones, libraries were subject to a novel
screening technique that relies upon the toxicity of adjacently-encoded holin
proteins (see Schmitz et al. 2010b or Chapter 4 for details). Briefly, E. coli TOP10
transformants were plated onto LB-agar supplemented with ampicillin and
sheep‘s blood. Following proliferation to macroscopic colonies, the plates were
exposed to a mist of arabinose to induce recombinant transcription. Toxic clones
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were revealed by the development of surrounding zone of hemolysis. These
colonies were identified, re-propagated and subject to a secondary screen in
which they were overlaid with heat-killed bacteria (to assay directly for the
production of lytic enzyme). For the S. suis strain (7711) that yielded the PlySs1
lysin, ~3,500 clones were subjected to the original hemolysis screen; 100 of these
were selected for the secondary screen, 2 of which encoded the lytic enzyme.

Sub-cloning of truncated PlySs1. For the positive hits identified above,
recombinant inserts were amplified and sequenced with pBAD-targeted primers
(Genewiz, Inc., South Plainfield, NJ). The specific position of the lysin gene was
located by analysis with ORF Finder (www.ncbi.nlm.nih.gov/projects/gorf/)
and BlastX (Altschul et al. 1990; blast.ncbi.nlm.nih.gov/Blast.cgi). For the
translated protein, putative enzymatic and binding domains assignments were
made via Pfam (Finn et al. 2009; pfam.sanger.ac.uk).
Based on this information, primers were designed for synthesizing a
truncated constructed (PlySs1) with an inserted stop codon preceding the Cterminal glucosaminidase domain (specifically, after D254). The primer
sequences were:
TTTGAATTCTTTATGACAATCAATCTTGAAACATCCATTCGT—fwd and
TTTGCATGCTTAGTCCCCGTCCTCCTTGAATTGC—rev. The engineered stop
codon is double-underlined, while the single-underlined nucleotides correspond
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to EcoRI and SphI restriction sites for ligation into pBAD24. The resultant
plasmid was cloned and maintained in TOP10 E. coli.

Genomic sequence analysis and cloning of PlySs2. The genomes of 8
sequenced isolates of S. suis were inspected for the presence of lysin-encoding
genes within integrated prophage (Holden et al. 2009; Chen et al. 2007). These
strains were: 05ZYH33 (NCBI Genome Project #17153); 98HAH33 (#17155);
BM407 (#32237); GZ1 (#18737); P1/7 (#352); SC84 (#32239); 05HAS68 05HAH33
(#17157); and 89/1591 (#12417). For each genome, the topologically-arranged list
of annotated ORFs was manually inspected for potential prophage regions. If a
prophage was suspected, the theoretical translations of each ORF in that region
were subject to BlastP and Pfam analysis. Putative lysin-status was assigned
based on the combination of predicted enzymatic and binding domains.
The only lysin gene identified in this manner (PlySs2 from strain 89/1591)
was PCR-cloned from genomic DNA with the following primers:
AATGCTAGCCTGATACACAGTTAGAGACC—fwd and
CCTAAGCTTCTTTTCACAAATCATAATCCCCAG—rev. The underlined
nucleotides again represent restriction sites (NheI and HindIII) for cloning into
pBAD24. It should be noted that the forward primer corresponds to a position
~60 bp upstream the start of the gene. For plySs2, several in-frame ATG triplets
are situated near one another at the 5‘-end. To avoid choosing the incorrect start
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codon, the upstream region was included so that transcription could be guided
by the native ribosome binding site (instead of the engineered RBS of pBAD24).
Recombinant expression and purification of PlySs1. To express PlySs1, the
clone was grown in Power Broth + LB-Booster (Athena Enzyme System) to OD600
≈ 1.0 and induced with 0.2% arabinose. The culture was shaken for 4 hr at 37C
(inclusion bodies would form at longer times). The expressing cells were
pelleted, resuspended in 15 mM phosphate buffer pH 6.2, and lysed by three
passages through an EmulsiFlex C-5 homogenizer. Residual debris was removed
by centrifugation (1 hr, 35,000 X G), and ammonium sulfate was added at 225
g/L (40% saturation). The precipitated protein was pelleted and resolubilized in
15 mM phosphate pH 7.4, and dialyzed against this buffer overnight.
The dialysate was next passed through a DEAE anion-exchange column
equilibrated against the same buffer (fast flow resin, General Electric). Quite
surprisingly, PlySs1 demonstrated the same sort atypical binding response
observed for PlyCM in Chapter 2. With a predicted pI of 7.7, one would expect
PlySs1 to bind weakly to DEAE at pH = 7.4, or perhaps flow directly through it.
Again, however, there was a transient interaction in which PlyCM would
initially bind the resin, but then slowly elute as excess Buffer A was passed over
the column (see Figure 5.1). The effect here was even more pronounced than
with PlyCM, as the initial flow-through trace would return almost completely to
baseline before PlySs1 began eluting.
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Figure 5.1 PlySs1 Purification
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Salt Elution
Wash (PlySs1)

Flow Through

Figure 5.1, continued
The dialyzed 40% ammonium sulfate cut of PlySs1-lysate was loaded onto
DEAE resin at pH = 7.4. Non-binding proteins flowed through the column
as the sample was loaded. After continued wash in the same buffer, an
extended secondary peak eluted. Non-transiently binding proteins eluted

with the addition of 1M NaCl. The extended-wash fraction, when analyzed
by SDS-PAGE, was observed to be high-purity PlySs1 (see Figure 5.3).
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This phenomenon led to a highly pure lysin preparation in only a single
chromatographic step. For every liter of original E. coli culture, 50-100 mg of
final PlySs1 could be obtained.
PlySs1 enzymatic specificity. To determine the bond specificity of the Nterminal enzymatic domain of PlySs1, cell-wall preparations were made from S.
suis type-strain S735. The Gram-positive protocol of Rosenthal and Dziarski (1994)
was utilized with only slight modifications. Purified cell walls were suspended
in phosphate buffered saline (pH 7.4); PlySs1 and hen egg-white lysozyme
(Sigma) were both added to 500 μg/ml, and the solution was shaken gently
overnight at room temperature. The digest was centrifuged (20 min, 16,000 X g),
and the supernatant passed through a 10,000 MWCO micro-filter (Ultracel YM10, Millipore) to remove the lytic enzymes and remaining macromolecular cellwall components. This sample and an undigested negative control were subject
to MALDI-TOF mass spectrometry (positive ion mode, Applied Biosystems DESTR spectrometer) by the Rockefeller University Proteomics Core Facility.
In vitro characterization of PlySs1. The biochemical properties and strainspecificity of PlySs1 were examined mainly through optical density-drop
experiments. All bacteria were maintained on Brain Heart Infusion (BHI) agar
plates. For each experiment, individual colonies were inoculated into 50 ml
liquid BHI, which were gently shaken (125 rpm) for several hours at 37C. When
the cells had reached mid-log phase (OD ≈ 0.5), they were pelleted, washed and
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resuspended in the appropriate buffer (which varied from experiment to
experiment) to an OD600 ≈ 0.8. Optical density measurements were performed in
96-well plates at 37C. PlySs1 or lysin vehicle was added immediately prior to
the start of each experiment, and measurements were taken every minute.
For CFU analysis, cells were treated with PlySs1 in a similar manner as
above. After 1 hr at 37C, samples were each diluted over five orders of
magnitude, with triplicate plating at each dilution onto BHI agar. For
(attempted) MIC-analysis, cells were suspended in 2X BHI to ~106 cells/ml
(determined by comparison with a McFarland standard). Sterile-filtered lysin
and/or vehicle was added at the appropriate concentrations, yielding a final
suspension of ~5 X 105 cells/ml in 1X broth (Wiegand et al. 2008). Cells were
distributed within a 96-well plate, and OD600-measurments were taken overnight
(every 2 minutes) with the plate maintained at 37C.
RESULTS AND DISCUSSION
Identification of PlySs1 and sub-cloning of truncated construct. A prophage
lytic enzyme, PlySs1, was cloned from a functional genomic screen of S. suis
strain 7711, a serotype 7 isolate originating from the Netherlands1. PlySs1 is a
452-residue protein: Pfam analysis predicts a type 5 alanine-amidase domain
(PF05832) at the N-terminus, followed by a double CPL-7 cell-wall binding
domain (PF08230) in the central region, and a secondary glucosaminidase
domain (PF01832) at the C-terminus (Figure 5.2a).
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(A)

(B)

PlySs1
LySMP

MTINLETSIRWMSDRVGKVSYSMDYRNGPNSYDCSSAVYYALMAGGAISAGWAVNTEYMH 60
MTINIETAIRWMTDRVGLVKYSMDYRNGPNSFDCSSSVYYALMAGGAISAGWAVNTEYEH 60
****:**:****:**** *.***********:****:********************* *

PlySs1
LySMP

DWLIRNGYVLVAENKPFNAQRHDVCILGKRGYSSGAGGHVVIFVDNVNVIHCNYARNGIS 120
DWLIKNGYKLIAENQDWDAKRGDIFIWGRRGQSSGAGGHTGIFVDPDNIIHCNYANNSIT 120
****:*** *:***: ::*:* *: * *:** *******. **** *:******.*.*:

PlySs1
LySMP

IDNYNQVHRG---MYYYLYRPANQPSIS--NKSLDQLVKETLAGVHGNGDTRKASLGSQY 175
INNYNQTAAASGWMYCYVYRLGNQPTTSPAGKTLDTLVKETLAGKYGNGDQRKAALGNQY 180
*:****. .
** *:** .***: * .*:** ******** :**** ***:**.**

PlySs1
LySMP

EAVMAVINGKASASEKSDEELAREVLAGKHGAGEDRKRSLGPRYEPVQAKVNELLK---- 231
EAVMAVINGKATAPKKTVDQLAQEVIQGKHGNGEDRKKSLGPDYDAVQKRVTEILQGSTS 240
***********:*.:*: ::**:**: **** *****:**** *:.** :*.*:*:

PlySs1
LySMP

--AKEKPSETAKN-------EPQTVQ------------FKEDGDLSFNGAILKKSVLEII 270
GNAPKLASDAPKNEVVNSSTEPKTEETWATGKATDTKITKEDGDLSFNGAILKKSVLDVI 300
* : .*::.**
**:* :
******************::*
↑

PlySs1
LySMP

LKKCKEHDILPSYALTILHYEGLWGTSAVGKADNNWGGMTWTGQGNRPSGVIVTQGLARP 330
LANCKKHDILPSYALTILHYEGLWGTSAVGKADNNWGGMTWTGKGERPSGVTVTQGTARP 360
* :**:*************************************:*:***** **** ***

PlySs1
LySMP

SNEGGHYMHYATVDDFLTDWFYLLRKDGSYKVSGALTFSESIKGMFQVGGAKYDYAAAGY 390
ACEGGHYMHYASVDDFLTDWFYLLRSGGSYKVSGAKTFSDAVKGMFKIGGAVYDYAASGF 420
: *********:*************..******** ***:::****::*** *****:*:

PlySs1
LySMP

DSYLVGATSRLKAIESENGSLTRFDATSNNVHSVD-PDKISVDIDGIEVTINGVVYKLEK 449
DSYIIGASSRLKAIEAENGSLDKFDKQT--VTDVGQSDKIEVTIEGIEISINGVTYTLSK 478
***::**:*******:***** :** : * .*. .***.* *:***::****.*.*.*

PlySs1
LySMP

KPV 452
KPV 481
***

Figure 5.2 PlySs1 Prophage Lysin
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Figure 5.2, continued

[A] The molecular architecture of PlySs1. The N- and C-terminal
enzymatic domains are shown, along with the central cell wall-binding
region. The N-terminal enzymatic domain is annotated according to its
observed activity (-endopeptidase), rather than its predicted activity
(alanine-amidase). Prior to purification and functional analysis, PlySs1
was recombinantly truncated to exclude its C-terminal glucosaminidase

domain (PlySs1). The position of that truncation, D254, is likewise
denoted (red lightning-bolt). [B] S. suis lysin alignment. The protein
sequences of PlySs1 and LySMP (YP_950557) are compared here. Residue
identities are denoted with underlying asterisks and (in most cases)
highlighting. The color of the highlighting indicates the particular domain
to which the sequence corresponds (endopeptidase-yellow, CPL-7-blue,
glucosaminidase-pink). Residue identities that do not fall within a
predicted domain are not highlighted (only denoted with an asterisk). The
position of the engineered C-terminal truncation of PlySs1 is designated
with an arrow.
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PlySs1 demonstrates high homology to the previously-characterized LySMP
lysin throughout its entire sequence (Figure 5.2b). The proteins share ~70%
nucleotide and amino-acid identity with one another (all E-values < 10-60).
Architecturally, the domain arrangement of PlySs1 (and LySMP) is highly
atypical. Gram-positive lysins typically consist of an N-terminal enzymatic
domain and a C-terminal binding domain (Fischetti 2008). While occasionally
lysins are seen with two N-terminal lytic domains (for instance, Baker et al. 2006;
Cheng and Fischetti 2005), it is rare for a second enzymatic functionally to be
encoded after the binding domain. Besides PlySs1 and LySMP, the only other
example characterized to date is the LambdaSa2 lysin of S. agalactiae (a few more
putative examples exist within nucleotide databases) (Pritchard et al. 2007).
Interestingly, the C-terminal enzymatic domains of these lysins demonstrate
homology to several annotated bacteriophage tail proteins; the latter are known
to possess muralytic activity for purpose of viral DNA injection (Kenny et al.
2004; Piuri and Hatfull 2006). Conceivably, the PlySs1/LySMP/LambdaSa2
group of enzymes could have evolved from a recombination event that
juxtaposed a tail enzyme with a phage lysin proper.
Working with LambdaSa2, Donovan and Foster-Frey surprisingly
observed increased enzymatic activity following removal of the C-terminal
glucosaminidase domain (2008). With this motivation, we engineered a
truncated PlySs1 construct with only the N-terminal enzymatic and central

227

binding domains. This construct was expressed and purified for subsequent
functional analysis (Figure 5.3); it will henceforth be referred to as PlySs1.

Identification of PlySs2. A second lysin, PlySs2, was identified (and,
subsequently, PCR-cloned) through sequence analysis of 8 published S. suis
genomes. PlySs2 is encoded in a prophage region of serotype 2 strain 89/1591
(the lysin-encoding ORF was originally annotated as SH3-type 5 domain protein,
ZP_03625529; Lucas et al. 2004); it was the only lysin identified through our
database search. The structure of PlySs2 is quite unlike that PlySs1 and LySMP.
It encodes a predicted N-terminal CHAP domain (cysteine-histidine
amidohydrolase/ peptidase, PF05257) and a C-terminal SH3-type 5 domain
(PF08460) (Figure 5.4a).
CHAP domains are included in several previously-characterized
streptococcal (Nelson et al. 2006; Baker et al. 2006) and staphylococcal (Daniel et
al. 2010; Becker et al. 2009) lysins. On a primary sequence level, however, the
CHAP domain of PlySs2 is rather divergent from other database CHAP domains
(all pairwise E-values > 10-15). In Figure 5.4b, CHAP domain of PlySs2 is aligned
with that of the well-characterized streptococcal PlyC lysin, demonstrating
conserved catalytic residues but only a modest level of identity overall (28%
sequence identity, E-value = 10-8) (Nelson et al. 2006). SH3 domains are
commonly seen in viral and bacterial cell wall-binding proteins, although the
exact molecular target remains unknown (Xu et al. 2009).
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(1)

(2)

(3)

(4)

Figure 5.3 Purified PlySs1
PlySs1 was chromatographically purified after recombinant

expression. Lane 1: molecular weight ladder. Lane 2: crude extract of
encoding strain prior to induction. Lane 3: crude extract of encoding
strain 4-hr after induction. Lane 4: final product following isolation
protocol. By visual approximation, PlySs1 is > 90% pure; its band
appears just above 25-kDa marker (predicted MW = 28.1 kDa).
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(A)

(B)

Figure 5.4 PlySs2 Prophage Lysin
[A] The molecular architecture of PlySs2. [B] Enzymatic domain
alignment. The CHAP domains of the streptococcal lysins PlySs2 and
PlyC (subunit A, GenBank no. AAP42310) are aligned here. Amino-acid
identities are indicated with underlying asterisks and highlighting. The
positions of the presumptive catalytic residues (cysteine and histidine,

for which the domain is named is named) are indicated with arrows.
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Enzymatic characterization of PlySs1. The first issue to be addressed for
PlySs1 was its enzymatic specificity. Although Pfam predicts a type 5 alanineamidase domain, this motif is historically associated with false computational
assignments. The same domain was predicted at the N-terminus of LambdaSa2,
but was instead shown to be a -glutaminyl-L-lysine-endopeptidase
experimentally (Pritchard et al. 2007). To clarify the situation here, purified S.
suis cell walls (from type strain S735) were subject to double digestion with
HEWL (a muramidase) and PlySs1. Mass spectrometric analysis of the filtered
digest revealed the expected peaks for combined muramidase/-endopeptidase
activity, demonstrating that PlySs1 hydrolyzes the same bond as LambdaSa2
(Figure 5.5).
The enzymatic specificity of PlySs2 currently remains in doubt. CHAP
domains are catalytically diverse and can possess either alanine-amidase (Nelson
et al. 2001) or cross-bridge endopeptidase activity (Daniel et al. 2010), depending
on the particular lysin. Further complicating the situation here is the fact that the
molecular nature of the peptidoglycan cross-bridge in S. suis can vary between
strains (Kilpper-Bälz and Schleifer 1987). Accordingly, mass-spectrometric
experiments with PlySs2 are ongoing.
Optimization of PlySs1 activity. The optimal biochemical conditions for
PlySs1 were determined against live cells of the encoding S. suis strain (7711).
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Figure 5.5 PlySs1 Enzymatic Specificity
Depicted here is the mass spectrum of digested (and filtered) S. suis S735 cell
wall. Hen egg-white lysozyme (a eukaryotic muramidase) was used in
combination with PlySs1. The two predominant peaks (with respective
isotopic tails) are m/z = 718 and m/z = 734. This corresponds exactly to the
predicted masses of the [Na-M]+ and [K-M]+ adducts of GlcNAc-MurNAc-LAla-D-Gln. This suggests that PlySs1 possesses gamma-endopeptidase
activity, cleaving the peptidoglycan stem between D-Gln and L-Lys. When a
mass spectrum was taken of undigested cell wall (not shown), the above two
peaks were absent.
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For these experiments, activity was gauged through the degree of turbidity
reduction (OD600) of an aqueous bacterial suspension following the addition of
lysin. The pH-dependence of the enzyme was first addressed using two buffer
sets with adjacent pH ranges, citrate/phosphate: 4.6 – 8.0; and bis-tris-propane
(BTP): 7.0 – 9.7. An extended spectrum of lysis was observed, from 5.4 – 9.4
(Figure 5.6). In BTP, lysis was maximal from 8.2 – 9.0; at commensurate pHvalues, however, the magnitude of the OD-drop was slightly more pronounced
in citrate/phosphate. The role of salt concentration was likewise considered,
although it did not greatly affect PlySs1-induced lysis. At constant enzyme
concentrations, bacteriolysis varied little from 0 – 1000 mM NaCl, with only
small numeric increases under the most hypotonic conditions (Figure 5.7).
Exposure of PlySs1 to an excess of DTT had no impact (either positive or
negative) on activity (Figure 5.8a). This indicates both that [1] the lysin does not
rely on intramolecular disulfide bridges, as well as [2] that it was properly folded
following recombinant expression and purification. The latter point is significant
given that LySMP had to be treated with reducing agents prior to use (Wang et
al. 2009). The reason for this discrepancy between two homologous lysins is
unclear, although (most likely) it involves the numerous variable cysteine
residues between the proteins (see Figure 5.2b).
Interestingly, treatment with EDTA enhanced PlySs1-induced lysis of S.
suis (Figure 5.8b).
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(A)

(B)

Figure 5.6 PlySs1 pH Dependence
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Figure 5.6, continued
[A] Cells of host strain 7711 were suspended in phosphate-citrate buffer
(40/20 mM) at a range of pH-values from 4.6 to 8.0. PlySs1 was added
(110 g/ml) and OD600 was measured over 60 min (horizontal axis) at 37C.
The vertical axis represents the treated/untreated OD600-ratio at each timepoint. For each pH-value, the curve depicts the running average of 3
independent experiments. Overall, activity was maximal at the upper end
of the buffering range. [B] Here, bis-tris-propane (40 mM) was employed
as the buffering agent with a pH-range from 7.0 to 9.7; PlySs1 was again
added to 110 g/ml. Each curve depicts the running average of 3
experiments. Maximal activity was observed at pH = 9.0, although the
quantitative degree of OD-decline was, in general, less than in phosphatecitrate.
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Figure 5.7 PlySs1 NaCl Dependence
S. suis 7711 cells were suspended in phosphate-citrate buffer pH = 7.8
(40/20 mM). NaCl was added to the above concentrations, followed by
PlySs1 at 110 g/ml. Optical density at 600 nm was observed over 60
min at 37C. In this figure, the vertical axis represents the treateduntreated OD600-ratio for each NaCl concentration, averaged over 3
independent experiments.
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(A)

(B)

Figure 5.8 PlySs1 DTT and EDTA Susceptibility
[A] PlySs1 was pre-incubated for 1 hr with 5 mM DTT (a large molar excess)
prior to addition to 7711 cells; activity was unchanged. [B] Here, various
concentrations of EDTA were included in the buffered suspension of cells prior

to addition of PlySs1 (110 μg/ml lysin). For both images, the vertical axis
represents the treated/untreated OD600-ratio for each condition, averaged over 3
independent experiments.
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The lack of inhibition naturally suggests that PlySs1 does not rely upon divalent
cations as cofactors, and several potential mechanisms could underlie the
increased activity. A particularly attractive scenario is that the lysin is
susceptible to metal-dependent proteases on the S. suis surface. Wang et al.
previously demonstrated that bacterial proteases desensitize S. suis to lysin
activity (2009). Unser this hypothesis, EDTA would mediate bacteriolysis by
inhibiting lysin-degradation and increasing the effective PlySs1 concentration.
The thermal stability of PlySs1 was examined by incubating the enzyme
at various elevated temperatures prior to use (the OD-drop experiment itself was
always conducted at 37C). When held at 35C – 60C for 30 min, lysin activity
was virtually unaffected until 50C, at which point it was completely abolished
(Figure 5.9a). For a 6-hr incubation, a partial decrease in activity was observed at
45C, while the 40C sample was unaffected (Figure 5.9b). The latter corresponds
to typical porcine body temperature.
PlySs1 activity against S. suis and other bacteria. Given the above
experiments, the following optimal buffering conditions were employed for all
further in vitro experiments with PlySs1: 20 mM phosphate buffer, pH = 7.8, 2
mM EDTA. A range of lysin concentrations, from 6.5 – 130 μg/ml, were
introduced to live S. suis cells in this buffer. Three strains were considered
particularly relevant: 7711, the serotype 7 strain that encodes PlySs1; S735, the
serotype 2 reference strain; and 7997, a highly virulent serotype 9 strain.
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(A)
30 min

(B)
6 hr

Figure 5.9 PlySs1 Temperature Stability
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Figure 5.9, continued
[A] A PlySs1 stock solution was held at each of the above temperature
for 30 minutes, followed by addition to 7711 cells (270 μg/ml final
enzyme concentration, final temperature = 37C, ideal buffering
conditions). The curves in this image represent running averages of 3
individual experiments. In each case, complete loss of activity was
observed between the 45C and 50C samples. The 3 hottest samples
show a slightly higher OD600 reading than the untreated control due to
flocculation of PlySs1 upon denaturation. [B] The above experiment
was repeated, but with 6 hours of heat-treatment prior to the assay. At
this longer incubation time, the 45C sample showed some loss of
activity, though not complete. The 40C sample maintained essentially
native activity.
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For each of these strains, the time-dependent OD600 response at various PlySs1
dosages is given in Figure 5.10.
Overall, these data are notable for the relatively high concentration of
PlySs1 needed to induce efficient bacteriolysis (> 65 μg/ml). For many phage
lysins, only low μg/ml-concentrations are required to lyse their respective
bacteria in vitro (see Nelson et al, 2001; Schuch et al. 2002; or Chapter 2 of this
thesis). At the same time, the higher concentrations needed here are highly
commensurate with the amount of LySMP that was needed in that study (in fact,
the magnitude of the turbidity-decreases is slightly more favorable here). In
terms of bacterial viability, only the highest PlySs1-concentration (130 μg/ml)
led to a >90% decrease in CFUs for 7711, S735, and 7997 after 1 hr treatment
(Table 5.1). The lysin was also tested against actively-dividing cells in broth
culture (strain 7711). Although it delayed bacterial proliferation in a dosedependent manner (Figure 5.11), these effects were generally mild and PlySs1
could not inhibit S. suis growth outright.
PlySs1 was further tested against a panel of 19 other S. suis strains of
diverse serotypes, as well as other species of Gram-positive bacteria. The same
lysin concentrations were used as above. For each dosage, the observed lysisvalues after 1 hr are listed in Table 5.2, and the information is summarized
graphically in Figure 5.12. All S. suis strains demonstrated some degree of
susceptibility—for certain isolates, lysis was more pronounced than that
observed in Figure 5.10.
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7711:
Serotype 7,
(encoding strain)

S735
Serotype 2
(type strain)

7997
Serotype 9

Figure 5.10 PlySs1 Bacteriolytic Activity
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Figure 5.10, continued
Depicted here are OD-drop curves for three strains of S. suis: 7711, the
serotype 7 strain from which PlySs1 was originally cloned (i.e. the host
strain); S735, a serotype 2 isolate that is the type-strain for the species; and
7997, a virulent serotype 9 strain. Bacteria were suspended in 20 mM
phosphate buffer pH 7.8, 2 mM EDTA (defined as optimal conditions).
PlySs1 was added to the cells at a range of concentrations (indicated by
the inset). For each sample, optical density at 600 nm (vertical axis) was
measured over the course of an hour (horizontal axis) at 37C. In this
image, all curves represent running averages of 3 or 4 independent
experiments.
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Strain

13 μg/ml

130 μg/ml

S735 (ST2)

80.4% – 92.6%

95.4% – 99.5%

7997 (ST9)

16.8% – 30.3%

89.9% – 93.9%

7711 (ST7)

0% – 35.6%

95.3% – 99.2%

Table 5.1 CFU Analysis of Strains 7711, S735, 7997
For two PlySs1 concentrations (130 and 13 g/ml), CFU analysis was
conducted on S. suis strains S735, 7997, and 7711 after 1 hr treatment (optimal

buffering conditions). In each experiment, the percentage-decrease in CFUs
was determined for the treated sample versus the untreated. The range of the
values observed (across 3 independent experiments) is reported here for each
strain. The serotype of each strain is indicated in parentheses.
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Figure 5.11 PlySs1 Growth Inhibition of S. suis 7711
PlySs1 was added at the above final concentrations to a dilute suspension of S.
suis strain 7711 in BHI broth (see Materials and Methods for experimental
details). The optical density of each sample was measured continuously
overnight in 96-well plate format. Overall, bacterial growth was delayed in a
dose-dependent manner. However, for enzyme-concentrations that were
sufficient to induce lysis in buffered solutions (130 and 50 g/ml), the effect
was quite minimal here. Moreover, none of the above PlySs1 concentrations

inhibited growth outright—hence, a MIC could not be assigned. For all of the
treated samples, one will note that the final optical densities are actually higher
than that of the untreated sample. This is an artifact of the accumulation of
aggregated bacterial debris that occurred in the presence of lytic enzyme.
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Strain

6.5 μg/ml

13 μg/ml

30 μg/ml

65 μg/ml

130 μg/ml

ST13

0.32

0.17

0.04

0.02

0.02

6112 (ST1)

0.14

0.11

0.06

0.02

0.01

ST8

0.25

0.12

0.06

0.03

0.03

6388 (ST1)

0.15

0.13

0.06

0.03

0.02

10 (ST2)

0.29

0.18

0.10

0.05

0.02

8076 (ST9)

0.52

0.40

0.21

0.14

0.04

ST9

0.50

0.30

0.23

0.13

0.05

ST4

0.63

0.47

0.32

0.22

0.12

ST11

0.64

0.47

0.32

0.19

0.07

ST14

0.79

0.57

0.33

0.15

0.06

ST7

0.65

0.47

0.34

0.22

0.11

ST1

0.80

0.34

0.36

0.19

0.06

ST5

0.78

0.59

0.39

0.22

0.10

7197 (ST7)

0.64

0.49

0.39

0.16

0.07

ST6

0.76

0.56

0.40

0.21

0.06

ST3

0.81

0.71

0.48

0.32

0.16

ST2

0.79

0.70

0.49

0.34

0.17

ST10

0.85

0.72

0.55

0.44

0.28

ST12

See Caption

Table 5.2a Analysis of Other S. Suis Strains
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Table 5.2a, continued
Various isolates of S. suis were exposed (at optimal buffering conditions)
to PlySs1 at the above concentrations. The majority of these bacteria are
unnamed clinical isolates of the indicated serotype (e.g. ST1, ST2, etc…).
For the named strains, the serotype is given in parentheses. The 1-hour
treated/untreated OD600-ratio is given for each PlySs1 concentration
(representing a single experiment), and the strains are listed in the order of
decreasing sensitivity. For strain ST12, it was not possible to conduct OD
analysis. Upon the addition of PlySs1 (all above concentrations), the cells
would rapidly self-adhere and fall out of suspension. This phenomenon
was not observed for untreated ST12-cells.
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Strain

6.5 μg/ml

13 μg/ml

30 μg/ml

65 μg/ml

130 μg/ml

S. oralis 35037

0.30

0.13

0.08

0.07

0.04

S. agalactiae type II

0.61

0.21

0.11

0.08

0.04

S. dysgalactiae 21597

0.26

0.18

0.12

0.10

0.09

S. pyogenes A486

0.12

0.13

0.13

0.11

0.10

S. pneumoniae R36

0.25

0.22

0.14

0.16

0.12

S. dysgalactiae GGS

0.30

0.27

0.15

0.11

0.14

S. equi 700400

0.48

0.25

0.15

0.07

0.09

S. uberis 27598

0.42

0.23

0.16

0.14

0.12

S. pyogenes D471

0.39

0.27

0.17

0.13

0.09

S. gordonii 10558

0.76

0.32

0.19

0.09

0.06

S. equi 9528

0.66

0.45

0.25

0.19

0.16

L. monocytogenes HER1084

0.63

0.52

0.26

0.14

0.04

S. sanguinis 10556

0.48

0.44

0.28

0.21

0.11

Group E streptococci K131

0.69

0.50

0.33

0.22

0.15

S. sobrinus 6715

0.64

0.48

0.39

0.32

0.23

E. faecium EFSK2

0.85

0.67

0.52

0.32

0.13

S. aureus RN4220

0.89

0.78

0.55

0.31

0.10

S. salivarius 9222

0.80

0.76

0.56

0.53

0.37

S. rattus BHT

0.82

0.84

0.82

0.83

0.79

M. luteus 4698

0.84

0.90

0.83

0.87

0.82

E. faecalis V583

0.98

0.93

0.84

0.71

0.52

B. cereus 14579

0.93

0.92

0.86

0.90

0.86

B. thuringiensis HD73

0.99

0.98

0.93

0.86

0.60

S. mutans U159

0.95

0.99

0.94

0.76

0.85

S. epidermidis HN1292

1.04

1.00

0.96

0.94

0.87

S. agalactiae 090R

0.97

0.99

0.97

0.98

0.93

S. simulans TNK3

0.96

1.00

1.00

1.00

0.96

B. anthracis Sterne

1.02

1.03

1.02

0.98

0.90

B. subtilis SL4

1.07

1.05

1.04

1.03

0.96

Table 5.2b Analysis of Other Gram-Positive Bacteria
The experiments summarized in 5.2a were repeated here for various Gram-positive
bacterial species other than S. suis. As before, 1-hr OD600-ratios are given (again,
each representing a single experiment).
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Figure 5.12 PlySs1 Bacterial Strain Panel
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Figure 5.12, continued
The information provided in Figure 5.10 and Tables 5.2a and 5.2b is
summarized graphically for two PlySs1 concentrations, 130 g/ml and
32.5 g/ml. In the image, strains of S. suis are denoted with double red
asterisks and non-suis streptococci are denoted with single black asterisks.
The optical density response (treated-versus-untreated OD600 ratio) after 1
hr is shown. The reader is referred to Table 5.2a for the serotype
definitions of the S. suis strains.
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Interestingly, many of the non-suis streptococci (and even some nonstreptococci) also lysed at commensurate enzyme concentrations. Classically, a
phage lysin demonstrates a marked decrease in activity when going from within
its host species to outside of it. Here, however, a broad range of susceptibility
was seen among non-suis bacteria, with some demonstrating identical lysis to S.
suis itself. This phenomenon raises interesting questions regarding the specificity
of the dual CPL-7 binding domain of PlySs1.
Comments on ongoing work. Admittedly, the characterization of PlySs1 does
not represent a tremendous theoretical step forward (given its similarity to the
previously-characterized LySMP). And we would prefer to have seen
bacteriolytic activity at lower overall concentrations. From a technical
perspective, however, PlySs1 can be purified rapidly (in a single
chromatographic step), solubly (without additional reducing agent), and in large
quantities (100‘s of mg in a single protocol), all of which offer practical
advantages over LySMP.
Although it was not discussed in this thesis—see Chapter 6 for further
explanation—PlySs2 has also been purified and tested in vitro against the same
panel of S. suis isolates. Fortunately, the potency of this enzyme seems far
greater that of PlySs1 (i.e. similar bacteriolytic responses at 10-fold lower
concentration). Among the two lysins, PlySs2 is clearly the superior enzybiotic
candidate. In this regard, combination therapy with both lysins (by intranasal
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lavage) is currently being tested as a means of preventing colonization/infection
of newborn piglets by serotype 2 and 9 strains of S. suis. This work is being
undertaken by collaborators at the University of Utrecht in the Netherlands (see
Acknowledgements).
Overall, an inherent advantage of applying phage lysins to veterinary
pathogens is that, ethically, one can rapidly progress to applying the agents in
their intended clinical setting. It is true that several previous reports have
investigated lysins from, broadly speaking, a veterinary perspective (Hoopes et
al. 2009; Celia et al. 2008; Nelson and Fischetti 2004). Nevertheless, the ongoing
trials with PlySs1 and PlySs2 represent the first instance of enzybiotic agents
being used to treat a bacterial disease in its natural context (as opposed to animal
models of human infections). The fact that the progression of this research—
from initial identification to in vivo experiments—took only slightly more than
half a year makes the work particularly exciting. From this perspective, we feel
that PlySs1 and PlySs2 are indeed expanding the horizons of the enzybiotics
field in a significant way.
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ENDNOTES
1. There was no pre-designed rationale for choosing this particular strain or
serotype for functional genomic screening. A variety of clinical isolates were
available for this purpose, and 7711 just happened to be the first (out of 4 tested)
to successfully yield a lysin. After the identification of PlySs1 (and,
concomitantly, PlySs2), no further strains were subject to functional screening.
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CHAPTER 6
Future Prospects for Enzybiotic Identification

REFLECTIONS ON THE CURRENT PROJECT
Looking back at the work presented in this thesis, it is tempting to
consider how I would expand on the various topics given the opportunity to
pursue them further. In the following paragraphs, I will examine briefly for each
chapter what I consider the most promising next steps for ongoing research.
Some of these possibilities were already mentioned in the Discussion sections of
the individual chapters. Here, however, I will focus exclusively on the most
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practical priorities in the context of an academic research lab (and, specifically,
the Laboratory of Bacterial Pathogenesis at Rockefeller).
For Chapter 2, one of the most straightforward extensions would be to
apply a similar in silico lysin screen to the published genomes of other Grampositive bacterial species. As the results of the chapter demonstrated, this
information can be valuable both in the identification of novel enzybiotic
candidates, as well in the generation of new hypotheses regarding the biology of
the host bacteria (with C. perfringens, for example, involving BCN5
externalization). In the present work, however, the search strategy was
essentially manual. In theory, however, the same set of steps (i.e. the algorithm)
could be conducted computationally, expediting the process tremendously. A
program such as this could readily be applied to all known genomes—as well as
new sequencing data, assembled or unassembled—with the goal of generating a
single, organized database of lysins.
Experimentally speaking, one of the most intriguing next steps does not
actually involve work with PlyCM itself, but rather the non-viral ―lysins‖ in the
C. perfringens genomes. In particular, the BCN5-assoicated lysins are a tempting
area for investigation. Although this possibility was mentioned in the chapter as
more of an afterthought, its potential implications (i.e. secretion-by-suicide) and
the relative ease with which the hypothesis could be tested make it an extremely
attractive project. Since these genes are already plasmid-encoded, it should be
straightforward to introduce them into a C. perfringens/E. coli shuttle plasmid
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while maintaining natural function. Knockouts or mutations of the lysin-like
ORF could then be constructed; the plasmid would be reintroduced to C.
perfringens, which would be observed phenotypic differences in response to UVradiation.
In contrast, the work in Chapter 3 could probably be considered a closed
topic from a theoretical perspective. This not to say that E-LASLs are no longer
relevant… to the contrary, the technique is still widely used within the
Laboratory of Bacterial Pathogenesis for screening genomes and metagenomes.
It is just that—from a methodological standpoint—any developments of the ELASL protocol would likely just represent incremental adjustments rather than
major advances.
In this regard, a more relevant issue involves the actual screens that are
conducted once the libraries are synthesized. Phages encode numerous
biotechnologically-relevant proteins other than lysins (Schoenfeld et al. 2010).
From a screening perspective, the biggest issue is how to readily identify their
associated properties within transformed clones. While a bacteriolytic or
hemolytic phenotype is visually straightforward, the same might not be true for
a colony that expresses, say, an interesting phage polymerase. Overall, as more
and more screening techniques are devised, the utility of the E-LASL can only
expand.
For Chapter 4, the most pressing avenue for ongoing research is
abundantly clear: applying the protocol to larger and more diverse viral
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metagenomes so that the holin-based method can be exploited for its full worth.
The 26 enzymes identified here demonstrate the validity of the technique, and
several possess interesting sequences that could merit future purification and
biochemical analysis. At the same, the true value of the method can only be
realized in the identification of novel enzymes that would not have been
approachable by genomic techniques alone.
Based on the extreme abundance of phage in the biosphere and the results
of previous viral metagenomic sequencing studies, there is good reason to
believe that we have only seen the tip of the iceberg when it comes to the diversity
of proteins that phages encode. These studies have been remarkable for the lack
of similarity between the new metagenomic sequences and genetic information
already in the databases (Edwards and Rohwer 2005). Personally, I am
optimistic that the same holds true specifically for lytic enzymes. In this regard,
our laboratory has been in contact with other research groups about potential
collaborations, so that we can apply our functional techniques to existing phage
libraries that have only been examined via sequencing to date.
Finally—regarding the S. suis lysins of Chapter 5—it is admittedly
difficult to surmise where the work presented here will lead in the future. Much
of this is dependent on the success of ongoing in vivo trials. At this point, we are
cautiously hopeful that combination treatment with PlySs1 and PlySs2 will have
a positive impact on experimentally-infected pigs. In a small cohort of animals,
lysin treatment prevented clinical progression of disease in 4/5 subjects, while
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4/5 untreated subjects experienced fulminant lethal infection (Dekker and
Wagennar, personal communications). At the same time, more data analysis and
further experimental trials are pending, and these will assuredly affect future
decision making on how intensely PlySs1 and PlySs2 will be pursued.
It is also important to emphasize that, of the two S. suis lysins, PlySs1
actually represents the less promising enzybiotic candidate. Although only the
characterization PlySs1 is presented in this thesis, it is the weaker enzyme
quantitatively. PlySs2 demonstrates similar anti-streptococcal activity, but at
~10-fold lower concentrations than PlySs1 (values that are more representative of
the typical potency of phage lysins). The reason that PlySs2 data is not presented
in this thesis is purely logistical. The PlySs1 and PlySs2 enzymes were initially
identified and cloned around the same time (autumn/winter 2009). Without
prior knowledge of their behavior, I chose to focus on the characterization of
PlySs1, while similar work on PlySs2 was undertaken by Mr. Daniel Gilmer (a
rotation student in the Laboratory of Bacterial Pathogenesis, who has since joined
as a permanent member). Mr. Gilmer has assumed PlySs2 as part of his own
doctoral research, and is actively pursuing its characterization. We plan to coauthor a manuscript that combines the in vitro characterization of both enzymes.
THE FUTURE OF GENOMICS AND METAGENOMICS
Looking beyond the specific work conducted here, it also valuable to
consider other potential developments that might impact lysin identification in
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the future. Overall, the ideal lysin screen (from an enzybiotic perspective) would
be one that combines the large number of enzymes encoded by metagenomic
samples with the specificity that individual lysins demonstrate toward their host
bacteria. One possible solution could involve screens in which genomic DNA
from numerous strains of a single pathogen is pooled to form a multi-genomic
library. Each strain would likely contain integrated prophage, such that a
combination of diverse strains should encode a large collection of lysins. A
functional screen of this library would generate many hits, like a metagenomic
screen, with the exception that all enzymes would target the same bacteria de
facto.
An alternative multi-genomic approach could involve large-scale proviral
induction. A collection of strains could be grown in liquid culture and treated
with an agent such as mitomycin or phosphomycin (Ryan and Hébert 2009).
This would induce lysogen activation, and the resultant viral particles would be
released into the culture supernatant. These could readily be purified by a
combination of filtration, nuclease treatment (to remove free bacterial
DNA/RNA), and polyethylene glycol precipitation. The DNA from a pooled
lysogen library could then be subject to a single functional screen. This method,
in fact, is currently being employed with success by other members of the
Fischetti Laboratory (Schuch and Pelzak, personal communications).
Comparing these two functional multi-genomic approaches, the main
advantage of the former is its ability to identify all proviral lysins, including ones
259

from cryptic prophages and those that do not induce well in vitro. At the same
time, considering the much larger size of bacterial genomes, the lysin-encoding
clones would represent a much smaller proportion of the overall library
population. With induced phages, by contrast, the total diversity of lysins might
be diminished somewhat, but the desired transformants would be relatively
abundant within the library.
Of course, both of these methodologies assume that whole-genome
sequencing is beyond the reach (and cost) of a typical academic laboratory.
While this technology is vastly more accessible than a decade ago (500+ phage
and 1,000+ bacteria been sequenced to date), the preceding statement still largely
rings true. For instance, at the time of writing, the in-house cost of a single run of
Solexa high-throughput sequencing at the Rockefeller University core facility is
upwards of $1,000 per sample. Although affordable for a limited number of
isolates, this figure is still likely excessive when numerous bacterial or phage
isolates are considered. And this does not even include the genomic-assembly
process from the short sequencing reads, or the time needed to mine the
assembled genomes for lysin-encoding ORFs (in this regard, the sort of
computational algorithm mentioned above would be valuable). At the present
time, while published genomes are valuable sources of enzymes, a search-forlysins in itself probably does not merit the cost of sequencing numerous
additional strains.
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Fortunately, high-throughput sequencing technology is still considered to
be in its infancy, and the associated efficiency and cost are only expected to
become more favorable in the future. Commentators have suggested the
eventual possibility of the $1 bacterial genome (Ussery et al. 2009). In this
circumstance, the sequencing of numerous genomes would definitely seem
warranted, even if it is only to identify a single class of proteins (lysins or
otherwise). The same holds true, of course, for metagenomic sequencing. For
metagenomics, in fact, sequencing advances could prove even more valuable due
to the extra complexity associated with assembling metagenomes beyond the
short initial sequencing reads, which—from a perspective of cloning recombinant
proteins—are not useful (Schoenfeld 2010).
All of this is not to say that DNA sequencing can completely replace
functional screening as a method for identifying new enzybiotics. No matter
how powerful the technology becomes, a sequence is only able to identify a
protein that demonstrates homology to something that has already been
characterized. To find something completely novel, functional screening is still a
necessity. Ultimately, in this regard, the two approaches are vital complements
to one another. Whenever a novel protein is uncovered, the vast database of
existing sequences makes it all the more likely that homologues can be
recognized immediately, facilitating rapid progression beyond the initial
discover.
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ENZYBIOTICS BEYOND PHAGE LYSINS
For this discussion to be complete, it is important to emphasize that phage
lytic enzymes are not the only molecules that can be included under the umbrella
of enzybiotics. The two terms are often used interchangeable, and understandably
so. Phage lysins have generated considerably more attention than any other
class of enzyme as far as antibiotic potential is concerned. Rigorously speaking,
however, any enzyme with antimicrobial properties could be considered an
enzybiotic. These other proteins will be considered briefly here, so that the
field—and ongoing developments within it—can be appreciated in their entirety.
First, bacteriophages encode enzymes other than lysins proper that have
been examined as potential antibacterial agents. Like the lysins, some of these
other proteins function as peptidoglycan hydrolases. It was mentioned briefly in
Chapter 1, for instance, that hydrolase motifs are often present within proteins of
the phage tail assembly (Kanamaru et al. 2004; Kenny et al. 2004; Piuri and
Hatfull 2006) or even the head (Moak and Molineux 2004). Presumably, these
structural enzymes facilitate the initial injection of viral DNA. Although it is not
their natural purpose, recent evidence has shown that these enzymes can lead to
Gram-positive lysis when added exogenously. Rashel et al. identified a tailassociated protein from the genome of an S. aureus phage that contains two
putative lytic motifs; when individually expressed and purified, both domains
induced staphylococcal death (2008).
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Despite these findings, no tail enzymes have ever been identified during a
functional screen of a phage genome. Several reasons could underline this
discrepancy. For instance, some enzymes might require the presence of the
entire macromolecular tail assembly for proper activity. Moreover, structural
lysins often represent component domains within much larger polypeptides; in
the context of a functional screen, these domains would not be expressed
individually and the bulk proteins could prove difficult to obtain due to their
size. Nevertheless, if future research could reliably harness the enzymatic
activity of tail lysins, it would represent another promising avenue within the
enzybiotics field.
Outside of their enzymatic activity, phage tail structures are additionally
remarkable for their ability to traverse the other components of the bacterial cell
envelope, including the outer membrane of Gram-negative bacteria. In this
regard, various Gram-negative species encode protein complexes (―monocins‖)
that kill closely-related organisms through a cell-envelope depolarization effect
(Zink et al. 1995; Strauch et al. 2001; Jabrane et al. 2002). These multimeric
structures resemble isolated phage-tail assemblies, and are believed to represent
proviral remnants that have been co-opted by the host. In a recent study,
Williams et al. demonstrated that, by exchanging a component gene of one such
complex with the tail fiber genes of another phage, they could engineer
complexes with species-targeted activity (2008). While not examined specifically,
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the study raises interesting questions about potential synergies between these
complexes and recombinant lysins.
Other than peptidoglycan hydrolases, several other classes of phageencoded enzymes have been examined for their overall antibacterial activity. For
instance, some phages are known to produce depolymerases that digest the
exopolysaccharide of bacterial capsules and biofilm matrices. (Although not
discussed at length in this thesis, the dynamics of biofilm communities are
thought to play a key role in pathogenesis of certain infections, as well as in the
bacterial contamination of medical and industrial devices.) These enzymes may
be associated with the actual viral particle or synthesized intracellularly during
phage infection (Donlan 2009). Although phage-associated depolymerases have
been known for some time (Eklund and Wyss 1962; Sutherland 1967), it is more
recently that these enzymes have been proposed as recombinant agents for
alterting the course of bacterial growth and infection (Glonti et al. 2009; Lu and
Collins 2007).
Another extracellular molecular complex with an important role in
bacterial pathogenesis is the arabanogalactan layer of mycobacteria. Although
this genus is considered a Gram-positive actinobacterium evolutionarily, it
possesses a unique cell-envelope structure in which covalently-linked
arabanogalactan and mycolic acid layers overlay the peptidoglycan. While
mycobacteriophage have been studied extensively (Pedulla et al. 2003), it is never
before been addressed whether specific phage-encoded proteins are responsible
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for attacking these layers during lysis. Recently, however, Payne et al. identified
a conserved arabanogalactan esterase that fulfills this role and is encoded
adjacently to the lysin within the phages‘ genomes (2009). Although the authors
did not demonstrate that exogenous enzyme was bacteriolytic (either by itself or
in combination with lysin), their work raises the possibility that enzybiotics
might still be possible against a group of pathogens for whom they were
previously assumed to be irrelevant.
Although unrelated to host lysis, a variety of other phage proteins (many
poorly described) exert an intracellular antibacterial effect (Liu et al. 2004; Sau et
al. 2008). They are believed to be anti-host factors that allow the viruses to
disrupt bacterial physiology following infection. From a perspective of drugdevelopment, these proteins (not necessarily enzymes) do face the additional
challenge of cytoplasmic delivery. Limited experimental evidence, however, also
suggests that phages encode other poorly-defined proteins that are bactericidal
from the outside. For instance, functional screening of the B. cereus Bcp-1 phage
genome revealed two distinct clones that prevented the growth of Bacillus cells in
soft-agar overlays. One clone encoded a typical modular lysin (PlyB), while the
other encoded a short, difficult-to-purify protein termed KOA (for Killer of
Anthrax). The latter is similar to only a limited number of hypothetical proteins
from several other Bacillus phage genomes (Schuch, unpublished observations).
While it is half the size of standard Gram-positive lysins and does not
contain any traditional sequences common to major lysin families, KOA
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nevertheless possesses lytic activity against a range of Bacillus cereus organisms,
including B. anthracis. It remains unclear what roles PlyB and KOA play
(independently or in conjunction) during Bcp-1 infection, as the identification of
this protein represents a fortuitous side-effect of the screening process. Overall,
it is difficult to predict what sort of antibacterial compounds (enzymatic or
otherwise) might be encoded by global phage, mainly because such a relative
few have undergone functional analysis.
At the same time, phages are not the only genetic entities that can encode
potential enzybiotic agents. As mentioned several times throughout this thesis,
bacteria likewise encode autolytic proteins that mediate activities such as
growth, division, and sporulation (Vollmer et al. 2008b). Some autolysins—like
pneumococcal LytA and the C. perfringens enzymes discussed here—demonstrate
high architectural homology to phage lysins, while others are more divergent.
Although phage lysins have received more attention, various reports have
documented the ability of recombinant autolysins to act as lytic agents against
Gram-positive organisms (for instance, Dhalluin et al., 2005; Fukushima et al.,
2008; Yokoi et al, 2008). And while their roles differ from those of phage lysins,
the process of identifying and developing autolysins as antibacterial agents
would follow essentially the same principals.
In fact, the categories of peptidoglycan hydrolases with enzybiotic
potential extends even beyond these proteins. Many bacteria also encode
proteins and peptides (broadly known as bacteriocins) that exert an antibiotic
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effect on other species, often closely related ones. Of these molecules, several
notable examples function through a cell wall-lytic mechanism1. The most
prominent example is lysostaphin, a poly-functional hydrolase originally
identified in Staphylococcus simulans that targets rival staphylococci (Kumar
2008). In light of growing resistance to traditional antibiotics, lysostaphin has
received considerable attention as a possible weapon against MRSA and nonMRSA isolates of S. aureus. Comparable enzymes, namely millericin B and
zoocin A, have been isolated from streptococcal strains (Beukes et al. 2000;
Akesson et al. 2007).
Going even further, other bacterial enzymes (glucanases and chitinases)
have evolved that digest the cell wall of competing fungal species (Salazar and
Asenjo 2007). Overall, biotechnological interest in these proteins stems more for
their ability to manipulate yeast in laboratory settings. Nevertheless, given the
existence of various fungal pathogens, these enzymes are still worth noting from
an enzybiotics perspective. They are also worth considering evolutionarily, as
mycolytic enzymes share certain structural and biochemical properties with their
glycosyl hydrolase cousins among the peptidoglycan hydrolases (Veiga-Crespo
and Villa 2010). All considered, the above proteins serve as important reminders
that the enzybiotics field covers more than phage lysins, and necessitates that
researchers cast a large net in search of novel antimicrobial agents.
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CONCLUDING REMARKS
In the field of phage-lysin research (and enzybiotics, in general), one
observation is unmistakably clear: between established strategies of enzyme
identification and novel techniques, there will be no shortage of candidate
molecules in the foreseeable future. As methods and technology continue to
advance, what is already a dense field is only likely to become more crowded.
Perhaps a greater challenge than merely identifying phage lysins, in fact, will be
the ability to compare them systematically on a protein level. Enzyme kinetics,
thermal and pH tolerance, immunogenicity, in vivo half-life, and biodistribution
are only a few of quantities that could vary from one lysin to the next and,
ultimately, they are the factors that will determine an enzyme‘s therapeutic
promise.
Unfortunately, none of these properties can be measured (as of yet) with a
mere shotgun screen or nucleotide sequence, as protein purification and oldfashioned pharmacological analyses are still required. In this regard, the
enzybiotics field is in a unique position, as cloning technologies have created a
pronounced gap between our ability to identify an enzyme-of-interest and the
effort it takes to study it in detail and move it through the drug-development
process. Nevertheless, if and when the first phage lysin progresses to human
useand an increasing body of experimental evidence suggests that day is
comingthere will already be a large reserve of similar agents set to join it in the
fight against infectious disease.
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ENDNOTES
1. As mentioned in the text, the term bacteriocin is commonly used to describe
bacteria-encoded proteins and peptides with antibacterial activity. The
classification of peptidoglycan hydrolases as bacteriocins, however, is an issue on
which a definitive consensus does not yet exist. Under some schemata, virtually
all antibacterial proteins encoded by bacteria themselves should be considered
bacteriocins (Heng and Tagg 2006). In this case, enzymes such as lysostaphin
and zoosin A are categorized as class IIIa bacteriocins. At the same time, other
systems reserve the term bacteriocin for distinct classes of peptides that function
through a non-hydrolytic mechanism (Cotter et al. 2005). In either case, it should
be emphasized that such schemata function only as organizational tools, and do
not affect the in vivo function or biotechnological potential of these proteins.
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APPENDIX OF DNA AND AMINO ACID SEQUENCES
A number of genes and their corresponding protein translations are
referred to throughout the text of this thesis (primarily involving cloned phage
lysins). This appendix reports their nucleotide and amino acid sequences. In a
majority of cases, the sequences have already been submitted to the National
Center for Biotechnology Information (NCBI) for inclusion in GenBank
(www.ncbi.nlm.nih.gov/genbank/), in which case the corresponding accession
numbers are provided.
Several basic parameters are also reported for each protein, including gene
and protein length, protein molecular mass, and theoretical isoelectric point. For
phage lysins, the predicted enzymatic and binding domains are also designated
here. The position of these domains within the amino acid sequences are
denoted with the following color scheme: enzymatic domains are highlighted in
blue and binding domains are highlighted in red. The positions of all domains
were predicted with the Pfam v24.0 algorithm (pfam.sanger.ac.uk). For several of
the metagenomic lysins from Chapter 4, the genes were cloned with a truncated
C-terminus (as described in the text); these cases are denoted as such in the
appendix. No predicted isoelectric point is provided for the truncated lysins.
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Chapter 2: PlyCM
GenBank Accession Number: YP_695420 (from C. perfringens ATCC 13124)
Originally annotated in GenBank as ―Glycosyl hydrolase family protein‖
1029 base pairs; 342 amino acids; 38.73 kDa; Theoretical pI = 6.04
Glycosyl Hydrolase Type 25 (i.e. muramidase) enzymatic domain (PF01183)
Dual SH3-Type 3 binding domain (PF08239)
ATGGAAAGTA
GAAAGGAAAT
TTTATATTAA
CAAAATTATG
TTTCTTTAGA
ATTATTTGAA
GATATAGAAA
TATAGAATTC
TATATACATA
AGTTATCCAG
CAATATATGG
TAGCTGGTGT
TTCATTGATT
AAGTATTAAA
TTGGTTCAAT
GATTATCTTG
AAATGCAGAT
GTACTTTTTT
GATAAGATAA
TTTTATAGGT
TTAATGCTGA

GAAACAATAA
ATAAATTTTC
AGCTACAGAA
AGAGAGCGAA
GCTAATAAAG
TGAAATAGGA
CTACTGAAGG
TTAGAAGAGG
TACAAGCTTT
TTTGGATAGC
AGTGAATGGG
AAGTGGTGGA
CAAATAATTT
TTAAATATAA
ACCAGCCAAT
GTTGGTATTA
TATGTAGAAA
AAATGTAAGA
ATACAGGTGA
TGGTATAGAG
ATTTGTTAAG

TAATTTAAAA
AAAGTGTAAA
GGTAATTACT
AGAACAAGGA
GAGCCAAGGA
GCAGTTAATT
GGTAGGAGCA
TAATAAGAAT
GCAAATAATA
TCATTATGGT
TTGGGTTCCA
TGTGATATGA
TACTTTAGAC
GAGCTAAAGG
GAGAAGTTTA
CGTTGAGTAT
AGCTACAAAT
GAAGAAGGAT
TATTTTTAGA
TAACAACTAA
AAATTATAA

GGAATTGATG
AAATGATGGT
TTAAGGATAA
TTAAGAGTAG
TCAAGCAAAT
ATGATTGTAA
AGAGATTTAA
TACTGGAAAA
ATTTAGATAG
GTAAACACTC
ATATTCAGAG
ATGAGTTCAC
AATGCTACTA
AACTACTAAT
AAATAAAATG
AATGGAATAG
GGCTACTACT
CATTAAATTC
ATAGATTGGG
AAATGGAAAA

TATCAAACTG
GTAGAAGTAG
ATATGCTAAA
GATTTTATCA
TTTTTCGTAA
ATTAGCTTTA
CTTCTATGTG
GAAGTTGTTG
TAGATTATCC
CTGGAGCTAA
AATGGAAGTG
TAATGGAATA
CTAAAAATGT
TCTAAAGTAA
GGTTGATGAA
TTGGCTATGT
CATAATGTAA
TAGAATAGTA
TGGATTCCGA
GTTGGATTTG

MQSRNNNNLK
QNYERAKEQG
DIETTEGVGA
SYPVWIAHYG
FIDSNNFTLD
DYLGWYYVEY
DKINTGDIFR

GIDVSNWKGN
LRVGFYHFFR
RDLTSMCIEF
VNTPGANNIW
NATTKNVSIK
NGIVGYVNAD
IDWVDSDFIG

INFQSVKNDG
ANKGAKDQAN
LEEVIRITGK
SEWVGFQYSE
LNIRAKGTTN
YVEKLQMATT
WYRVTTKNGK

VEVVYIKATE
FFVNYLNEIG
EVVVYTYTSF
NGSVAGVSGG
SKVIGSIPAN
HNVSTFLNVR
VGFVNAEFVK

GNYFKDKYAK
AVNYDCKLAL
ANNNLDSRLS
CDMNEFTNGI
EKFKIKWVDE
EEGSLNSRIV
KL
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**NOTE: In the preceding sequences for PlyCM, the underlined residues
represent positions at which the experimentally-observed sequence differed from
that in GenBank. 4G / 2E was intentionally changed from the wild-type 4C / 2Q
to introduce an NcoI restriction site. 374T / 125I differed from the reported 374A
/ 125K, but the change was not intentional.
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Chapter 3: BG-1 Phage Lysin (i.e. PlyBeta)
GenBank Accession Number: EU258891
867 base pairs; 288 amino acids; 32.27 kDa; Theoretical pI = 5.96
Glycosyl Hydrolase Type 25 (i.e. muramidase) enzymatic domain (PF01183)
SH3-Type 5 binding domain (PF08460)
ATGGGTTATA
CGTTGCAGCA
CGAACTATGT
CGTAACGTGC
AGATGCAAAA
CTTTATTTTG
GCGGGAACAC
AGTAGGTCTA
ACATTAGATG
GATTTCCCTT
AATCGGTAAA
GGTTCACAGG
GGAGCTTACG
AGATCGTACG
TTGCCCAATT
GAAAAAGACG
CGGTTACATC
GGGGAACTTT

TTGTTGATAT
GGTCAATTGG
TGACCCTATG
CATTTGGTAA
GTAGAAGCTA
GGTAGCGGAC
AAGCATTCAT
TATGTCGGGC
TGACTTCACT
GTGATCTATG
TGTGACATTA
TAAAGATTGC
ATTCTAGTTG
ATTAACTTAC
AAACGCAGGA
GTTACGTTTG
GCATCAGGCG
TAAATAA

TTCTAAATGG
ATTTAGCAAT
TATAAGTCTT
CTACGCTTTC
GAGACTTTTG
GTAGAAGTAA
TGACGAGCTA
ATCACACTTA
TGGATTCCTC
GCAGTACACT
ACAGCTTAAA
AACAACGGTA
GTTCACTAAG
GTACTGCACC
GATAACGTTA
GTTACGTCAG
AAACTAAAAA

AACGGTGACA
TGCTCGTGTT
ACGTAGCATC
TGTCGTTTCG
GGCTCGTGGA
AAACTATGGG
TATCGTTTAG
TGTGGCTTTC
GTTATGGTGG
GAAACAGGTA
CAGCGACAAG
ACGTGACTCC
CAAACTGGTG
ATTCCCAAAT
ACTACGAAGC
CATCGTGGTA
CGGTCAACGT

TTAACTGGGA
CAAGACGGTT
TATGAAAGCT
TATCTGTAGA
GACAAAGACG
CGACATGCAA
GAGCTAAAAA
GGTGCTAAAA
ACTAAAGCCT
ATGTTCCTGG
ACACTAGAAT
GCCACCACAG
TCTTCACTTT
GCACCGTTAA
GTACGGATAT
ATGGTAACTT
ATCTCTACTT

MGYIVDISKW
RNVPFGNYAF
AGTQAFIDEL
DFPCDLWQYT
GAYDSSWFTK
EKDGYVWLRQ

NGDINWDVAA
CRFVSVEDAK
YRLGAKKVGL
ETGNVPGIGK
QTGVFTLDRT
HRGNGNFGYI

GQLDLAIARV
VEARDFWARG
YVGHHTYVAF
CDINSLNSDK
INLRTAPFPN
ASGETKNGQR

QDGSNYVDPM
DKDALFWVAD
GAKNIRCDFT
TLEWFTGKDC
APLIAQLNAG
ISTWGTFK

YKSYVASMKA
VEVKTMGDMQ
WIPRYGGLKP
NNGNVTPPPQ
DNVNYEAYGY
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Chapter 3: BG-2 Phage Lysin
GenBank Accession Number: EU258892
936 base pairs; 311 amino acids; 34.31 kDa; Theoretical pI = 9.19
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510)
Dual SH3-Type 3 binding domain (PF08239)
ATGGCTATTT
AAAATGTCCT
ACAATGATGC
AATGCAACTT
TATTCCAACA
GTAACCGTAA
GATAGATATC
TTTAAGAGAA
GGAGTGGAAA
TCAGTTCTAA
TGGAGGAACA
TAACAGCAGA
ATCGTTGGTA
TAACGGATGG
TACAAGTAAT
ATTGCATATA
AGGTTACTCA
GGGGAATGAA
AACGACTCTT

CAGTAAGACA
TATGCTATGA
AAGTGCGAAC
CATTTCACTA
AACCGTAATG
ATCTATCGGT
GTAAAGCACA
CGTGGATGGG
ATATTGTCCA
ATGCTATTAA
ACTCAACCAC
TGTTCTAAAC
AAATCTACAA
TACAACTTAG
TAGTGGAGGA
TCACTGGATA
GTAATCCGTC
GGACGGTTGG
CATTTGTTAG

AAAAATGGTG
CAGCAGAGTA
AATGAGGTTC
TGCAATTGAT
CATGGCATTG
GTTGAAATCT
AGCTTTAGTT
GAATTGATAG
CACCGTATCC
AGCAGAATTA
CAGTTGATAA
TTGCGTAATC
AGGTCAAGAT
GTGGTAACCA
ACGCCACAAC
CAATGTTAAT
AATTAAATGC
TTAAACCTTG
ATTTGTACAA

GATTCAAGTA
CATTACAATC
AATACATGAT
GATTTCGAAG
TGGAGATGGA
GTTACTCTAT
ATCAAATTCG
AGTTAAGAAA
TAGACGAAGG
AATGGTGGAG
CTCTACAGGT
AACCATCTAC
TACAAGTTCT
ATGGGCTTCT
CACCAAAAGC
ATGCGTACAG
ACCAGAATCT
GTGGCGACCA
GACTAA

AGTATTCTTT
CACAACACGT
TACTAATAGT
TTGTACAAGG
AACGGTAATG
GAGTGGTGGC
TTGCACAACT
CACCAAGATT
ACGTTGGCAA
GTTCTACAGG
GTAGTTAGAG
TAACGGTTCT
GGGCTATCTC
GGTACTTATT
AGTAACAGGT
GTGCAGGAAC
TACAAAGTTT
ATGGATTAAG

MAISVRQKMV
NATSFHYAID
DRYRKAQALV
SVLNAIKAEL
IVGKIYKGQD
IAYITGYNVN
NDSSFVRFVQ

DSSKYSLKCP
DFEVVQGIPT
IKFVAQLLRE
NGGGSTGGGT
YKFWAISNGW
MRTGAGTGYS
D

YAMTAEYITI
NRNAWHCGDG
RGWGIDRVKK
TQPPVDNSTG
YNLGGNQWAS
VIRQLNAPES

HNTYNDASAN
NGNGNRKSIG
HQDWSGKYCP
VVRVTADVLN
GTYLQVISGG
YKVWGMKDGW

NEVQYMITNS
VEICYSMSGG
HRILDEGRWQ
LRNQPSTNGS
TPQPPKAVTG
LNLGGDQWIK
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Chapter 3: BG-3 Phage Lysin
GenBank Accession Number: EU258893
1056 base pairs; 351 amino acids; 39.35 kDa; Theoretical pI = 9.37
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510)
SH3-Type 3 binding domain (PF08239)
ATGAAAAAAA
AGCGTTATCC
CTGATTTGCC
GTAGTGGCGC
ACGTTATGAA
ACTGGGATGA
GCTGGACCAG
TTCAGATTAT
TAGCAAAAAT
ACACATGATG
ACTGGATTAT
ATGTGAAACG
TCTAAACCAG
TGAAGGATAT
TTATTCGTCA
GGCGGATGGC
GTATATCCGA
GTGTAGTGTC
GAAGATAAGT
TGACGCAACG
GTAAAGGAAC
AAGTAG

CGTTAAAACA
ATTACAACAA
GAAGCAAGGA
ATAGTACAGC
ACGCGTACTT
AGTTATTCAA
CTGCTAACGC
AGCAAGTTTA
TTTACGTGAT
ACGTAAGGAA
CTAAAAAAAC
TGCTTATAAT
CGGAAAAACC
AATGTAAATC
ATTAAATAAA
TAAATTTAGG
TTTGAAAAGA
GAAAGTGAAT
ATGTTGCAGG
GTAATGGTAA
CACATACTAT

CATTTCTTCT
GTGCTGTTGC
TATAGAAATG
GACTCCAGAA
GGAGAAGTGC
ATTGCAGATA
ACGTTTTGTA
AGCGAAGCTA
CGTGGACTTT
ATATCTTGGT
ATGGTATATC
AACACGGGTA
AACAGCCAAT
TACGCAAAGG
CCAGAGGCTT
TTGGAATCAG
AAGAAGCTGT
AATCTCAGAT
TACTGTAGAT
ATGGTTCCCC
ATCCCAGCAA

GTAGTCTTTG
TGACAGAGTA
GGGTAGGAGC
GCTCCAGCAA
ATTTGTACAT
CACGTTATAT
CACGTTGAAC
TGACAAGTAT
CAGTAGAAAA
GGAACAACTC
TGAAGCTCAA
TTTCTATTCC
GTAGAAGGTG
CCCAGATGCA
ATAAGGTTTG
TGGGTAAAAT
AAGTCCAGTT
TTTATAGCGC
GTAGGATTAG
ACAATACAAA
GTGAAGCCTA

CAACTATTTT
TTGATCATTC
TTATGAAGGT
TCAATATCCA
TATGCAGTTG
TGCGTATGGC
TTTGTGAGAC
GTAAAATTAC
AGGATTATGG
ACACGGATCC
TTCCGAGCAG
TGAACAACCT
TAGCTTATAT
AGCTATTCTG
GGGAGAAAAG
ATAATCAATC
GCTGGAAAAC
TCCATCGTGG
GTTTTACGAT
GTACACAATA
TGTGTATGTG

MKKTLKHISS
VVAHSTATPE
AGPAANARFV
THDDVRKYLG
SKPAEKPTAN
GGWLNLGWNQ
EDKYVAGTVD

VVFATILALS
APAINIQRYE
HVELCETSDY
GTTHTDPLDY
VEGVAYIEGY
WVKYNQSYIR
VGLGFTIDAT

ITTSAVADRV
TRTWRSAFVH
SKFKRSYDKY
LKKHGISEAQ
NVNLRKGPDA
FEKKEAVSPV
VMVNGSPQYK

LIIPDLPKQG
YAVDWDEVIQ
VKLLAKILRD
FRADVKRAYN
SYSVIRQLNK
AGKRVVSKVN
VHNSKGTTYY

YRNGVGAYEG
IADTRYIAYG
RGLSVEKGLW
NTGISIPEQP
PEAYKVWGEK
NLRFYSAPSW
IPASEAYVYV K
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Chapter 3: BG-4 Phage Lysin
GenBank Accession Number: Not yet submitted
1068 base pairs; 355 amino acids; 39.94 kDa; Theoretical pI = 9.11
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510)
SH3-Type 3 binding domain (PF08239)
ATGAAAAAGA
TGCCGTTTCG
CTGATTTACC
GTTGTAGCAC
AAAATATGAG
ATTGGAATGA
GCTGGACCAG
AAAGGATTAT
TAGCTAAAAT
ACTCACTATG
ACTTGATTAC
ATGTACAACG
AAGCCATCTA
GTATATTGAA
ATTCTAAGAT
GAAAAGGATG
TCCATCTTAT
TAGGTAAACG
CCATCTTGGC
ATTTACAATT
TGCACAATAG
GTGTATGTAG

CAGTGAAACA
TTTGCTACAA
GAAACAACCA
ATTCTACAGC
TCTCGTACAT
AACAATCCAA
GAGCAAATAA
GAGAAATTCA
TCTTCGTGAC
ATGTTACAAA
TTACGTAGTC
AGCATACAAT
AACCAGCGGA
GGTTACAATG
TCGTCAGTTA
GTTGGTTAAA
GTAAAGTTTA
CGTTGTTTCT
AGGATAAAGA
GATGCAAAAA
TAAGGGTATA
TAAAGTAA

TATTACCTCG
GTGCTTTCGC
TACCGTAACG
AACACCAGAA
GGCGTTCAGC
ATTGCTGATA
ACGATTTGTT
AACGCAGCTA
CGTGGATTAT
GTATCTTTTC
ATGGAGTTTC
AATTCTAATG
AGTTCCAATG
TTAACTTACG
AACAAACCAG
TCTTGGTGGC
GTAAGAAAAG
AAAGTTAATA
TGTTGCTGGT
TAAACGTCAA
ACATATTATG

TTCCTTATGA
GGATAGAACA
GTGTAGGTGC
GCGCCAGCTA
ATTCGTACAT
CGAAATACAT
CATGTGGAAT
TGATAAATAC
CTGTAGAAAA
GGTACAGATC
AGAAGCGCAA
TTGATGTTTC
GCTGTAACAG
TAAAGGACCT
AAGCTTATGT
GAACAATGGA
CACTGTGGAT
ATCTACGATT
TCTGTAGATG
TGGATCACCA
TTACTGCAAA

TTCTAGTACT
CTTATTATTC
TTATGAGGGT
TTAATATTCA
TATGCAGTTG
TGCTTATGGT
TATGCGAAAC
GTTAAGCTAT
AGGATTATGG
ATGAAGATCC
TTTAGAACAG
TGTACCGGAG
ACGGAATCGC
GGTTCAAGTT
TGTATGGGCT
TTAAGAACGA
TCCTCTATTG
CTATGATGTT
CAGGATTAGG
CAATACAAAG
TGAAGCCTAT

MKKTVKHITS
VVAHSTATPE
AGPGANKRFV
THYDVTKYLF
KPSKPAEVPM
EKDGWLNLGG
PSWQDKDVAG
VYVVK

FLMILVLAVS
APAINIQKYE
HVELCETKDY
GTDHEDPLDY
AVTDGIAYIE
EQWIKNDPSY
SVDAGLGFTI

FATSAFADRT
SRTWRSAFVH
EKFKRSYDKY
LRSHGVSEAQ
GYNVNLRKGP
VKFSKKSTVD
DAKINVNGSP

LIIPDLPKQP
YAVDWNETIQ
VKLLAKILRD
FRTDVQRAYN
GSSYSKIRQL
SSIVGKRVVS
QYKVHNSKGI

YRNGVGAYEG
IADTKYIAYG
RGLSVEKGLW
NSNVDVSVPE
NKPEAYVVWA
KVNNLRFYDV
TYYVTANEAY
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Chapter 3: A14 Phage Lysin
GenBank Accession Number: Not yet submitted
954 base pairs; 317 amino acids; 34.84 kDa; Theoretical pI = 8.74
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510)
Dual SH3-Type 3 binding domain (PF08239)
ATGACTATTT
AAAGTGTCCA
ACAATGATGC
AATGCTACTT
TATCCCTACA
GTAACATGAA
GACAGATATC
TTTAAGAGAG
GGTCTGGTAA
TCATTCCTTA
ACCACCAGTA
TAAATCTACG
GGTATCGGTG
CTTAGGTGGA
TTATTAGCGG
CCAAAACCAA
GCGTAAAGGT
CAGAATCATA
GGAGACCAAT
CTAA

CAGTAAGACA
AACGCTATGA
AAGTGCAAAC
CATTCCACTT
AACCGTAATG
GTCTATCGGA
GTAAAGCAGA
CGTGGATGGG
ATATTGTCCA
ATGCTGTTCA
AACAATACTA
TACACAACCA
AAACTTACCA
GACCAATGGG
TGGAAGTTCT
TTACAGGTGT
GCAGGAACAG
TCAAGTGTGG
GGATTAAGAA

AAAATTGGTG
CAGCAGAATA
AATGAGGTTC
TGCAATTGAT
CTTGGCATTG
ATCGAAATCT
AGCTTTAGCT
GAATTAGCCG
CACCGTATCT
AACAGAACTT
CAGGTGTTGT
AGTGCAAGCG
GTTCTGGGCA
CTTATGGAGA
GTAGCACCTG
TGCTTATATC
GTTACGCTGT
GCAGTTAAAG
TGACGCTTCA

GATTCTAGTA
CATTACTATC
AGTACATGAT
GATTTCGAGG
TGGAGATGGA
GCTACTCTCT
GTAAAATTTA
AGTTAAGAAG
TAGATGAAGG
AATGGTGGAG
TCAAGTAATG
CTCCAATCAT
ATTTCTAATG
CAATGGCAAC
CTCCACAACC
ACTGGATATA
AATCCGTCAA
ACGGTTGGTT
TTTGTCAGAT

AGTATGGTTT
CACAATACTT
TACAAATGGT
TTGTCCAAGG
ACAGGTAGCG
TTCTGGTGGA
CTGCTCAACT
CATCAAGATT
ACGTTGGCAG
GTTCTACACA
GTTGCAGATT
CCGTAAATTA
GATGGTACAA
TACTTAAAAG
AAAACCAGAG
ATGTTAACAT
TTGAATGCAC
GAATCTTGGT
TCGTACAAGA

MTISVRQKLV
NATSFHFAID
DRYRKAEALA
SFLNAVQTEL
GIGETYQFWA
PKPITGVAYI
GDQWIKNDAS

DSSKYGLKCP
DFEVVQGIPT
VKFTAQLLRE
NGGGSTQPPV
ISNGWYNLGG
TGYNVNMRKG
FVRFVQD

NAMTAEYITI
NRNAWHCGDG
RGWGISRVKK
NNTTGVVQVM
DQWAYGDNGN
AGTGYAVIRQ

HNTYNDASAN
TGSGNMKSIG
HQDWSGKYCP
VADLNLRTQP
YLKVISGGSS
LNAPESYQVW

NEVQYMITNG
IEICYSLSGG
HRILDEGRWQ
SASAPIIRKL
VAPAPQPKPE
AVKDGWLNLG
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Chapter 3: TSH Phage Lysin
GenBank Accession Number: Not yet submitted
819 base pairs; 272 amino acids; 29.22 kDa; Theoretical pI = 6.65
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520)
SH3-Type 5 binding domain (PF08460)
ATGGGAACAT
TAACTGGGGT
CTTTAATTAG
GACGAAACAG
ATGTAATGCT
ACAATGGTTC
TTAGCTGCTA
CCGTGGAGCT
CACCTGCTAT
GCTAAATGGA
AGGGCAACGT
GAAGCACTGG
GGTGTATTCA
AAATGCAACT
CTTCATTCGG
GGTACATACG
CTGGGGAACT

ATAACGTACA
AACCGAAAAG
CAAACTTCGT
GTTCTACGCA
CACCGAGTAG
TGCTAGTGGC
AAGTTTCTAA
AAACCTCGTA
CCTAATCGAG
ATGTAGACAA
ACAGGCTCTA
TGGAGGTGGA
CAGCTAACAC
CACCTTCGTA
AATGGAGAAA
TTGCAACAGG
TTCCAGTAA

CGGTGGTCAC
AACACGTTAT
AGCCTTGGTC
AAGCGCTAAC
ACTTAGACAT
GTAGAGGTTT
ACAGCTTTCA
CAGACCTTTA
CTTGGTTTCA
AATTGCAGAC
CTGGTGGAAG
TACGACTCTA
TACAATCAAA
CTCTGTACAG
GACGGTTACG
TGAAACTAGT

AACTCGATCG
GGATCGCCAG
ACACAGTTTA
TTACGTAACA
TTCATTACAC
GTTACTACGA
GACGACATCG
CGTATTAAAT
TCGACAACGA
TCTATCTGCT
CACAGGAGGT
GTTGGTTCAC
GTAAGAAGCG
TGGTGGAACG
TTTGGATCAA
AACGGAAAAC

TACAAGGTGC
GTTAAAGACG
TGACTGCACA
TCGTAGCGAA
TTAAATGCTT
CCAACAAGCA
GTTGGTCTAA
AGCACGTCTG
GAGCGATATG
ATGCTATCAC
TCTACAGGCG
ACCACAAAAC
AGCCAAGCGT
TTCACGTATA
AGGCGTAGAC
GTACCTCTTA

MGTYNVHGGH
DETGSTQSAN
LAAKVSKQLS
AKWNVDKIAD
GVFTANTTIK
GTYVATGETS

NSIVQGANWG
LRNIVAKCNA
DDIGWSNRGA
SICYAITGQR
VRSEPSVNAT
NGKRTSYWGT

NRKEHVMDRQ
HRVDLDISLH
KPRTDLYVLN
TGSTGGSTGG
HLRTLYSGGT
FQ

VKDALISKLR
LNAYNGSASG
STSAPAILIE
STGGSTGGGG
FTYTSFGMEK

SLGHTVYDCT
VEVCYYDQQA
LGFIDNESDM
YDSSWFTPQN
DGYVWIKGVD
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Chapter 3: AerM (Hemolysin, not a lysin)
GenBank Accession Number: EU258894
ATGGATAAAG
GATGAGCCAG
ACTTCAGCCT
CGCAATGAGG
GTGGCAGATC
ATAATGGCGA
ACGAAACCGG
AGCTGGTGAC
ATTTTATCAG
GTCAGTGGAA
CGTCAGTGAT
GTTATCGCTG
ACCCTGGATC
GCAGCTGGTC
CCCAGCAGGT
AAGACCGACA
CCAGATCCCA
GCCAGAGCTG
ATAGAAGCCC
TGCGCTCTAC
TCAACTATGA
TGGCACACCC
CGGTCCGTTT
GCTACATCCC
CAGAACGGTG
GGTGCGCGCC
GCAATATCGA
CGTCGTGCCC
CCCGCTCGAT
TCACGCTGGA

TAAAAATAAC
GCTCATGGGG
CGGTAGCCAG
CCATGAGTAT
ACCGGTCTGG
AATAAAGCAA
TAGCGGGGGA
GAGATCGATG
ACCGATAAGT
ACCATAGCCA
GGCTGGCTCA
TAGCGAGAAG
CCGGTTCGTT
AAGACCATCA
GGTGGTGACC
CTTATGGTCT
CAAGTATCCA
GGCTCGCCAA
GCCCGACGGT
AAGGCCAATG
CCTCACCTTG
ATCCGGACAA
AAGGACAAGG
GGGTGAGGTG
CCGACACCAT
AGCATCACGG
GATAGGTGCG
GCAGCGTCGA
GCCAGCGAGC
ACCCGCTACC

GGGTTTGGCG
CAGAGCCCGT
CGCTGTGGCG
CCGCAGCGAT
CTGACAACTG
GGCAGCGCGA
AATACCAGTT
TGCAATGGCG
TATCTTGCGC
ATATGTGGGT
TTCAGGGAAA
AGCTCCATCA
CAGCCATGGC
CAGCTACGGC
CTCAAATATG
GAGTGAGAAG
GTACCGAATA
GAAGGGGGGT
GCCGCCTCAC
TATCTTATCC
AATGGTTTCC
CCGGCCGACC
CGAGCAGCAT
AAGTGGTGGG
GAAGAATGCC
GGGACTTCCA
GCCGTGCCCA
CAGCCCGGCA
TCTCGGCGCT
GACAAATAA

TTGAGCATTT
CTATCCTGAT
ATGATTATCG
ATAGTCAGCA
GGTCATCATG
GCGATACCTG
CTATCCGCAT
AATGGTCCAT
ATAATTTGGG
GAGGATATGG
TAATGGGGGT
AGGTGAGCAA
CTGGTGACTG
GACCAACTAT
ACAAGGCCAC
GTGGGCATCA
CTCGGTGGAG
CGGCAACCGA
TCCAGCGTGC
GTATGAGTTC
TGCGCTGGGG
TGGAATCACA
CCGTTACCAG
ACTGGAACTG
CTGGCCAGGG
CGCCGAGAGC
TCGGGGGCGA
ACTGGCCTGC
GGGCTTTGAC

CGACGCTGTT
CAGCTGAGAC
TGCCCTGACG
AGATGGGGCA
GGGTCAGGTT
GTGTTATCCC
GGAATATTCC
GATAATGATT
TTATGCCTGG
ACGTCACTCG
GGCTGCAGTG
CTTCTCCTAC
AAAGCGGCAA
ACCGATTTGC
CAACTGGTCC
AGAAGACCTT
ATATCGTCCA
GACGGTATCG
CGGTCCGGGT
AAAGCAGATA
CGGCAACGCC
CCTTCGTCAT
TGGGACAAGC
GACCATACAA
TGCTGCGCCC
CAGTTCGCCG
CAGCAAGGTG
GCCTGGAGAT
AACGTCCAGC

MDKVKITGLA
RNEAMSIRSD
TKPVAGEIPV
VSGNHSQYVG
TLDPGSFSHG
KTDTYGLSEK
IEARPTVPPH
WHTHPDNRPT
QNGADTMKNA
RRARSVDSPA

LSISTLLMSQ
IVSKMGQWQI
LSAWNIPAGD
EDMDVTRVSD
LVTESGKQLV
VGIKKTFQIP
SSVPVRVALY
WNHTFVIGPF
LARVLRPVRA
TGLRLEIPLD

AHGAEPVYPD
TGLADNWVIM
EIDVQWRMVH
GWLIQGNNGG
KTITATATNY
QVSSTEYSVE
KANVSYPYEF
KDKASSIRYQ
SITGDFHAES
ASELSALGFD

QLRHFSLGSQ
GSGYNGEIKQ
DNDYFIRPIS
GCSGYRCSEK
TDLPQQVVVT
ISSSQSWARQ
KADINYDLTL
WDKRYIPGEV
QFAGNIEIGA
NVQLTLEPAT

RCGDDYRALT
GSASDTWCYP
YLAHNLGYAW
SSIKVSNFSY
LKYDKATNWS
EGGSATETVS
NGFLRWGGNA
KWWDWNWTIQ
AVPIGGDSKV
DK
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**NOTE: The above gene/protein is for a bacterial virulence factor of the
aerolysin gene family. Aerolysin exotoxins are initially translated in the bacterial
cytoplasm as preproaerolysin; this corresponds to the sequences listed above in
their entirety. Preproaerolysin is recognized by the type II (i.e. Sec-dependent)
secretion apparatus and translocated across the cytoplasmic membrane, with
concomitant cleavage of the N-terminal signal peptide (designated with a singleunderline), yielding proaerolysin. Following outer-membrane translocation,
proaerolysin undergoes a C-terminal cleavage event (cleaved portion designated
with a double-underline). This yields the final aerolysin protein, which
undergoes subsequent insertion and homopentamerization in the target
eukaryotic membrane. In the above amino-acid sequence, the position of the
cleaved signal peptide was predicted with the SignalP v3.0 algorithm
(www.cbs.dtu.dk/services/SignalP/) and verified experimentally by N-terminal
sequencing. The position of the C-terminal cleavage point was predicted (but
not experimentally confirmed) by homology analysis with previouslycharacterized aerolysin proteins.
Gene length: 1479 bp
Initial protein transcript (preproaerolysin): 492 amino acids; 54.45 kDa; pI = 6.14
Translocated protein (proaerolysin): 469 amino acids; 52.05 kDa; pI = 5.97
Final, active protein (aerolysin): 426 amino acids; 47.45 kDa; pI = 6.23

339

Chapter 4: PlyM1 (Truncated)
GenBank Accession Number: HM011589
591+ base pairs; 197+ amino acids; 22.12+ kDa
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510)
No C-terminal binding domain was recognized. However, given the fact that
this lysin was cloned as a truncated construct—along with the fact that its Nterminal region demonstrated Blast homology to other Gram-positive enzymes—
it is likely that a binding domain does exist but could not be recognized by Pfam
due to the truncation.
ATGAGTATTA
TAAGTGTCCT
CAAACGATGC
AATGAAGTTT
ATTGCCATTA
GTGGTAACAG
GGTATTAAAT
ATTATTACAT
AGATGAATGG
GATGATGTAC
GGAAGTAAAA
AACCAAATAA

ATGTAGTTAA
TATCCTATGA
ATCGGCTAAG
CCTACCATTT
AATCGAAATG
AAAAGGTATT
ATAAAAAAGC
GAAAGAAATT
CAAGTATTGT
TACGAGCAAT
CCTGCTCCAG
ACCAAAAGAA

GAATTTGGTG
ATCCAGAAAT
TCAGAAATTT
CGCTGTTGAT
GTTGGCATGC
GGAGTTGAAA
AGAAGTTTTA
GGTCAATTGA
CCCCATAGAA
CCAAAAAGAG
ATACTCAAGT
GAAAACAAAG

TCTTCAAGTA
AATTGTCGTA
CTTATATGAT
GACAAAGAAG
AGGTGACGGT
TTTGTTATTC
GCTATCAAAT
TAGAGTAAAA
TCCTATCTGA
TTAGATAGAT
GGATTCAGAA
TGGAATCAAT

AATATAGTGT
CACAATACGG
TAACAACAAT
TTGTTCAAGG
GGTTCGGGAC
TAAGTCTGGT
TTATTGCACA
ACTCATAATC
AGGAAGATGG
TAAATAATGT
ATAACAACTA
T…

MSINVVKNLV
NEVSYHFAVD
GIKYKKAEVL
DDVLRAIQKE

SSSKYSVKCP
DKEVVQGLPL
AIKFIAQLLH
LDRLNNVEVK

YPMNPEIIVV
NRNGWHAGDG
ERNWSIDRVK
PAPDTQVDSE

HNTANDASAK
GSGRGNRKGI
THNQMNGKYC
ITTKPNKPKE

SEISYMINNN
GVEICYSKSG
PHRILSEGRW
ENKVESI…
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Chapter 4: PlyM2
GenBank Accession Number: HM011590
750 base pairs; 249 amino acids; 28.23 kDa; Theoretical pI = 9.11
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510)
Alanine-amidase-type-2-associated putative binding domain (PF12123)
ATGAAAATCC
TAAATGTCCT
ATAATGATGC
CACGAAGTAT
ATTGCCATTA
CTGGAAATCG
GGTACCAAAT
ACTTTTGCAT
ATTGGTCAAA
CAGTCAGTGC
TGTTAAAACT
TCCAGACGGG
TTCATACAAA
AAATCCAACA
TTGAATCCTG

CCGTAAGACA
TTCGACATGC
AAGCGCCAAT
CCTTTCACTT
AACCGTAACG
AAAGTCTATT
ACTACAAAGC
GAAAGAGGAT
GAAACATTGC
TGGATGCAAT
TCCGTTGTTG
TGGTTTAAAT
ACAAATGGTA
GCTGTGACAG
GCTAAAAGAA

AATGCTCGTT
AAGCAGAGTA
AACGAAATAC
TGCTGTAGAT
GATGGCACTG
GGTGTTGAAA
AGAAGGATTA
GGGGGATTGA
CCACATCGTA
CTCAAAGGAA
CTGCCGTTGA
CCTGAAATGG
TGCTGAAATC
GAGGTTTATC
CGCGGCTGGT

AATTCAAAGA
TATTACCATC
AATATATGAT
GACAATGAGG
CGGAGATGGC
TCTGTTACTC
GCTATCCAAT
TCGAGTAAAA
TTTTAGATGA
TTAGATGCAC
AAATTCCCCT
TAAAGGAAAT
ACGTTCAATT
CGGGGCTACC
GGTATAAAGT

ATCATAACAT
CACAATACCT
TAACAATGCA
TTGTTCAAGG
GGAAAAGGTT
CAAGTCAGGA
TTGTTGCTCA
AAACATCAGG
AGGTCGCTGG
TTAAAAAACC
TCTGTTAAAA
ATCTGATTTC
TCAAAAAAGG
AGGGATAAAT
AATTAAGTAA

MKIPVRQMLV
HEVSFHFAVD
GTKYYKAEGL
QSVLDAISKE
FIQNKWYAEI

NSKNHNIKCP
DNEVVQGLPL
AIQFVAQLLH
LDALKKPVKT
TFNFKKGNPT

FDMQAEYITI
NRNGWHCGDG
ERGWGIDRVK
SVVAAVENSP
AVTGGLSGAT

HNTYNDASAN
GKGSGNRKSI
KHQDWSKKHC
SVKIQTGGLN
RDKFESWLKE

NEIQYMINNA
GVEICYSKSG
PHRILDEGRW
PEMVKEISDF
RGWWYKVIK
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Chapter 4: PlyM3 (Truncated)
GenBank Accession Number: HM011591
921+ base pairs; 307+ amino acids; 33.21+ kDa
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510)
PG-1 binding domain (PF01471)
ATGGCATACA
AAAAGCGCCA
CAAATGACGC
AATCAAACTT
GATTCCGTTC
GAAATCGCAA
GTGAAATATG
TCTCAAAGAT
GGTCGGGTAA
AGTGTGCGTA
GGTCGTTGAA
ATGGCGATAC
GCAGGTTTCT
AGCGGTTAAG
TCGGAACAGG
AAGAAGCCGG
CACAGTGGAG
AAGAAGCGGT
GTCACAAGAC

CAATTGTTAA
TACTCGATGA
AACTGCGTTA
CCTATCACGT
AACCGGTCAG
GTCTATTGGT
CGGCGGCAGA
AAAGGTTGGG
AAATTGCCCG
ACCGAATCAG
GTTGCATCGC
AGGCGCAGCG
TACTATCTGT
GCGTTCCAGC
CTCACAGGCT
TAGTTAAGCC
AAAACAAACG
GAAGATTGGC
AGGAAGCAAT

CAAATATATC
ATGCAGAAAC
GGCGAGATTT
CGCTATTGAT
CTTGGCACGC
ATCGAGGTGT
AGAAAACGCC
GAATTGATCG
CATCGCGTAT
CGCTAAATTA
CTTCCACAGT
GTTAAAACGC
GGATGGCATA
GTGCGAATGG
AAACTCAACG
TGCAGCGCCA
AACCCTCAAA
GTTACCGATG
T…

CCTACATCTA
TATCACCTTC
CTTACATGAC
GATAAACACG
AGGCGATGGT
GCTATAGCAA
ATTGAATATA
CGTGAAATGG
TAGATGAAGG
GCAGAGTTGA
GAAGAGAGAC
TACAAAGCGA
TTCGGAAAAG
ATTAGCCGTT
CAATACTGGC
ACAAAACCAA
ATGGGCAGAA
GCAGCAACTT

AATACGGTAG
CACAATACAG
GAATAACAAT
CTGTGCAGGC
CAGGGAGCAG
AAGCGGCGGC
TCGCACACAT
CATCGTGACT
AAGAGCAACG
AAGGTGAGAA
TACCTATTAG
ATTGAAGCAA
GCACAGAGAC
GATGGCGTGT
TAATTTGAAT
AGGAGGAATC
GCGACGATTA
GCACGATCCA

MAYTIVNKYI
NQTSYHVAID
VKYAAAEENA
SVRNRISAKL
AGFLLSVDGI
KKPVVKPAAP
VTRQEAI…

PTSKYGRKAP
DKHAVQAIPF
IEYIAHILKD
AELKGEKVVE
FGKGTETAVK
TKPKEESTVE

YSMNAETITF
NRSAWHAGDG
KGWGIDRVKW
VASPSTVKRD
AFQRANGLAV
KTNEPSKWAE

HNTANDATAL
QGAGNRKSIG
HRDWSGKNCP
YLLDGDTGAA
DGVFGTGSQA
ATIKEAVKIG

GEISYMTNNN
IEVCYSKSGG
HRVLDEGRAT
VKTLQSELKQ
KLNAILANLN
VTDGSNLHDP
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Chapter 4: PlyM4
GenBank Accession Number: HM011592
990 base pairs; 329 amino acids; 35.61 kDa; Theoretical pI = 9.69
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510)
PG-1 binding domain (PF01471)
ATGGTTACAA
CACGTTTGGC
GTAACGCCAG
AACACAAATC
AGCGATTCAA
GGCGAGGGAA
AGTGATGGCG
GTATATAATG
ACAAGTGGTC
GGCATTAATT
GGCTACGCCT
ATACAGGCGA
TTCTTACTAT
TAAGGCGTTC
CAGGCTCACA
CCGGTAGTTA
GGAGAAAACA
CGGTGAAGAT
AGACAGGAGG
ACTTAAACAA

TCAAAAAACA
AGGTTGAACA
TAGAGGTGCA
CACGCGCAGC
TCATACGATC
TGGCAACATG
ACTATTTGAA
AAGGAAGAGA
TGGCAAGAAT
GGGGCGGCTT
AAGCCTTCCA
TAACGTCAGA
CTGTGGATGG
CAACGTGCGA
GGCTAAACTC
AGCCTGCAGC
AACCAACCCT
TGGCGTTACG
CAATTGTGCT
CACACTTATA

GATAGTTCCG
AGAAGCGGTA
GGCGCTCAAA
TTCCTGGCAT
ATTCGGTATC
AATTCGATTC
AACGATAGAA
ATATTCCGTT
TGCCCTACGT
CCTTAGCAAA
CAGTGAAGAG
GCGCTACAGA
CATATTCGGT
ATGGATTAGC
AACGCAATAC
GCCATCAAAA
CAAAATGGGC
GATGGCAGCA
GGCGATGCGT
AATATTGTAA

GAATCGAACG
CATCACAATC
GCCACGCCAA
TGGCAAGTGG
GTGTTGGGCC
ACATTGAAAT
AACGCAGCGC
GGCTAATGTG
TGTTACGCGC
GTTAACGGTG
AGACTACCTA
CCGGATTAAA
AAAGGCACAG
AGTTGATGGC
TGGCGAATTT
CCAAAGGAGG
AGAAGCGACG
ACTTGCACGA
GCCGCAGGAC
GAATTGTTAA

TTAGAACGCG
CACGAAACGG
TCTACAAAGC
ATGAAAAGGT
GGTGGCGATG
TTGTATCAAC
AATTGGTCAA
GTGCAGCATA
AGGCAATCGC
CGGTTGTATC
TTAGATGGCG
GCAAGCAGGT
AGACAGCGGT
GTGTTCGGAA
GAATAAGAAG
AATCCACAGT
ATTAAAGAAG
TCCAGTTACA
TTGCGCCAAG

MVTIKKQIVP
NTNPRAASWH
SDGDYLKTIE
GINWGGFLSK
FLLSVDGIFG
PVVKPAAPSK
RQEAIVLAMR

ESNVRTRTFG
WQVDEKVAIQ
NAAQLVKYIM
VNGAVVSATP
KGTETAVKAF
PKEESTVEKT
AAGLAPRLKQ

RLNKKRYITI
SYDHSVSCWA
KEENIPLANV
KPSTVKRDYL
QRANGLAVDG
NQPSKWAEAT
HTYKYCKNC

HETGNASRGA
GGDGRGNGNM
VQHNKWSGKN
LDGDTGDNVR
VFGTGSQAKL
IKEAVKIGVT

GAQSHANLQS
NSIHIEICIN
CPTLLRAGNR
ALQTGLKQAG
NAILANLNKK
DGSNLHDPVT
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Chapter 4: PlyM5 (Truncated)
GenBank Accession Number: HM011593
853+ base pairs; 284+ amino acids; 30.86+ kDa
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520)
PG-1 binding domain (PF01471)
ATGGCAAAAT
AAGCAAAGGG
ATTTTAATGC
CTAACGACTT
GACGCGCACG
TTGGCTTCTC
TTCGGTGTAT
AATGCTACTC
GCAGCGGGAT
CTGCGCGATA
GAATGATGAA
GCGGTAAGGT
ACTGATTTCA
CCTGTTAGAT
TGAAACAAGC
ACAGAGACAG
TGGCGTGTTC

TATATAACGA
ACGCGCGCGA
AGCTGTAGCA
ATAGCGCGCA
CGCCTATATA
GCATCACGGA
TCTACTGGGG
GCGGCGTATA
ATTCGAAAGC
CATCAGCGCC
GCGCGGAAAC
GGCGGCAAGT
CAGCAGCGAA
GGCGATACAG
AGGTTTCTTA
CGGTGAAGGC
GGAACAGGCT

ACCAGGACAC
GTGGTGGCGT
GATGAAGTGA
GCCGAGTCGC
ATGAAGAGTT
AACGCCAACG
TGGATCTGCA
AAAAAGAATT
AAGCGCGGAG
TTTCGTGTTG
GTATGCTATC
GTCGCGTGTG
ACCTACGCCT
GCGCAGCGGT
CTATCTGTGG
GTTTCAGCGC
CACAGGCTAA

GGCGTAAATA
TCCTGAAATG
ATCGCCTGTT
GGCAAGGATG
TCGCAAAGAT
CTAACAAAGC
ACGGGTAAGA
CCCTGGCTAT
ACTGGACTAA
ATCGAGTGGG
CACAGATTAT
ATTGGTACGG
TCCACAGTGA
TAAAACGCTA
ATGGCATATT
GGCAACGGAC
ACTCAACGCA

CATGGCCGCC
GCAGAACATG
AAGCGGCAAG
TTTCGCTAAC
AAGAGCGCAA
GACAAAAGGA
AGTTGGCGCA
CCAATTTGGG
CTTCGCAATC
ATTTCTTTAC
AGAAAGCGCT
GATTCCGTTT
AGAGAGACTA
CAAAGCGAAT
CGGAAAAGGC
TAGTTGTTGA
ATACTGGCTA ATT…

MAKLYNEPGH
LTTYSAQPSR
FGVFYWGGSA
LRDTSAPFVL
TDFTAAKPTP
TETAVKAFQR

GVNTWPPSKG
GKDVSLTTRT
TGKKLAQMLL
IEWDFFTNDE
STVKRDYLLD
GNGLVVDGVF

TRASGGVPEM
RLYNEEFRKD
AAYKKEFPGY
ARKRMLSTDY
GDTGAAVKTL
GTGSQAKLNA

AEHDFNAAVA
KSAIGFSHHG
PIWGSGIFES
RKRCGKVAAS
QSELKQAGFL
ILAN…

DEVNRLLSGK
NANANKATKG
KRGDWTNFAI
VACDWYGIPF
LSVDGIFGKG
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Chapter 4: PlyM6
GenBank Accession Number: HM011594
1074 base pairs; 357 amino acids; 38.63 kDa; Theoretical pI = 9.62
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520)
PG-1 binding domain (PF01471)
GTGGCGAAGT
AAGCAAAGGG
ATTTTAACGC
CTAACGACTT
GACGCGCACA
TCGGATTTTC
TTCGGTGTAT
AATGCTACTT
GCAGCGGGAT
TTGCGTGATA
GAATGATGAA
GCGGTAAGGT
ACTGATTTTA
CCTATTAGAT
TGAAGCAAGC
ACAGAGACAG
TGGCGTGTTC
ATCTGAATAA
GAGGAATCCA
GACGATTAAA
ACGATCCAGT
GGACTTGCGC

TATATAACGA
ACTCGCGCAA
AGCGGTAGCA
ATAGCGCGCA
CGCCTATATA
ACACCACGGA
TCTACTGGGG
GCTGCATACA
ATTTGAAAGC
CGTCAGCGCC
GCGCGCAAAC
GGCGGCAAGT
CAGCAGCGAA
GGCGTTACAG
AGGTTTCTTA
CGGTTAAGGC
GGAACAGGCT
GAAGCCGGCA
CAGTGGAGAA
GAAGCAGTGA
CACAAGACAG
CAAAACTTAA

ACCAGGACAC
GTGGCGGCGT
GATGAAGTGA
GCCTAGTCGC
ATGAAGAGTT
AACGCCAATG
CGGATCTGCA
AGAAAGAATT
AAGCGCAGCG
TTTCGTGTTG
GTATGCTATC
GTCGCGTGTG
GCCTACGCCT
GCGCAGCGGT
CTATCTGTGG
GTTCCAACGT
CACAGGCTAA
GTTAAGCCTG
AACAAACCAA
AGATTGGCGT
GAAGCAATTG
GTAG

GGCGTAAACA
TCCCGAAATG
ATCGCCTATT
GGCAAGGATG
TAAGAAGGAC
CCAACAAAGC
ACAGGCAAAA
CCCTGGCTAT
ACTGGACCAA
ATCGAGTGGG
CACAGATTAT
ATTGGTACGG
TCCACAGTGA
TAAAACGCTA
ATGGCGTATT
GCGAATGGAT
ACTCAACGCA
CAGCGCCAAC
CCCTCAAAAT
TACGGATGGC
TGCTGGCGAT

CATGGCCGCC
GCGGAACATG
AAGCGGCAAG
TTTCGCTAAC
AGAAGCGCAA
AACTAAAGGA
AGTTGGCGCA
CCGATTTGGG
CTTTGCTATC
ATTTCTTTAC
AGAAAGCGCT
CATTCCGTTT
AGAGAGACTA
CAAAGCGAAT
CGGAAAAGGC
TAGCCGTTGA
ATACTGGCGA
AAAACCAAGG
GGGCAGAAGC
AGCAGCTTAC
GCGTGCTGCA

MAKLYNEPGH
LTTYSAQPSR
FGVFYWGGSA
LRDTSAPFVL
TDFTAAKPTP
TETAVKAFQR
EESTVEKTNQ
GLAPKLK

GVNTWPPSKG
GKDVSLTTRT
TGKKLAQMLL
IEWDFFTNDE
STVKRDYLLD
ANGLAVDGVF
PSKWAEATIK

TRASGGVPEM
RLYNEEFKKD
AAYKKEFPGY
ARKRMLSTDY
GVTGAAVKTL
GTGSQAKLNA
EAVKIGVTDG

AEHDFNAAVA
RSAIGFSHHG
PIWGSGIFES
RKRCGKVAAS
QSELKQAGFL
ILANLNKKPA
SSLHDPVTRQ

DEVNRLLSGK
NANANKATKG
KRSDWTNFAI
VACDWYGIPF
LSVDGVFGKG
VKPAAPTKPR
EAIVLAMRAA
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Chapter 4: PlyM7
GenBank Accession Number: HM011595
1071 base pairs; 356 amino acids; 38.53 kDa; Theoretical pI = 9.41
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520)
PG-1 binding domain (PF01471)
ATGGCAAAAT
AAGCAAAGGG
ATTTTAATTC
CTAACGACTT
GACGCGCACA
TCGGCTTCTC
TTCGGCGTAT
AATGCTACTC
GCAGCGGGAT
TTGCGTGATA
GAACGATGAA
GCGGTAAAGT
ACTGATTTCA
ATTAGATGGC
AGCAAGCGGG
GAGACAGCGG
TGTTTTCGGA
TGAATAAGAA
GAATCCACAG
GATTAAAGAA
ATCCAGTTAC
CTTGCGCCAA

TATATAACGA
ACGCGCGCAA
AGCTGTAGCA
ATAGCGCGCA
CGCCTATATA
GCATCACGGA
TCTACTGGGG
GCGGCGTATA
TTTTGAAAGC
CGTCAGCGCC
GCGCGCAAAC
GGCAGCGAGT
CTGCAGCTAA
GATACAGGCG
TTTCTTACTA
TTAAGGCGTT
ACAGGCTCAC
GCCGGTAGTT
TGGAGAAAAC
GCGGTGAAGA
ACGACAGGAG
AACTTAAGTA

ACCAGGACAC
GTGGTGGCGT
GATGAAGTGA
GCCTAGTCGC
ATGAAGAGTT
AATGCCAACG
CGGATCGGCA
AAAAAGAACT
AAACGCGGCG
TTTTGTATTA
GGATGCTATC
GTTGCGTGTG
ACCTTCGCCG
CAGCGGTTAA
TCTGTGGATG
CCAACGTGCG
AGGCTAAACT
AAGCCTGCAG
AAACCAACCC
TTGGCGTTAC
GCAATTGTGC
A

GGCGTAAACA
TCCCGAAATG
ATCGCCTGTT
GGCAAGGATG
TCGCAAAGAT
CTAACAAAGC
ACGGGTAAGA
CCCTGGCTAT
ACTGGACCAA
ATCGAGTGGG
CACAGATTAT
ATTGGTACGG
TCCACAGAGA
AACGCTACAA
GCATATTCGG
AATGGATTAG
CGACGCAATA
CGCCAACAAA
TCAAAATGGG
GGATGGCAGC
TGGCGATGCG

CATGGCCGCC
GCGGAACATG
AAGTGGCAAG
TTTCGCTAAC
AAGAGCGCAA
GACAAAAGGA
AGTTAGCGCA
CCGATTTGGG
CTTCGCTATC
ATTTCTTTAC
AGAAAGCGTT
CATTCCGTTT
GAGACTACCT
AGCGAATTGA
AAAAGGCACA
CAGTTGATGG
CTGGCTAATC
ACCAAAGGAG
CAGAGGCGAC
AACTTACACG
TGCTGCAGGA

MAKLYNEPGH
LTTYSAQPSR
FGVFYWGGSA
LRDTSAPFVL
TDFTAAKPSP
ETAVKAFQRA
ESTVEKTNQP
LAPKLK

GVNTWPPSKG
GKDVSLTTRT
TGKKLAQMLL
IEWDFFTNDE
STERDYLLDG
NGLAVDGVFG
SKWAEATIKE

TRASGGVPEM
RLYNEEFRKD
AAYKKELPGY
ARKRMLSTDY
DTGAAVKTLQ
TGSQAKLDAI
AVKIGVTDGS

AEHDFNSAVA
KSAIGFSHHG
PIWGSGIFES
RKRCGKVAAS
SELKQAGFLL
LANLNKKPVV
NLHDPVTRQE

DEVNRLLSGK
NANANKATKG
KRGDWTNFAI
VACDWYGIPF
SVDGIFGKGT
KPAAPTKPKE
AIVLAMRAAG
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Chapter 4: PlyM8
GenBank Accession Number: HM011596
1074 base pairs; 357 amino acids; 38.72 kDa; Theoretical pI = 9.62
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520)
PG-1 binding domain (PF01471)
ATGGCGAAAT
AAGCAAAGGG
ATTTTAACGC
CTAACGACTT
GACGCGTACA
TCGGTTTTTC
TTCGGCGTAT
AATGCTACTC
GCAGTGGGAT
CTGCGCGACA
GAATGATGAA
GCGGTAAAGT
ACTGATTTTA
CCTACTACTT
TGAAACAAGC
ACAGAGACAG
TGGCGTGTTC
ATCTGAATAA
GAGGAATCCA
TACGATTAAA
ACGATCCGGT
GGACTCGCGC

TATATAACGA
ACGCGCGCAA
AGCGGTAACA
ATAGCGCGCA
CGCCTATATA
TCACCACGGA
TCTACTGGGG
GCGGCGTATA
ATTCGAAAGC
CATCAGCGCC
GCGCGCAAAC
GGCAGCGAGT
CAGCAGCGAA
GACGATACCG
AGGTTTCTTA
CGGTTAAGGC
GGAACAGGCT
GAAGCCGGTA
CAGTGGAGAA
GAAGCGGTGA
CACAAGACAG
CAAAACTCAA

ACCAGGGCAC
GTGGCGGCGT
GATGAAGTGA
GCCGAGTCGC
ATGAAGAGTT
AACGCCCATG
CGGATCTGCA
AAAAAGAATT
AAGCGCGGCG
TTTCGTATTA
GGATGCTATC
GTCGCGTGCG
ACCTACGCCT
GCGCAGCGGT
CTATCTGTGG
GTTCCAACGT
CACAGGCTAA
GTTAAGCCTG
AACAAACCTA
AGATTGGCGT
GAGGCAATTG
GTAG

GGCGTAAACA
TCCCGAAATG
ATCGCCTGTT
GGCAAGGATG
TCGCAAAGAT
CCAACAAAGC
ACGGGTAAGA
CCCTGGTTAT
ACTGGACAAA
ATCGAGTGGG
CACAGATTAC
ATTGGTACGG
TCCACAGTGA
TAAAACGCTA
GTGGCATATT
GCGAATGGAT
ACTCAACGCA
CAGCGCCAAC
CCCTCAAAAT
TACCGATGGC
TGCTGGCGAT

CATGGCCGCC
GCGGAACATG
AAGCGGCAAG
TTTCGCTAAC
AGAAGCGCAA
GACAAAAGGA
AGTTGGCGCA
CCAATTTGGG
CTTTGCAATT
ATTTCTTTAC
AGAAAGCGTT
TATTCCGTTT
AGAGAGATTA
CAAAGCGAAT
TGGTAAAGGT
TAGCAGTTGA
ATACTGGCGA
AAAACCAAAG
GGGCAGAAGC
AGTAACTTAC
GCGTGCTGCG

MAKLYNEPGH
LTTYSAQPSR
FGVFYWGGSA
LRDTSAPFVL
TDFTAAKPTP
TETAVKAFQR
EESTVEKTNL
GLAPKLK

GVNTWPPSKG
GKDVSLTTRT
TGKKLAQMLL
IEWDFFTNDE
STVKRDYLLL
ANGLAVDGVF
PSKWAEATIK

TRASGGVPEM
RLYNEEFRKD
AAYKKEFPGY
ARKRMLSTDY
DDTGAAVKTL
GTGSQAKLNA
EAVKIGVTDG

AEHDFNAAVT
RSAIGFSHHG
PIWGSGIFES
RKRCGKVAAS
QSELKQAGFL
ILANLNKKPV
SNLHDPVTRQ

DEVNRLLSGK
NAHANKATKG
KRGDWTNFAI
VACDWYGIPF
LSVGGIFGKG
VKPAAPTKPK
EAIVLAMRAA
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Chapter 4: PlyM9 (Truncated)
GenBank Accession Number: HM011597
1029+ base pairs; 343+ amino acids; 37.2+ kDa
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520)
PG-1 binding domain (PF01471)
ATGGCAAAAT
AAGCAAAGGG
ATTTTAACGC
CTAACGACTT
GACGCGCACA
TCGGTATGTC
TTCGGCGTAT
AATGCTACTC
GCAGCGGGAT
CTGCGCGATA
GAATGATGAA
GCGGTAAAGT
ACTGATTTTA
CCTATTAGAT
TGAAGCAAGC
ACAGAGACAG
TGGCGTGTTC
ATTTGAATAA
GAGGAATCCA
GACGATTAAA
ACGATCCAGT

TATATAACGA
ACGCGCGCAA
AGCGGTAGCA
ATAGCGCACA
CGCCTTTACA
ACATCACGGA
TCTATTGGGG
GCGGCGTATA
ATTCGAAAGT
CATCAGCGCC
GCGCGGAAAC
GGCAGCGAGT
CAGCAGCGAA
GGCGATACAG
AGGTTTCTTA
CGGTTAAGGC
GGAACAGGCT
GAAGCCGGTA
CAGTGGAGAA
GAAGCAGTTA
CACAAGACAG

ACCAGGACAC
GTGGTGGCGT
GATGAAGTGA
GCCGAGTCGC
ACGCTGAATA
AACGCCCACG
CGGATCTACC
AGAAAGAATT
AAGCGCGGAG
TTTTGTATTA
GTATGCTGTC
GTCGCGTGTG
ACCTACGCCT
GCGCAGCGGT
CTATCTGTGG
GTTCCAACGT
CACAGGCTAA
GTTAATCCTG
AACAAACCAA
AGATTGGCGT
GAAGCAATT…

GGCGTAAATA
TCCTGAAATG
ATCGCCTTTT
GGCAAGGATG
CAGCAAAGAC
CCCACAAAGC
ACAGGTAAGA
CCCTGGCTAT
ACTGGACTAA
ATTGAGTGGG
CACAGATTAT
ATTGGTACGG
TCCACAGAGA
TAAAACGCTA
ATGGCATATT
GCGAATGGAT
ACTCAACGCA
CAGCGCCAAC
CCCTCAAAAT
TACCGATGGC

CATGGCCGCC
GCGGAACATG
AAGCGGCAAG
TTTCGCTAAC
AGAAGCGCAA
AACAAAAGGT
AGTTGGCGCA
CCGATTTGGG
CTTTGCAATC
ATTTCTTTAC
AGAAAGCGTT
TATTCCGTTT
AGAGAAACTA
CAAAGCGAGT
CGGAAAAGGC
TAGCGGTTGA
ATACTGGCTA
GAAACCAAAG
GGGCAGAAGC
AGCAGCTTAC

MAKLYNEPGH
LTTYSAQPSR
FGVFYWGGST
LRDTSAPFVL
TDFTAAKPTP
TETAVKAFQR
EESTVEKTNQ

GVNTWPPSKG
GKDVSLTTRT
TGKKLAQMLL
IEWDFFTNDE
STEKRNYLLD
ANGLAVDGVF
PSKWAEATIK

TRASGGVPEM
RLYNAEYSKD
AAYKKEFPGY
ARKRMLSTDY
GDTGAAVKTL
GTGSQAKLNA
EAVKIGVTDG

AEHDFNAAVA
RSAIGMSHHG
PIWGSGIFES
RKRCGKVAAS
QSELKQAGFL
ILANLNKKPV
SSLHDPVTRQ

DEVNRLLSGK
NAHAHKATKG
KRGDWTNFAI
VACDWYGIPF
LSVDGIFGKG
VNPAAPTKPK
EAI…
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Chapter 4: PlyM10 (Truncated)
GenBank Accession Number: HM011598
848+ base pairs; 282+ amino acids; 30.7+ kDa
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520)
PG-1 binding domain (PF01471)
ATGGCAAAAT
AAGCAAAGGG
ATTTTAACGC
CTAACGACTT
GACGCGCACA
TTGGCTTCTC
TTCGGCGTAT
AATGCTACTC
GCAGCGGGAT
TTGCGTGATA
GAATGACGAA
GCGGTAAAGT
ACTGATTTCA
ATTAGATGGC
AACAAGCGGG
GAGACAGCGG
CGTGTTCGGA

TATATAACGA
ACGCGCGCAA
AGCGGTAGCA
ATAGCGCACA
CGCCTATATA
ACATCACGGA
TCTATTGGGG
GCGGCGTATA
ATTCGAAAGT
CGTCAGCGCC
GCGCGCAAAC
GGCAGCGAGT
CAGCAGCGAA
GATACAGGCG
TTTCTTACTA
TTAAGGCGTT
ACAGGCTCAC

ACCAGGACAC
GTGGTGGCGT
GATGAAGTAA
GCCTAGTCGC
ATGAAGAGTT
AACGCTAATT
TGGATCTGCA
AGAAAGAATT
AAGCGCGGCG
TTTCGTGTTA
GGATGCTATC
GTCGCGTGTG
ACCTTCGCCG
CAGCGGTTAA
TCTGTGGATG
CCAACGTGCG
AGGCTAAACT

GGCGTAAACA
TCCCGAAATG
ATCGCCTGTT
GGCAAGGATG
TCGCAAAGAT
CCAACAAAGC
ACGGGTAAGA
CCCTGGCTAT
ACTGGACCAA
ATCGAGTGGG
CACAGATTAT
ATTGGTACGG
TCCACAGAGA
AACGCTACAA
GCATATTCGA
AATGGATTAG
CAACGCAATA

CATGGCCGCC
GCGGAACATG
AAGCGGCAAG
TTTCGCTAAC
AAGAGCGCAA
GACAAAAGGT
AGTTGGCGCA
CCGATTTGGG
CTTCGCTATC
ATTTCTTTAC
AGAAAGCGTT
GATTCCGTTT
GAGACTACCT
AGCGAATTGA
TAAAGGTACA
CCGTTGATGG
CTGGCTTA…

MAKLYNEPGH
LTTYSAQPSR
FGVFYWGGSA
LRDTSAPFVL
TDFTAAKPSP
ETAVKAFQRA

GVNTWPPSKG
GKDVSLTTRT
TGKKLAQMLL
IEWDFFTNDE
STERDYLLDG
NGLAVDGVFG

TRASGGVPEM
RLYNEEFRKD
AAYKKEFPGY
ARKRMLSTDY
DTGAAVKTLQ
TGSQAKLNAI

AEHDFNAAVA
KSAIGFSHHG
PIWGSGIFES
RKRCGKVAAS
SELKQAGFLL
LA…

DEVNRLLSGK
NANSNKATKG
KRGDWTNFAI
VACDWYGIPF
SVDGIFDKGT
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Chapter 4: PlyM11
GenBank Accession Number: HM011599
1071 base pairs; 356 amino acids; 38.52 kDa; Theoretical pI = 9.45
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520)
PG-1 binding domain (PF01471)
ATGGCGAAGT
AAGTAAAGGG
ATTTTAACGC
CTAACGACTT
GACGCGCACA
TTGGCTTCTC
TTCGGCGTAT
AATGCTACTC
GCAGCGGAAT
CTGCGCGACA
GAATGATGAA
GCGGTAAAGT
ACTGATTTTA
ATTAGATGGC
AACAAGCGGG
GAGACAGCGG
CGTGTTCGGA
TGAATAAGAA
GAATCCACAG
GATTAAAGAA
ATCCAATTAC
CTTGCACCAA

TATATAACGA
ACGCGCGCAA
AGCGGTAGCA
ATAGCGCACA
CGCCTATATA
ACATCACGGA
TTTATTGGGG
GCGGCGTATA
ATTCGAAAGT
CATCAGCGCC
GCGCGTAAAC
GGCAGCGAGT
CAGCAGCGAA
GATACCGGCG
TTTCTTACTA
TTAAGGCGTT
ACAGGCTCAC
GCCGGTAGTT
TGGAGAAAAC
GCCGTTAAGA
ACGACAGGAA
AACTTAAGTA

ACCAGGACAC
GTGGTGGCGT
GATGAAGTTA
GCCTAGTCGC
ATGAAGAGTT
AATGCTAATG
CGGATCGGCA
AAAAAGAATA
AAACGCGGCG
ATTTGTATTA
GGATGCTATC
GTCGCGTGTG
ACCTACGCCT
CAGCGGTTAA
TCTGTGGATG
CCAACGTGCG
AGGCTAAACT
AAGTCGGCAG
AAACCAACCA
TTGGCGTTAC
GCAATTGTGC
A

GGCGCTAACA
TCCTGAAATG
ATCGCCTGTT
GGCAAGGATG
TCGCAAAGAT
CTAACAAAGC
ACGGGTAAGA
CCCTGGCTAT
ACTGGACAAA
ATCGAGTGGG
CACAGATTAT
ATTGGTACGG
TCCACAGAGA
AACGCTACAA
GCATATTCGG
AATGGATTAG
CAACGCAATA
CGCCAACAAA
TCAAAATGGG
GGATGGCAGC
TGGCGATGCG

CATGGCCGCC
GCGGAGCATG
AAGCGGAAAG
TTTCGCTGAC
AAGAGCGCAA
GACAAAAGGA
AGTTAGCGCA
CCGATTTGGG
CTTTGCAATT
ATTTCTTTAC
AGAAAGCGTT
AATTCCGTTT
GAGACTACCT
AGCGAATTGA
AAAAGGCACA
CCGTTGATGG
CTGGCTAATT
ACCAAAGGAG
CAGAAGCGAC
AGCTTACACG
TGCTGCAGGA

MAKLYNEPGH
LTTYSAQPSR
FGVFYWGGSA
LRDTSAPFVL
TDFTAAKPTP
ETAVKAFQRA
ESTVEKTNQP
LAPKLK

GANTWPPSKG
GKDVSLTTRT
TGKKLAQMLL
IEWDFFTNDE
STERDYLLDG
NGLAVDGVFG
SKWAEATIKE

TRASGGVPEM
RLYNEEFRKD
AAYKKEYPGY
ARKRMLSTDY
DTGAAVKTLQ
TGSQAKLNAI
AVKIGVTDGS

AEHDFNAAVA
KSAIGFSHHG
PIWGSGIFES
RKRCGKVAAS
SELKQAGFLL
LANLNKKPVV
SLHDPITRQE

DEVNRLLSGK
NANANKATKG
KRGDWTNFAI
VACDWYGIPF
SVDGIFGKGT
KSAAPTKPKE
AIVLAMRAAG
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Chapter 4: PlyM12
GenBank Accession Number: HM011600
1017 base pairs; 338 amino acids; 37.39 kDa; Theoretical pI = 9.36
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510)
Additional conserved domain of unknown function DUF 3957 (PF12200)
PG-1 binding domain (PF01471); PG-3 binding domain (PF09374)
**NOTE: The above binding domains show only low homology to the consensus
sequences for PG-1 and PG-3, with respective E-value scores of 0.0045 and
0.0056.
ATGGTAGCAT
ACGCCCTGGG
CGGCTAGTCC
GCTGACGGAG
AAAGGAAGCA
ACGAGAGGTC
AACGGAAATG
AGACGGATCC
AGAAGCTACG
GTAACAGGCA
GAAGGCGTTC
CTAAAACCGA
GTCGAGTATC
AGAACTAGCG
AAAACCTAGA
CTGACGGTAG
TTACTTCGGT
TAAAAGCCCT
CCAATCACGA
CGTAATTAGC
ATAACGGTAA

TAAATTATAA
TTGAAGCTAC
GGGAGGTTCC
GCGCCTACCG
ATCGAGATCA
GCCTAAACTG
CGAACCTAAC
TTCCACCCGG
TAAACAGTTC
AGATCTGCCC
TTAAAGCGCT
AGTTAAGGCC
TGAAAGATCT
AAGGATTACG
GTTGCTCGAT
ACGGTTACTT
ACCCCGGTTG
GCAGGGGTTA
TCAAGGCGTT
AAACCGTCTC
ACTGTAA

GAAAGATTAC
TTGGCGTAAG
GCGCAAAACC
TTACGCAGGG
TCCCGTTAAA
TCGTACCTAC
AACGATCGGC
ACACTGTCGA
GGCAAAGTCC
GAAACCTTTC
TAGACGGTGG
GTGTCCACAG
CGGAAAACCT
GGATCACTAA
CTTCTCCAAA
CGGACCGGCA
ACGGCGTAAT
CTAGACGTGA
ACAGAAACGT
TCGTCATCAA
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GTAATTAAAA
GGCTATCGTT
ACCAAGACTT
GCGCACATAT
CGAGGTTGCA
GGGCGTCAAC
ATCGAGATGT
GCGTACAGCG
CTGTAATCCG
GTAGAGGACG
CGTTACGGTC
AAAAAGAATA
TACTCGTTCT
TTACGAAGGT
ACGGAAGACC
ACGATAAAAG
CAGCGAACCT
GACAAGACGG
TTCGGCACTC
AGAGTTACAA

ATAAATACTC
CTACACTACA
CTTCGATGGG
TCGTAGATAA
TATCACGCCA
GTCTTCTTAC
GTATCGAAAA
CTAGTAGTCG
TCACTACGAT
TATCTGCGTG
AAGCCTGCGC
CACGAGCATC
CTTACCGTAA
TCAGCAGCGC
GAAAGCCAAC
CATTACAGCG
TCGTTGGTTG
TTACATGGGT
CGGTTGACGG
AGACGTTTAA

MVALNYKKDY
ADGGAYRYAG
NGNANLTTIG
VTGKICPKPF
VEYLKDLGKP
LTVDGYFGPA
PITIKALQKR

VIKNKYSRPG
AHIFVDKKEA
IEMCIEKDGS
VEDVSAWKAF
YSFSYRKELA
TIKALQRYFG
FGTPVDGVIS

LKLLGVRAIV
IEIIPLNEVA
FHPDTVERTA
LKRLDGGVTV
KDYGITNYEG
TPVDGVISEP
KPSLVIKELQ
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LHYTASPGGS
YHANERSPKL
LVVEKLRKQF
KPAPKTEVKA
SAAQNLELLD
SLVVKALQGL
RRLNNGKL

AQNHQDFFDG
SYLRASTSSY
GKVPVIRHYD
VSTEKEYTSI
LLQNGRPKAN
LDVRQDGYMG

Chapter 4: PlyM13
GenBank Accession Number: HM011601
699 base pairs; 232 amino acids; 25.07 kDa; Theoretical pI = 9.52
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520)
SPOR binding domain (PF05036)
ATGGCGAAAA
GGGAATGGAT
TTTTAGAGAT
GTAGAAGTGA
GCGCACGAAT
ATATTAATGC
GCAGGATCAG
GGGAACAGGG
ATATGTTAAG
ATTGATAACG
CGCTATAGCT
AAAAGAAACC
AAAGTTCAAG
TGCTGAACTA

GGAAAGTATA
CCTGGAGCAG
TGGGAAGTAT
AGTTTTCAAG
GAAGCTAATG
AGGCGGCGGT
CAACGCAGGC
GTATTCACGA
AGAATCTAAA
GTACAGACGC
TCAGGTCATG
TGTTTCTAAA
TAGGTGCTTT
AAGAAAATAG

TATTGATTTA
TTGCCAATGG
ATGAAAGATA
ATTGGCAAAT
CCTGGGGTGC
AAAGGGTTTG
TTTCCAAAAT
CAGACAGAGG
ATGACCGCAA
AGCAACTTTG
TGGAGGGAGT
CCAGAGCCGA
CTCTGACCGA
GCTATTCAAC

GGGCACGAAG
GTTGAAAGAA
TGTTTGCCAA
AAAAATCTTT
TGATGTTCTC
AATCCTTCAT
GCTGTTCATG
GAAGAAAAAG
TCTTAACCGA
AAAAACAGAG
AGCTTCTTTC
AACCATCTGG
AAGAACGCTG
TTATATTGTT

GCGACGGAAA
GCTAATGTTG
CTATGAGAAT
CTTTAAATCA
TGTTCAATCC
ATATCCAGGT
CCAAGATTAT
GCGAATTTCC
AAATGGGTTC
CAAAGTTAAT
CTTAACCTTA
TAAGTTATAC
ACAACTTAGC
CACGAATAA

MAKRKVYIDL
VEVKFSRLAN
AGSATQAFQN
IDNGTDAATL
KVQVGAFSDR

GHEGDGKGMD
KNLSLNQRTN
AVHAKIMGTG
KNRAKLIAIA
KNADNLAAEL

PGAVANGLKE
EANAWGADVL
VFTTDRGKKK
SGHVEGVASF
KKIGYSTYIV

ANVVLEIGKY
CSIHINAGGG
ANFHMLRESK
LNLKKKPVSK
HE

MKDMFANYEN
KGFESFIYPG
MTAILTENGF
PEPKPSGKLY
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Chapter 4: PlyM14
GenBank Accession Number: HM011602
792 base pairs; 263 amino acids; 28.8 kDa; Theoretical pI = 9.78
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520)
SPOR binding domain (PF05036)
ATGACGAAGA
CAAACGTACG
CACTAGCCGC
AGACTCGACG
CGACAAGGCG
ATGCGCTCAC
TATCTCGGAA
TCGTATCCTA
ACTTCCACAT
GGCTTCATGG
CCTCGATGAA
GATTAAAGAA
ATCGGAGCTT
TAAACGCGCA
AAGTTCAAAT
TCGGAATTGA

TAATCGCTAT
CCGGATAATG
GATTAAGTAT
ATCCGACCGG
AATAAGGCGA
GGGCAAGTGG
ACTGGCCGGA
AAAGCTTACG
GGTACGCGAG
ACTCGACCGT
GCCGGCAAAG
GAAGAAACCC
ATTCGGTAAA
GGCTATTCGC
CGGAGCTTAT
AGCGCAAAGG

CGACGCTGGC
AGCGCGAATG
TTGAACGATT
TAAATCGGAC
AGGCTGACGT
GGAACGCACG
CGCGGAAAGG
GATTAAAGAG
AGCGCTATGC
CGATATTAAG
CTATCGCGGA
GCAGCACCTT
AGCGAACGCT
CATATATCGC
TCCGTCAAAG
CTTCAACGTA

CACGGACTTA
GTCGTTTAAT
ATGAAGGCGT
GTACCTTTAA
ACTAGTGTCG
GCGGTACGGA
CTGGCGAAGT
TCGCGGACTA
CTGCGATATT
AAGATGCGCG
AGCACTGGCG
CGAAACTGTA
GACGCACAAG
ACGCGAAGGC
CGAACGCCGA
TATATTGCGT

ATACTCCGGG
AATAAGGTCA
TAAAATCGTA
AAGCGCGCAC
ATTCATCATA
AGTATTTACG
TAGTACTCGA
AAGAAGGCTA
AATCGAAGGA
ACGATAAAGT
GTCTACTTCG
TCGCGTACAA
CTGCGAAAGC
GGACTTTACA
TAAAATGGCA
AA

MTKIIAIDAG
RLDDPTGKSD
YLGNWPDAER
GFMDSTVDIK
IGAYSVKANA
SELKRKGFNV

HGLNTPGKRT
VPLKARTDKA
LAKLVLDRIL
KMRDDKVLDE
DAQAAKAKRA
YIA

PDNEREWSFN
NKAKADVLVS
KAYGLKSRGL
AGKAIAEALA
GYSPYIAREG

NKVTLAAIKY
IHHNALTGKW
KKANFHMVRE
VYFGLKKKKP
GLYKVQIGAY

LNDYEGVKIV
GTHGGTEVFT
SAMPAILIEG
AAPSKLYRVQ
SVKANADKMA

354

Chapter 4: PlyM15
GenBank Accession Number: HM011603
693 base pairs; 230 amino acids; 25.71 kDa; Theoretical pI = 9.17
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520)
SPOR binding domain (PF05036)
ATGAGCAAAT
AGTTACGAAA
ATGTAGACAA
TCAAGTGATG
TTTCGACAAG
TTGAAGCAAT
GCAGAAGAAT
TTTTAAAAAA
GTAAATGTCG
TCTGAAAAGA
AGTGCGAGCC
AACCTAAACC
CAAGTAGGTG
TCTAAAGAAA

GGATTCAAGA
GGAAATACCG
GCGTCTGGAT
TTACGTTAGA
TGTATTTCTC
TCATTCTATC
TTAAAAAAGC
TACGGAAACA
GACTACGATT
TTAAGGATAA
ATTTGCCGTG
ACAATCTAAA
CATTTTCGGA
AAAGGCTACA

TGCAGGACAC
AAAAAGTTTA
GAATTAGGGA
TCAAGGCCCG
ACCACTTTAA
TACTCAAACG
GGGATATCCA
ACGATTATTA
GTAGAATATG
AGCCTATCGT
ATGAAGGGGT
CCATCTAATA
TAAATCAAAC
GCACCTATAT

GGAGGAAAAG
CACTCTTGAA
TTAAAAGTGA
CGTACTGGAA
CGCAGGGGGC
GGAAGTTTGA
GTGCGACCTC
CTACATGCAC
ACTTTGTGGA
GAAGGCATGT
AACATATAAA
AAGGCGGATT
GCAGATAAAC
TGTACAGGAA

ACCCTGGCGC
GCTGCACTTT
TGTGACTCGT
AAGTTAAAGC
GGTAGTGGTT
ACACCTAATT
GTTCAGTGTA
CGCCAAACAG
CGGTCCGCAA
ATGAATGTGT
GCGCCTAATC
ATACAAGGTG
TTGCAGCAGA
TAA

MSKWIQDAGH
SSDVTLDQGP
AEEFKKAGYP
SEKIKDKAYR
QVGAFSDKSN

GGKDPGAVTK
RTGKVKAFDK
VRPRSVYFKK
EGMYECVVRA
ADKLAADLKK

GNTEKVYTLE
CISHHFNAGG
YGNNDYYYMH
ICRDEGVTYK
KGYSTYIVQE

AALYVDKRLD
GSGFEAIHSI
RQTGKCRTTI
APNQPKPQSK

ELGIKSDVTR
YSNGKFEHLI
VEYDFVDGPQ
PSNKGGLYKV
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Chapter 4: PlyM16
GenBank Accession Number: HM011604
702 base pairs; 233 amino acids; 26.15 kDa; Theoretical pI = 8.98
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520)
SPOR binding domain (PF05036)
ATGAGTGAAA
AGCGGTTGCC
TATATGTAGA
AGAGATAAAG
AGCTTCTAAA
GTGCCGGTGC
AACATGCTTG
ATTCTGCAAA
GGGAAACGGG
GGCCCGAACG
TGAGTGCGTA
CTGTCGAGCA
TACAAGGTTC
CGCCAAAGAA

AGTGGAAAAA
AATGGTATCA
CAAGCGTTTA
ACATCACCCT
GCACCATTCG
AGAGTTCATC
CTGATGAATT
GCTGGCAAAA
CTTTTGCAGA
CTGAAAAGCT
GTGAGGGCTG
ACCGAAACTA
AAGTGGGCGC
TTAGAGGGCA

CGATGGTGGT
AGGAAAAGGA
AAGGAGCATG
TGAACCAAAC
GATTAAGTCA
CATTCCATTC
TAAAAGAGCC
ACCCGGCAAA
ATGACGATTG
GAAAGACCGT
TATGTCGTCA
AAGCCACAGG
ATTCGGCGAT
AAGGGTATAA

CATGGCGGTA
ATACACGCTT
GTATTGACTC
GCGCGTACTG
CCATTACAAT
ATTCTGATGG
GGTTATCCTG
GGACTATTAC
TGGAATATGA
AAATATCGCG
GGAAGGGAAA
AAGCCCCTAA
AAATCAAATG
AACGTATATT

CAGATCCCGG
GAAGCGGCTT
AGGACTCACA
CGGTTGTCAG
GCCGGCGGTG
CAAGTTTGAA
TTCGTAGAGT
TACATGCACA
TTTTGTTGAC
AGTGTATGTA
GCCTATAAAC
GAAGGGATTA
CTGACCGACT
GTGCAGGAGT AA

MSEKWKNDGG
RDKDITLEPN
NMLADEFKRA
GPNAEKLKDR
YKVQVGAFGD

HGGTDPGAVA
ARTAVVRASK
GYPVRRVFCK
KYRECMYECV
KSNADRLAKE

NGIKEKEYTL
APFGLSHHYN
AGKNPAKDYY
VRAVCRQEGK
LEGKGYKTYI

EAALYVDKRL
AGGGAGAEFI
YMHRETGFCR
AYKPVEQPKL
VQE

KEHGIDSGLT
HSIHSDGKFE
MTIVEYDFVD
KPQEAPKKGL
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Chapter 4: PlyM17
GenBank Accession Number: HM011605
771 base pairs; 256 amino acids; 28.98 kDa; Theoretical pI = 8.86
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510)
No recognized binding domain
ATGTACCAAA
GCAACAAATT
CTGGTAGTAC
AGTGCGTCAG
CCCTATCTAT
ATCAAATGTT
TGTTGGGGGA
GTATCATGCT
TCGTATCTCA
TGCTTTAAAC
AAATGTGTTT
TTCTAATAGG
CGATTAAAAG
TACAAAAGAA
ACAAAGTAAT
GTTAAAAAGT

TCACAAGGGA
AAGAAAGTGT
AGCATACGGG
CCCACACGTT
GAGAAAGCAT
TGGTGATGAT
ATGGTATCAA
CATCTTTGTA
TAAGACATTG
GTCATGGTAT
GTAGGGAAAA
TGGATTCCCT
CACCTATCTA
TTATTTGTAG
CAATCTATCC
TTATCGGATA

TTACATTAAA
TGTTTATCGT
AATCGAAATT
CATTGATGAT
GGCACGTACA
GCGAATGATG
CTTCAATGAA
AGACATTTAA
GATCCAGAAC
TACATGGGAA
AGGAGGAAAA
GATTTTGCAG
CACTCGTGAT
TCGGTGGTTC
GGAAAAGACC
A

TTCGGTAATT
AAGCCATGAC
ACTTTAATAA
AAATACATTT
GTATCAAAAA
CAGCTATCGG
GCATACAAGC
ACTCAATCCT
GTAAAGTAGA
CAATTCATAA
TGATATGTTA
TAGCGGAGAT
GCTTATCCGG
TACCGCAGGC
GATTTGCTGT

CTCGATGCGG
ACAGGGAATC
TCAACAACCT
TGGAGATCAT
CCAAAAGATA
GGTTGAACTT
GTTTTGTGTG
AGAAAGCACA
CCCGATAGAC
ATGATGTAGA
GAAAAAGCGA
ATTAGCAGCA
GTGGAAAGGT
CTACAAGCAG
TGCTGCAGCA

MYQITRDYIK
SASAHTFIDD
CWGNGINFNE
CFKRHGITWE
RLKAPIYTRD
VKKFIG

FGNSRCGQQI
KYILEIIPIY
AYKRFVWYHA
QFINDVENVF
AYPGGKVTKE

KKVLFIVSHD
EKAWHVQYQK
HLCKTFKLNP
VGKKEENDML
LFVVGGSTAG

TGNPGSTAYG
PKDNQMFGDD
RKHIVSHKTL
EKAILIGGFP
LQADKVINLS

NRNYFNNQQP
ANDAAIGVEL
DPERKVDPID
DFAVAEILAA
GKDRFAVAAA
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Chapter 4: PlyM18
GenBank Accession Number: HM011606
762 base pairs; 253 amino acids; 28.71 kDa; Theoretical pI = 7.77
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510)
LysM binding domain (PF01476)
ATGTTGACGG
CCACCCCAGC
ACGAATTGAG
AATACAGCGA
AAATTGGGAG
CCCATTACGT
GATACGGCTT
CATTGAGTGC
AGCTGGTGGC
CATAAGCAAG
CTGCCCGGGC
GGTACACGAA
CACACGGTCG
AGGCGATGGC
ATCCGAGTGC
GCTAAGCACT

TCCAGCAGAT
GACTATCAGG
AGACAATAGA
TTGACGTCAT
AACTTAACCA
TGCCATGGCT
ACCATGGTGG
CGTCCAGAAG
TGATATCTGG
TGCCATCCGT
AGATACGATG
GAAGTACGCC
TGAGTGGCGA
ATGAGGTACA
CTTATTAGTC
GA

CATCCGGCAG
TCGCTTTTTT
CGCTCTACCT
TGTTATCCAT
CCTACACGGC
GGCAAGGTCG
CAATCCACCG
CCACAGACGG
AACAGGCACG
CAGGCCGGGT
TGGAGCGGAT
AAGAAGGACA
ATCCTACTGG
CAGAAATATT
GGACAGGTCT

GGTGGCAAGA
AATGGAGATT
ACCTGGCTAA
CACTGGGGTG
CAATAACCGC
AGCGACAGGT
ATCAATCAAC
CGATTACGAC
GCAAGCTACC
CAGCAATACG
CCGTAAAGAA
GCGACGCACG
AGTATTGCAG
AGACCTGAAC
TGGAACTGCC

GATTGATTAG
TTTATGGCAT
AGGCAGAGCC
TTGACGGTCA
AATATGAGTA
GGACGAGGAG
GCTCTATCGG
ACAGTGGCTG
CTTGGTCGGC
TGGCGACAAG
GCGGAGGGTT
ACCTAAGACG
CCAAGTACCT
AAGGTCAAAG
TGAAAAGTAC

MLTVQQIIRQ
NTAIDVIVIH
DTAYHGGNPP
HKQVPSVRPG
HTVVSGESYW

GGKRLISHPS
HWGVDGQNWE
INQRSIGIEC
QQYVATSCPG
SIAAKYLGDG

DYQVAFLMEI
NLTTYTANNR
RPEATDGDYD
RYDVERIRKE
MRYTEILDLN

FMAYELRDNR
NMSTHYVAMA
TVAELVADIW
AEGWYTKKYA
KVKDPSALLV

RSTYLAKGRA
GKVERQVDEE
NRHGKLPLVG
KKDSDARPKT
GQVLELPEKY AKH
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Chapter 4: PlyM19
GenBank Accession Number: HM011607
819 base pairs; 272 amino acids; 29.1 kDa; Theoretical pI = 7.05
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520)
SH3-Type 5 binding domain (PF08460)
ATGGGTACAT
TAACTGGGGT
CTTTAATTAG
GACGAAACAG
ATGTAATGCT
ACAATGGTTC
TTAGCTGCTA
CCGAGGAGCT
CACCTGCTAT
GGTAAATGGA
GGGTCAACGT
GCGGAAGCAC
GGTGTATTCA
AAATGCAACT
CTTCATTCGG
GGTACATACG
CTGGGGTTCT

ATAACGTTCA
GCTCGTAAAG
CAGGCTACGT
GTTCTACGCA
CACCGAGTAG
TGCTAACGGA
AAGTTTCTAA
AAACCTCGTA
CCTAATCGAG
ACGTGGATAA
GCAGGTTCTA
TGGTGGTGGA
CAGCTAACAC
CATCTTCGTA
AATGGAGAAA
TTGCAACAGG
TTCGAGTAA

TGGTGGTCAC
AACACGTTAT
AGCCTTGGTC
ATCTGCTAAC
ACTTAGGCAT
GTAGAGGTTT
GCAATTGTCT
CAGACCTTTA
TTAGGTTTCA
AATCGCAGAC
CAGGTGGAAA
TACGACTCTA
AGCAATCAAA
CTCTGTACAG
GACGGTTACG
GGAAACTCGT

AACTCTATCG
GGATCGCCAA
ACACAGTTTA
TTACGTAACA
TTCGTTACAC
GCTATTCCGA
GACGACATCG
CGTACTAAAC
TCGATAACGA
TCCATCTGCT
CACAGGTGGA
GTTGGTTCAC
GTTAGAAGCG
TGGCGGCACA
TTTGGATCAA
GACGGTAAAC

TACAAGGTGC
GTAAAAGATG
TGACTGCACA
TCGTAGCTAA
TTAAACGCAT
CCAACAAGCG
GATGGTCTAA
AGCACATCTG
GGGCGATATG
ATGCTATCAC
GGTTCTACAG
TCCACAAAAT
AACCAAGTGT
TACAAGTACA
GGGAGCAGAC
GTATCTCTTA

MGTYNVHGGH
DETGSTQSAN
LAAKVSKQLS
GKWNVDKIAD
GVFTANTAIK
GTYVATGETR

NSIVQGANWG
LRNIVAKCNA
DDIGWSNRGA
SICYAITGQR
VRSEPSVNAT
DGKRISYWGS

ARKEHVMDRQ
HRVDLGISLH
KPRTDLYVLN
AGSTGGNTGG
HLRTLYSGGT
FE

VKDALISRLR
LNAYNGSANG
STSAPAILIE
GSTGGSTGGG
YKYTSFGMEK

SLGHTVYDCT
VEVCYSDQQA
LGFIDNEGDM
YDSSWFTPQN
DGYVWIKGAD
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Chapter 4: PlyM20
GenBank Accession Number: HM011608
909 base pairs; 302 amino acids; 33.34 kDa; Theoretical pI = 8.81
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510)
SPOR binding domain (PF05036)
ATGGCTTATA
TCATTCGGGA
TAGTAGGTCA
TCGAGACAGG
AATGTATGTT
ACGACCACAG
TATGCGGTAA
TATTTGCAAG
CCGACAGAGT
TATGCGAATA
GATTGCAGAT
GCAAGGTGCT
GCCGAAAAGC
TATCGTTAAG
AAGAACCCGA
GATGCTCCTG
CTCTGTGCTT
CCTTGAAGAC
AAAGTATAA

CGAACAGTCC
CAGAGAAACC
ATGCTCGGTA
CATCTTCCAA
GAAGAGAAGA
AGCAATCACC
ACGACAAAGC
AGAAATGGTA
GAATCACAAA
AGTCCTGTCC
GAGGTCAACA
ATACAAGGTA
AGTTAGAGAA
ACTGTCGTAG
AGTGGTTTTA
TTTATGGAAA
TATGTTCGTG
AGGTGCAGTA

TTTGGTGGAC
ACGCTATTGA
GAGACTCTTG
CTACGGCGTA
ATCGTTCTTG
ATTGAGGTTG
GTATGCCGCA
TCAAGAAGTT
AACGGATGCA
CGGCAAGTAT
AGAGATTGAA
CAAATCGGTG
AGCAAAGGCA
AAAATGAACC
GCCGTTGGCG
GACCACTAAG
AAATCAACGG
ACGGGTGCAG

TACACGAAAC
CACCATCACA
GAGAGATTTT
GGCGTGGATG
GTGTACTTCT
CAAGTGATAC
ATGCTCGACC
GGTATGGTCT
ATATGACCGT
CTGTATGACC
TGGTGCAAAT
CTTACTCTAA
GCAGGTTTCA
TGCGAAGCAA
ATAAGGTCAA
TTTCAGTCTT
CTCTCGTGTG
TTGACAAGAA

TGAGTCCCAA
ATCCATTGTG
CGCACCTACT
GTCGAATCGG
TCTGCATCCA
CACCGAACCT
TTGTAACCGA
ACCAACAAAT
TCACAGAGAC
GCCATCAGCA
GAGGAGGGAA
GGTAGAGAAC
CCGATGCTTT
GAACCCCCGA
GATGGCTAAG
GGGTTTATGA
GTTATTTCCA
ATATCTTACC

MAYTNSPLVD
SRQASSNYGV
YAVNDKAYAA
YANKSCPGKY
AEKQLEKAKA
DAPVYGKTTK

YTKLSPNHSG
GVDGRIGMYV
MLDLVTDICK
LYDRHQQIAD
AGFTDAFIVK
FQSWVYDSVL

QRNHAIDTIT
EEKNRSWCTS
RNGIKKLVWS
EVNKRLNGAN
TVVENEPAKQ
YVREINGSRV

IHCVVGQCSV
SASNDHRAIT
TNKSDRVNHK
EEGSKVLYKV
EPPKEPEVVL
VISTLKTGAV

ETLGEIFAPT
IEVASDTTEP
NGCNMTVHRD
QIGAYSKVEN
AVGDKVKMAK
TGAVDKKYLT KV
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Chapter 4: PlyM21
GenBank Accession Number: HM011609
1092 base pairs; 363 amino acids; 41.07 kDa; Theoretical pI = 9.26
N-terminal M23 peptidase enzymatic domain (PF01551)
Central phage lysozyme (i.e. muramidase) enzymatic domain (PF00959)
No recognized binding domain
ATGATTTTTA
TCCTTTAAGG
TTGATTTAAT
AATGGTAAAG
CGTCATCATA
CACATTTAGA
CAGAAAATAG
GCATTTTGAG
CTAATAGCTT
AAAGTATCTA
CGATAAAACT
CAACTAAGTG
AAGGTTGAAG
GACAATATTC
CTTTAGCTTC
CCATCTATTG
CGTTATGAAG
ATAAACGTAG
AATAAGGAGG
CATTGTTAAG
AGTCATGGTT
ACAGGTTTAC

AACCGCCAGT
TTGCATCCAG
TAACACCAAA
TACGCTTAGT
ACACATAAAG
TTCATACGAG
GCGTAATGGG
TTACATAGGA
CAATCCATGG
AAGAAGGATT
TACTTGGATC
GCCTAATGGT
CTGATATTTT
AATTACGTTA
TTTCCAATAC
CTGCATATAT
CTATACAATA
GATTGCTGAA
ATGACGATAC
CAATTCTTAG
AACTAAGTTT
AAATGATTGC

ACAGAACATG
TATTGAAGAT
TTAGGAAAAG
TAAAACAACA
TAGGTGGACA
GTAAAAGTTG
TAATACAGGT
ATCAGTGGGA
CCTTGGATAA
GGATTTAATT
CTATTGGACT
AATTCTGTAA
ACTAGAGCAA
AGGTTGATTT
AACTTAGGTA
TAATAAAAAG
AGGCTGGTGG
GCTGAATTGT
ATTGAAATTC
AACAATCAAT
AATGAAGGAA
TAACAACAAA

AAGCTAACTA
TGTACGCAAA
CTCCGATATT
GTAGATGGTT
AGTGTACGAG
GTCAAGAAGT
ATAGGAACGG
ATTCGATAAC
ACGAAGGGGA
AAGTTTTACG
TCCTACTATT
AAATGGGTGA
CAGGTTAATG
AACTCAAAAT
GTGGAATACT
GATTGGGCTA
TAAAGTATTA
TTATGAAGCA
ACTAACGAAG
TAAAGCGGGT
CTATTACTAA
AAGAATAAAT

GCGAATACGA
CATGCAGGTG
TGCAACTGCT
ATGGTAAGCA
AGTGTATACG
TTTACAAGGC
GAATCCACTT
TATAATTATC
GTTTAAAATG
AAGGTTTTTA
GGCTACGGTA
AAAGATTAGT
AACACGCTAA
CAATTCGATT
TAAAAAGGAC
ACGCTACTCG
GCTGGATTGG
ATCTGATAAG
CCACAAAGAG
TACTTCGATA
TGGAGACATT
AA

MIFKPPVQNM
NGKVRLVKTT
QKIGVMGNTG
KVSKEGLDLI
KVEADILLEQ
PSIAAYINKK
NKEDDDTLKF
TGLQMIANNK

KLTSEYDPLR
VDGYGKHVII
IGTGIHLHFE
KFYEGFYDKT
QVNEHAKTIF
DWANATRVMK
TNEATKSIVK
KNK

LHPVLKIVRK
THKVGGQVYE
LHRNQWEFDN
YLDPIGLPTI
NYVKVDLTQN
LYNKAGGKVL
QFLEQSIKAG

HAGVDLINTK
SVYAHLDSYE
YNYPNSFNPW
GYGTTKWPNG
QFDSLASFQY
AGLDKRRIAE
YFDKSWLTKF

LGKAPIFATA
VKVGQEVLQG
PWINEGEFKM
NSVKMGEKIS
NLGSGILKKD
AELFMKQSDK
NEGTITNGDI
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Chapter 4: PlyM22
GenBank Accession Number: HM011610
480 base pairs; 159 amino acids; 17.38 kDa; Theoretical pI = 8.49
Phage lysozyme (i.e. muramidase) enzymatic domain (PF00959)
No recognized binding domain
ATGGCGCGCG
GATTGGTTGG
GGTATAACGT
GACTACGCCG
TGCGGGCAGA
AACTCAAGTT
CAATTGATCC
TGGTCGAGCA
CCGGGTACGG
ATTGCGTATG

CAAAAGGCTT
TCTGAGATTG
TATCGTTGGC
CTCATCCGCA
TATCAGATTC
GCCTGATTTT
GCGAATGCAA
ATCACTGCTT
CCAACGTGAG
GTGGAGTTCT

GAGTCGCAAC
GCGATAAATT
TCCACCCCCA
AATTTATGTG
TCGGTAAGTA
GCCCCTGCAT
GGCGGTCCAG
GCAAAAGCCG
CACTCTATTG
TGCAAAATGA

ATGGCTGCAT
GTTGGCAGTG
CCAAACCAAA
AAGTCGGTTA
CGCAACTCAT
CACAAGACAA
TTGATTGAAG
CTGGGCGAGT
ATGATTTGAT

TCTTGGATAT
TCCGACGATG
GCTGTTTGAC
ACTCGACCGC
TACATGGCCC
AATTGCAATT
ATGGCCACAT
TTTGAGGGTG
TTCCCATTTC

MARAKGLSRN MAAFLDMIGW SEIGDKLLAV SDDGYNVIVG STPTKPKLFD
DYAAHPQIYV KSVNSTAAGR YQILGKYATH YMAQLKLPDF APASQDKIAI
QLIRECKAVQ LIEDGHIGRA ITACKSRWAS FEGAGYGQRE HSIDDLISHF
IAYGGVLAK
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Chapter 4: PlyM23
GenBank Accession Number: HM011611
450 base pairs; 149 amino acids; 16.39 kDa; Theoretical pI = 9.38
Phage lysozyme (i.e. muramidase) enzymatic domain (PF00959)
No recognized binding domain
ATGCAAGTTA
CCGCGCTAAC
TTGGCTACGG
GATAAGGTAA
GAAGTTTGCA
GCCAGTATGA
TTCCGCACGT
TGCTGCTGAT
CTGGATTACG

GTGATGCAGG
GCATATCCCG
CACCACCAAA
CGCCTGGCCA
AACTCAGTTG
TGCGCTGGTG
CCACCCTACT
GAATTTCTCC
CCGCCGTCGC

TATTGAGTTA
ACCCGAAATC
TTCCCATCCG
GGCTGAGCTA
ACGCTCTTGT
TCATTCGTTT
GAAGAAATTG
GCTGGGTATC
ACGGCAGAGC

ATCAAGTCAT
AGGTGGCGAC
GCAGACCAGT
TATCTTCGCG
CACCGCCCCT
ACAACCTTGG
AACGCCAAAG
TCCCGGCTCA
GCGCTATGTT

TCGAGGGATT
CCGTGGACCG
CAAGCAAGGC
AGGATGTGAA
CTGAAGCAAT
CGCAACCAAT
ACTACAATGG
TCCGTTGAGG
CCTTTCGTAA

MQVSDAGIEL IKSFEGFRAN AYPDPKSGGD PWTVGYGTTK FPSGRPVKQG
DKVTPGQAEL YLREDVKKFA NSVDALVTAP LKQCQYDALV SFVYNLGATN
FRTSTLLKKL NAKDYNGAAD EFLRWVSPGS SVEAGLRRRR TAERAMFLS
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Chapter 4: PlyM24
GenBank Accession Number: HM011612
546 base pairs; 181 amino acids; 20.15 kDa; Theoretical pI = 9.59
Phage lysozyme (i.e. muramidase) enzymatic domain (PF00959)
No recognized binding domain
ATGAAACTCA
GCAAGCGCAA
AGTCTATGAA
GGGCTGCGCC
ATGGGGAACA
AAATCACACT
TTTGAAAAAG
GTTTAACGCT
CTAACAGCAC
GCTGATCAGT
CTTAGTCAAT

TATTCGACGA
GTGGATAAAA
GGTCGATGCG
TAAATTCCTA
ACGGTTTACC
AGAGCAGGCG
CTGTCAATGA
TTGGTGTCAC
ATTAGTCAAG
TTTTAGTGTG
CGACGTAATA

GTTCCGAAAA
TCAATGCTCT
GCAGGGATTG
TGATGATGGC
CAAACGGTCA
AAGCAATACA
TGCGGTTAAA
TGGCCTATAA
CGGTTAAACG
GGTCAATGCA
AAGAACGGGA

CTGGCAGGCG
GATTGATGAA
ACTTGATTGG
GTTGGTGTGT
AAAGGTCAAG
AGGCGCATGA
GTGCCGCTGA
TATTGGGGTA
AAGGCAACTA
GGCGGTAAAC
GTTATTTTTA

MKLIFDEFRK
GLRLNSYDDG
FEKAVNDAVK
ADQFLVWVNA

LAGGKLTQAQ
VGVWTIGWGT
VPLNQNQFNA
GGKRMQGLVN

VDKINALIDE
TVYPNGQKVK
LVSLAYNIGV
RRNKERELFL

IQVKSMKVDA AGIDLIGQFE
KGDKITLEQA KQYKAHDLAK
SAFSNSTLVK RLNEGNYKAA
K
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GTAAATTAAC
ATCCAGGTTA
TCAGTTTGAA
GGACTATCGG
AAAGGCGATA
TTTAGCTAAG
ATCAAAACCA
TCTGCTTTCT
TAAGGCTGCT
GTATGCAGGG
AAATGA

Chapter 4: PlyM25
GenBank Accession Number: HM011613
771 base pairs; 256 amino acids; 28.17 kDa; Theoretical pI = 8.76
N-terminal PG-1 binding domain (PF01471)
Domain of unknown function DUF3380 (PF11860), likely enzymatic domain
**NOTE: The above binding domain shows only low homology to the consensus
sequences for PG-1, with an E-value score of 0.0007.
ATGGCGAAAA
TTATTATAAC
CAGTGCAAAA
AAGCCTGATA
TATCGCAGTG
TCATTGATGT
ACAATACTTT
TTACTACACT
CACCAAAGTG
AAGTTAAAGA
ATCATGGGGT
ATGCAACGCT
CAACTTAAAG
GCTACAGCGC
CTTATGCCAA
GCTAAAAAAC

CACACATAGT
GGTAAGATTG
TTTAATCGAC
TTGCTGAGCC
GCTAATGATT
TGAGGCAGCC
TTGAGCCTCA
AAACGCGCCG
GGATAGGTCG
TTGCTGCTGA
TTGGGGCAAA
TAAAGAGTTT
CGATGGGAAT
CATGATTGGG
AAATCAGTAT
AAGGTTGGTA

ACAGGCACAA
ACGGCGATTT
AATACAGATA
AGTAGATAAA
TAAACATTGA
GGCAATGGTT
TGTGTTTTGG
AACTAGCTAA
CTATATCGCA
TCTACACTGG
TCATGGGGTT
ATTGATGATA
GTTTTTAAAA
CGGGGTTTGC
GATGTAAAAC
G

ACAGCACTGG
TGGCGGCGGT
AGGCGGTTGA
AAACTATCTA
GCCAGCAGCA
TTGATAATCA
GATGAATTAG
AAAGCATAAC
TTGGTGGTAG
GAGGCGGCGC
TAACGCACAA
TGTATGAGAG
GCTAACGGCT
ACGAGGTTAT
TCGCTGATGC

CGGCGGCAGG
TCATTGCGAG
TATTTTGAGC
AAGCTGATAT
CTTAAAGCAG
AGGTCGTCCG
GTAAAATACA
GGGTTGTTGT
CTCGCATGAT
ACAAATCTGC
AAGATAGGCT
CGAAGCTAAG
TAATCAGTAA
AACGGCTCGG
CTACAATCTG

MAKTHIVQAQ
KPDIAEPVDK
TILFEPHVFW
KLKIAADLHW
QLKAMGMFLK
AKKQGW

TALAAAGYYN
KLSKADIIAV
DELGKIHYYT
EAAHKSASWG
ANGLISKLQR

GKIDGDFGGG
ANDLNIEPAA
KRAELAKKHN
LGQIMGFNAQ
HDWAGFARGY

SLRAVQNLID
LKAVIDVEAA
GLLSPKWDRS
KIGYATLKEF
NGSAYAKNQY

NTDKAVDILS
GNGFDNQGRP
LYRIGGSSHD
IDDMYESEAK
DVKLADAYNL
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Chapter 4: PlyM26
GenBank Accession Number: HM011614
567 base pairs; 188 amino acids; 21.16 kDa; Theoretical pI = 9.56
Glycosyl Hydrolase Type 19 (i.e. chitinase class I) enzymatic domain (PF00182),
not likely a dedicated chitinase
No recognized binding domain

ATGATCCTGA
ATTAAACCAG
ACAAAGACAA
ACATGGCATG
GGGCAAAGGT
ATACTGGCTT
TGGCTTAGCA
GAACAAGCCT
TTACCGGAAT
ATCCATCAAT
AACTGATAAA
CTTTGAGGTC

CTGCCGGTGG
AGCCAGGTTA
ATCTATTTCC
AAACTGCGGC
CGCACCTATG
GGATCATATT
ACTACGTTCT
GAATTGGCTC
GAAGGAAGGT
CCAAAAAGGA
GCAAAACTTA
CTTATAA

TTTTAATATT
ATGAGATTAA
TACCCACAAG
AACCATGCTG
GCAAAAAAAT
TATTATGGTC
AGCCAAAAAG
TGGTTCCTGA
TGGTTTACCG
CTACATTAAC
TCGCCGGCTA

CTTCGCAATG
TTTTCTAGTA
CTGCCTATAT
CCAATTGAGG
TGATAGTAAT
GTGGTTATGT
AAACTTGGCA
GCATGCAGTC
GCAAGAAACT
GCTCGACGTA
TGCCGAAATA

MILTAGGFNI
TWHETAATML
WLSNYVLAKK
IHQSKKDYIN

LRNGLGRLNQ
PIEEYGKGKG
KLGIDFVNKP
ARRIINGTDK

SQVNEINFLV
RTYGKKIDSN
ELALVPEHAV
AKLIAGYAEI

SQFDKDKSIS YPQAAYMLAT
GSAYTGLDHI YYGRGYVQLT
KILITGMKEG WFTGKKLSDY
FERALRSL
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GCTTGGGTCG
TCCCAATTCG
GTTGGCGACA
AATATGGAAA
GGCTCTGCCT
TCAGCTCACC
TTGATTTTGT
AAGATTCTGA
TTCCGACTAT
TTATCAATGG
TTTGAACGTG

Chapter 4: PlyM27 (Not actively expressed)
GenBank Accession Number: HM011615
534 base pairs; 177 amino acids; 19.93 kDa; Theoretical pI = 9.7
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510)
SH3-Type 3 binding domain (PF08239)
ATGCAGAGCA
GGAAGTCATC
ATGGCAGAAA
TACTCCAAGA
AAAGCTTATC
TAACTAAGCA
GATATGGGAT
ATCTTTTAAG
CTGGGATCAA
ACAATCGTTG
CTGGATAAAT

ACAATAAGCA
CAAGGTATCC
CGGAAAAGGG
GTGGCGGGTC
GCTGATATTC
TAGGGATTAT
GGGACCGATT
GTTAGAGTAA
ATACAAGATA
ATCAGACTAA
TTGAAATATA

GACATCATTC
CCCTTGATAG
AATAGAGAGG
TCGTTTTATT
TGGACGAGAA
TCAGGCAAGT
CCTTAAGCTG
CTGCAGACTC
AATGGAGCGA
TGGCTGGGGC
CGAAAAGAGT

MQSNNKQTSF
YSKSGGSRFI
DMGWDRFLKL
TIVDQTNGWG

HYAVDDKEVI
LAEKRAAKLI
VESERKTSFK
KLKSGAGWIN

QGIPLDRNAW HAGDGRNGKG NREGISIEIC
ADILDEKGWD ISKVTKHRDY SGKYCPHRTL
VRVTADSLNY RAGAGIKYKI NGAITDKGVY
LKYTKRV
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CATTACGCTG
GAATGCCTGG
GAATAAGTAT
TTGGCTGAAA
AGGATGGGAT
ATTGCCCACA
GTTGAATCAG
CCTGAACTAC
TTACGGATAA
AAACTTAAGA
ATAA

TTGATGACAA
CATGCGGGGG
CGAGATCTGT
AGAGGGCTGC
ATCTCAAAAG
TCGTACACTG
AACGAAAGAC
AGGGCAGGAG
GGGAGTATAT
GCGGGGCAGG

Chapter 4: PlyM28 (Not actively expressed)
GenBank Accession Number: HM011616
711 base pairs; 236 amino acids; 26.42 kDa; Theoretical pI = 9.62
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520)
SPOR binding domain (PF05036)
ATGAAAATTA
GAGTCCTGAC
TCATGAAAGC
CACGATCCCA
TAAGCTTTGC
GCAAGATGGG
CCGAAGGAAG
GGCCACTAAA
TGCGCGAAAC
TCGAAGACCG
CGCAGTAACT
AGAAGGTTGC
TTTTATCGCG
GCGTATGGCT
ATAAAAAATA

TATTAGACGC
GGAATGCGCG
GGAGCTTGAG
AGCGCGACGT
GTCGACCTAT
CGATTGGGGC
CGCGCAAGCT
CTGCGTAATC
ACATATGACA
ACTTGCCGTA
AACGTAAAGT
GCCAAAGCCT
TTGTGACCGG
CAGTTGAAGA
A

AGGTCACGGA
AATTTCAGTT
AAATACGAAG
TCCGTTGAAG
TCTTCAGTAT
GGAATCGATT
GGCCGACATT
GCGGCGTCAA
GCAATCCTCG
CTTGAAATCG
CAATCGCGCA
GCGGTCAAAC
CTCATTTGGC
AAGCCGGATT

CCAAACACGC
TAATAGTCGA
GCGTGACGGT
GAGCGGACTG
TCACGCGAAC
CGTTCGTCTA
GTGCAACGCA
GACGGCCGAC
TCGAGCACGG
GACGCCTATC
AATGTACGGA
CTGCCGTCAG
GACAGAGAAA
CGAATCGTTC

CAGGCAAACG
GTTGCTGACG
CTACTTTGCG
ACAAGGCGAA
GCTAACACCG
CACGTCTAAT
ATCTGATTGC
TTCCTCGTAC
ATTTATGGAT
GCAAGCTTTG
TTGAAGCCAA
CTCTGACGTA
ACGCCGAAAA
ATTGACGCTT

MKIILDAGHG
HDPKRDVPLK
PKEARKLADI
SKTDLPYLKS
FYRVVTGSFG

PNTPGKRSPD
ERTDKANKLC
VQRNLIAATK
DAYRKLCAVT
DRENAEKRMA

GMREFQFNSR
VDLFFSIHAN
LRNRGVKTAD
NVKSIAQMYG
QLKKAGFESF

VADVMKAELE
ANTGKMGDWG
FLVLRETHMT
LKPKKVAPKP
IDAYKK

KYEGVTVYFA
GIDSFVYTSN
AILVEHGFMD
AVKPAVSSDV
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Chapter 4: PlyM29 (Not actively expressed)
GenBank Accession Number: HM011617
708 base pairs; 235 amino acids; 26.33 kDa; Theoretical pI = 9.34
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520)
SPOR binding domain (PF05036)
ATGAAAATAT
GAGTCCTGAC
TCATGAAGGC
CATGAGCCTA
CAAACTTTGC
GCAAGATGGG
CCGAAGGAAG
GGCTACTAAA
TGCGCGAAAC
TCGAAGACAG
CGCTGAGTCT
AGCCTGCGCC
TATCGCGTTG
CCTGGCTGAG
AAAAGTAA

TAATCGATGC
GGAATGCGCG
GGAGCTTGAA
AGCGCGATGT
GTCGACCTAT
CGACTGGGGC
CACGGAAGCT
CTTCGTAATC
GCACATGACG
ACTTGCCGTA
AACGTAAAGT
GAAGCCCGTG
TGACCGGTTC
CTGAAAAAGG

CGGCCACGGA
AATTCGAATT
GAATACGAGG
GCCGTTGAAA
TCTTCAGTAT
GGAATTGATT
GGCCGACATT
GCGGCGTCAA
GCAATCCTCG
CTTGAAGTCG
CAATCGCGCA
GTCAAGCCAG
ATTTGGCGAC
CCGGCTTTGA

CCAAACACGC
TAATAGCCGA
GTGTGACGGT
GAGCGGACTG
TCACGCGAAC
CGTTCGTCTA
GTGCAGCGCA
GACGGCCGAC
TCGAGCACGG
GATGCCTATC
AATGTACGGA
CCGTCAGCTC
AGGGATAACG
TTCGTTCATT

CAGGCAAACG
GCTGCTGACG
CTACTTTGCG
ACAACGCGAA
GCTAACACCG
TACGTCCAAT
ATCTAATCGC
TTTCACGTAC
CTTTATGGAT
GCAAGCTTTG
CTCAAGCGCA
CGACGTATTC
CCGGACGACG
GACGTTTATA

MKILIDAGHG
HEPKRDVPLK
PKEARKLADI
SKTDLPYLKS
YRVVTGSFGD

PNTPGKRSPD
ERTDNANKLC
VQRNLIAATK
DAYRKLCAES
RDNAGRRLAE

GMREFEFNSR
VDLFFSIHAN
LRNRGVKTAD
NVKSIAQMYG
LKKAGFDSFI

AADVMKAELE
ANTGKMGDWG
FHVLRETHMT
LKRKPAPKPV
DVYKK

EYEGVTVYFA
GIDSFVYTSN
AILVEHGFMD
VKPAVSSDVF
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Chapter 4: PlyM30 (Not actively expressed)
GenBank Accession Number: HM011618
1017 base pairs; 338 amino acids; 36.89 kDa; Theoretical pI = 9.61
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510)
PG-1 binding domain (PF01471)
ATGCGCTTAC
TGATATTGTG
ATCCGCGTTT
GACGCGAAAA
ACGCGACACA
TCATTCAACA
TGGGCGACGA
GCACAGAGGC
ATGCGTATCT
CATCAGCATT
CGGTTCGTTT
GCGCAGTAAC
GATGGCGATA
AGCAGGTTTC
CAGCGGTTAA
TTCGGAACGG
TAAGAAGCCG
CCACAGTGGA
AAAGAAGCGG
AGTGACTCGT
CGCCGAGACT

TAAAAAATGG
GACGGCGCAA
CTTGACGGAC
GTCATAATCG
AGCCATATTT
TATCCCATTT
CTAGCGGGAA
GCGGATCGAA
AATGAAGGAA
GGAGCGGCAA
ACGCCATTCC
GGCAGCGAAG
CAGGCGCGGC
TTACTATCTG
GGCGTTTCAA
GCTCACAGGC
GTAGTTAAGC
GAAAACAAAA
TGAAGATTGG
GAAGAATCAA
TAAATAA

CACAAAAATA
ACAGAGAGAT
CACGACACGG
CTACATCCAC
CCTGGCATGT
GACGAGTGTG
TCGCACAAGT
ATAAGATTGA
CTCAAAATAC
ATACTGTCCA
GCAATAAGAT
CCTTCCACAG
GGTTAAAACG
TGGATGGCAT
CGTGCGAATG
TAAACTCAAC
CGGCAGCGCC
CAACCCTCAA
TGTATCGGAC
TTGTAATCGC

GGAAACGCCA
TCGACCGCGC
GTAACTCGGG
AACTTGGGCG
AACTGTGGAT
CTTATCATTG
ATCGGCATAG
GGCCAACGCG
CGATTACATC
CAGTTGATAT
TGAAGCGGCG
TGAAGAGAGA
CTACAAAGCG
ATTCGGAAAA
GATTAGCAGT
GCAATACTGG
AACAAAACCA
AATGGGCAGA
GGATCTCGCT
CATGCGCGCT

CAGTAATTGT
ACAAAAATGA
TAATGGCGCA
ATAAGCTACC
GAAAACTTCA
CGGCGACGGT
AGAAGTGCAT
ATTGCGCTTT
TGTACGCCCT
TGAATCGGTA
TTTAAAGGTG
CTACCTATTA
AATTGAAACA
GGTACAGAGA
TGATGGCGTG
CGAATCTGAA
AAGGAGGAAT
AGTGACGATT
TGCATGATAC
GCAGGACTTG

MRLLKNGTKI
DAKSHNRYIH
WATTSGNRTS
HQHWSGKYCP
DGDTGAAVKT
FGTGSQAKLN
KEAVKIGVSD

GNATVIVDIV
NLGDKLPRDT
IGIEKCMHRG
QLILNRYGSF
LQSELKQAGF
AILANLNKKP
GSRLHDTVTR

DGANREIRPR
SHISWHVTVD
ADRNKIEANA
TPFRNKIEAA
LLSVDGIFGK
VVKPAAPTKP
EESIVIAMRA

TKMNPRFLTD
ENFIIQHIPF
IALYAYLMKE
FKGGAVTAAK
GTETAVKAFQ
KEESTVEKTK
AGLAPRLK

HDTGNSGNGA
DECAYHCGDG
LKIPITSVRP
PSTVKRDYLL
RANGLAVDGV
QPSKWAEVTI
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Chapter 4: PlyM31 (Not actively expressed)
GenBank Accession Number: HM011619
1074 base pairs; 357 amino acids; 38.61 kDa; Theoretical pI = 9.57
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520)
PG-1 binding domain (PF01471)
ATGGCAAAGA
AAGCAAAGGG
ATTTTAACGC
CTAACGACTT
GACGCGCACG
TTGGCTTCTC
TTCGGTGTAT
AATGCTTCTC
GCAGCGGGAT
CTGCGCGACA
GAATGATGAA
GCGGTAAAGT
ACTGATTTCA
CCTATTAGAT
TGAAACAAGC
ACAGAGACAG
TGGCGTGTTC
ATTTGAATAA
GAGGAGTCCA
GACGATTAAA
ACGATCCAAT
GGGCTTGCGC

TTATGAATGA
GTGCGCGCAA
AGCGGTAGCA
ATAGCGCACA
CGCCTATATA
ACATCACGGA
TCTACTGGGG
GCGGCGTATA
ATTCGAAAGT
CGTCAGCGCC
GCGCGTAAAC
GGCAGCGAGT
CAGCAGCTAA
GGCGATACTG
GGGTTTCTTA
CGGTTAAGGC
GGAACAGGCT
GAAGCCGGTA
CAGTGGAGAA
GAAGCGGTGA
TACACGACAG
CAAAACTTAA

GCCGGGGCAC
GTGGTGGCGT
GATGAAGTGA
GCCTAGTCGC
ATGAAGAGTT
AACGCCAACG
CGGATCTGCA
AAAAAGAATT
AAACGCGGAG
TTTCGTGTTA
GGATGCTATC
GTCGCGTGTG
ACCTGCGCCT
GCGCAGCGGT
CTATCTGTGG
GTTCCAACGT
CACAGGCTAA
GTTAAGCCTG
AACAAACCAA
AAATTGGTGT
GAAGCAATTG
GTAA

GGCAACAACA
TCCCGAAATG
ATCGCCTATT
GGCAAGGATG
TCGCAAAGAT
CTAACAAAGC
ACGGGTAAGA
CCCTGGCTAT
ACTGGACAAA
ATCGAGTGGG
TACAGATTAT
ATTGGTACGG
TCCACAGTGA
TAAAACGCTA
ATGGCATATT
GCGAATGGAT
GCTCAACGCA
CAGCGCCATC
CCCTCAAAAT
TACGGATGGC
TGCTGGCGAT

CATGGCCGCC
GCGGAGCATG
AAGCGGCAAG
TTTCGCTAAC
AAGAGCGCAA
GACAAAAGGT
AGTTGGCGCA
CCGATTTGGG
CTTTGCAATC
ATTTCTTTAC
AGAAAGCGTT
TATTCCGTTT
AGAGAGACTA
CAAAGCGAAT
CGGAAAAGGC
TAGCAGTTGA
ATACTGGCTA
AAAACCAAAG
GGGCAGAAGC
AGCAACTTAC
GCGTGCTGCA

MAKIMNEPGH
LTTYSAQPSR
FGVFYWGGSA
LRDTSAPFVL
TDFTAAKPAP
TETAVKAFQR
EESTVEKTNQ
GLAPKLK

GNNTWPPSKG
GKDVSLTTRT
TGKKLAQMLL
IEWDFFTNDE
STVKRDYLLD
ANGLAVDGVF
PSKWAEATIK

VRASGGVPEM
RLYNEEFRKD
AAYKKEFPGY
ARKRMLSTDY
GDTGAAVKTL
GTGSQAKLNA
EAVKIGVTDG

AEHDFNAAVA
KSAIGFSHHG
PIWGSGIFES
RKRCGKVAAS
QSELKQAGFL
ILANLNKKPV
SNLHDPITRQ

DEVNRLLSGK
NANANKATKG
KRGDWTNFAI
VACDWYGIPF
LSVDGIFGKG
VKPAAPSKPK
EAIVLAMRAA
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Chapter 4: PlyM32 (Not actively expressed)
GenBank Accession Number: HM011620
423 base pairs; 140 amino acids; 15.78 kDa; Theoretical pI = 9.16
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510)
No recognized binding domain
ATGAGAAAAA
CAAGCCCTTC
GGAAGGGCTG
CAGGGCAGAC
CGAGAGCATA
GCAAGGACAC
CGTCAGCTCA
TAATGAGTTC
ACAAGGAAAT

TCAAGGAAAT
ACCGTTGCCG
TGGCTATCAC
CAGAGCAGAT
GGCGTATGCT
ACGCACACCA
TGCAGACACA
AGCACAAGGG
ACTGGAAGGA

AATAGTCCAT
ATATTGAGCG
TACGTTATCA
TGCTGGCGCA
ACATCGGTGG
GAGCAGAAGA
CGGCATCAGC
CTTGCCCCAG
TGA

TGCTCTGCAA
TTGGCATCGG
CCCTTGACGG
CATTGCTCTG
ATGCGACCTC
AGGCAATGGT
ATCAAGGATG
TTTCTCTGTC

CGAGAGAAGG
GAAAGAGGAT
AAAGGTGGAG
GCAGAAACAG
GTGGGCAAGA
AACACTCATT
TCCGCTGCCA
CAGAAGTTGC

MRKIKEIIVH CSATREGKPF TVADIERWHR ERGWKGCGYH YVITLDGKVE
QGRPEQIAGA HCSGRNSESI GVCYIGGCDL VGKSKDTRTP EQKKAMVTLI
RQLMQTHGIS IKDVRCHNEF STRACPSFSV QKLHKEILEG
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Chapter 5: PlySs1
GenBank Accession Number: Not yet submitted
Full-length construct: 1359 bp; 452 amino acids; 49.67 kDa; Theoretical pI = 6.87
Truncated construct: 765 bp; 254 amino acids; 28.09 kDa; Theoretical pI = 7.7
N-terminus: Pfam predicts an N-acetylmuramoyl-L-alanine-amidase-Type 5
enzymatic domain (PF05382); it was experimentally verified, however, that this
region actually possesses –D-glutaminyl-L-lysine endopeptidase activity against
S. suis peptidoglycan.
Dual CPL-7 binding domain (PF08230)
C-terminus: Endo-beta-N-acetylglucosaminidase enzymatic domain (PF01832)

ATGACAATCA
CAAAGTCTCT
GCTCTAGTGC
GGTTGGGCGG
ATATGTTTTG
TTTGTATTTT
GTTATCTTTG
CGGAATTTCC
ATCTATATCG
CAGCTTGTTA
TAAGGCAAGT
GCAAAGCTTC
TTAGCAGGTA
ACGCTATGAG
AAAAACCGTC
GAGGACGGGG
CGAAATTATC
CCCTAACTAT
AAGGCCGACA
TCCGAGCGGA
GAGGCCACTA

ATCTTGAAAC
TACTCAATGG
TGTATATTAT
TTAACACTGA
GTAGCTGAAA
GGGTAAACGT
TGGATAATGT
ATTGATAATT
CCCAGCAAAT
AGGAGACTTT
CTTGGCAGTC
GGCAAGCGAG
AGCACGGGGC
CCTGTTCAAG
TGAGACGGCC
ACTTGTCTTT
CTGAAAAAGT
CCTACACTAT
ACAACTGGGG
GTAATTGTGA
CATGCACTAT

ATCCATTCGT
ACTATCGTAA
GCGCTAATGG
GTATATGCAT
ATAAACCATT
GGCTATTCGA
TAATGTGATA
ATAATCAAGT
CAACCCAGCA
GGCTGGGGTA
AATACGAGGC
AAATCTGATG
TGGAGAGGAC
CCAAGGTCAA
AAAAATGAAC
CAATGGTGCC
GTAAAGAACA
GAAGGGCTTT
CGGTATGACC
CTCAAGGTTT
GCCACCGTGG
373

TGGATGAGCG
CGGTCCGAAT
CGGGTGGTGC
GACTGGTTGA
TAACGCTCAA
GCGGAGCAGG
CATTGTAACT
GCATCGTGGT
TCAGCAACAA
CATGGCAACG
TGTCATGGCG
AGGAACTTGC
CGAAAACGGT
CGAATTGCTC
CACAGACGGT
ATTCTTAAGA
TGACATCTTA
GGGGCACTTC
TGGACTGGCC
GGCTCGGCCA
ATGATTTCCT

ACCGTGTCGG
AGTTATGACT
AATTTCTGCA
TACGTAACGG
AGACATGACG
TGGTCACGTC
ATGCACGTAA
ATGTATTACT
ATCACTGGAT
GGGACACCCG
GTTATCAATG
TAGGGAAGTC
CATTAGGACC
AAGGCTAAGG
GCAATTCAAG
AGTCTGTCCT
CCAAGCTATG
TGCTGTCGGT
AAGGCAACCG
TCGAACGAGG
GACGGACTGG

TTCTACCTGC
CTTCAGCGAG
ACTATGCAGC
CTAAAAGCTA
ATCAAATAAT
ACGGCATTGA
CCAGTCTAA

TTCGCAAGGA
TCCATTAAGG
CGCCGGCTAC
TCGAGTCCGA
GTCCATTCGG
AGTTACGATC

CGGGTCTTAC
GCATGTTCCA
GATAGTTACC
AAATGGCAGT
TTGACCCTGA
AATGGTGTTG

AAGGTATCTG
GGTTGGCGGA
TGGTCGGCGC
CTGACACGGT
TAAAATCTCT
TCTACAAGCT

GTGCATTGAC
GCTAAATACG
CACTAGCAGG
TTGATGCCAC
GTTGATATTG
GGAAAAGAAA

MTINLETSIR
GWAVNTEYMH
VIFVDNVNVI
QLVKETLAGV
LAGKHGAGED
EDGDLSFNGA
KADNNWGGMT
FYLLRKDGSY
LKAIESENGS

WMSDRVGKVS
DWLIRNGYVL
HCNYARNGIS
HGNGDTRKAS
RKRSLGPRYE
ILKKSVLEII
WTGQGNRPSG
KVSGALTFSE
LTRFDATSNN

YSMDYRNGPN
VAENKPFNAQ
IDNYNQVHRG
LGSQYEAVMA
PVQAKVNELL
LKKCKEHDIL
VIVTQGLARP
SIKGMFQVGG
VHSVDPDKIS

SYDCSSAVYY
RHDVCILGKR
MYYYLYRPAN
VINGKASASE
KAKEKPSETA
PSYALTILHY
SNEGGHYMHY
AKYDYAAAGY
VDIDGIEVTI

ALMAGGAISA
GYSSGAGGHV
QPSISNKSLD
KSDEELAREV
KNEPQTVQFK
EGLWGTSAVG
ATVDDFLTDW
DSYLVGATSR
NGVVYKLEKK PV

**NOTE: The full-length gene/protein shown here is what was cloned during the
initial functional screen of the S. suis 7711 genome. For large-scale expression,
purification, and functional analysis, a truncated construct was sub-cloned that
omitted the C-terminal enzymatic domain. The residues included in this
construct are underlined above.
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Chapter 5: PlySs2
GenBank Accession Number: ZP_03625529 (from S. suis strain 89/1591)
Originally annotated in GenBank as ―SH3-type 5 domain protein‖
738 base pairs; 245 amino acids; 26.06 kDa; Theoretical pI = 9.06
CHAP enzymatic domain (PF05257)
SH3-Type 5 binding domain (PF08460)
ATGACAACAG
CGGTGTGTCT
AGCGCATGAT
TGGGTCAGCG
ATCATACAAC
TTAAAGCAGG
GGACATGTGG
GGAGCAAAAC
CTGCAAGCTA
GTCGCACAGT
GGGCACTATG
ATACTTCAGG
TATGATACTG
AGGCGGCAGC
GTAAGCGTTT

TAAATGAAGC
GTTGGCAACG
TAGTCCGGAT
GTGCAATCGG
TGGCAAGCTA
TCAGATTGTG
TAATCGTCGA
TACGGCGGGA
TCGTCAACAG
CAGCACCCAA
ACTGTCACGG
CGAGATTGTA
TCATCATCGA
GGCAAACGTA
CGGCAATGCT

ATTAAATAAT
GCGAATGCTA
GCAACTGTCG
CGATACAATC
ACGGCTGGAC
ACGCTTGGGG
AGCAGTGGAC
AACGTTATCC
GTCGTGCATT
CCTTGCAGGC
TCGATGCTCT
GCAGTATACA
TGTCAATGGC
ACTACGTTGC
TGGGGTACAT

GTAAGAGCTC
CGCTTTGGCT
GACTTGGCGC
TCTGCCAAAA
AGTTTCCACA
CAACACCAGG
GGCGATAGAT
CGTCCGTAAT
ACATCACACC
TCTCGTTCCT
CAATGTTCGC
AGCGTGGTGA
TATGTCTGGG
GACGGGCGCT
TTAAATAA

AGGTTGGGTC
AGTTGGTACG
TGGTGTGGGC
ACATCGGCTC
TCTGGTCCAT
AAACCCTTAC
TGACTATTTT
TATTACAGCG
GCCTGGCACG
ATCGCGAGAC
AGGGCGCCAA
ATCATTTGAC
TGTCTTACAT
ACCAAAGACG

MTTVNEALNN
WVSGAIGDTI
GHVVIVEAVD
VAQSAPNLAG
YDTVIIDVNG

VRAQVGSGVS
SAKNIGSSYN
GDRLTILEQN
SRSYRETGTM
YVWVSYIGGS

VGNGECYALA
WQANGWTVST
YGGKRYPVRN
TVTVDALNVR
GKRNYVATGA

SWYERMISPD
SGPFKAGQIV
YYSAASYRQQ
RAPNTSGEIV
TKDGKRFGNA

ATVGLGAGVG
TLGATPGNPY
VVHYITPPGT
AVYKRGESFD
WGTFK
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